WorldWideScience

Sample records for po leczeniu 131i

  1. Probiotyki i prebiotyki w profilaktyce i leczeniu chorób u dzieci

    Directory of Open Access Journals (Sweden)

    Leokadia Bąk-Romaniszyn

    2010-11-01

    Full Text Available Probiotyki to mikroorganizmy, które wywierają korzystne działanie na organizm gospodarza po spożyciu przez niego odpowiedniej dawki określonego szczepu. Najczęściej jako probiotyki stosowane są bakterie kwasu mlekowego Lactobacillus i Bifidobacterium oraz wybrane szczepy Streptococcus, Bacillus, a także drożdże Saccharomyces boulardii. Probiotyki wpływają korzystnie na skład środowiska ekologicznego przewodu pokarmowego, wykazując antagonizm w stosunku do drobnoustrojów chorobotwórczych kolonizujących błonę śluzową przewodu pokarmowego. Obecność w jelicie bakterii fermentacyjnych, głównie pałeczek kwasu mlekowego, a zwłaszcza typów adhezyjnych, chroni przed dyslokacją bakteryjną i enterotoksemią, normalizuje zaburzenia motoryki jelit i zmniejsza objawy nietolerancji laktozy. Prebiotyki to substancje naturalnie zawarte w żywności (bądź do niej dodawane, które selektywnie pobudzają wzrost i/lub aktywność wybranych szczepów bakterii probiotycznych obecnych w przewodzie pokarmowym. Probiotyki i prebiotyki, jak również ich połączenie – synbiotyki, występują w pożywieniu, mieszankach mlecznych, preparatach farmakologicznych, dodatkach do żywności, suplementach dietetycznych i w sposób naturalny poprawiają stan naszego zdrowia oraz mają coraz większe znaczenie w nowoczesnej medycynie. W pracy omówiono udział probiotyków i prebiotyków w kształtowaniu się biocenozy przewodu pokarmowego oraz w profilaktyce i leczeniu wybranych chorób u dzieci, jak: biegunki bakteryjne i wirusowe, dysbioza poantybiotykowa, martwica jelit noworodków, kolka jelitowa, nieswoiste zapalenia jelit, zaburzenia czynnościowe przewodu pokarmowego.

  2. Miejsce psychoterapii w prewencji i leczeniu depresji poudarowej

    Directory of Open Access Journals (Sweden)

    Hubert M. Wichowicz

    2018-06-01

    Full Text Available Depresja poudarowa jest najczęstszym psychiatrycznym powikłaniem udaru. Jej wystąpienie koreluje z opóźnieniem procesu rehabilitacji, głębszym upośledzeniem procesów poznawczych czy pogorszeniem jakości życia chorych. Większość artykułów dotyczących prewencji i leczenia depresji poudarowej koncentruje się na środkach farmakologicznych. Psychoterapia pozostaje zaś w tle, chociaż jako forma wskazana dla osób z lekkimi i umiarkowanymi postaciami depresji wydaje się odpowiednia dla chorych po udarze, u których dominują takie właśnie postacie. Jakkolwiek u znacznego odsetka pacjentów psychoterapia jest trudna do przeprowadzenia ze względu na ciężki stan neurologiczny i zaburzenia wyższych funkcji poznawczych, afazję czy otępienie, wiele udarów mózgu ma lżejszy przebieg i potencjalnie kwalifikuje się do tej formy zapobiegania albo terapii depresji. W świetle medycyny opartej na dowodach psychoterapia wykazuje u chorych po udarze wpływ prewencyjny. Wpływ leczniczy nie został udowodniony, jednak rozmaitość stosowanych podejść, czyniących każde doniesienie nieporównywalnym z innymi, nakazuje ostrożność we wnioskowaniu. W artykule zaprezentowano wybrane prace i proponowane formy terapii. Ich przegląd sugeruje, że w odniesieniu do osób po udarze lepsze będzie zastosowanie prostszych form psychoterapii, które najbliższe są psychoedukacji czy nawet grupom wsparcia oraz koncentrują się na codziennych problemach. Nie ma i prawdopodobnie długo nie będzie jasnych wskazówek co do tego, jaka metoda jest najbardziej wskazana. Mimo to – jeśli uwzględnić liczebność populacji pacjentów po udarze, brak możliwości zastosowania farmakoterapii w niektórych przypadkach i etyczne wątpliwości związane z profilaktycznym podawaniem leków psychotropowych – psychoterapia poszerza repertuar środków potencjalnie użytecznych w prewencji i leczeniu depresji.

  3. PRACTALL – nowe zalecenia w leczeniu astmy u dzieci

    Directory of Open Access Journals (Sweden)

    Rafał Pawliczak

    2009-09-01

    Full Text Available Astma oskrzelowa jest najczęstszą przewlekłą chorobą układu oddechowego występującą u dzieci. Chociaż jej rozpoznawanie w większości przypadków oparte jest na wywiadzie i stosunkowo prostych badaniach dodatkowych, wydaje się, że choroba ta często pozostaje niezdiagnozowana przez lekarzy rodzinnych i pediatrów. Również leczenie astmy – choć stosunkowo proste – pozostawia wiele do życzenia. Taka sytuacja występuje nie tylko w Polsce, podobnie jest na całym świecie. W zależności od kraju lub kontynentu to samo dziecko chore na astmę może zostać poddane leczeniu różnego rodzaju. Dzieje się tak z wielu powodów, między innymi dlatego, że leczeniem astmy na świecie zajmuje się szerokie grono specjalistów, począwszy od lekarzy rodzinnych, przez pediatrów i pulmonologów, a na alergologach skończywszy. Dotychczasowe zalecenia dotyczące diagnostyki i leczenia astmy u dzieci stanowiły zaledwie część dokumentów poświęconych dorosłym pacjentom. Opublikowane niedawno zalecenia PRACTALL dotyczą diagnostyki i leczenia astmy oskrzelowej u dzieci. W niniejszej pracy zawarto omówienie tego ważnego konsensusu pediatrycznego, pierwszego ogólnoświatowego tak obszernego dokumentu poświęconego chorobie, która stanowi ważne wyzwanie dla lekarzy rodzinnych, pediatrów, pulmonologów dziecięcych i alergologów. Konsensus ten omawia i wprowadza do praktyki klinicznej większość najnowszych badań nad astmą oskrzelową i świstami u dzieci. Niektóre zmiany mają charakter nowatorski i przełomowy, gdy chodzi o diagnostykę i leczenie astmy dziecięcej. W poniższym artykule podjęto próbę omówienia najważniejszych elementów zaleceń PRACTALL.

  4. *sp131*I-3-iodobenzylguanidine (*sp131*I-3-IBG) as a scintigraphic agent for the visualization of adrenal medulla tumors

    International Nuclear Information System (INIS)

    Heggeli, D.E.; Brorson, B.I.; Bremper, P.O.

    1983-06-01

    A method of labelling 3-iodobenzylguanidine with *sp131*I is described. 3-IBG . 0.5 H*sb2*SO*sb4* and Cu(II)SO*sb4* were dissolved in a 0.1 M NH*sb4*H*sb2*PO*sb4* buffer and mixed with *sp131*I-NaI. The solution was evaporated to dryness by heating. After addition of water, the solution was heated with reflux for two hours. The I*sp-* ions were removed after labelling by anionic exchange chromatography. The final product was made isotonic and bacteriostatic by the addition of acetate buffer, saline and benzylalcohol. The product was filtered through a membrane filter with a pore size of 0.22*my*m and was apyrogenically tested by limulus test. The tumors of adrenal medulla, pheochromocytomas and neuroplastomas may in some cases be small or located extra-adrenally. In those cases *sp131*I-labelled 3-IBG is a valuable tool, since 3-IBG concentrates in adrenal medulla tumors because ot its analogy to the catecholamines. Injecting a dose of 0.5 mCi *sp131*I-3-IBG (2.5 mCi/mg), which is an adult dose, allows the scintigraphic localization of the tumours, thus guiding the surgeon. Adrenal uptake in mice and dog is described in the report, as well as a rapid method for the control of radiochemical purity. The radioactive concentration of the *sp131*I-3-IBG has been found to be important for the radiochemical stability of the product. (RF)

  5. A new anticancer agent--131I BGTP

    International Nuclear Information System (INIS)

    He Jiaheng; Jiang Shubin; Wang Guanquan

    2007-12-01

    A new anticancer precursor, di-peptide[p-Boc-Gly-Tyr-NH(CH 2 ) 2 NH-PO (ONH 4 )-O-PhI*], was synthesized and labelled with 131 I using enveloped-tube technique, the labelling yield could reach 85%. Using cell coalescent method, the biological activity in vitro of the labelled compounds was evaluated, showing that the primary appetency was kept and not damaged obviously during labelling. Results on judgement of their stability, lipophilicity and toxicity demonstrated lower toxicity, higher lipophilicity and lower iodium disassociation percentage (<12% after 72 h); furthermore, a tumour-bearing animal model, was establishd successfully, on which, the biological properties of the labelled agent was studied. (authors)

  6. 131I Metaiodobenzylguanidine scintigraphy

    International Nuclear Information System (INIS)

    Izumi, Motomori; Morimoto, Isao; Yamashita, Shunichi; Hirayu, Hideshi; Nagataki, Shigenobu

    1988-01-01

    A newly developed radiopharmaceutical agent, 131 I-metaiodobenzylguanidine ( 131 I-MIBG) has been reported to be very useful for locating pheochromocytoma and to be specific for pheochromocytoma and safe for humans. The first 131 I-MIBG scintiscanning in Japan which has been carried out in our clinic and the analysis of clinical experience of 131 I-MIBG scanning in Japan are presented

  7. 131I Metaiodobenzylguanidine (131I MIBG) kinetics in a carcinoid tumor

    International Nuclear Information System (INIS)

    Schiavo, R.; Concolino, G.; Fazi, F.; Iannantuono, P.; Voti, S. Li; Manzara, A.; Pavoni, P.

    1987-01-01

    The 131 I-MIBG kinetics was studied in vivo in patients with carcinoid tumors and liver metastases. Activity curve analysis showed that the maximum uptake of 131 I-MIBG in a carcinoid tumor occurred after 48 hours, while its biological half time was of 8 days and a half. Although more data are necessary to understand a significant variation in 131 I-MIBG kinetics between the different kinds of APUD neoplasms, it is thought that a dynamic-funtional study allowing the evaluation of the different biological half-time, could be helpful for the selection of these neoplasms, which could be treated with 131 I-MIBG. Radiation doses required for the treatment are also estimated. (M.E.L.) [es

  8. A new anticancer agent--{sup 131}I BGTP

    Energy Technology Data Exchange (ETDEWEB)

    Jiaheng, He; Shubin, Jiang; Guanquan, Wang [China Academy of Engineering Physics, Mianyang (China). Inst. of Nuclear Physics and Chemistry

    2007-12-15

    A new anticancer precursor, di-peptide[p-Boc-Gly-Tyr-NH(CH{sub 2}){sub 2} NH-PO (ONH{sub 4})-O-PhI*], was synthesized and labelled with {sup 131}I using enveloped-tube technique, the labelling yield could reach 85%. Using cell coalescent method, the biological activity in vitro of the labelled compounds was evaluated, showing that the primary appetency was kept and not damaged obviously during labelling. Results on judgement of their stability, lipophilicity and toxicity demonstrated lower toxicity, higher lipophilicity and lower iodium disassociation percentage (<12% after 72 h); furthermore, a tumour-bearing animal model, was establishd successfully, on which, the biological properties of the labelled agent was studied. (authors)

  9. Quality control procedures for iodinated radiopharmaceuticals 131I-Hippuran and 131I-Risa

    International Nuclear Information System (INIS)

    Toledo e Souza, I.T. de; Pereira, N.P.S. de; Silva, C.P.G. da.

    1986-02-01

    A rapid miniaturized chromatography system was developed for fast determination of the proportion of inorganic radioactive iodide from radiopharmaceutical 131 I-Hippuran and 131 I-Risa. The technical parameters associated with miniaturized chromatography system were evaluated. One of the problems found in this system was the movement of the 131 I-Risa from the origin with consequent overestimation of the inorganic iodide. A correct spot placement eliminated this problem. (Author) [pt

  10. Synthesis of (131)I-labeled-[(131)I]iodo-17-allylamino-17-demethoxy geldanamycin ([(131)I]iodo-17-AAG) and its biodistribution in mice.

    Science.gov (United States)

    Daozhen, Chen; Lu, Liu; Min, Yang; Xinyu, Jiang; Ying, Huang

    2007-10-01

    The aim of this study was to examine the radioiodinating condition of 17-allylamino-17-demethoxy geldanamycin (17-AAG) and observe its biodistribution in the hepatoma cell line HepA tumorearing ICR mice for understanding the possibility of its application in nuclear medicine. [(131)I]iodo-17-AAG was prepared by the reaction of 17-AAG with Na[(131)I] in the presence of hydrogen peroxide. [(131)I]iodo-17-AAG was purified by high-performance liquid chromatography (HPLC). The stability of [(131)I]iodo-17-AAG was measured by thin-layer chromatography (TLC). The distributions in HepA tumor-bearing ICR mice at 0.5, 1, 4, 8, 24, and 48 hours after injection of [(131)I]iodo-17-AAG were measured. Tumor uptake studies were performed in HepA tumor-bearing ICR mice. The labeling yield was over 83%. The radiochemical purity of [(131)I]iodo-17-AAG was 99.6% after purification. The specific activity was greater than 4 Ci/micromol. The labeled compound was stable for at least 120 hours in saline at 4 degrees C. It was initially in blood at 5 minutes with 4.79% of injected dose per g of tissue (%ID/g), and then dropped 0.33% ID/g at 24 hours. The uptake in liver, lung, and kidney at 4.44% ID/g, 2.03% ID/g, and 2.17% ID/g decreased with time, and less than 1% ID/g was measured after 24 hours in those organs. There was rapid tumor uptake, which reached 1.26% ID/g at 0.5 hours, the highest uptake at 8 hours. Yet, the [(131)I]iodo-17-AAG in the contralateral muscle was at a low level during the 48 hours. The tumor-contralateral muscle (T/CM) radioactivity ratio for [(131)I]iodo-17-AAG remained constant at all time points. [(131)I]iodo-17-AAG can be efficiently radiolabeled at high specific activity, purified by HPLC and stored with little radiolysis at this specific activities. [(131)I]iodo-17-AAG is a promising radiopharmaceutical in nuclear medicine, especially for tumor-targeted radionuclide brachytherapy.

  11. In vivo biological evaluation of 131I radiolabeled-paclitaxel glucuronide (131I-PAC-G)

    International Nuclear Information System (INIS)

    Aslan, O.; Biber Muftuler, F.Z.; Yurt Kilcar, A.; Ichedef, C.; Unak, P.

    2012-01-01

    Paclitaxel (PAC) is a natural occurring diterpene alkoloid originally isolated from the bark of Taxus Brevifolia. It is one of the most important antitumor agents for clinical treatment of ovarian, breast non-small cell lung and prostate cancers. It is known that these types of cancer cells have high β-glucuronidase enzyme which can catalyze the hydrolysis of glucuronides. This is why the synthesis compounds which undergo glucuronidation come into question in the imaging and therapy of these cancer cells. The aim of current study is conjugation of glucuronic acid (G) to the starting substance PAC, labeling with 131 I and to perform its in vivo biological evaluation. Glucuronic acid derived paclitaxel compound [paclitaxel-glucuronide (PAC-G)] was labeled with 131 I using iodogen method. According to thin layer radio chromatography (TLRC) method, the radiochemical yield of 131 I-PAC-G was 84.30 ± 7.40% (n=10). The biodistribution of 131 I-PAC-G in healthy female and male Wistar Albino rats has been investigated. Imaging studies on male Balb-C mice were performed by using the Kodak FX PRO in vivo Imaging System. The range of the breast/blood, breast/muscle; ovary/blood, ovary/muscle ratios is approximately between 1.29 and 11.34 in 240 min, and between 0.71 and 8.24 in 240 min for female rats. The prostate/blood and prostate/muscle ratio is between 1.94 and 6.95 in 30 min for male rats. All these experimental studies indicate that 131 I-PAC-G may potentially be used in breast, ovary and prostate tissues as an imaging agent. Also it is thought that 131 I-PAC-G bears a therapy potential because of the 131 I radionuclide and can be improved with further investigations. (orig.)

  12. Analysis of pelvic 131I uptake after 131I whole body scan in patients with thyroid cancer

    International Nuclear Information System (INIS)

    Kou Ying; Liu Jianzhong; Hao Xinzhong; Wu Lixiang; Lu Keyi; Yang Suyun; Shi Xiaoli; Hu Tingting

    2014-01-01

    Objective: To analyze and explore the possible mechanism for pelvic 131 I uptake after 131 I post treatment whole body scan (Rx-WBS)in patients with differentiated thyroid cancer. Methods: (1) Data were retrospectively reviewed from 168 female patients with differentiated thyroid cancer (everyone has a Rx-WBS). (2) 46 patients were accepted by analyzing the characteristics of Rx-WBS and combing with some inclusion criteria,and then followed up. Results: Among the 46 patients (46 positions accumulated 131 I) with significant pelvic 131 I uptake, 6 patients had two reasons leading to pelvic 131 I uptake, and 2 patients had no specific reason. Among the 50 reasons for pelvic 131 I uptake, 41 reasons related with uterus, 3 reasons related to rectum, 5 related to bladder and 1 related to ovarian chocolate cyst. Among the 41 reasons related to uterus, by combining the examinations of SPECT/CT, ultrasound, CT and the follow-up results, 18 were uterine leiomyomas, 9 were intrauterine devices, 2 were endometrial thickening, 3 were uterine cavity effusion, 7 were menstrual periods, 1 were uterine adenomyosis, 1 were gestational sac. Conclusions: (1) In the Rx-WBS of female, the significant pelvic 131 I uptake is generally caused by uterus, but not bladder. And it usually means gynecological disease, especially uterine leiomyomas when excluding physiological factors. (2) It is generally easy to differentiate bladder from rectum because they have different characteristic features of the pelvic 131 I uptake. (3) SPECT/CT plays a very important role in locating 131 I uptake in uterus. (authors)

  13. Biološki učincl radiongklida joda-131

    OpenAIRE

    Kašuba, Vilena

    1997-01-01

    U radu je prikazano djelovanje radioizotopa joda-131 na organizam, stanicu i na genetski materijal somatskih stanica. Uz akcidentalnu kontaminaciju jodom-131, njegova široka dijagnostička i terapijska primjena pridonose ukupnoj dozi zračenja. Bioioška raspodjeia ovog radiofarmaka u organizmu ovisi uz ostalo o načinu primjene i o kemijskom i fizikalno-kemijskom obliku radiofarmaka. Već nekoliko minuta nakon aplikacije jod-131 se prenoseći se putem krvi raspoređuje po organizmu. Doza zračenja n...

  14. Comparative study of 131I with 131I plus lithium carbonate in the treatment of Graves' hyperthyroidism

    International Nuclear Information System (INIS)

    Kang Yuguo; Kuang Anren; Guan Changtian

    2003-01-01

    Objective: To evaluate the effects of lithium carbonate on serum TSH, FT 3 , FT 4 and thyroid mass volume in patients with Graves' hyperthyroidism treated with 131 I. Methods: Thirty patients with newly diagnosed, untreated Graves' disease (GD) and nonsevere or absent Graves' ophthalmopathy, were randomly assigned to group 1 and group 2. The 1st group was treated with 131 I therapy only, the 2nd group with 131 I plus lithium carbonate. All subjects were evaluated for changes in serum TSH, FT 3 and FT 4 as well as thyroid mass volume at the 7, 14, 30 d after 131 I therapy. Differences between the two groups in thyroid mass volume, serum FT 4 , FT 3 , and TSH levels at each interval were evaluated by ANCOVA. Results: Serum FT 4 and FT 3 levels increased shortly after 131 I therapy only in group 1, and decreased in group 2. The differences of serum FT 3 and FT 4 levels between the two groups were significant. Conclusion: It is important for GD patients to accept lithium carbonate treatment and 131 I therapy simultaneously in order to decrease the serum FT 3 and FT 4 levels caused by 131 I therapy

  15. Leczenie schizofrenii elektrowstrząsami oraz lekami przeciwpsychotycznymi, łącznie z elektrowstrząsami

    Directory of Open Access Journals (Sweden)

    Emilia Kołodziej‑Kowalska

    2011-12-01

    Full Text Available Elektrowstrząsy (EW były stosowane w leczeniu schizofrenii od czasu ich wynalezienia w 1938 roku. Wprowadzenie efektywnej farmakoterapii schizofrenii oraz zaburzeń nastroju doprowadziło do znacznego spadku ich wykonywania w latach 60. i 70. XX wieku. Stopniowe wykazanie ograniczeń skuteczności i występowanie objawów niepożądanych le‑ ków przeciwpsychotycznych doprowadziło w kolejnych dekadach do powrotu zainteresowania elektrowstrząsami jako metodą leczenia lekoopornej schizofrenii. Niestety, wskazania do zastosowania EW w schizofrenii i ich miejsce w algoryt‑ mach leczniczych są niejasne, głównie w związku z brakiem odpowiedniej jakości badań klinicznych. Kontrowersje zwią‑ zane z oceną efektywności EW w leczeniu schizofrenii, zwłaszcza opornej na farmakoterapię, znalazły odzwierciedlenie w różnicach w rekomendacjach wydawanych przez różne towarzystwa naukowe. Analiza danych z literatury (nieliczne badania randomizowane i otwarte, głównie badania retrospektywne i opisy kazuistyczne wykazuje, że strategia polegająca na leczeniu skojarzonym lekami przeciwpsychotycznymi i elektrowstrząsami jest efektywniejsza od każdej z tych metod z osobna. Badania sugerują także, że połączenie EW i klozapiny jest raczej bezpieczne i skuteczne; doniesienia oceniające połączenie z nowymi LPP drugiej generacji są nieliczne. Identyfikowano różne czynniki predykcyjne poprawy po leczeniu skojarzonym EW i LPP. Częsta jest konkluzja, że elektrowstrząsy w połączeniu z lekami przeciwpsychotyczny‑ mi mogą być rozważane jako opcja terapeutyczna u pacjentów, u których farmakoterapia wykazuje ograniczoną skutecz‑ ność. Profil objawów ubocznych terapii skojarzonej nie różni się od samych zabiegów EW, jest ona bezpieczna i dobrze tolerowana.

  16. Thyroid cancer following 131I therapy for hyperthyroidism

    International Nuclear Information System (INIS)

    Watanabe, Iwao

    1980-01-01

    A women aged 37 who had thyroid cancer after 131 I therapy for hyperthyroidism was reported. She had received various conservative therapies and surgical treatments for hyperthyroidism for 10 years before 131 I therapy. Similar cases were picked out from many reports, and their clinical characteristics were discussed. The incidence of thyroid cancer after 131 I therapy, age and sex of patients, dosage of 131 I, histological changes after the irradiation of 131 I, sites of thyroid cancer, and the relationship between 131 I therapy and the occurrence time of thyroid cancer were also considered. (Tsunoda, M.)

  17. In vivo biological evaluation of {sup 131}I radiolabeled-paclitaxel glucuronide ({sup 131}I-PAC-G)

    Energy Technology Data Exchange (ETDEWEB)

    Aslan, O.; Biber Muftuler, F.Z.; Yurt Kilcar, A.; Ichedef, C.; Unak, P. [Ege Univ., Izmir (Turkey). Dept. of Nuclear Applications

    2012-07-01

    Paclitaxel (PAC) is a natural occurring diterpene alkoloid originally isolated from the bark of Taxus Brevifolia. It is one of the most important antitumor agents for clinical treatment of ovarian, breast non-small cell lung and prostate cancers. It is known that these types of cancer cells have high {beta}-glucuronidase enzyme which can catalyze the hydrolysis of glucuronides. This is why the synthesis compounds which undergo glucuronidation come into question in the imaging and therapy of these cancer cells. The aim of current study is conjugation of glucuronic acid (G) to the starting substance PAC, labeling with {sup 131}I and to perform its in vivo biological evaluation. Glucuronic acid derived paclitaxel compound [paclitaxel-glucuronide (PAC-G)] was labeled with {sup 131}I using iodogen method. According to thin layer radio chromatography (TLRC) method, the radiochemical yield of {sup 131}I-PAC-G was 84.30 {+-} 7.40% (n=10). The biodistribution of {sup 131}I-PAC-G in healthy female and male Wistar Albino rats has been investigated. Imaging studies on male Balb-C mice were performed by using the Kodak FX PRO in vivo Imaging System. The range of the breast/blood, breast/muscle; ovary/blood, ovary/muscle ratios is approximately between 1.29 and 11.34 in 240 min, and between 0.71 and 8.24 in 240 min for female rats. The prostate/blood and prostate/muscle ratio is between 1.94 and 6.95 in 30 min for male rats. All these experimental studies indicate that {sup 131}I-PAC-G may potentially be used in breast, ovary and prostate tissues as an imaging agent. Also it is thought that {sup 131}I-PAC-G bears a therapy potential because of the {sup 131}I radionuclide and can be improved with further investigations. (orig.)

  18. Toxicity of upfront {sup 131}I-metaiodobenzylguanidine ({sup 131}I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis

    Energy Technology Data Exchange (ETDEWEB)

    Bleeker, Gitta; Schoot, Reineke A.; Caron, Huib N.; Kraker, Jan de; Tytgat, Godelieve A. [Emma Children' s Hospital, Academic Medical Centre (AMC), Department of Paediatric Oncology, PO Box 22700, Amsterdam (Netherlands); Hoefnagel, Cees A. [National Cancer Institute (NKI-AvL), Department of Nuclear Medicine, Amsterdam (Netherlands); Eck, Berthe L. van [Academic Medical Centre (AMC), Department of Nuclear Medicine, Amsterdam (Netherlands)

    2013-10-15

    In the treatment of patients with high-risk neuroblastoma, different doses of {sup 131}I-metaiodobenzylguanidine ({sup 131}I-MIBG) are administered at different time points during treatment. Toxicity, mainly haematological (thrombocytopenia), from {sup 131}I-MIBG therapy is known to occur in extensively chemotherapy pretreated neuroblastoma patients. Up to now, acute toxicity from {sup 131}I-MIBG as initial treatment has never been studied in a large cohort. The aim of this retrospective study was to document acute toxicity related to upfront {sup 131}I-MIBG. All neuroblastoma patients (stages 1-4 and 4S) treated upfront with {sup 131}I-MIBG at the Emma Children's Hospital, Academic Medical Centre (1992 - 2008) were included in this retrospective analysis. The acute toxicity (during therapy) and short-term toxicity (1st month following therapy) of the first two {sup 131}I-MIBG therapies were studied. Of 66 patients (34 boys, 32 girls; median age 2.2 years, range 0.1 - 9.4 years), 49 had stage 4 disease, 5 stage 4S, 6 stage 3, 1 stage 2 and 5 stage 1. The median first dose was 441 MBq/kg (range 157 - 804 MBq/kg). The median second dose was 328 MBq/kg (range 113 - 727 MBq/kg). The most frequently observed symptoms were nausea and vomiting (21 %, maximum grade II). The main toxicity was grade IV haematological, occurring only in stage 4 patients, after the first and second {sup 131}I-MIBG therapies: anaemia (5 % and 4 %, respectively), leucocytopenia (3 % and 4 %) and thrombocytopenia (2 % and 4 %). No stem cell rescue was needed. The main acute toxicity observed was haematological followed by nausea and vomiting. One patient developed posterior reversible encephalopathy syndrome during {sup 131}I-MIBG therapy, possibly related to {sup 131}I-MIBG. We consider {sup 131}I-MIBG therapy to be a safe treatment modality. (orig.)

  19. Certolizumab pegol w leczeniu reumatoidalnego zapalenia stawów

    Directory of Open Access Journals (Sweden)

    Piotr Wiland

    2011-08-01

    Full Text Available Wostatnich latach wyprodukowano i oceniono w wielu badaniachlaboratoryjnych i klinicznych nowy lek hamujący funkcje biologiczneczynnika martwicy nowotworu (tumour necrosis factor – TNF –certolizumab pegol. Dzięki pegylacji (dołączeniu do fragmentuFab przeciwciała neutralizującego TNF cząsteczki glikolu polietylenowegozwiązek ten wykazuje nieco odmienne właściwościw porównaniu z innymi lekami blokującymi TNF. W artykule przedstawionopodobieństwa i różnice mechanizmów działania, farmakokinetyki,metabolizmu, skuteczności klinicznej, wpływu na progresjęradiologiczną i bezpieczeństwa stosowania certolizumabuw porównaniu z innymi lekami biologicznymi hamującymi funkcjebiologiczne TNF w leczeniu chorych na reumatoidalne zapaleniestawów (tab. I–III. Badania kliniczne wykazały bardzo szybkąodpowiedź kliniczną na zastosowany certolizumab (tab. II, ryc. 1.Dodatkowo można z dużym prawdopodobieństwem przewidziećdługoterminową skuteczność tego leku, co może mieć istotnywpływ na farmakoekonomikę leczenia.

  20. Recurrent thyrotoxicosis after I-131 induced hypothyroidism

    International Nuclear Information System (INIS)

    Liu, L.; Borowski, G.D.; Shtasel, P.; Rose, L.I.

    1984-01-01

    The first clinically and biochemically documented case of recurrent thyrotoxicosis after I-131 induced hypothyroidism in a patient with Graves' disease is reported. Two months after the administration of 9.2 mCi of I-131, the subject developed hypothyroidism. One month later, the patient became euthyroid. Then, nine months following ablation, the patient again developed thyrotoxicosis. A second dose of I-131 of 12.5 mCi was required to finally produce permanent hypothyroidism. This case illustrates the recurrence of hypothyroidism after what had seemed to have been adequate I-131 radiation

  1. Behavior of Na131I and meta(131I) iodobenzylguanidine (MIBG) in municipal sewerage.

    Science.gov (United States)

    Fenner, F D; Martin, J E

    1997-08-01

    Behavior of 131I activity in primary sludge at the Ann Arbor, Michigan, Municipal Waste Water Treatment Plant was studied in relation to known radioiodine therapy events at the University of Michigan Hospital complex. The principal compounds administered are Na131I, which has widespread use, and meta (131I) iodobenzylguanidine (MIBG), which is a compound unique to the University of Michigan, although labeled antibodies and other forms are also used in therapy and research. The objectives of the study were to determine the environmental fate of such discharges and to determine radiation exposures to workers and the public when sludges are incinerated. Approximately 17% of the MIBG activity administered in a therapy was found in the primary sludge, whereas only 1.1% of the Na131I was in sludge. When land applied, the short half life of 131I in the sludge presents few radiological health concerns; however, incineration, which is done in winter months, is assumed to release organically bound 131I to the atmosphere. Radiation doses due to incineration of sludge containing measured concentrations were calculated for a maximally exposed worker to be 1.7 microSv (0.17 mrem) of which 0.48 microSv (0.048 mrem) was due to a 2-d upset condition. For a more typically exposed worker, and a member of the public, the committed effective dose equivalents were 1.2 microSv (0.12 mrem) and 0.06 microSv (0.006 mrem), respectively, for a 22-wk incineration period with release of all radioiodine in the sludge. Transport time to the treatment plant for radioiodine was found to be much longer than that of normal sewage, possibly due to organic material in sewer lines that absorb iodine. The residence time of radioiodine in the sewer also appears to be longer than expected; whether other radioactive materials are held up the same way is not known but chemical form is surely a factor.

  2. Determination of inorganic radioiodine in 131I- Rose Bengal and 131I- bromosulphthalein

    International Nuclear Information System (INIS)

    Toledo e Souza, I.T. de; Pereira, N.P.S. de; Silva, C.P.G. da.

    1985-01-01

    A rapid miniaturized chromatographic system was developed for fast determination of the proportion of inorganic radioactive iodide from radiopharmaceuticals 131 I-Rose Bengal and 131 I-Bromosulphthalein. Using 33% W/V aqueous solution of ammonium sulphate pH 7,5 as a solvent Rf values for radiopharmaceuticals, iodide, iodate to Rf 0,0 0,5 0,9 respectively. The chromatographic quality control procedures are easy to use, rapid and can be incorporated in a routine quality control program. (Author) [pt

  3. Diagnosis of pheochromocytoma using (123I)-compared with (131I)-metaiodobenzylguanidine scintigraphy

    International Nuclear Information System (INIS)

    Furuta, Nozomu; Kiyota, Hiroshi; Yoshigoe, Fukuo; Hasegawa, Norio; Ohishi, Yukihiko

    1999-01-01

    Patient with pheochromocytoma (PCT) cannot be cured without operation, therefore, preoperative determination of the localization of PCT should be performed accurately. ( 131 I)-Metaiodobenzylguanidine (MIBG) scintigraphy is a gold standard for the diagnosis of PCT. However, ( 123 I)-MIBG is also found to accumulate in PCT. In order to clarify the usefulness of ( 123 I)-MIBG scintigraphy for the local detection of PCT, we compared the distribution of ( 123 I)- and ( 131 I)-MIBG in patients with or without PCT. ( 131 I)- and ( 123 I)-MIBG scintigraphy was performed in 29 and 16 patients, respectively. In the former group, 14 patients had PCT, 12 had hypertension without any adrenal disorder and three had other diseases. In the latter group, eight patients had PCT, two had hypertension without any adrenal disorder and six had other diseases. The sensitivity, specificity and accuracy of ( 123 I)- with ( 131 I)-MIBG scintigraphy were compared. The sensitivity of ( 131 I)- and ( 123 I)-MIBG scintigraphy was 85.7 and 90%, respectively. The specificity of each test was 100%. The accuracy of ( 131 I)- and ( 123 I)-MIBG scintigraphy was 93.1 and 95%, respectively. The quality of images obtained using ( 123 I)-MIBG was better than with ( 131 I)-MIBG, because ( 123 I)-MIBG generated a higher dose of γ-rays with a higher specificity than ( 131 I)-MIBG. In addition, normal adrenal grands were visualized in 50% of patients tested with ( 123 I)-MIBG scintigraphy. These results indicate that ( 123 I)-MIBG scintigraphy is a valuable tool for the local detection of PCT, as is ( 131 I)-MIBG scintigraphy. Furthermore, it is possible that ( 123 I)-MIBG can be used as an alternative to ( 131 I)-MIBG for the detection of PCT. Our study was not a prospective study and the background of the patients was not matched. Further prospective studies are needed in order to determine the efficacy of ( 123 I)-MIBG scintigraphy for the diagnosis of PCT. (author)

  4. Zmiany czynności kory ruchowej mózgu po leczeniu botuliną u pacjentów ze stwardnieniem rozsianym i spazmem kończyn dolnych

    Directory of Open Access Journals (Sweden)

    Pavel Hok

    2011-12-01

    Full Text Available Miejscowe skurcze toniczne to powszechnie spotykany objaw stwardnienia rozsianego (łac. sclerosis multiplex, SM. Do ich zwalczania coraz częściej stosowany jest zastrzyk domięśniowy botuliny typu A. Do analizy statystycznej zaakceptowaliśmy 4 z 10 badanych pacjentów z SM i spastycznością kończyn dolnych oraz 5 zdrowych wolontariuszy. Pacjenci zostali poddani badaniu fMRI trzykrotnie: w tygodniu przed zastrzykiem botuliny A, a następnie w 4. i 12. tygodniu po iniekcji. Podczas badań fMRI probanci wykonywali zginanie i prostowanie stawu kolanowego według planu blokowego, przy czym faza czynna zamieniała się z fazą spoczynku w 15-sekundowych odstępach. Obraz przeciętnej aktywacji pacjentów podczas pierwszej sesji wskazywał, w porównaniu z grupą kontrolną, na istotny wzrost aktywacji obustronnej kory czuciowo-ruchowej płatu czołowego i ciemieniowego. Podczas drugiej sesji w 4. tygodniu aktywacja zmalała do tego stopnia, że statystycznie nie różniła się od zdrowej kontroli. Z kolei w obrazach trzeciej sesji po 12 tygodniach odnotowano w związku z wygaśnięciem efektu botuliny A ponowny wzrost aktywacji niemal do objętości pierwotnej. Wnioski: Stwierdzamy, że aktywacja kory ruchowej odzwierciedla zmiany w obwodowym układzie nerwowym zachodzące podczas leczenia za pomocą botuliny A, w czym prawdopodobnie pośredniczą zmiany w aferentacji. Jest to nowe odkrycie, aczkolwiek nie wykracza poza stwierdzenia podobnych badań przeprowadzonych innymi metodami.

  5. Malign pheochromocytoma: importance of the scintigraphic follow-up with metaiodobenzulguanidine 131I (MIBG-131I)

    International Nuclear Information System (INIS)

    Kato, M.; Velhote, V.V.; Souto, F.J.P.; Long, Y.J.; Costa, P.L.A.

    1989-01-01

    The authors report a case of pheochromocytoma investigated with metaiodobenzylguanidine labeled with 131 I (MIBG- 131 I). The methodology identify primitive lesion, its recurrence and metastasis. The authors mention the advantage of the technique due to the high specificity, sensitivity and because it is harmless, offering optimal information about the morphology and functional nature, concerning diagnosis and follow-up of the disease. (author) [pt

  6. Effective Half-life of I-131 in Patients with Differentiated Thyroid Cancer Treated by Radioactive I-131

    Energy Technology Data Exchange (ETDEWEB)

    Park, Seok Gun [Dankook University, Cheonan (Korea, Republic of)

    2008-12-15

    Effective half life of I-131 (T{sub eff}) in patients with differentiated thyroid cancer treated by I-131 is must-know value for dose calculation and determination of release time from isolation room. There has been no report about T{sub eff} in Koreans. Thus, author tried to measure dose rate without radiation exposure to faculty members and calculated T{sub eff}. Probe of radiation survey meter was fixed at the wall of isolation room, and body of survey meter was placed outside the room. With this simple arrangement, author could measure radiation frequently without radiation exposure to faculty members in 68 patient (F=55, M=13, age=47{+-}13.7) treated by I-131 (3.7{approx}7.4 GBq) for differentiated thyroid cancer from Jan 2006 to Dec 2006. From this data, T{sub eff}, 48 hr retention rate, and the time necessary to whole body retention of I-131 become less than 1.1 GBq were calculated. Serum creatinine levels were measured before and after thyroid hormone withdrawal. T{sub eff} was 15.4{+-}4.3 hr (9.4{approx}32.5 hr). There was a loose correlation between T{sub eff} and serum creatinine concentration (r=0.45). 48hr retention was 4.9{+-}4.2% (1{approx}23%). Time necessary to whole body retention of I-131 become less than 1.1 GBq was calculated as 47.1{+-}13.2 hr for 9.25 GBq, 42.1{+-}11.9 hr for 7.4 GBq, 35.7{+-}10.0 hr for 5.55 GBq, and 26.7{+-}7.5 hr for 3.7 GBq dose of I-131. Author successfully measured radiation dose rates in isolated patients treated by high dose of I-131 without radiation exposure to the faculty members with simple arrangement of survey meter probe. Using those data, T{sub eff} and some other indices were calculated.

  7. 131I therapy of Graves' disease using lithium

    International Nuclear Information System (INIS)

    Sato, Kenshi

    1983-01-01

    Lithium is known to cause goiter and hypothyroidism. In the mechanism of goitrogenesis, there is general agreement that lithium inhibits the release of the thyroid hormones from the thyroid gland without significantly impairing other thyroid functions. The present study was undertaken, therefore, to investigate the usefulness of lithium in the radioiodine treatment of Graves' disease. Nine patients with Graves' disease who were all, except one, previously treated with antithyroid drugs were studied. 600 mg of lithium carbonate were administered daily to investigate the effects on thyroidal 131 I uptake, disappearance rate of 131 I from the prelabeled thyroid and the serum concentrations of thyroid hormones. Lithium showed no significant effect on the thyroidal 131 I uptake when the 24 hour thyroidal 131 I uptakes were determined both before and during lithium treatment in the five cases. On the other hand, lithium clearly prolonged the mean value of effective half-lives of 131 I to approximately 8 days vs. 5.1 days before lithium treatment (p 4 and T 3 levels significantly decreased during lithium treatment, from 21.3 to 12.4μg/dl (n=9, p 131 I for the Graves' disease can be reduced by using lithium, the radiation exposure to the total body is decreased. Moreover, it is possible to perform the 131 I therapy while improving the thyrotoxicosis with lithium. Finally, it is concluded that lithium is a very useful drug to be combined with the 131 I therapy of Graves' disease. (author)

  8. Hypothyroidism following 131I therapy for hyperthyroidism

    International Nuclear Information System (INIS)

    Kubo, Atsushi; Kondo, Makoto; Kinoshita, Fumio; Maekawa, Akira; Okamoto, Jiro.

    1977-01-01

    Of 890 patients who received 131 I therapy for hyperthyroidism, the results of therapy were examined on 584 who could be followed up. Of these 502 (86%), were sured including 3 patients who had been completely healed after recurrence, 9 patients are still under medical treatment, and 10 died. The incidence of hypothyroidism following 131 I therapy was 1.6% after 1 year, 2.3% after 2 years, 4.7% after 5 years, 15.0% after 10-12 years, 22.1% after 13-15 years and 27.5% after 16-20 years. The incidence increased constantly with the passage of time. Factors influencing the response to treatment have been investigated. As a consequence, the number of rads delivered to the thyroid gland, the gland size, and previous surgery correlated with the incidence of hypothyroidism. The number of doses of 131 I, uptake and half-life of 131 I in the thyroid, previous antithyroid medication, time between the onset of hyperthyroid symptoms and 131 I therapy, and the age or sex of the patients appeared unrelated. The times taken to become euthyroid following a single dose of 131 I were 5.6 months with 2000-4000 rads, 4.4 months with 4001-7000 rads, 4.2 months with 7001-10000 rads and 3.5 months with more than 10001 rads. The time was prolonged with decrease of rads delivered to the thyroid gland. It was found that the patients who passed through a transient hypothyroid phase in the period of three to four months after administration of 131 I had a high incidence of late permanent hypothyroidism. (Evans, J.)

  9. Kinesio taping in conservative treatment of mild-to-moderate cases of carpal tunnel syndrome = Kinesio taping w leczeniu zachowawczym łagodnego i umiarkowanego przebiegu zespołu cieśni nadgarstka

    OpenAIRE

    Kocjan, Janusz

    2016-01-01

    Kocjan Janusz. Kinesio taping in conservative treatment of mild-to-moderate cases of carpal tunnel syndrome = Kinesio taping w leczeniu zachowawczym łagodnego i umiarkowanego przebiegu zespołu cieśni nadgarstka. Journal of Education, Health and Sport. 2016;6(9):604-609. eISSN 2391-8306. DOI http://dx.doi.org/10.5281/zenodo.155060 http://ojs.ukw.edu.pl/index.php/johs/article/view/3886 The journal has had 7 points in Ministry of Science and Higher Education param...

  10. Breast cancer following 131I therapy for hyperthyroidism

    International Nuclear Information System (INIS)

    Hoffman, D.A.; McConahey, W.M.

    1983-01-01

    A retrospective cohort study of women treated for hyperthyroidism at the Mayo Clinic between 1946 and 1964 was conducted to determine if 1,005 women treated with ( 131 I) were at increased risk of breast cancer compared with 2,141 women traced, and a response (death certificate or questionnaire) was received for 99% of the traced women. The average duration of follow-up was 15 years for the 131 I-treated women and 21 years for women treated surgically. No increased risk of breast cancer was observed in the 131 I-treated women (adjusted relative risk . 0.8). No patterns were found of increased breast cancer risk by age at first treatment, by time since treatment, or by total exposure to 131 I. Failure to detect an increased risk of breast cancer in the 131 I-treated women was attributed to the moderately low doses from 131 I therapy and the relatively small number of exposed women. The study also failed to find any increased risk of breast cancer associated with hyperthyroidism

  11. Radioactive Iodine (I-131) Therapy for Hyperthyroidism

    Science.gov (United States)

    ... Physician Resources Professions Site Index A-Z Radioactive Iodine (I-131) Therapy Radioiodine therapy is a nuclear ... thyroid cancer. When a small dose of radioactive iodine I-131 (an isotope of iodine that emits ...

  12. Local delivery of 131I-MIBG to treat peritoneal neuroblastoma

    International Nuclear Information System (INIS)

    Kinuya, Seigo; Li, Xiao-Feng; Yokoyama, Kunihiko; Michigishi, Takatoshi; Tonami, Norihisa; Mori, Hirofumi; Shiba, Kazuhiro; Watanabe, Naoto; Shuke, Noriyuki; Bunko, Hisashi

    2003-01-01

    Internal radiotherapy involving systemic administration of iodine-131 metaiodobenzylguanidine ( 131 I-MIBG) in neural crest tumours such as neuroblastoma has shown considerable success. Although peritoneal seeding of neuroblastoma occurs less often than metastases to organs such as the liver, no effective treatments exist in this clinical setting. Previous reports have demonstrated the effectiveness of peritoneal application of chemotherapeutic drugs or radiolabelled monoclonal antibodies in several kinds of carcinomas. Local delivery of 131 I-MIBG should produce more favourable dosimetry in comparison with its systemic administration in the treatment of peritoneal neuroblastoma. In the current investigation, a peritoneal model of neuroblastoma was established in Balb/c nu/nu mice by i.p. injection of SK-N-SH neuroblastoma cells. Two weeks after cell inoculation, comparative biodistribution studies were performed following i.v. or i.p. administration of 131 I-MIBG. Mice were treated with 55.5 MBq of 131 I-MIBG administered either i.v. or i.p. at 2 weeks. Intraperitoneal injection of 131 I-MIBG produced significantly higher tumour accumulation than did i.v. injection (P 131 I-MIBG failed to improve the survival of mice; mean survival of untreated mice and mice treated with i.v. administration of 131 I-MIBG was 59.3±3.9 days and 60.6±2.8 days, respectively. On the other hand, radiotherapy delivered via i.p. administration of 131 I-MIBG prolonged survival of mice to 94.7±17.5 days (P 131 I-MIBG therapy). Radiation doses absorbed by tumours at 55.5 MBq of 131 I-MIBG were estimated to be 4,140 cGy with i.p. injection and 450 cGy with i.v. injection. These results indicate the benefits of locoregional delivery of 131 I-MIBG in the treatment of peritoneal neuroblastoma. (orig.)

  13. Standardization of 131I therapy for Graves disease

    International Nuclear Information System (INIS)

    Tang Jianlin; Li Yuying; Gao Liuyan; Tang Xiuping; Hu Hongyong

    2011-01-01

    Objective: To establish the normative and standard measures, to ensure medical safety and quality of care of the patients with Graves disease treated by 131 I therapy. Methods: Formulating and strictly implementing the medical organizational and technical measures of 131 I therapy for Graves disease and regular follow-up. Results: Receiving 131 I treatment of 104 patients, follow-up 6-36 months, no adverse events, the cure rate of 59.6%, the efficient rate is 99.9%. Conclusion: It is important guarantee for the medical quality and safety to standardize the 131 I therapy of Graves disease. (authors)

  14. A Comparative Study of 131I-Hippuran Renogram, 131I-Hippuran Urinary Excretion Test and Intravenous Pyelogram in Obstructive Uropathy due to Cancerous Invasion

    International Nuclear Information System (INIS)

    Park, Kee Bok; Rhee, Chong Heon; Hong, Chang Gi; Park, Soo Seong; Koh, Chang Soon

    1968-01-01

    A comparative study of 131 I-hippuran renogram, 131 I-hippuran excretion test and intravenous pyelogram were performed in 61 cases of gynecological cancer. The following were the results: 1) Among 40 cases of cervix cancer showing normal excretory urography 7 cases (17.5%) were found to have unilateral or bilateral delayed excretory pattern on 131 I-hippuran renogram and on the contrary only 2 cases (5.7%) showed a mild caliectatic change on excretory urography among 35 cases of gynecological cancer showing normal pattern of 131 I-hippuran renogram. 2) In the group showing unilateral of bilateral delayed excretory pattern of 131 I-hippuran renogram there was a reduction of 131 I-hippuran excretion in the first 20 minutes, but there was no significant difference of 131 I-hippuran excretion in 60 minutes compared with that of normal renogram group. 3) In the group showing unilateral non-functioning pattern of 131 I-hippuran renogram in one side and normal pattern in the other side there was found to be no difference in 131 I-hippuran excretion amount compared with that of normal renogram group. 4) It was evident from these experimental study that 131 I-hippuran renogram was considered as a good examination method for the evaluation of obstructive uropathy, and if one side kidney was intact it might compensate for the other diseased kidney so far as to renal excretory function. It was also shown that the more severe the cancerous spread in the pelvic wall the more changes on 131 I-hippuran renogram.

  15. Hydrochlorothiazide-induced 131I excretion facilitated by salt and water

    International Nuclear Information System (INIS)

    Beyer, K.H. Jr.; Fehr, D.M.; Gelarden, R.T.; White, W.J.; Lang, C.M.; Vesell, E.S.

    1981-01-01

    Salt intake is restricted under clinical conditions for which thiazide diuretics are customarily used. Dietary iodide intake offsets any effect of thiazide on iodide loss. However, our correlation coefficients relating Na+ to Cl- to I- excretion indicate that as thiazide administration or sodium chloride intake increases renal Na+ and Cl- excretion, I- reabsorption by the nephron coordinately decreases. Increased sodium chloride and water intake by the dog doubled I-excretion rates. Hydrochlorothiazide increased the sodium chloride and water enhanced I-excretion rate as much as eight-fold. Without added NaCl, hydrochlorothiazide increased the excretion rate of 131I by three- to eightfold, acutely. Within five to seven days after 131I oral administration, hydrochlorothiazide (1 or 2 mg/kg twice daily) doubled the rate of 131I disappearance from plasma, reduced the fecal output of 131I, and increased its rate of renal excretion. When hydrochlorothiazide was administered, as much 131I was excreted in the first 24 hours as occurred in 48 hours when sodium chloride and water were given without hydrochlorothiazide. Thiazide administration in customary clinical dosage twice a day with substantial sodium chloride and water for the first two days after exposure to 131I, should therefore facilitate the safe excretion of 131I. This accelerated removal of 131I might be enhanced even more if thyroid uptake of 131I is blocked by administration of potassium iodide, as judged by the greater 131I recovery from thyroidectomized dogs

  16. Sodium Iodide-131 (Na131I) AS Gelatin Capsules At TNRC-In Libya

    International Nuclear Information System (INIS)

    Sherief, M. F.; Abudeeb, F. N.; Abudaia, J. A.; Elghanoudy, Y. A.

    2004-01-01

    In this contribution, the production of a capsulated Na 131 I radiopharmaceutical, for treatment of variety of hyperthyroidism diseases, at Tajoura Nuclear Research Center in Tripoli-Libya is described. The process requires the application of a very small volume of iodine-131 (not more than 25μ l in some cases) with radioactivities reaching some 37 GBq per capsule. The application of such volume is necessary to prevent damage to gelatin material. Loading a volume of 100 μ l of radioactive Na 131 I solution containing 37 GBq. radioactivity within a capsule filled with anhydrous sodium hydrogen phosphate as an adsorption material for Na 131 I solution brings such solution into a direct interaction with the gelatin material. This is assumed to have an inadequate effect in therapy. To overcome this problem, the work team has introduced some substantial alterations on the irradiation procedure and the process of the pre-irradiation treatment of the target. As a consequence, that has successfully culminated in production of Na 131 I capsules with proper perspective (e.g. radioactive yield of 74 GBq from 37 GBq previously and radioactive concentration of 37 GBq/ml). (Authors)

  17. [sup 131]I-metaiodobenzylguanidine therapy for malignant pheochromocytoma

    Energy Technology Data Exchange (ETDEWEB)

    Sakahara, Harumi; Saga, Tsuneo; Hosono, Makoto; Kobayashi, Hisataka; Konishi, Junji (Kyoto Univ. (Japan). Faculty of Medicine); Endo, Keigo

    1994-05-01

    [sup 131]I-metaiodobenzylguanidine (MIBG) therapy was given to five patients with malignant pheochromocytoma. The patients received 1-3 doses of 3.33-4.625 GBq (total dose: 3.7 to 10.73 GBq). Partial tumor regression was observed in two patients, the tumor was unchanged in two patients, and slow progression was noted in one patient. Marked improvement in clinical symptoms was achieved in four patients. The other patients had no symptoms before [sup 131]I-MIBG treatment, but the serum epinephrine and dopamine decreased. There were no severe untoward responses in four patients. However, one patient developed transient but severe orthostatic hypotension, hypertension, and hyperglycemia from 1 week to 1 month after [sup 131]I-MIBG administration. Although complete remission was not obtained, all the patients achieved some benefit from [sup 131]I-MIBG therapy. Thus, [sup 131]I-MIBG appears to be useful for the palliation of malignant pheochromocytoma. (author).

  18. Visualization of adrenocortical carcinoma with 131I-Adosterol

    International Nuclear Information System (INIS)

    Maruoka, Shin; Nakamura, Mamoru

    1987-01-01

    There are very few literatures on successful visualization of adrenocortical carcinoma by means of 131 I-iodocholesterol scintigraphy, although many reports have referred to utility of 131 I-iodocholesterol scintigraphy for adrenal disorders. Since 1976, we have experienced 4 cases of adrenocortical carcinoma which were delineated by 131 I-6β-iodomethyl-19-norcholesterol ( 131 I-Adosterol). Three of 4 cases were adrenocortical carcinoma with Cushing's syndrome, and one was adrenocortical carcinoma with adrenogenital syndrome. In 3 cases of cortisol secreting adrenocortical carcinoma, uptake in the tumor and lack of uptake in the contralateral adrenal gland were seen. Faint to moderate uptakes were observed in the 2 cases, but another one showed as high uptake as seen in adenoma. Patient with androgen secreting adrenocortical carcinoma had increased uptake in the tumor and showed faint uptake in the contralateral adrenal gland. Intensity of 131 I-Adosterol uptake in adrenocortical carcinoma seems to depend on the extent of tumor necrosis, cell differentiation and function. (author)

  19. Stability of /sup 131/I--thyroxine and of /sup 131/I-tri-iodothyronine: the influence of radiolytic disintegration on certain diagnostic tests

    Energy Technology Data Exchange (ETDEWEB)

    Reviczky, A.L.; Szanto, L.

    1974-01-01

    The blood-protein fractions responsible for the transport of thyroid hormones (TBG, TBPA, TBA) were assayed for their thyroxine-binding capacity in the serum of the same control subject over a one-year period, by a procedure based on the isotope-dilution technique. In the dilutions of /sup 131/I--T/sub 4/ (Amersham RCC) required for the procedure, the ratio /sup 131/I--T/sub 4/:/sup 131/I--T/sub 3/ was measured in every case. Parallel with the accumulation of /sup 131/I--T/sub 3/ resulting from deiodination of /sup 131/I--T/sub 4/, the binding capacity of the individual fractions was found to have shifted from TBG to TBPA. The fact that, in contrast to the principle of the isotope-dilution technique, the labelled substance and the non-radioactive T/sub 4/ were partly different, suggests that the measurements of radioactivity do not reflect the true binding conditions of T/sub 4/. Successive batches of /sup 131/I--T/sub 3/ were examined in the same manner, and the values of the Hamolsky test were determined in the same serum. The figures displayed little variations and /sup 131/I--T/sub 3/ was also found significantly more stable than /sup 131/I--T/sub 4/. Thus, the Hamolsky test was found to represent a fairly reliable indicator of thyroid function, in contrast to measurement of the T/sub 4/-binding capacity of the blood protein fractions by the isotope-dilution technique, the results of which are uncertain and therefore inconclusive in both clinical and therapeutic respects. It is suggested that the /sup 131/I--T/sub 4/ serving for the assays should be supplied as a substance and diluted before use, but not later than a few days after preparation. The advantages of doublet tagging are pointed out.

  20. Comparison of thallium-201, Tc-99m MIBI and I-131 scan in the follow-up assessment after I-131 ablative therapy in differentiated thyroid cancer

    International Nuclear Information System (INIS)

    Kwon, Jae Sung; Lee, Sung Keun; Kim, Doe Min; Park, Sae Jong; Jang, Kyong Sun; Kim, Eun Sil; Kim, Chong Soon

    1999-01-01

    We conducted a comparative study to evaluate the diagnostic values of Tl-201, Tc-99m MIBI and I-131 scans in the follow-up assessment after ablative I-131 therapy in differentiated thyroid cancer. The study population consisted of 20 patients who underwent surgical removal of thyroid cancer and ablative radioactive iodine therapy, and followed by one or more times of I-131 retreatment (33 cases). In all patients, Tl-201, Tc-99m MIBI, diagnostic and therapeutic I-131 scans were performed and the results were analyzed retrospectively. Also serum thyroglobulin levels were measured in all patients. The final diagnosis of recurrent or metastatic thyroid cancer was determined by clinical, biochemical, radiologic and/or biopsy findings. Positive rates (PR) of Tc-99m MIBI, Tl-201, diagnostic and therapeutic I-131 scans in detecting malignant thyroid tissue lesions were 70% (19/27), 54% (15/28), 35% (17/48) and 63% (30/48), respectively. The PR in the group of 20 cases (28 lesions) who underwent concomitant Tl-201 and I-131 scans were in the order of therapeutic 131 scan 71%, Tl-201 scan 54% and diagnostic I-131 scan 36%. There was no statistically significant difference between Tl-201 and diagnostic I-131 scans (p>0.05). In the group of 20 cases (27 lesions) who underwent concomitant Tc-99m MIBI and I-131 scans, the PR were in the order of Tc-99m MIBI scan 70%, I-131 therapeutic scan 52% and I-131 diagnostic scan 33%. The PR of Tc-99m MIBI was significantly higher than that of diagnostic I-131 scan (p<0.05). Tc-99m MIBI scan is superior to diagnostic I-131 scan in detecting recurrent or metastatic thyroid cancer following ablation therapy in patients with differentiated thyroid cancer. Tl-201 scan did not showed significantly higher positive rate than diagnostic I-131 scan. Instead of diagnostic I-131 scan before the I-131 retreatment, Tc-99m MIBI scan without discontinuing thyroid hormone replacement would be a prudent and effective approach in the management of these

  1. Management of thyroid carcinoma with radioactive 131I

    International Nuclear Information System (INIS)

    Paryani, Shyam B.; Chobe, Rashmi J.; Scott, Walter; Wells, John; Johnson, Douglas; Kuruvilla, Anand; Schoeppel, Sonja; Deshmukh, Abhijit; Miller, Robert; Dajani, Lorraine; Montgomery, Charles Ted; Puestow, Eric; Purcell, John; Roura, Miguel; Sutton, David; Mallett, Ruth; Peer, Jan

    1996-01-01

    Purpose: To evaluate the role of radioactive 131 I in the management of patients with well differentiated carcinoma of the thyroid. Methods and Materials: Between 1965 and 1995, a total of 117 patients with well-differentiated carcinoma of the thyroid underwent either lobectomy or thyroidectomy followed by 100-150 mCi of 131 I. Results: With a median follow-up of 8 years, only four patients (3%) developed a recurrence of their disease. The 5-year actuarial survival was 97% with a 10-year survival of 91%. There were no severe side effects noted after 131 I therapy. Conclusions: Radioactive 131 I is a safe and effective procedure for the majority of patients with well-differentiated thyroid carcinoma. We currently recommend that all patients undergo a subtotal or total thyroidectomy followed by 131 I thyroid scanning approximately 4 weeks after surgery. If the thyroid scan shows no residual uptake and all disease is confined to the thyroid, we recommend following patients with annual thyroid scans and serum thyroglobulin levels. If there is any residual uptake detected in the neck or if the tumor extends beyond the thyroid, we recommend routine thyroid ablation of 100-150 mCi of radioactive 131 I

  2. Renal 131I-hippuran extraction in man

    DEFF Research Database (Denmark)

    Hutchings, M; Hesse, B; Grønvall, J

    2002-01-01

    This study examined the 131I-hippuran extraction fraction during baseline renal blood flow rates and at high flow rates induced by dopamine.......This study examined the 131I-hippuran extraction fraction during baseline renal blood flow rates and at high flow rates induced by dopamine....

  3. 131I-BSP liver function test by BSP tolerance

    International Nuclear Information System (INIS)

    Kanda, Koichi

    1974-01-01

    131 I-BSP liver function test after BSP intravenous tolerance was discussed, assuming that the reason why measurements of 131 I-BSP retention rate at 30 minutes and 131 I-BSP disappearance rate in blood showed respectable overlapping between normal group and group with slight liver disorders as compared with BSP test and the reason why differential diagnosis was difficult were due to underestimate of tolerance volume of 131 I-BSP. 131 I-BSP was observed with time as to 70 persons with normal liver function and 257 cases of liver diseases, using 5, 3 and 2 mg of non-radioactive BSP tolerance volume per kilogram of body weight. 131 I-BSP retention rate at 30 minutes and 131 I-BSP disappearance rate in blood are possible to separate overlapping over control in each measurement value at 3-5 mg/kg of tolerance, and in comparison of 3 mg and 5 mg, the latter showed a little excellent result. So, it was decided that tolerance of 3 mg/kg was a proper dose, considering tolerance to liver cells. 131 I-BSP retention rate at 30 minutes was a little excellent in accuracy and disappearance rate in blood after BSP tolerance is simple and profitable for practical use because collection of blood was only one time and measurement could be made with whole blood. As mentioned above, this method is seemed to be useful to practice of liver function test. (Kanao, N.)

  4. Effficacy of 131I therapy hyperthyroidism in adolescent

    International Nuclear Information System (INIS)

    Qin Lan; Wang Junqi; Feng Xuemin; Yin Le

    2004-01-01

    To investigate the possibility of 131 I therapy hyperthyroidism in adolescent, 117 adolescent patients treated with 131 I are analyzed retrospectively. In the first treatment of 131 I, 76 patients gain with euthyroidism (65.0%), 28 patients have remission (23.9%), 13 patients have hypothyroidism (11.0%), the total efficacy is 88.9%. The administered dose to the patients with younger than 14 years is significantly lower than the patients aged from 15 years to 18 years. There is no significantly difference in cure rate or incidence of hypothyroidism between the two groups. The second treatment may improve the cure rate and not exert any significant impact to the incidence of hypothyroidism. Therefore, 131 I treatment hyperthyroidism in younger is efficacious, inexpensive and safe. The dosages given to patients are different between age groups. (authors)

  5. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study

    International Nuclear Information System (INIS)

    Qiu, Zhong-Ling; Shen, Chen-Tian; Song, Hong-Jun; Wei, Wei-Jun; Luo, Quan-Yong

    2015-01-01

    Introduction: Loss of the ability to concentrate 131 I is one of the important causes of radioiodine-refractory disease in papillary thyroid carcinoma (PTC). Recent advantages of serum microRNAs (miRNAs) open a new realm of possibilities for noninvasive diagnosis and prognosis of many cancers. The aim of the current study was to identify differential expression profiling of circulation miRNAs in PTC patients with non- 131 I and 131 I-avid lungs metastases. Methods: The expressions of miRNAs were examined using miRNA microarray chip. The most significantly changed miRNAs from microarray were verified by using qRT-PCR. The potential miRNAs regulating target genes and their preliminary biological functions were forecasted by Bioinformatic analysis. Results: Compared to 131 I-avid lung metastases, 13 kinds of significantly differential serum miRNAs including 5 upregulated miRNAs (miR-1249, miR-106a, miR-503, miR-34c-5p, miR-1281) and 8 downregulated miRNAs (miR-1915, miR-2861, miR-3196, miR-500, miR-572, miR-33b, miR-554, miR-18a) in PTC patients with non- 131 I-avid lung metastases were identified. Bioinformatic analysis demonstrated that miR-106a was the core miRNA regulating 193 genes in the network. The results of validation confirmed the up-regulation of miR-106a in non- 131 I-avid lungs metastatic PTC patients. Conclusion: Differentially expressed serum miRNA profiles between PTC patients with non- 131 I and 131 I-avid lungs metastases were analyzed. These findings in our present study could represent new clues for the diagnostic and therapeutic strategy in PTC patients with non- 131 I-avid metastatic disease

  6. Analysis of 131I therapy in 71 patients with hyperthyroidism

    International Nuclear Information System (INIS)

    Wang Ping; Chen Zequan; Wang Yuanzhi; Ye Shiqing

    2001-01-01

    Objective: To evaluate the clinical significance of iodine-131 treatment in patients with hyperthyroidism. Methods: The dose of 131 I was determined according to thyroid absorption of 131 I at 24 hrs post administration and thyroid weight estimated in ECT examination. Results: One dose cure rate of 131 I treatment was 96% (68/71). Hypothyroidism occurred in 3 of 71 patients (4%) in one year after administration. No other serious complication was observed. Conclusion: The therapeutic effect of 131 I in treating hyperthyroidism was quite encouraging. The administration regime was also simple

  7. Radioiodine 131I metabolism in human

    International Nuclear Information System (INIS)

    Mori, Toru

    1976-01-01

    Metabolic fate of orally administered 131 I in human was studied. Chronological observations of whole body radioactivity distribution and thyroid 131 I uptake curve revealed that 131 I metabolism was greatly affected by the amount of dietary iodine intake. Under the high iodine intake exceeding 1 mg per day, uptake curve showed biphasic descending type, that is, rapid accumulation during 3 to 6 hours and rapid fall up to 48 hours and gradual decrease afterwards. While, ascending type, monophasic and maximal at 24 hours, was found universary under low iodine intake less than 500 μg per day. Thyroid function should not be affected by the amount of iodine intake, and we analysed 131 I metabolism using a new four compartments which included intrathyroidal inorganic iodine pool. The results, especially hormone production rate, were found quite useful even under high iodine intake. Thyroidal organic iodine contents were calculated as approximately 2.5 mg and this value was much less than previously reported values from other countries. Administered radioiodine were mixed up with stable body iodine and reached equilibration by around 10 days. From seroimmunological, histological (microscopic and electron microscopic) studies, and irradiation studies to the cultured human thyroid cells, we concluded that this unexpected phenomenon was derived from chromosomal damage which induced gradual decrease in cell population because of inability to reproduce. Carcinogenic and genetic effects were not serious, and only three leukemic patients were reported in this country and 484 normal babies were born from 7,500 treated parents. Thus, therapeutic dose of 131 I was proved rather safe, and even when exposed to radioiodine, administration of perchlorate or thiocyanate, excessive iodine and TSH seemed effective to avoid radiation injuries. (auth.)

  8. Quality control of 131I treatment of graves' disease

    International Nuclear Information System (INIS)

    Liu Zeng; Liu Guoqiang

    2009-01-01

    To make a preliminary quality control (QC) criteria and apply on the various stages of clinic 131 I treatment of Graves' disease in order to decrease the early happening of hypothyroidism and enhance the onetime 131 I cure rate of Graves' disease, the quality control criteria in the stochastic outpatient with 131 I treatment, such as plan of the indication, contraindication, method of treatment, matters needing attention, follow-up observation and curative effect appraisal, patient selection, RAIU, thyroid gland weight measurement and 131 I dose criteria for the various steps of 131 I medication were determined. The 131 I treatment effects of Graves' disease including the once-cure rate, the improving rate, duplicate cure rate and the early happening rate of hypothyroidism were analyzed in patients with applying QC and without QC ccriteria. The results showed that the oncecure rate in patients with applying QC criteria was increased from 76.6% to 90.9% (P≤0.01); the improving rate was decreased from 12.2% to 7.0% (P≤0.01); the duplicate cure rate was increased from 90.1% to 93.0% (P>0.05); the early happening rate of hypothyroidism was decreased from 11.0% to 2.1% (P≤0.01). The 131 I treatment of Graves' disease applying with QC criteria had tremendously improved the oncecure rate and decreased the early happening of hypothyroidism rate. (authors)

  9. The clinical significance of measuring the thyroid 131I uptake rate to identify the type of premature hypothyroidism for hyperthyroid after 131I treatment

    International Nuclear Information System (INIS)

    Deng Bo; Chen Huaming; Zhu Tianfeng

    2001-01-01

    The 3 h thyroid 131 I uptake rate and the content of serum TT 3 , TT 4 , TSH are measured in 63 patients of premature hypothyroidism (consisting of 33 provisional hypothyroids and 30 perpetual hypothyroidism) before and after thyroxine substitutes treatment for six moths. The results show that there is obvious difference in 131 I uptake rate compared provisional hypothyroidism with perpetual hypothyroidism, and no difference in the content of serum TT 3 , TT 4 , TSH before the treatment. Compared with normal conditions, there is no difference in 131 I uptake rate of provisional hypothyroidism, but the 131 I uptake rate of perpetual hypothyroidism has obvious decrease before and after the treatment. Therefore the type of patients who suffer from premature hypothyroidism can be distinguished according to the 131 I uptake rate: if the 3 h thyroid 131 I uptake rate is normal, it is provisional hypothyroidism; if not, it is perpetual hypothyroidism

  10. Distribution and Bioaccumulation of I-131 Within The Water-Fish System

    International Nuclear Information System (INIS)

    Darussalam, M; Wijaya, DGO; Sutrisno

    1996-01-01

    Distribution and Bioaccumulation of I-131 Within The Water-Fish System. As one of fission products, radioiodine I-131 potentially become a pollutant either resulted froma fallout or radioactive waste. Therefore, special interest has been given to handle I-131 starting from its production implementation and its waste management. The observations in this research have been focussed on distribution and bio accumulation of I-131 within the water-fish systems. Some number of Tilapia fish were put in aquaria containing I-131 contamined water with certain radioactivity concentration. Within time interval of 0, 6, 24, 48 and 72 hours after treatment the radioactivities of water media. fish and their organs have been measured. The results show that the radioactivity percentage different water media containing different I-131 concentration tend to have similar patterns. Meanwhile, the I-131 concentrations of fish and their organs were varied with similar patterns for different I-131 content in water media

  11. Radiological Risk for Patients Treated with 131I

    International Nuclear Information System (INIS)

    Chas, J.; Janiak, M.K.; Kowalczyk, A.; Siekierzynski, M.; Dziuk, E.

    2001-01-01

    Full text: Dose equivalents were measured during the three-day therapy with 131 I in patients treated at the Clinic of Endocrinology and Radioisotope Therapy, Central Clinical Hospital, Military University School of Medicine, Warsaw, Poland, for thyroid cancer (supplementary treatment; 21 cases), hyperthyroidism in the Graves-Basedov's disease (18 cases), and toxic nodular goiter (19 cases). The absorbed doses were measured with thermoluminescent dosimeters placed above the jugular incisure and above the pubic symphysis; the readings were used for calculation of the dose equivalent over the thyroid and in the ovaries. Following the radical treatment of thyroid cancer iodine uptake in the thyroid gland was very low and most of the applied 131 I was excreted within one to three days. In our 21 patients who were given on average 2.8 GBq (76 mCi) 131 I and stimulated with TSH (approx. 60 μIU/mL) the mean dose equivalents over the thyroid and in the ovaries were 115±123 mSv and 56±19 mSv, respectively. In comparison, the calculated dose equivalents in the Graves-Basedov's disease patients (424 MBq mean activity of the applied 131 I) and the goiter patients (544 MBq mean activity of the applied 131 I) were approx. 3.5 times higher over the thyroid and approx. 2.5 times lower in the ovaries. No disfunctions of the ovaries were detected in the treated young women. Based on these results it is recommended to stimulate diuresis during the first two-three days after the injection of 131 I. The results also indicate that exposure to ionising radiation of patients treated for various thyroid disorders with 131 I does not lead to the development of clinically detectable non-stochastic effects. (author)

  12. A Comparative Study of {sup 131}I-Hippuran Renogram, {sup 131}I-Hippuran Urinary Excretion Test and Intravenous Pyelogram in Obstructive Uropathy due to Cancerous Invasion

    Energy Technology Data Exchange (ETDEWEB)

    Park, Kee Bok; Rhee, Chong Heon; Hong, Chang Gi; Park, Soo Seong; Koh, Chang Soon [Radiological Research Institue, Seoul (Korea, Republic of)

    1968-03-15

    A comparative study of {sup 131}I-hippuran renogram, {sup 131}I-hippuran excretion test and intravenous pyelogram were performed in 61 cases of gynecological cancer. The following were the results: 1) Among 40 cases of cervix cancer showing normal excretory urography 7 cases (17.5%) were found to have unilateral or bilateral delayed excretory pattern on {sup 131}I-hippuran renogram and on the contrary only 2 cases (5.7%) showed a mild caliectatic change on excretory urography among 35 cases of gynecological cancer showing normal pattern of {sup 131}I-hippuran renogram. 2) In the group showing unilateral of bilateral delayed excretory pattern of {sup 131}I-hippuran renogram there was a reduction of {sup 131}I-hippuran excretion in the first 20 minutes, but there was no significant difference of {sup 131}I-hippuran excretion in 60 minutes compared with that of normal renogram group. 3) In the group showing unilateral non-functioning pattern of {sup 131}I-hippuran renogram in one side and normal pattern in the other side there was found to be no difference in {sup 131}I-hippuran excretion amount compared with that of normal renogram group. 4) It was evident from these experimental study that {sup 131}I-hippuran renogram was considered as a good examination method for the evaluation of obstructive uropathy, and if one side kidney was intact it might compensate for the other diseased kidney so far as to renal excretory function. It was also shown that the more severe the cancerous spread in the pelvic wall the more changes on {sup 131}I-hippuran renogram.

  13. Normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man; evaluation by scintigraphy

    International Nuclear Information System (INIS)

    Nakajo, M.; Shapiro, B.; Copp, J.; Kalff, V.; Gross, M.D.; Sisson, J.C.; Beierwaltes, W.H.

    1983-01-01

    The scintigraphic distribution of m-[ 131 I]iodobenzylguanidine (I-131 MIBG), an adrenal medullary imaging agent, was studied to determine the patterns of uptake of this agent in man. The normal distribution of I-131 MIBG includes clear portrayal of the salivary glands, liver, spleen, and urinary bladder. The heart, middle and lower lung zones, and colon were less frequently or less clearly seen. The upper lung zones and kidneys were seldom visualized. The thyroid appeared only in cases of inadequate thyroidal blockade. The normal adrenal glands were seldom seen and faintly imaged in 2% at 24 h after injection and in 16% at 48 h, in patients shown not to have pheochromocytomas, whereas intra-adrenal, extra-adrenal, and malignant pheochromocytomas usually appeared as intense focal areas of I-131 MIBG uptake at 24 through 72 h

  14. Effect of 131I therapy on outcomes of Graves' ophthalmopathy

    International Nuclear Information System (INIS)

    Wang Renfei; Tan Jian; Zhang Guizhi; Yin Liang

    2011-01-01

    Objective: To analyze the correlation between the therapeutic effect of Graves' hyperthyroidism and the outcomes of Graves' ophthalmopathy after 131 I therapy, and to explore the effect of 131 I treatment on turnout of Graves' ophthalmopathy. Methods: Six hundreds and fifty-two patients of Graves' disease accompanied with Graves' ophthalmopathy, received one-time 131 I treatment according to routine procedure. We recorded exophthalmometer readings, the signs and symptoms of eyes before therapy. Regular follow-up and appraisal of curative effect were carried out. Results: At least six months after 131 I therapy, the effective rate of Graves' hyperthyroidism and Graves' ophthalmopathy were 94.3% and 73.3% respectively. The total effective rate of hyperthyroidism with ophthalmopathy was 71.2%. There was a significant correlation between the prognosis of Graves' ophthalmopathy and therapeutic efficacy of hyperthyroidism (r=0.302, P 131 I therapy (χ 2 =0.296, P>0.05). Conclusions: The key to treat Graves' ophthalmopathy is the cure of Graves' hyperthyroidism through 131 I therapy. The timely diagnosis and replacement treatment of hypothyroidism can effectively avoid the aggravation of Graves' ophthalmopathy after 131 I therapy. (authors)

  15. Clinical evaluation of 131I in treatment hyperthyroidism

    International Nuclear Information System (INIS)

    Wang Jing; Deng Jinglan; Qiao Hongqing

    2001-01-01

    The clinical value of 131 I in the treatment of hyperthyroidism is observed. The weight of the thyroid was evaluated by palpation, 131 I was taken orally by one dose method. The dose was calculated by actual absorption of 131 I/per gram of thyroid. 3 - 6 months after drug administration, the symptom, clinical manifestation and the serum hormone of the pituitary-hypothyroid axis were observed. In 105 cases, 80(76.2%) were nearly recovered, among them 16(15.2%) had hypothyroidism in the early period. The all over recovering rate was 91.4% in one dose, but 9(8.6%) were recurred and can be controlled at a second dose. Therefore 131 I for the hyperthyroidism had a high recovering rate, low recurring rate and was very convenient. If prospect on the Chinese effort the controlled, the occurrence of hypothyroidism can be reduced to the acceptable level

  16. {sup 131}I treatment of nodular non-toxic goitre

    Energy Technology Data Exchange (ETDEWEB)

    Nygaard, B.; Faber, J.; Hegdeues, L.; Hansen, J.M. [Herlev Hospital (Denmark)

    1996-01-01

    The traditional treatment of a growing nodular non-toxic goitre has for many years been surgical resection or levothyroxine suppressive treatment. During recent years, several studies have reported promising results of {sup 131}I treatment in terms of thyroid size reduction. This review outlines the different treatment modalities on non-toxic nodular goitre with special emphasis on {sup 131}I treatment. By the term nodular goitre the authors include glands with solitary or multiple thyroid nodules with uptake on a scintiscan. At what point of the natural history of non-toxic multinodular goitre {sup 131}I therapy should be used is not clear. In principle, the best result is obtained in smaller goitres and it is possible that the best effect of {sup 131}I is seen if treatment is given to patients with diffuse goitre before these become nodular. However, then there is a potential risk to swing in the direction to where {sup 131}I is used in an indiscriminate way, since the prevalence of non-toxic multinodular goitre is much higher than that of hyperthyroidism. Although we have data on the long-term hazards of {sup 131}I treatment in hyperthyroidism in terms of risk of cancer, we have only follow-up periods of 5 to 10 years for non-toxic goitres in small groups of patients and no data regarding the long-term risk of high-dose {sup 131}I treatment (>600 MBq) for this condition. Ideally, long term randomized studies comparing the effect, side effect and cost-benefit of surgery as opposed to {sup 131}I treatment should be performed. Awaiting this, it is at present mandatory that each individual patient be given a choice of treatment after proper information. 44 refs.

  17. Therapeutical uses of 131I

    International Nuclear Information System (INIS)

    Lago, Graciela.

    1994-01-01

    Physiology of thyroid gland, pathology of thyroid , papillary, follicular cancer is considered together as differentiated thyroid cancer with very good results under therapy with iodine, invitro determination of calcitonin, search of metastasis, anaplastic carcinoma, as indifferentiated carcinoma with similar results as medullary carcinoma. This work gives a protocol for therapeutical use of 131I , in hyperthyroidism due to Graves-Basedow disease, thyrotoxic adenoma or Plummer disease, toxic multi nodular goiter, subacute thyroiditis. Is studied too the treatment with pharmaceuticals, surgery and radioactive iodine. A recommended use of each and protocol for iodine administration, fixed dose technique, dose estimation,absorbed dose, recommendations about when to use and not use 131I are included in this work

  18. /sup 131/I-meta-iodobenzylguanidine scintigraphy of neuroblastomas

    International Nuclear Information System (INIS)

    Munkner, T.

    1986-01-01

    Sixteen neuroblastoma patients have been studied by /sup 131/I-meta-iodobenzylguanidine scintigraphy. Three patients were possibly cured, and their scintigraphy results were normal. Thirteen patients had tumors and metastases demonstrated by /sup 131/I-MIBG, two of these patients had a normal vanillylmandelic acid excretion levels. One patient has been treated by /sup 131/I-MIBG, but died. /sup 131/I-MIBG was concentrated in other cells too, e.g., in erythrocytes and platelets. Neuroblastoma is the most common solid malignant disease in children. It has a poor prognosis in patients more than one year old. Early detection and a display of the spread of the tumor is of utmost importance for planning and controlling the treatment. Mass screening for neuroblastoma in infants has been suggested and tried in Japan. Scintigraphy after injection of /sup 131/I-meta-iodobenzylguanidine has been used successfully for locating neuroblastomas. An initial study failed to demonstrate neuroblastoma by means of MIBG in two patients. Since the latter part of 1983, MIBG has been used in a number of European centers for imaging neuroblastomas with very promising results, and a multicenter investigation has been initiated. The Ann Arbor group has recently extended its studies to a group of ten patients and has confirmed the European results

  19. Studies on the radiation burden using I-131 for thyroid therapy

    International Nuclear Information System (INIS)

    Krzesniak, J.W.; Chomicki, O.A.

    1980-01-01

    The exposure to personnel from 131 I inhaled from open sources during laboratory procedures and that exhaled by patients treated with 131 I was estimated. The method and the apparatus used to detect airborne 131 I are described. It was found that the ratio of the activity absorbed through the lungs to that permissible for a given category of exposure is not higher than 10%. The kinetics of the 131 I exhaled by patients seems to be complementary to that of 131 I concentration changes in the blood. (H.K.)

  20. Therapy of hyperthyroidism with Na131I

    International Nuclear Information System (INIS)

    Kakehi, Hirotake; Furukawa, Takashi; Fukakusa, Shunichi; Futonaka, Hiroshi; Takahashi, Yuji

    1984-01-01

    Forty one patients of hyperthyroidism were treated with Na 131 I. Men and women are in the ratio 1:3.1. The ages of patients are between twenties and sixties and the forties are the highest in number. The observation period of clinical courses is between 1 and 8 years. The number of patients observed over 5 years are 51% of them and over 2 years are 83%. The treatment frequency is as follows: On 37 cases each one was treated once with Na 131 I. 2 cases twice, 1 case at 4 times in 3 years and 1 case at 5 times in 6 years. The treatment doses are between 4,000-6,000 rad (40-60 Gray). In the cases treated with the irradiation dose of 6,000 rad, we often saw hypothyroidism. In cases aiming 4,000-5,000 rad, there is a tendency of leaving hyperthyroidism unrecovered. In conclusion, the patients should be treated giving 4,000-5,000 rad or with Na 131 I doses of 3-6mCi. If the effects of the treatment are insufficient, the patients should be further treated with anti-thyroid drug or treated again with Na 131 I. As the result, there are at present 25 cases (61.0%) in normal status of the thyroid gland, 12 cases (29.2%) in hyperthyroidism and 4 cases (9.8%) in hypothyroidism totaling 41 cases in all. (author)

  1. Transient hypothyroidism after 131I treatment of Graves disease

    International Nuclear Information System (INIS)

    Liu Jianfeng; Fang Yi; Zhang Xiuli; Ye Genyao; Xing Jialiu; Zhang Youren

    2003-01-01

    Objective: To evaluate the results of the transient hypothyroidism after 131 I treatment of Graves disease. Methods: A total of 32 transient hypothyroidism patients treated with 131 I for Graves disease were studied and followed up. Results: Transient hypothyroidism occurred within 2-6 months after 131 I treatment and 19 patients were symptomatic. At diagnosis of transient hypothyroidism, T 3 and T 4 levels were decreased had normal, TSH levels were increased, normal or low. Follow-up examination found that 20 patients were normal and 12 patients had relapse of hyperthyroidism. Conclusions: Therapy of Graves disease with low doses of 131 I causes a high incidence of transient hypothyroidism. After recovery of transient hypothyroidism, some patients have relapse of hyperthyroidism

  2. The development and current status of 131I treatment for hyperthyroidism

    International Nuclear Information System (INIS)

    Wang Chunmei; Wang Xuemei

    2010-01-01

    Hyperthyroidism is an autoimmune diseasein which excessive amounts of thyroid hormones circulate in the blood. The treatments for hyperthyroidism mainly include antithyroid drugs, 131 I treatment, and surgery. 131 I had been verified as an effective, safe, simple method to treat adult and children hyperthyroidism. Current research trends of 131 I treatment mainly are problems of 131 I treatment of hyperthyroidism and its long-term security. (authors)

  3. 131I therapy for hyperthyroidism with large goitre

    International Nuclear Information System (INIS)

    Zhang Chenggang

    2002-01-01

    Objective: This retrospective analysis is to study the effects of radioiodine in hyperthyroidism with large goitre and observe the possibility to take the place of surgery. Methods: 82 patients (pts) with hyperthyroidism including 51 female and 31 male, age ranging from 11 to 75 years old (mean 35.43 ± 12.14), were treated with 131 I. All patients presented with typical clinical and biochemical hyperthyroidism and were followed up for 3-38 months after 131 I treatment. Patients were categorized into 2 diagnostic groups: Graves disease (43 pts) and toxic multinodular goitres (39 pts). Gland weights were estimated by palpation and scintigraphy. Cold nodule had not been found in scintigraphy in all pts. The dose in mCi administered were determined according to therapeutic history, thyroid weight (g), rate of uptake 131 I, patient's symptoms and course of disease, etc. 76 pts (92.7%) had iII degree goitre. Goitre weight was stratified into 150-200 g (67 pts), 201-300 g (13 pts) and 400-500 g (2pts). 71 pts (86.6%) were given one dose of 131 I, 10 pts (12.2%) two doses, one patient had three doses. The mean first dose was 39.26 ± 19.63 mCi (14-130 mCi). The mean first μCi/g was 142.89±32.29 μCi (59-200). Results: 24 pts (29.3%) had complete remission (euthyroid), 19 pts (23.2%) had partial resolution. 39 (47.6%) pts had hypothyroidism (HP) including 8 permanent HP, 11 transient HP, 3 subclinical HP and 17 indeterminate HP. The later group had HP that could not be decided to be transient or permanent because the time of following up was less than one year. After 131 I therapy, goitres of 43 pts (52.4%) became 0 degree, 34 pts (41.5%) became I degree, 4 pts (4.9%) had II degree and only one pt still had a III degree goitre. Conclusions: 131 I therapy is a safe and effective method for treating hyperthyroidism with large goitre. If the large goitre does not have cold nodule in scintigraphy, 131 I treatment may replace surgery

  4. Graves hyperthyroidism 131I treatment the clinical curative effect of observation

    International Nuclear Information System (INIS)

    Duan Yongqiang; Wang Zuobing; Yu Hui; Wang Jing; Li Xiaoqin; Chen Yuanhao; Wu Jiquan

    2012-01-01

    Objective: to study the clinical treatment of 131 I Graves hyperthyroidism curative effect. Methods: the clinical data of Graves hyperthyroidism patients were retrospectively analyzed. Results: 258 cases of patients with hyperthyroidism Graves. 131 I treatment 1∼2 times after healed 200 cases, improvement of 38 patients, a low, 10 cases were invalid 10 cases failure; the total effective 96.12%. 1 year after treatment 131 I thyroid quality by before treatment 43.6 + 20.9 grams shrinks to 1.98 + 18.5 grams (p 131 I before treatment with prominent eyes 68 cases (26.4%) 131 I after treatment, the prominent eyes healed 24 cases (34.8%), improvement 30 patients (43.5%), invalid in 12 cases (17.4%), aggravating in 2 cases (2.9%), efficient for 79.7%. Concurrent hyperthyroidism 131 I before treatment in patients with 31 patients (heart), after the treatment of 131 I 12.0% in 25 patients recovered, 6 patients get better, efficient 100%. After the treatment of 131 I temporary armor low in 25 patients (9.7%) , permanent armour low 27 cases (10.5%). After the treatment of 131 I 15 cases have been reduced to a sex WBC (5.8%), 8 cases of liver function mild damage (3.1%), 13 cases itchy skin (1 case), cholesterol by 5.0% compared appear suspected hyperthyroidism crises (0.4%). 258 patients with thyroid type micronodular 41 cases, treatment cured after 131 I in 25 patients (61.0%), improvement in 16 (39.0%), laseris 100%, Diffuse 217 example, cure 175 cases (80.6%), improvement 22 patients (10%), a low 10 (4.6%), invalid 10 (4.6%), laseris 95.4 percent. Conclusion: 131 I treatment Graves hyperthyroidism is simple, safe, effective, and can be used as the preferred treatment method outperforms that of anti-thyroid drugs. (authors)

  5. Current status of radioiodine (131I) treatment of hyperthyroidism

    International Nuclear Information System (INIS)

    Becker, D.V.; Hurley, J.R.

    1982-01-01

    Radioiodine appears to be increasingly selected as the primary form of therapy for most hyperthyroid adults. Some controversy exists concerning the use of I-131 in children and adolescents as well as in some patients with toxic nodular goiter. The technical aspects of radioiodine administration reviewed in this chapter include the biologic basis of I-131 use, dose strategies, measurement and evaluation of radioiodine parameters, and I-125 treatment of hyperthyroidism. The management of patients before and after I-131 treatment is discussed as well as posttreatment hypothyroidism and complications of radioiodine treatment

  6. Comparison of 131I whole-body imaging, 131I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer

    International Nuclear Information System (INIS)

    Oh, Jong-Ryool; Chong, Ari; Kim, Jahae; Kang, Sae-Ryung; Song, Ho-Chun; Bom, Hee-Seung; Byun, Byung-Hyun; Hong, Sun-Pyo; Yoo, Su-Woong; Kim, Dong-Yeon; Min, Jung-Joon

    2011-01-01

    The aim of this study was to compare 131 I whole-body scintigraphy (WBS), WBS with 131 I single photon emission computed tomography/computed tomography (SPECT/CT), and 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in the detection of distant metastases of differentiated thyroid cancer (DTC). A total of 140 patients with 258 foci of suspected distant metastases were evaluated. 131 I WBS, 131 I SPECT/CT, and 18 F-FDG PET/CT images were interpreted separately. The final diagnosis was obtained from histopathologic study, serum thyroglobulin level, other imaging modalities, and/or clinical follow-up. Of the 140 patients with 258 foci, 46 patients with 166 foci were diagnosed as positive for distant metastasis. The sensitivity, specificity, and diagnostic accuracy of each imaging modality were 65, 55, and 59%, respectively, for 131 I WBS; 65, 95, and 85% for 131 I SPECT/CT, respectively; and 61, 98, and 86%, respectively, for 18 F-FDG PET/CT in patient-based analyses. Lesion-based analyses demonstrated that both SPECT/CT and PET/CT were superior to WBS (p 18 F-FDG PET/CT presented the highest diagnostic performance in patients who underwent multiple challenges of radioiodine therapy. (orig.)

  7. Visualization of adrenocortical carcinoma with /sup 131/I-Adosterol

    Energy Technology Data Exchange (ETDEWEB)

    Maruoka, Shin; Nakamura, Mamoru

    1987-01-01

    There are very few literatures on successful visualization of adrenocortical carcinoma by means of /sup 131/I-iodocholesterol scintigraphy, although many reports have referred to utility of /sup 131/I-iodocholesterol scintigraphy for adrenal disorders. Since 1976, we have experienced 4 cases of adrenocortical carcinoma which were delineated by /sup 131/I-6US -iodomethyl-19-norcholesterol (/sup 131/I-Adosterol). Three of 4 cases were adrenocortical carcinoma with Cushing's syndrome, and one was adrenocortical carcinoma with adrenogenital syndrome. In 3 cases of cortisol secreting adrenocortical carcinoma, uptake in the tumor and lack of uptake in the contralateral adrenal gland were seen. Faint to moderate uptakes were observed in the 2 cases, but another one showed as high uptake as seen in adenoma. Patient with androgen secreting adrenocortical carcinoma had increased uptake in the tumor and showed faint uptake in the contralateral adrenal gland. Intensity of /sup 131/I-Adosterol uptake in adrenocortical carcinoma seems to depend on the extent of tumor necrosis, cell differentiation and function.

  8. Metabolic comparison of radiolabeled aniline- and phenol-phthaleins with 131I

    International Nuclear Information System (INIS)

    Avcibasi, Ugur; Avcibasi, Nesibe; Unak, Turan; Unak, Perihan; Mueftueler, Fazilet Zuemruet; Yildirim, Yeliz; Dincalp, Haluk; Guemueser, Fikriye Guel; Dursun, Ebru Rueksen

    2008-01-01

    The metabolic comparison of aniline- and phenol-phthaleins radiolabeled with 131 I ( 131 I-APH and 131 I-PPH, respectively) has been investigated in this study. To compare the metabolic behavior of these phthaleins and their glucuronide conjugates radiolabeled with 131 I, scintigraphic and biodistributional techniques were applied using male Albino rabbits. The results obtained have shown that these compounds were successfully radioiodinated with a radioiodination yield of about 100%. Maximum uptakes of 131 I-APH and 131 I-PPH, which were metabolized as N- and O-glucuronides, were observed within 2 h in the bladder and in the small intestine, respectively. In the case of verification of considerably up taking of these compounds also by tumors developed in the small intestine and in the bladder tissues, these results can be expected to be encouraging to test these compounds, which will be radiolabeled with other radioiodines such as 125 I, 123 I and 124 I as imaging and therapeutic agents in nuclear medical applications

  9. Metabolic comparison of radiolabeled aniline- and phenol-phthaleins with (131)I.

    Science.gov (United States)

    Avcibaşi, Uğur; Avcibaşi, Nesibe; Unak, Turan; Unak, Perihan; Müftüler, Fazilet Zümrüt; Yildirim, Yeliz; Dinçalp, Haluk; Gümüşer, Fikriye Gül; Dursun, Ebru Rükşen

    2008-05-01

    The metabolic comparison of aniline- and phenol-phthaleins radiolabeled with (131)I ((131)I-APH and (131)I-PPH, respectively) has been investigated in this study. To compare the metabolic behavior of these phthaleins and their glucuronide conjugates radiolabeled with (131)I, scintigraphic and biodistributional techniques were applied using male Albino rabbits. The results obtained have shown that these compounds were successfully radioiodinated with a radioiodination yield of about 100%. Maximum uptakes of (131)I-APH and (131)I-PPH, which were metabolized as N- and O-glucuronides, were observed within 2 h in the bladder and in the small intestine, respectively. In the case of verification of considerably up taking of these compounds also by tumors developed in the small intestine and in the bladder tissues, these results can be expected to be encouraging to test these compounds, which will be radiolabeled with other radioiodines such as (125)I, (123)I and (124)I as imaging and therapeutic agents in nuclear medical applications.

  10. Cytogenetic in thyroid carcinoma and therapy with 131{sup I}; Citogenetica en cancer de tiroides y terapia con 131''I

    Energy Technology Data Exchange (ETDEWEB)

    Popova, L.; Hadjidekova, V.; Christova, R.; Agova, S.; Grudeva, V.; Hadjieva, T.; Dominguez, I.

    2007-07-01

    In order to assess the genotoxic risk of the therapy with radioiodine-131(''131I), the production of micronuclei (MN) and chromosome aberrations (CA) were analyzed in the peripheral blood lymphocytes of group of 26 patients undergoing therapy with this radionuclide for differentiated thyroid carcinoma (DTC). Blood samples were taken immediately before ''131 I administration and 1 month later. The patients underwent radioiodine ablation (RIA) or radioiodine therapy (RIT) after radical thyroidectomy. The amount of orally administered ''131I activity varied from 3330 to 4030 MBq according to the king of therapy (RIA or RIT). results show that after radioiodine therapy there is a significant increase in the frequency of MN and CA. The mean frequencies of MN {+-} Sd before and after the therapy were 10.72 % {+-} 5.84 % and 25.28 %{+-} 12.6% respectively. For CA, the mean frequencies obtained were 1.16% {+-} 0.36% before and 2.3% {+-} 0.87% after the therapy. These findings indicate a genotoxic activity of ''131I therapy estimated after a period of one month. (Author) 38 refs.

  11. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy

    International Nuclear Information System (INIS)

    Nakajo, M.; Shapiro, B.; Copp, J.; Kalff, V.; Gross, M.D.; Sisson, J.C.; Beierwaltes, W.H.

    1983-01-01

    The scintigraphic distribution of m-[ 131 I]iodobenzylguanidine (I- 131 MIBG), an adrenal medullary imaging agent, was studied to determine the patterns of uptake of this agent in man. The normal distribution of I- 131 MIBG includes clear portrayal of the salivary glands, liver, spleen, and urinary bladder. The heart, middle and lower lung zones, and colon were less frequently or less clearly seen. The upper lung zones and kidneys were seldom visualized. The thyroid appeared only in cases of inadequate thyroidal blockade. The ''normal'' adrenal glands were seldom seen and faintly imaged in 2% at 24 hr after injection and in 16% at 48 hr, in patients shown not to have pheochromocytomas, whereas intra-adrenal, extraadrenal, and malignant pheochromocytomas usually appeared as intense focal areas of I- 131 MIBG uptake at 24 through 72 hr

  12. Doticaj moderne kozmologije i religije: poimanje početka svemira

    OpenAIRE

    Petković, Tomislav

    2007-01-01

    Ujedinjenje velikih teorija fizike − teorije relativnosti, kvantne mehanike i fizike svemira i čestica − ostaje snom fizike i filozofije znanosti i na početku 21. stoljeća. Sve se one u pogledu konačnih zakona svemira (teorija svega) slažu da je početak bio, te da su konačni zakoni oni koji su već vladali u početku evolucije svemira. Početak svemira podrazumijeva njegovo stvaranje i nužno upućuje na Stvoritelja−religijskog Boga, na uspostavljanje mosta između moderne kozmologije i religije. U...

  13. /sup 131/I-BSP liver function test by BSP tolerance

    Energy Technology Data Exchange (ETDEWEB)

    Kanda, K [Minami Osaka Hospital (Japan)

    1974-11-01

    /sup 131/I-BSP liver function test after BSP intravenous tolerance was discussed, assuming that the reason why measurements of /sup 131/I-BSP retention rate at 30 minutes and /sup 131/I-BSP disappearance rate in blood showed respectable overlapping between normal group and group with slight liver disorders as compared with BSP test and the reason why differential diagnosis was difficult were due to underestimate of tolerance volume of /sup 131/I-BSP. /sup 131/I-BSP was observed with time as to 70 persons with normal liver function and 257 cases of liver diseases, using 5, 3 and 2 mg of non-radioactive BSP tolerance volume per kilogram of body weight. /sup 131/I-BSP retention rate at 30 minutes and /sup 131/I-BSP disappearance rate in blood are possible to separate overlapping over control in each measurement value at 3 to 5 mg/kg of tolerance, and in comparison of 3 mg and 5 mg, the latter showed a little excellent result. So, it was decided that tolerance of 3 mg/kg was a proper dose, considering tolerance to liver cells. /sup 131/I-BSP retention rate at 30 minutes was a little excellent in accuracy and disappearance rate in blood after BSP tolerance is simple and profitable for practical use because collection of blood was only one time and measurement could be made with whole blood. As mentioned above, this method is seemed to be useful to practice of liver function test.

  14. Preparation and evaluation of (131I)AgI particles: potential lungs perfusion imaging agent

    International Nuclear Information System (INIS)

    Chattopadhyay, Sankha; Das, Sujata Saha; Sinha, Samarendu; Sarkar, Bharat Ranjan; Ganguly, Shantanu; Chandra, Susmita; De, Kakali; Mishra, Mridula

    2010-01-01

    Since the discovery of iodine-131 (t 1/2 : 8 d) by Livingood and Seaborg (1938), this, and other radioisotopes of iodine, have found widespread use in nuclear medicine. The purpose of the present work was to formulate Ag 131 I particles and bio-evaluate the same. The Ag 131 I particles were prepared in acidic condition having 100% R.C. Purity. The biological evaluation of Ag 131 1 particles was made by injecting about 111-185 MBq of Ag 131 I particles preparations in female albino rabbits (2-2.5 kg weight) intravenously by femoral vein under urethane anesthesia. Imaging studies were performed under Gamma Camera. The entire amount of the Ag 131 I particles were found to deposit in the lungs and remained there almost unchanged for a certain period of time after the intervenous administration. The images showed excellent, uniform lung uptake with no interference from liver and spleen to the lower regions of right and left lobes. It showed a high accumulation in the rabbits lungs (>99%) and remained constant for at least for 20 min. It is also worthy to study with 123 I/ 124 I labelled AgI for lung imaging study. In conclusion, the synthetic radiopharmaceutical ( 131 I)-Silver iodide colloid can be prepared with a large particle size, in a simple and practical manner, and it has good potential for use as a perfusion imaging agent in lung scans

  15. Value of 201Tl imaging in predicting therapeutic 131I uptake in patients with thyroglobulin-positive but 131I scan-negative differentiated thyroid carcinoma

    International Nuclear Information System (INIS)

    Conlu, R.A.O.; Obaldo, J.M.

    2004-01-01

    Background: Serum thyroglobulin assay and 131Iodine (1311) whole body scan are considered complementary in detecting malignant thyroid tissue or metastases. A large number of patients, however, are encountered presenting with scan-negative, thyroglobulin-positive differentiated thyroid carcinoma posing a dilemma in therapeutic management. One of the first alternative scanning agents to be employed is 201Thallium (201Tl). Recent studies have demonstrated its usefulness in identifying lesions that are not visualized with traditional 131I whole body scan. It is not clear, however, whether 201Tl scan helps in the decision-making for subsequent 131I therapy. This study was conducted to determine if 201Tl scan can predict therapeutic 131I uptake and to define the clinical role of 201Tl scanning in these patients. Methods and results: A total of 12 patients (20-63 y/o), 5 males and 7 females, underwent surgery for differentiated thyroid cancer and all had serum thyroglobulin values above 10 ng/ml and normal TPO autoantibodies. Pre-therapy 131I scan using 111 MBq (3mCi) of 131I were obtained. As required for inclusion, all patients had negative pre-therapy scan and negative TPO autoantibody results and underwent 20lTl scanning within 3 weeks. All patients were given 131I therapy (3.7-5.5 GBq or 100-150 mCi) between one to two months after 201Tl scanning. Within a week after therapy, all patients underwent whole body 1311 scanning. 201Tl imaging demonstrated thyroid remnants in 9 out of 12 patients having positive 201Tl scan but negative pre-therapy 1311 scan. However, only 2 of the positive 201Tl scans showed 131I uptake post-therapy (positive predictive value of 20%). None of the subjects presented with a negative 201Tl scan and a positive post-therapy 131I scan. Conclusion: Our study suggests that evidence of remnants or metastases on 201Tl scanning may be an inappropriate basis for the decision to proceed with 131I therapy. The role of 20lTl imaging in this subset of

  16. β-CIT labelled with 131I and its preliminary clinical practice

    International Nuclear Information System (INIS)

    Ye Bin; Kuang Anren; Ding Hao; Zheng Hongbo; Yuan Qiang; He Li

    2002-01-01

    β-CIT is labelled with 131 I by the peracetic acid method. 4 normal controls, 8 patients with PD and 3 patients with PS are studied by 131 I-β-CIT SPECT imaging. Striatal specific uptake of 131 I-β-CIT is calculated by the radioactivity ratio of striatal to cerebellar. The results shows that the radiochemical purity of 131 I-β-CIT is (97.6 +- 0.3)%. 131 I-β-CIT remains stable for at least 4 h after incubated with waters and serum respectively. The striatal specific uptake of 131 I-β-CIT in normal controls, PD and PS patients are (4.39 +- 0.14)%, (2.95 +- 0.68)% and (3.96 +- 0.52)% at 4h and (6.60 +- 0.06)%, (3.85 +- 0.71)% and (6.14 +- 0.08)% at 20 h after administration. There is a significant reduction of striatal tracer uptake in PD patients compared to the controls and PS patients. Striatal specific uptake in contralateral to the clinical symptom side is more pronounced reduced than the ipsilateral side in PD patients. 131 I-β-CIT uptake in PD patients is correlated with disease severity. These results suggest that 131 I-β-CIT can be used for the diagnosis of Parkinsion's disease

  17. Observation of radioactive iodine ({sup 131}I, {sup 129}I) in cropland soil after the Fukushima nuclear accident

    Energy Technology Data Exchange (ETDEWEB)

    Fujiwara, Hideshi, E-mail: hfuji@affrc.go.jp

    2016-10-01

    During the early stages of the Fukushima nuclear accident, the temporal variations of {sup 131}I deposited on the ground and of {sup 131}I accumulated in cropland soil were monitored at a fixed location in Japan. Moreover, concentrations of long-lived radioactive iodine ({sup 129}I) in atmospheric deposits and soil were measured to examine the feasibility of retrospectively reconstructing {sup 131}I levels from the levels of accident-derived {sup 129}I. The exceptionally high levels of {sup 131}I in deposits and soil were attributed to rainfall-related deposition of radionuclides. In the crop field studied, the losses of deposited {sup 131}I and {sup 129}I due to volatilization were small. The atomic ratio {sup 129}I/{sup 131}I in the topsoil corresponded to the same ratio in deposits. The {sup 131}I concentrations measured in the topsoil were very consistent with the {sup 131}I concentrations reconstructed from the {sup 129}I concentrations in the soil. - Highlights: • A high level of {sup 131}I contamination occurs through rainfall-related deposition. • Only a small loss of deposited radioactive iodine occurs via volatilization. • The {sup 129}I/{sup 131}I ratio in soil corresponds to the ratio in atmospheric deposit. • The feasibility of retrospectively reconstructing {sup 131}I is confirmed.

  18. I-131 and thyroid-associated ophthalmopathy

    Energy Technology Data Exchange (ETDEWEB)

    Rasmussen, Aase Krogh; Nygaard, Birte; Feldt-Rasmussen, Ulla

    2000-07-01

    Objective: Radioiodine (I-131) used to obtain euthyroidism in thyrotoxic patients is suspected of having a worsening or provoking effect on thyroid-associated ophthalmopathy (TAO), an autoimmune disease closely related to Graves' disease. Design: This review summarises the existing literature and describes risk factors influencing the course of TAO including thyroid function, cigarette smoking and treatment of Graves' hyperthyroidism especially I-131 therapy. Conclusion: It is recommended that patients who may be at a greater risk of worsening ophthalmopathy are considered when choosing the modality of therapy of hyperthyroidism and also in deciding whether prophylactic systemic glucocorticoid treatment is indicated.

  19. Histological changes of the thyroid gland after /sup 131/I treatment for hyperthyroidism. I. Analysis by the frequency of administration and dosage of /sup 131/I

    Energy Technology Data Exchange (ETDEWEB)

    Takeichi, N; Inoue, S; Niimoto, M; Nagata, N [Hiroshima Univ. (Japan). Research Inst. for Nuclear Medicine and Biology; Yasuda, K

    1976-01-01

    The histological changes of the thyroid tissues due to /sup 131/I treatment were classified by the frequency of administration and dosage of /sup 131/I, and the chronological changes were examined. The histopathological findings including nuclear alteration, tissue infiltration, vascular alteration and regeneration of the follicular epithelium were examined. In the cases which received 2-3 doses, there were many atypical regeneration of the follicular epithelium, and in the cases with long observation duration, Askanazy cells and fibrotic proliferation were observed. These histological changes indicated the possibility of the occurrence of tumor due to the administration of /sup 131/I.

  20. Radiopharmaceutical potential of I-131 labelled diazepam

    International Nuclear Information System (INIS)

    Yurt, F.; Unek, P.; Asikoglu, M.; Baggi, S.; Erener, G.; Ozkilic, H.; Uluc, F.; Tuglular, I.

    1998-01-01

    In this study, diazepam is a derivative of the 1.4 benzodiazepine family that the most widely used drug as anticonvulsant agent has been labeled with I-131, as a new radiopharmaceutical and its radiopharmaceutical potential has been determined. Labeling of diazepam has been performed by iodogen method and optimum labeling conditions have been determined. Optimum reaction conditions are 1 mg for iodogen amount; 1-5 mg for diazepam amount, 15-20 minutes for reaction time and room temperature for reaction temperature. Specific activity of labeled compound was 0,15 Ci/mmol level. N-octanol/water ratio was found 1.9 for 131 IDZ ( 131 I labeled diazepam). In vivo experiments have been carried out to determine radiopharmaceutical potentials of labeled compound. Biodistribution studies on rats showed that 131 IDZ have accumulated in kidneys, liver, lungs and brain tissues. Scintigraphic results taken with gamma camera on rabbits agree with biodistribution results of rats. (author)

  1. Stability studies of therapeutic 131I-meta-iodobenzylguanidine (131I-mIBG) using high performance liquid chromatography

    International Nuclear Information System (INIS)

    Murhekar, V.V.; Mathur, Anupam; Pilkhwal, Neelam S.; Prabhakar, G.; Padmanabhan, D.; Sachdev, S.S.

    2014-01-01

    BRIT is a manufacturer and supplier of therapeutic doses (100 mCi) of the radiopharmaceutical 131 I-mIBG to various nuclear medicine centers in India. The therapeutic formulation is of high radioactive concentration (>10 mCi/ml) and is thus prone to radiolytic damage during transport, storage until administration. Earlier stability studies at this laboratory were done using conventional methods like Thin Layer Chromatography (TLC) which has an inherent limitation in terms of resolution. In view of this, a suitable HPLC method has been developed and the stability of therapeutic 131 I-mIBG was monitored at various conditions

  2. Unremitted hyperthyroidism following 131I treatment: an analysis of clinical markers in 48 patients

    International Nuclear Information System (INIS)

    Fang Yi; Zhang Xiuli; Liu Jianfeng; Zhang Youren

    2002-01-01

    Objective: To evaluate changes in clinical markers of unremitted hyperthyroidism patients after the first 131 I treatment. Methods: Forth eight unremitted hyperthyroidism patients were selected. Their thyroid function, the peak of 131 I uptake rate and thyroid weight before and after 131 I treatment were compared. Results: TT 3 , TT 4 , TSH were relatively stable and the peak of 131 I uptake rate and thyroid weight were reduced after 131 I treatment. Conclusions: Thyroid volume was reduced after 131 I treatment even if patients' clinical symptoms still existed; the peak of 131 I uptake rate was reduced after 131 I treatment, suggesting that their sensibility to 131 I decreased, so the absorbed dose should be adjusted when the 131 I dosage of second treatment is calculated

  3. Feasibility study on standardization of 131I dose in hyperthyrodisom treatment

    International Nuclear Information System (INIS)

    Tang Yi

    2011-01-01

    To explore feasibility of standardization of 131 I dose in Graves' hyperthyroidism treatment, the data of 681 Graves' disease cases treated with 131 I was retrospective studied. The software was developed to re-calculate the 131 I doses for the patients and compared with original doses given by traditional method. 313 patients with complete information were taken and divided to three groups base on the remedial effect, Cured Group (123 patients), Uncured Group (125 patients) and Hypothyroid Group (65 patients). The results showed that there was no statistically significant difference between the 131 I dose for Graves' hyperthyroidism treatment calculated by two methods (P>0.05). There was obviously statistically significant difference in hypothyroid Group (P 131 I calculated by software method (174.27 MBq) was less than that of traditional method (190.18 MBq). In uncured group, there was still obviously statistically significant difference (P 131 I calculated by software method (187.22 MBq) was more than that of the traditional method (169.46 MBq). In cured group, there was no statistically significant difference (P>0.005), the mean dose of 131 I calculated by software method (185 MBq) was slightly smaller than that of the traditional method(192.03 MBq). The results indicate the calculation of standard 131 I dose for Graves' hyperthyroidism treatment by software developed in this study is feasible. (authors)

  4. Tumor localization of 131I-labeled antibodies by radionuclide imaging

    International Nuclear Information System (INIS)

    Ghose, T.; Tai, J.; Aquino, J.; Guclu, A.; Norvell, S.; MacDondald, A.

    1975-01-01

    Intravenous injections of 131 I-labeled anti-EL4 lymphoma antibodies showed progressive localization of radioactivity in EL4 transplants but not in B16 melanoma in mice carrying both tumors. Normal rabbit globulin labeled with 131 I did not localize in either tumor and cleared more slowly from the internal organs. Metastatic localization of intravenous 131 I-labeled anti-tumor antibodies was also observed in two cancer patients. (U.S.)

  5. Observation of curative effect of 131I in treatment of hyperthyroidism

    International Nuclear Information System (INIS)

    Huang Kebin; Xu Fan; Zhang Yaping; Wang Jingchang; Zhao Mingli; Ye Ming

    2012-01-01

    Objective: To explore the curative effect of 131 I in the treatment of hyperthyroidism. Method: 126 patients with hyperthyroidism were treated with 131 I and the curative effect was analyzed. Result: The results showed that among 126 cases of hyperthyroidism treated with 131 I, 117 cases had recovered and the cure rate was 92.9%. 9 cases were found hypothyroidism in one-year follow-up and the occurrence rate was 7.1%. Conclusion: The treatment of hyperthyroidism with 131 I is safe and effective method. (authors)

  6. I131-meta-iodobenzylguanidine in the diagnosis and treatment of neural crest tumours

    International Nuclear Information System (INIS)

    Hoefnagel, C.A.; Hartog Jager, F.C.A. den; Taal, B.G.; Engelsman, E.; Kraker, J. de; Voute, P.A.

    1988-01-01

    Iodine-131-meta-iodobenzylguanidine (I-131-MIBG) was used for scintigraphic detection and therapy of neural crest tumours. The methodology of both techniques is described. Based upon experience with I-131-MIBG-scintigraphy in 170 patients with neural crest tumours, of whom 46 received multiple therapeutic doses of I-131-MIBG, and upon the cumulative reports in the literature, the role of I-131-MIBG in diagnosis and treatment of each of these diseases is indicated. I-131-MIBG-scintigraphy is one of the most sensitive and specific techniques for the diagnosis, staging and follow-up of phaeochromocytoma and neuroblastoma and I-131-MIBG-therapy may induce remission in a number of these patients. In carcinoid and medullary thyroid carcinoma the diagnostic sensitivity is less; however, once the diagnosis has been made, it is useful to establish that the tumour concentrates I-131-MIBG, to see if the patients at some point in time may be amenable to I-131-MIBG-therapy

  7. 131I treatment in patients undergoing renal dialysis: our experience

    International Nuclear Information System (INIS)

    Tobarra, Bonifacio; Campos, Pedro A.; Gonzalez Lopez, Antonio; Palma, Juan D.

    2008-01-01

    Radiation Protection issues concerning patients, public and staff must be considered carefully in hemodialysis for chronic renal failure patients scheduled for 131 I high dose therapy. In order to assess the risks related to this medical procedure, hemodialysis clearance of 131 I and contamination measurements were carried out. We have studied 12 hemodialysis procedures corresponding to 2 cases of hyperthyroidism disease (555MBq of 131 I administered) and 3 patients with carcinoma of the thyroid (5550 MBq of 131 I administered). The arterio-venous difference of 131 I across the artificial kidney and dose rate reduction at one meter of patient were measured. Contamination levels of the dialyser machine, filters and tubes were measured after dialysis with a contamination monitor. Direct read-out dosimeters were used to assess the radiation doses to nursery staff involved. The result obtained for mean 131 I clearance in blood was 75±11%. The mean dose rate reduction at one meter of the patient was 58±18%. We also checked that contamination levels for the dialyser machine, filters, tubes and accessories were lower than 10Bq/cm 2 . For the nursery staff the radiation dose was found to be lower than 0.1mSv. (author)

  8. Evaluation for Preparation of I-131-MIBG for Diagnosis and Therapy Neuroblastoma

    International Nuclear Information System (INIS)

    Laksmi Andri A; Purwoko; Sri Setyowati; Maskur; Cahya Nova Ardianto; Adang Hardi G

    2012-01-01

    Evaluation for preparation of 131 I-MIBG have been carried out. Production/preparation of 131 I-MIBG was carried out by labeling MIBG with I-131, the radiochemical purity of 131 I-MIBG was analysed using TLC/paper chromatography. The stability in the human body by using fresh human plasma, at room temperature and at 8°C was carried out. The chemical purity of synthesized MIBG was found to be > 95%, the labeled MIBG with I-131 was analysed using TLC/paper chromatography. The radiochemical purity of 131 I-MIBG was obtained at higher than 95 %. The stability of labeled MIBG in fresh human plasma and at 8°C was stable up to 141 hours, while at room temperature was stable up to 120 hours. The results of labeling of 131 I-MIBG from 2010-2012 showed that these products were colorless clear solution with pH between 5.5.0-7.0, sterile and pyrogen-free, radiochemical purity > 95%. The quality control results were found to be met with the requirements of 131 I-MIBG injection solution used for diagnosis and therapy of neuroblastoma in Hospital. (author)

  9. Determination of 131I and thorium in urine

    International Nuclear Information System (INIS)

    Tomida, Rute Miwa

    1978-01-01

    Methods for the determination of 131 I and Thorium in urine have been developed taking into account the monitoring needs for people who handle with these radioisotopes. The method for determining 131 I is based in the use of silver chloride to separate iodine by precipitation from the sample; the detection was carried out in a Nal (Tl) well type scintillator connected to a single channel analyser. This method has the following advantages; it is easy and relatively fast as well as selective, showing a separation yield higher than 80%. Thorium in urine was determined by colorimetry after the mineralization of the sample using nitric acid, and sulphuric acid, and then oxygen peroxide. The chromophore reagent used was Thoron (disodium salt of 2-(2-hydroxy-3,6-disulfo-l-naphthylazo) benzenearsonic acid).The absorbance was measured in a spectro colorimeter at a fixed wavelength (530 nm). The method proved to be simple allowing a separation yield of about 80%. The most representative sample for a monitoring program in a 131 I production laboratory has been established. The 131 I concentration in urine of individuals with chronic contamination have also been measured; an interpretation of these results is discussed. (author)

  10. Application of an imaging plate system to in vivo thyroid 131I monitoring

    International Nuclear Information System (INIS)

    Hirota, M.; Saze, T.; Nishizawa, K.

    2002-01-01

    An imaging plate (IP) system was applied to in vivo thyroid radioactive iodine 131 ( 131 I) monitoring. Thyroid contamination by 131 I occurs when medical staffs and patient's families take in 131 I used as treatment agent for thyroid cancer and hyperthyroidism in nuclear medicine, inhabitants take in 131 I released into environment by an accident of nuclear facilities, or worker take in 131 I used by experiment of research. The IP system is a two-dimensional integrating radiation detector which is a plate thinly coated plastic sheet with a kind of phosphore. The IP was exposed to a neck-thyroid phantom loaded 131 I aqueous solution. The IP system displayed a thyroid image that reflects a unique shape characteristic of the thyroid gland. A 131 I thyroid imaging allows visual confirmation of thyroid contamination by 131 I. The counting efficiency was approximately constant when neck diameter, thyroid volume and prethyroid tissue thickness varied within the normal adult. The detection limit of 450Bq was about 1/65 of the screening level of 30kBq. The IP system is applicable for thyroid 131 I monitoring

  11. Labelling of tung oil with 131I

    International Nuclear Information System (INIS)

    Correia, R.J.; Mitta, A.E.A.

    1975-01-01

    A method for labelling Tung Oil with 131 I is described. The oil is dissolved in peroxide free, dry ethyl ether and then it is treated with 131 ICl. A 2,5% mercuric acetate solution in glacial acetic acid is added as a catalist. A radiochemical yield of 100% is achieved in 20 minutes. (author)

  12. Evaluation of an internalizing monoclonal antibody labeled using N-succinimidyl 3-[{sup 131}i]iodo-4-phosphonomethylbenzoate ([{sup 131}i]SIPMB), a negatively charged substituent bearing acylation agent

    Energy Technology Data Exchange (ETDEWEB)

    Shankar, Sriram; Vaidyanathan, Ganesan; Affleck, Donna J.; Peixoto, Katia; Bigner, Darell D.; Zalutsky, Michael R. E-mail: zalut001@mc.duke.edu

    2004-10-01

    Monoclonal antibodies such as L8A4, reactive with the epidermal growth factor receptor variant III, internalize after receptor binding resulting in proteolytic degradation by lysosomes. Labeling internalizing mAbs requires the use of methodologies that result in the trapping of labeled catabolites in tumor cells after intracellular processing. Herein we have investigated the potential utility of N-succinimidyl-3-[{sup 131}I]iodo-4-phosphonomethylbenzoate ([{sup 131}I]SIPMB), an acylation agent that couples the corresponding negatively charged acid [{sup 131}I]IPMBA to the protein, for this purpose. Biodistribution studies demonstrated that [{sup 131}I]IPMBA cleared rapidly from normal tissues and exhibited thyroid levels {<=}0.1% injected dose, consistent with a low degree of dehalogenation. Biodistribution experiments in athymic mice bearing subcutaneous D-256 human glioma xenografts were performed to compare L8A4 labeled using [{sup 131}I]SIPMB to L8A4 labeled with {sup 125}I using both the analogous positively charged acylation agent N-succinimidyl-4-guanidinomethyl-3-[{sup 125}I]iodobenzoate ([{sup 125}I]SGMIB) and Iodogen. Tumor uptake of [{sup 131}I]SIPMB-L8A4 (41.9{+-}3.5% ID/g) was nearly threefold that of L8A4 labeled using Iodogen (14.0{+-}1.1% ID/g) after 2 days, and tumor to tissue ratios remained uniformly high throughout with [{sup 131}I]SIPMB-L8A4. Thyroid uptake increased for the Iodogen labeled mAb (3.55{+-}0.36 %ID at 5 days) whereas that of [{sup 131}I]SIPMB labeled mAb remained low (0.21{+-}0.04% ID at 5 days). In the second biodistribution, L8A4 labeled using [{sup 131}I]SIPMB and [{sup 125}I]SGMIB showed no difference in normal tissue uptake and had nearly identical tumor uptake ([{sup 131}I]SIPMB, 41.8{+-}14.2% ID/g; [{sup 125}I]SGMIB, 41.6{+-}15.8% ID/g, at 4 days). These results suggest that [{sup 131}I]SIPMB may be a viable acylation agent for the radioiodination of internalizing mAbs.

  13. 131I-MIBG and neuroendocrine tumours

    International Nuclear Information System (INIS)

    Oliva Gonzalez, Juan Perfecto; Gonzalez Gonzalez, Joaquin Jorge; Calderon Marin, Carlos Fabian

    2012-01-01

    Neuroendocrine tumours are neoplasms that arise from various tissues closely linked to the neural crest by their common embryological origin. These tumours have the ability to synthesize neurotransmitter peptides and hormones, as well as to store catecholamines. Some of these tumours express somatostatin receptors at their membranes, what have allowed nuclear medicine to be involved in their diagnosis, treatment and monitoring. Since they arise from different and varied types of tissues, these tumours have a wide range of signs and symptoms different for every one of them. These signs and symptoms mainly depend on their biochemical characteristics, given by the substances they secrete, as well as by their location, and consequently, they also depend on the place where the tumour appears, its local infiltration, and potential long-distance metastasis resulting from the tumour). Neuroendocrine tumours are diagnosed by means of nuclear medicine images, which are obtained by using different techniques and radiopharmaceuticals such as 99 mTc dimercaptosuccinic acid (DMSA(V)), 99 mTc-methoxy-isobutyl-isonitrile (MIBI), metaiodobenzylguanidine (MIBG) labelled with 131 I or 123 I ( 131 I-MIBG or 123 I -MIBG), 111 In-labelled octreotide, positron emission tomography, using 68 Ga-labelled somatostatin analogues and carcinoembryonic antigen monoclonal antibodies. Nuclear medicine uses mainly somatostatin analogues labelled with 90 Y or 177 Lu for the treatment of these tumours. This paper is aimed at showing our experience in the use of 131 I-MIBG for the diagnosis and treatment of neuroendocrine tumours.(author)

  14. Behavior of medically-derived 131I in the tidal Potomac River

    International Nuclear Information System (INIS)

    Rose, Paula S.; Smith, Joseph P.; Cochran, J. Kirk; Aller, Robert C.; Swanson, R. Lawrence

    2013-01-01

    Iodine-131 (t 1/2 = 8.04 d) is administered to patients for treatment of thyroid disorders, excreted by patients and discharged to surface waters via sewage effluent. Radionuclides generally behave like their stable analogs; therefore, medically-derived 131 I is useful as a transport-reaction tracer of anthropogenic inputs and the aquatic biogeochemistry of iodine. Iodine-131 was measured in Potomac River water and sediments in the vicinity of the Blue Plains Water Pollution Control Plant (WPCP), Washington, DC, USA. Concentrations measured in sewage effluent from Blue Plains WPCP and in the Potomac River suggest a relatively continuous source of this radionuclide. The range of 131 I concentrations detected in surface water was 0.076 ± 0.006 to 6.07 ± 0.07 Bq L −1 . Iodine-131 concentrations in sediments ranged from 1.3 ± 0.8 to 117 ± 2 Bq kg −1 dry weight. Partitioning in the sewage effluent from Blue Plains and in surface waters indicated that 131 I is associated with colloidal and particulate organic material. The behavior of medically-derived 131 I in the Potomac River is consistent with the nutrient-like behavior of natural iodine in aquatic environments. After discharge to the river via sewage effluent, it is incorporated into biogenic particulate material and deposited in sediments. Solid phase sediment profiles of 131 I indicated rapid mixing or sedimentation of particulate debris and diagenetic remineralization and recycling on short time scales. - Highlights: ► Medically-derived 131 I was measured in sewage effluent, river water, and sediments. ► Sediment 210 Pb and 7 Be profiles help characterize the sedimentary environment. ► 131 I flux to sediments in study area is ∼ 1% of that discharged in sewage effluent. ► 131 I distributions constrain reaction-transport processes to weekly time scales. ► Collectively these data are used to better understand iodine biogeochemistry

  15. Fixed dose 131-I treatment in Basedow patients

    International Nuclear Information System (INIS)

    Klisarova, A; Bochev, P.; Hristosov, K.

    2003-01-01

    The choice of a treatment for Basedow patients is still unsolved problem. The treatment with 131-I has certain advantages but the determination of the individual therapeutic dose is impossible. The aim of the study is to assess the efficiency of the treatment with a fixed dose. 23 patient have been treated, 30 women and 3 men, age between 48 and 78. All patients are with chronic disease with relapses (1 to 4 relapses). 5 of the patients are with a thyrotoxic heart, 3 - with ophtalmopatia, 2 - with toxic medicamentous hepatitis and 2 with allergies to thyreostatics. Before the treatment with 131-I all patients have been in euthyroid state with normal levels of the peripheral hormones. All patients have received initial doses of 5 mCi 131-I. The hormone levels have been followed on 3rd, 6th, 12th and 24th month after the uptake. From a total of 23 patients, in 3 cases a transitional hypothyroidism has been found between 3th and 6th month, in 3 patients - permanent hypothyroidism. In 5 patients after the 6th month an additional dose of 5 mCi 131-I is given (in one woman a permanent hypothyroidism is reached). Four of the patients have been with a significant thyroid hyperplasia with volume above 60 ml. In three patients in the period between 6th and 12th month a slight hyperthyroidism is registered, which have been suppressed by a low dose thyreostatic. A year after the treatment they have been found euthyroid. The decision for giving a second dose have been based on the evident heptahydrate symptomatic s and the persisting increased thyroid volume. In one case it is observed an acute thyrotoxicosis for 3-5 days after the 131 I uptake. No cases of worsening of the eye symptoms are observed. In conclusion, the treatment with 131 I is a appropriate method for patients with cardiovascular complications, contraindication for surgery or side effects of the thyreostatic treatment. the dose od 5 mCi is sufficient for patients with mild to medium form of Basedow disease and a

  16. Statyny i astma

    Directory of Open Access Journals (Sweden)

    Joanna Pawlak

    2011-01-01

    Full Text Available Statyny należą do leków powszechnie stosowanych w leczeniu hiperlipidemii oraz chorób układu sercowo-naczyniowego. Hamując aktywność reduktazy 3-hydroksy-metyloglutarylo-koenzymu A (HMG-CoA zmniejszają syntezę cholesterolu. Wykazano, że leki te cechują się znacznie szerszym zakresem działania, które określono jako pozalipidowe (plejotropowe. Mimo że korzyści z działania inhibitorów reduktazy HMG-CoA zostały już dowiedzione w leczeniu chorób układu sercowo-naczyniowego, podejmuje się próby ich wykorzystywania w innych dziedzinach medycyny, takich jak neurologia czy reumatologia. Obecnie szczególną uwagę zwraca się na działanie przeciwzapalne i immunomodulujące tych leków. Na podstawie powyższych obserwacji w ostatnich latach podjęto próby zastosowania statyn również w alergologii.W pracy przedstawiono wybrane aspekty wpływu statyn na reakcje immunologiczne i proces zapalny wskazując na możliwość wykorzystania tych leków w leczeniu astmy.

  17. Evaluation of infection imaging potential of 131I-labeled imidazolium salt

    International Nuclear Information System (INIS)

    Ayca Tuncel; Fatma Yurt; Osman Yilmaz; Ismail Oeztuerk

    2018-01-01

    Effective antimicrobial compounds are necessary due to increased resistance of antibiotics against microorganisms causing infectious diseases. In this study, imidazolium-TFSI salt [ITFSI: octyl-bis(3-methylimidazolium)-di(bis(trifluoromethane)sulfonimide)] was labeled with 131 I with high efficiency. In vitro uptake experiments of 131 I-ITFSI showed high uptake in gram-positive Staphylococcus aureus bacteria. 131 I-ITFSI was also evaluated for comparison between bacterial infection and sterile inflammation by in vivo studies. The biodistribution results revealed that 131 I-ITFSI might be used as a nuclear imaging agent for detection of bacterial infection. (author)

  18. Recommendations for the measurement 131I in human thyroid using a detector of NaI(Tl)

    International Nuclear Information System (INIS)

    Puerta Yepes, N.; Rojo, A.M.; Andres, P.A.

    2010-01-01

    The Argentine Total Body Counter Laboratory of the Nuclear Regulatory Authority participated in the last regional intercomparison Exercise organized in the frame of the IAEA Project RLA 9/066 related with in vivo measurements of 131 I in the thyroid. There were identified some difficulties in determining the efficiency and calibration factor (CF) for the 131 I when a source of 133 Ba and a detector of NaI (Tl) are used in the calibration process. Independent measurements were performed for two calibration sources of known activity ( 133 Ba and 131 I) with identical geometry pattern and using a gamma spectrometry system with NaI(Ti) detector. It was found that the region of interest (ROI) which, both in the spectrum of 133 Ba as in the spectrum of 131 I, had the same efficiency. It was determined the activity of the source of 133 Ba , distributed in the intercomparison, and the calibrated source of 131 I using different values of efficiency and FC obtained. It was analyzed the conditions under which the use of 133 Ba as a source of calibration is effective for the measurement of 131 I. (authors) [es

  19. Vocal cord paralysis following I-131 ablation of a postthyroidectomy remnant

    International Nuclear Information System (INIS)

    Lee, T.C.; Harbert, J.C.; Dejter, S.W.; Mariner, D.R.; VanDam, J.

    1985-01-01

    Vocal cord paralysis has been reported following I-131 therapy of thyrotoxicosis and following ablation of the whole thryoid. However, this rare complication has not previously been described following I-131 ablation of a postthyroidectomy remnant. The authors report a patient who required tracheostomy for bilateral vocal cord paralysis following I-131 ablation after near-total thyroidectomy for papillary thyroid carcinoma

  20. The interactions among impact factors affecting 131I treatment efficacy of Graves' disease

    International Nuclear Information System (INIS)

    Wang Peng; Tan Jian; Zhang Guizhi; He Yajing; Dong Feng; Wang Renfei; Xiao Qian

    2011-01-01

    Objective: To evaluate the possible interactions among different impact factors possibly affecting the treatment efficacy of 131 I in Graves' disease (GD). Methods: Six hundred and thirty two GD patients that had been treated by 131 I, with or without antithyroid drugs (ATD), were included in this study. The impact factors were pre-defined as age (x 1 ), sex (x 2 ), mass of thyroid (x 3 ), course of disease (x 4 ), initial symptom (x 5 ), condition of disease (x 6 ), ATD treatment duration (x 7 ), effective half life time (x 8 ), maximum 131 I uptake rate (x 9 ), total dose of 131 I (x 10 ), dose of 131 I per gram of thyroid (x 11 ), TRAb (x 12 ), TSI (x 13 ), TgAb (x 14 ), and thyroid microsomal antibody(TMAb) level (x 15 ). Interactions among different impact factors were studied by t-test, χ 2 test and multi-variant logistic regression. Results: Age, mass of thyroid, ATD treatment duration, maximum 131 I uptake rate, dose of 131 I per gram of thyroid tissue and TSI level were identified as independent impact factors affecting the 131 I treatment efficacy on GD (χ 2 =6.908, t=-4.063, χ 2 =13.558, t=-2.553, t=4.528, χ 2 =9.716, all P 131 I uptake rate (likelihood χ 2 =8.176, P>0.05; F=2.928, 1.992, 2.629, 2.215, all P 131 I treatment, which might guide the prescription of 131 I dosage for GD treatment. (authors)

  1. Evaluation of 131I retention in several adsorbers

    International Nuclear Information System (INIS)

    Catanoso, Marcela F.; Osso Junior, Joao Alberto

    2011-01-01

    Several iodine radioisotopes are used in nuclear medicine for treatment and diagnostic purposes. The radioisotope 131 I is used both in diagnosis and therapy due to its physical characteristics of decay by β - and its γ-ray emissions suitable for diagnosis. It is routinely produced at IPEN through the irradiation of TeO 2 targets in the IEA-R1m nuclear reactor. After the irradiation, the 131 I is separated by dry distillation, where the targets are put in an oven, heated at 760 deg C for 2 hours and the 131 I, volatile, is carried by an O 2 gas stream. The aim of this work was to evaluate the retention and elution of 131 I samples produced at IPEN in several adsorbers as part of a project aiming the purification of these radioisotopes, allowing the labeling of biomolecules. Samples of 131 I were used for retention and elution studies with the following adsorbers: commercial cartridges, anionic resin columns and cationic resin column. The results showed that Ag cartridges and anionic resins Dowex 1X8, Dowex 3 and IRA 400 had a great iodine retention but no elution after using specific eluents. The QMA light, acid alumina, neutral alumina and cationic resin Dowex 50WX4 showed high retention and elution and QMA plus and cationic resin Dowex 50WX8 and Dowex 50WX12 had a good retention but lower elution. Regarding to the better retention and elution, Ag cartridges and resins showed a higher percentage of iodine retention but lower elution yield and QMA light, acid and neutral alumina cartridges showed better results. (author)

  2. Longterm results of 131I treatment of hyperthyroidism

    International Nuclear Information System (INIS)

    Hamada, Noboru; Ito, Kunihiko; Mimura, Takashi; Nishikawa, Yoshihiko; Momotani, Naoko

    1979-01-01

    The results of 131 I treatment were analyzed in 512 out of 1,620 cases of hyperthyroid patients treated with 131 I from 1963 to 1967 at Ito Hospital, Tokyo. The incidence of hypothyroidism, diagnosed clinically referring serum T 3 , T 4 and metabolic index, was 28.5%, euthyroidism 66.4% and hyperthyroidism 5.1%. Fourty one percent of euthyroid cases had high levels of serum TSH. While TRH tests were performed in 11 euthyroid cases with normal TSH levels, TSH response was normal in only 3 of the cases. Since there was no difference in the incidence of hypothyroidism among patients receiving a single dose of 6,001 - 7,000, 7,001 - 8,000 and 8,001 - 9,000 rads, relationship between the results of therapy and various factors which might influence the outcome of therapy was investigated in these cases. The incidence of hypothyroidism was higher in patients with shorter period between the onset of hyperthyroid symptoms and 131 I therapy, previous therapy with external irradiation, small goiter, severe exophthalmus, and shorter effective half life of 131 I at the time of treatment. Three cases of thyroid cancer and 2 cases of leukemia were observed in 823 patients which included 311 cases followed up only by inquiry. (author)

  3. Therapeutic efficacy of intralesional 131I-labelled hyaluronectin in grafted human glioblastoma

    Energy Technology Data Exchange (ETDEWEB)

    Girard, N.; Courel, M.N.; Vera, P.; Delpech, B. [Centre Henri-Becquerel, Rouen (France). Laboratoire d' Oncologie Moleculaire

    2000-07-01

    The grafted human glioblastoma cell CB109 was used as a model for intralesional therapy with 131I-labelled hyaluronectin glycoprotein (131I-HN). 131I-HN bound specifically to in situ hyaluronic acid (HA), a main component of the extracellular matrix which is involved in tumour invasion. Labelling experimental conditions were determined and, finally, 25 {mu}Ci/{mu}gHN, 1 {mu}g chloramine-T/{mu}gHN and a 60-s stirring period provided a 131I-HN preparation with an optimal affinity for HA (64% compared to unlabelled HN). Following intratumoral injection, 131I-HN was retained with a limited diffusion outside the tumour. On day 4 the radioactivity concentrated in the tumour was still 25 times greater than that in the liver, spleen and kidneys combined. For therapeutic assays, 65 {mu}Ci 131I-HN was injected into the tumour, resulting in a delivery of 6.8 Gy over a 7-day period. Controls received unlabelled HN, heat-inactivated HN, a mixture of inactivated HN plus free 131I or no treatment (six animals per group). Tumour volumes were evaluated every second day from treatment day and the rate of tumour growth was expressed as a ratio of tumour size at time intervals to the tumour size at the time of injection. Growth curves were compared: heat-inactivated with or without free 131I had no anti-tumour effect. Unlabelled HN-injected tumours had a slightly slower growth rate than untreated tumours (p < 0.02) and growth rate of 131I-HN-injected tumours was much lower (p < 0.00002). A pronounced inhibitory effect with intralesional 131I-labelled HN injection resulted from a combination of a) blockage of HA, a proliferation facilitating factor, and b) local irradiation of tumoral tissue, while uptake in normal tissues was minimized.

  4. Therapeutic efficacy of intralesional 131I-labelled hyaluronectin in grafted human glioblastoma

    International Nuclear Information System (INIS)

    Girard, N.; Courel, M.N.; Vera, P.; Delpech, B.

    2000-01-01

    The grafted human glioblastoma cell CB109 was used as a model for intralesional therapy with 131I-labelled hyaluronectin glycoprotein (131I-HN). 131I-HN bound specifically to in situ hyaluronic acid (HA), a main component of the extracellular matrix which is involved in tumour invasion. Labelling experimental conditions were determined and, finally, 25 μCi/μgHN, 1 μg chloramine-T/μgHN and a 60-s stirring period provided a 131I-HN preparation with an optimal affinity for HA (64% compared to unlabelled HN). Following intratumoral injection, 131I-HN was retained with a limited diffusion outside the tumour. On day 4 the radioactivity concentrated in the tumour was still 25 times greater than that in the liver, spleen and kidneys combined. For therapeutic assays, 65 μCi 131I-HN was injected into the tumour, resulting in a delivery of 6.8 Gy over a 7-day period. Controls received unlabelled HN, heat-inactivated HN, a mixture of inactivated HN plus free 131I or no treatment (six animals per group). Tumour volumes were evaluated every second day from treatment day and the rate of tumour growth was expressed as a ratio of tumour size at time intervals to the tumour size at the time of injection. Growth curves were compared: heat-inactivated with or without free 131I had no anti-tumour effect. Unlabelled HN-injected tumours had a slightly slower growth rate than untreated tumours (p < 0.02) and growth rate of 131I-HN-injected tumours was much lower (p < 0.00002). A pronounced inhibitory effect with intralesional 131I-labelled HN injection resulted from a combination of a) blockage of HA, a proliferation facilitating factor, and b) local irradiation of tumoral tissue, while uptake in normal tissues was minimized

  5. Migration of radionuclide I-131 through a clayey porous matrix

    International Nuclear Information System (INIS)

    Hamlat, M.S.

    1996-01-01

    The chemical and physical behavior of the radiotracer I-131 through a porous matrix are described. The study was evaluated using the laboratory column, which contains porous soils. The collected activities have been measured by gamma counting with a NaI(Tl) detector. The indicators were observed and analyzed by using the one dimension mass transport equation. The solution was utilized to interpret the obtaining experimental data. The experimental values of I-131 are in agreement with those calculated by the model. However, the utilization of (I-131) in the punctual hydrogeological studies is proved. (author). 5 refs., 2 figs., 2 tabs

  6. Predictive value of tracer studies for 131I treatment in hyperthyroid cats

    International Nuclear Information System (INIS)

    Broome, M.R.; Turrel, J.M.; Hays, M.T.

    1988-01-01

    In 76 cats with hyperthyroidism, peak thyroidal radioiodine ( 131 I) uptakes and effective half-lives were determined after administration of tracer and therapeutic activities of 131 I. In 6 additional hyperthyroid cats, only peak thyroidal uptakes after administration of tracer and therapeutic activities of 131 I were determined. Good correlation was found between peak thyroidal uptakes of tracer and therapeutic 131 I; however, only fair correlation was observed between effective half-lives. In 79% of the cats, the effective half-life for therapeutic 131 I was longer than that for tracer 131 I. After administration of therapeutic activity of 131 I, monoexponential and biphasic decay curves were observed in 51 and 16 cats, respectively. Using therapeutic kinetic data, radiation doses to the thyroid gland were calculated retrospectively on the basis of 2 methods for determining the activity of 131 I administered: (1) actual administration of tracer-compensated activity and (2) hypothetic administration of uniform activity (3 mCi). Because of the good predictive ability of tracer kinetic data for the therapeutic kinetic data, the tracer-compensated radiation doses came significantly (P = 0.008) closer to the therapeutic goal than did the uniform-activity doses. In addition, the use of tracer kinetic information reduced the extent of the tendency for consistently high uniform-activity doses. A manual method for acquiring tracer kinetic data was developed and was an acceptable alternative to computerized techniques. Adoption of this method gives individuals and institutions with limited finances the opportunity to characterize the iodine kinetics in cats before proceeding with administration of therapeutic activities of 131 I

  7. An accurate method of 131I dosimetry in the rat thyroid

    International Nuclear Information System (INIS)

    Lee, W.; Shleien, B.; Telles, N.C.; Chiacchierini, R.P.

    1979-01-01

    An accurate method of thyroid 131 I dosimetry was developed by imploying the dose formulation recommended by the Medical Internal Radiation Dose (MIRD) Committee. Six-week-old female Long-Evans rats were injected intraperitonealy with 0.5, 1.9, and 5.4 μCi of Na 131 I. The accumulated 131 I activities in the thyroid were precisely determined by integrating the 131 I activities per gram of the thyroid as functions of postinjection time. When the mean thyroid doses derived from this method are compared to those derived from the conventional method, the conventional method over-estimated the doses by 60 to 70%. Similarly, the conventional method yielded effective half-lives of 2.5 to 2.8 days; these estimates were found to be high by factors of 1.4 to 2.0. This finding implies that the biological elimination of iodide from the rat thyroid is much more rapid (up to 2.5 times) that once believed. Results from this study showed that the basic assumption in the conventional method of thyroid 131 I dosimetry in the rat, i.e., that the thyroid iodide retention function is a single exponential, is invalid. Results from this study also demonstrated that variations in animal body weight of 6 to 7-week-old animals and diurnal variation have no significant influence on the mean thyroid doses for a given injected activity of 131 I. However, as expected, variation in iodide content of the animal diets significantly altered the thyroid doses for a given 131 I injected activity

  8. Development of a calibration system for airborne "1"3"1I monitoring devices

    International Nuclear Information System (INIS)

    Zhao, C.; Tang, F.; He, L.; Xu, Y.; Lu, X.

    2016-01-01

    A prototype calibration system for airborne "1"3"1I monitoring devices was developed at the Shanghai Institute of Measurement and Testing Technology (SIMT). This system consists of a gaseous "1"3"1I_2 generator, an airborne storage chamber, an airborne iodine sampler, and an HPGe spectrometer. With this system, "1"3"1I reference samples in the form of charcoal filters and charcoal cartridges, with activities ranging from 100 to 10,000 Bq, were produced with overall relative standard uncertainties of 2.8% (for filter samples) and 3.5% (for cartridge samples); the activities range could be extended according to need. - Highlights: • Original calibration system for airborne "1"3"1I monitoring devices was developed. • Two types of "1"3"1I reference samples was prepared. • The activity of the produced "1"3"1I reference sample could be easily controlled. • The influence of uneven distribution of "1"3"1I in cartridge samples was considered.

  9. Preparation and biodistribution of [131I]linezolid in animal model infection and inflammation

    International Nuclear Information System (INIS)

    Yurt Lambrecht, F.; Durkan, K.; Unak, P.; Bayrak, E.; Yilmaz, O.

    2009-01-01

    Linezolid is the first of new class of antibiotics, the oxazolidinones, and exhibits activity against many gram-positive organisms, including vancomycin-resistant Enterococcus faecium, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. Aim of the study: Linezolid was to label with I-131 and potential of the radiolabeled antibiotic was to investigate in inflamed rats with S. aureus (S. aureus) and sterile inflamed rats with turpentine oil. Linezolid was labeled with I-131 by iodogen method. Biodistribution of [ 131 I]linezolid was carried out in bacterial inflamed and sterile inflamed rats. Radiolabeling yield of [ 131 I]linezolid was determined as 85 ± 1% at pH 2. After injecting of [ 131 I]linezolid into bacterial inflamed and sterile inflamed rats, radiolabeled linezolid was rapidly removed from the circulation via the kidneys. Binding of [ 131 I]linezolid to bacterial inflamed muscle (T/NT = 77.48 at 30 min) was five times higher than binding to sterile inflamed muscle (T/NT = 14.87 at 30 min) of rats. [ 131 I]linezolid showed good localization in bacterial inflamed tissue. It was demonstrated that [ 131 I]linezolid can be used to detect S. aureus inflammation in rats. (author)

  10. Calculated activity incorporated in the therapy with I131

    International Nuclear Information System (INIS)

    Chica, L.G.; Puerta, J.A.

    1998-01-01

    By means of the product S(T→ S).A s (T e ), the absorbed dose to thyroid delivered by I 131 incorporated is calculated. Where S(T→ S) is the absorbed dose in the thyroid per nuclear transformation (tn.) of I 131 localized in the thyroid and as a potential function of the mass is expressed. A s (T e ) is the number of tn. of I 131 in the thyroid since the moment of the incorporation until the time T e (the effective middle time); to find A s (T e ) to normal as different pathological conditions, the metabolic model of the iodo proposed by the ICRP is used. Of the expressions of the doses, the incorporated activity, l o , is obtained

  11. Clinical discussion of adrenal scan by 131I-adosterol

    International Nuclear Information System (INIS)

    Kubo, Atsushi

    1976-01-01

    131 I-adosterol adrenal scan was conducted to 31 patients. Clear positive images were obtained at the adrenal gland at the side of cortical adenoma on scintigram in all of 5 patients with primary aldosteronism and 5 patients with Cushing's syndrome. It was found that the quantitative measurements of 131 I-adosterol % uptake and of right-to-left uptake ratio do not only make a regional diagnosis of adrenocortical tumor more positive, but also they make the state of adrenocortical function known to an extent. Adrenal scan is easy to be used, and is non-invasive to patients. The obtained results are diagnostically valuable. It is considered that 131 I-Adosterol is an excellent radiopharmaceutical having the sufficient efficacy for adrenal diseases. (Ichikawa, K.)

  12. 131I-iodine treatment of hyperthyroidism in children and adolescents

    International Nuclear Information System (INIS)

    Zhao Deshan

    2004-01-01

    Purpose: To evaluate the efficacy of 131 I-iodine treatment of hyperthyroidism in children and adolescents. Methods: Twenty-nine, patients aged 11-18 years (mean 15.9±2.32 years old), with hyperthyroidism received 131 I-iodine treatment in a dose of 25-90μCi/g (median 50μCi/g) of thyroid. Of the 29 patients, 3 patient required 2 doses, 14 received ATD therapy before 131 I, 11 patients suffered from TAO(thyroid associated ophthalmopathy). The total maximum and minimum doses were 15 and 1.6 mCi respectively. Results: All patients treated with 131 I-iodine, follow-up after the most recent treatment (median 14, range 4 to 60 months), 15 patients were euthyroid, 5 suffered from late-onset hypothyroidism, 9 were still hyperthyroidism, but their symptoms and signs of hyperthyroidism were improved or markedly. Of the 16 patients with TAO, TAO in 11 patients disappeared or were improved, TAO in 5 patients didn't or mildly change. The size of thyroid in all patients had largely been reduced. Conclusions: 131 I-iodine is effective for initial treatment of hyperthyroidism, the treatment of medical treatment failures and the patients with TAO in children and adolescents. (authors)

  13. Production technology of 131I-rose bengal

    International Nuclear Information System (INIS)

    Hradilek, P.; Miklik, M.; Kopicka, K.; Kronrad, L.

    1983-01-01

    A detailed description is presented of the production equipment and production process used for Rose Bengal labelled with 131 I designed for use in nuclear medicine. The apparatus was installed in the semi-hot cell laboratory of the Nuclear Research Institute at Rez. The processed activity is around 20 GBq, the average yield of the ion exchange reaction between non-radioactive Rose Bengal and 131 I-labelled sodium iodide is 90%. The unreacted active sodium iodide is separated and the resulting product is diluted and processed into a drug presentation, sterilized and after random control is distributed in 14 days intervals to medical workplaces. (M.D.)

  14. Antithyroid drug regimens before and after 131I-therapy for hyperthyroidism: evidence-based?

    Science.gov (United States)

    Mijnhout, G S; Franken, A A M

    2008-06-01

    In view of the new national guideline on thyroid dysfunction, the evidence base for current practice as well as the new guideline is assessed with regard to the use of antithyroid drugs (ATDs) before and after radioiodine (131I) therapy. In December 2006, we surveyed 16 hospitals by telephone about different aspects of their antithyroid drug regimen: all eight academic centres and eight nonacademic teaching hospitals. The literature was searched for an evidence-based answer to each question in the inquiry. 13 of 16 hospitals (81%) use antithyroid drugs for pretreatment before 131I. ATDs are discontinued on average four days before 131I or diagnostic scan. However, 27% stop only three days beforehand, which may diminish the effect of 131I. Propylthiouracil (PTU) is also withdrawn four days before 131I, although the literature shows that PTU diminishes the effect of 131I even if it is stopped 15 days beforehand. Resumption of ATDs after 131I to prevent thyrotoxicosis is common practice (81%). One hospital (6%) never restarts ATDs, two (13%) only by indication. Adjunctive treatment consists of combination therapy in 93%, is usually resumed within two days after 131I therapy, and then continued for two to six months. Routine adjunctive treatment is not evidence-based and may be limited to a high-risk subset, especially elderly patients (>70 years) and patients with cardiac comorbidity. Resumption of ATDs within five to seven days after 131I may diminish the effect of 131I. Antithyroid drug regimens in the Netherlands are heterogeneous. The evidence base of current practice and the new guideline are discussed.

  15. Leczenie skojarzone astmy wziewnymi glikokortykosteroidami i β2-agonistami

    Directory of Open Access Journals (Sweden)

    Iwona Grzelewska-Rzymowska

    2009-09-01

    Full Text Available Dokonany w tym artykule przegląd badań ocenia dowody dotyczące leczenia astmy kombinacją wziewnych glikokortykosteroidów (wGKS i długo działających β2-agonistów (LAβA. Za leki pierwszego wyboru w astmie uznaje się wGKS. Integralną częścią leczenia astmy są β2-agoniści, najsilniejsze leki rozszerzające oskrzela. Obecnie dostępne są dwa leki z grupy długo działających β2-agonistów – formoterol i salmeterol. W kilku badaniach klinicznych udowodniono, że kombinacja wGKS i LAβA stanowi skuteczną i bezpieczną opcję w leczeniu astmy. Raporty GINA zalecają dodanie LAβA do małych i średnich dawek wGKS, co pozwala na uzyskanie kontroli astmy. Także z badań klinicznych uzyskaliśmy wiedzę, że kombinacja wGKS i LAβA daje większe korzyści w kontroli objawów astmy niż dwukrotnie większa dawka wGKS. Astma jest przewlekłą chorobą zapalną z rozwojem nadreaktywności oskrzeli. Przebieg kliniczny astmy jest zazwyczaj inny u różnych chorych, a nawet u tej samej osoby. W praktyce klinicznej choremu zaleca się podawanie stałych dawek wGKS, odpowiednich do stopnia ciężkości astmy, lub kombinacji wGKS i LAβA dwa razy dziennie i dodatkowo krótko działającego β2-agonisty „według potrzeby” (lub „na żądanie” dla złagodzenia objawów astmy. Ostatnio wprowadzono nowy model stosowania kombinacji wGKS i LAβA (budezonid/formoterol – tzw. SMART (Single Maintenance and Reliever Therapy. Jest to połączenie leków według koncepcji SMART stosowane zarówno w leczeniu przewlekłym dwa razy dziennie, jak i „według potrzeby” dla złagodzenia objawów bez dodatkowego stosowania leków tylko przynoszących ulgę. Badania kliniczne wykazały, że metoda SMART zmniejsza ryzyko ostrych zaostrzeń i jest dobrze tolerowana. Metoda ta ma korzystne działanie u pacjentów, u których utrzymują się objawy astmy pomimo leczenia kombinacją leków stosowanych tylko w leczeniu przewlekłym.

  16. Analysis of factors for early hypothyroidism after 131I treatment of hyperthyroidism

    International Nuclear Information System (INIS)

    Zhou Youjun; Quan Xinsheng; Zhang Ling; He Meiqiong

    2008-01-01

    To explore the factors for the early hypothyroidism following 131 I treatment of hyperthyroidism, clinic data of 120 hyperthyroidism patients including 8 independent and 1 dependent variables after one year 131 I treatment were analyzed by logistic regression analysis method. The results showed that the average 131 I dosage given to one gram thyroid tissue was correlated positively with early hypothyroidism occurrence, and the weight of thyroid was negatively correlated to early hypothyroidism occurrence. The positive and negative prediction accuracy of the early hypothyroidism were 53.3% and 96.1% respectively, and the total prediction accuracy was 46.7%. The results suggest that the 131 I dosage and the weight of thyroid are key factors for early hypothyroidism; the appropriate adjustment of 131 I dosage based on the thyroid mass could prevent the early hypothyroidism occurrence in certain degree. (authors)

  17. Sequelae and survivorship in patients treated with (131)I-MIBG therapy.

    Science.gov (United States)

    Sze, W C C; Grossman, A B; Goddard, I; Amendra, D; Shieh, S C C; Plowman, P N; Drake, W M; Akker, S A; Druce, M R

    2013-08-06

    (131)I-meta-iodobenzylguanidine ((131)I-MIBG) has been in therapeutic use since 1980s. Newer treatment modalities are emerging for neuroendocrine tumours (NETs) and chromaffin cell tumours (CCTs), but many of these do not yet have adequate long-term follow-up to determine their longer term efficacy and sequelae. Fifty-eight patients with metastatic NETs and CCTs who had received (131)I-MIBG therapy between 2000 and 2011 were analysed. Survival and any long-term haematological or renal sequelae were investigated. In the NET group, the overall median survival and median survival following the diagnosis of metastatic disease was 124 months. The median survival following the commencement of (131)I-MIBG was 66 months. For the CCT group, median survival had not been reached. The 5-year survival from diagnosis and following the diagnosis of metastatic disease was 67% and 67.5% for NETs and CCTs, respectively. The 5-year survival following the commencement of (131)I-MIBG therapy was 68%. Thirty-two patients had long-term haematological sequelae: 5 of these 32 patients developed haematological malignancies. Two patients developed a mild deterioration in renal function. Long follow up of (131)I-MIBG therapy reveals a noteable rate of bone marrow toxicities and malignancy and long term review of all patients receiving radionuclide therapies is recommended.

  18. Long-term follow-up study of I-131 therapy for Graves' disease

    International Nuclear Information System (INIS)

    Kusakabe, Kiyoko; Nakano, Keiko; Maki, Masako

    1990-01-01

    We have studied the follow-up of thyroid function in the patients with late-onset hypothyroidism and euthyroidism after I-131 therapy of hyperthyroidism. Thirty three patients who did not need the thyroid treatment until ten years after I-131 therapy were classified as euthyroid group. And eleven patients who needed the thyroid supplement of thyroid hormone for late-onset hypothyroidism were classified as hypothyroid group. Patients in both groups who required only a single dose of I-131 for successful treatment of hyperthyroidism had similar age, gland size, 24 hour I-131 uptake, pretreatment serum T 3 uptake level and T 4 concentration, and I-131 treatment dose. Subclinical hypothyroidism occurred in 28.6% of euthyroid group and 66.7% of hypothyroid group four months after I-131 therapy. The levels of T 3 were recovered to higher than normal range at 6 months in euthyroid group, while the levels of T 3 were kept within the normal range in the seventy percent of hypothyroid group. Patients who were still lower in the level of T 3 uptake than normal range at 6 months had a higher incidence of late-onset hypothyroidism. Our observation showed no significant difference in the course of follow-up studies after I-131 therapy between the patients with late-onset hypothyroidism and euthyroidism. (author)

  19. {sup 131}I-induced changes in rat thyroid gland function

    Energy Technology Data Exchange (ETDEWEB)

    Torlak, V.; Capkun, V.; Stanicic, A. [Clinical Hospital Split, Split (Croatia). Dept. of Nuclear Medicine; Zemunik, T. [University of Split, Split (Croatia). Dept. of Medical Biology]. E-mail: tzemunik@bsb.mefst.hr; Modun, D. [University of Split, Split (Croatia). Dept. of Pharmacology; Pesutic-Pisac, V. [Clinical Hospital Split, Split (Croatia). Dept. of Pathology; Markotic, A. [University of Split, Split (Croatia). School of Medicine. Dept. of Biochemistry; Pavela-Vrancic, M. [University of Split, Split (Croatia). Faculty of Natural Sciences. Dept. of Chemistry

    2007-08-15

    Therapeutic doses of {sup 131}I administered to thyrotoxic patients may cause thyroid failure. The present study used a rat model to determine thyroid function after the administration of different doses of {sup 131}I (64-277 {mu}Ci). Thirty male Fisher rats in the experimental group and 30 in the control group (untreated) were followed for 6 months. The animals were 4 months old at the beginning of the experiment and were sacrificed at an age of 9 months. Hormone concentration was determined before {sup 131}I administration (4-month-old animals) and three times following {sup 131}I administration, when the animals were 7, 8, and 9 months old. The thyroid glands were removed and weighed, their volume was determined and histopathological examination was performed at the end of the experiment. Significant differences in serum triiodothyronine and thyroid-stimulating hormone concentration, measured at the age of 7, 8, and 9 months, were found in the experimental group. During aging of the animals, the concentration of thyroxin fell from 64.8 {+-} 8.16 to 55.0 {+-} 6.1 nM in the control group and from 69.4 {+-} 6.9 to 25.4 {+-} 3.2 nM in the experimental group. Thyroid gland volume and weight were significantly lower in the experimental than in the control group. Thyroid glands from the experimental group showed hyaline thickness of the blood vessel wall, necrotic follicles, a strong inflammatory reaction, and peeling of necrotic cells in the follicles. In conclusion, significant differences in hormone levels and histopathological findings indicated prolonged hypothyroidism after {sup 131}I administration to rats, which was not {sup 131}I dose dependent. (author)

  20. The hepatic handling of 131I-labeled sulfobromophtalein in the dog. Comparison with sulfobromophthalein

    International Nuclear Information System (INIS)

    Glasinovic, J.C.; Delage, Y.; Erlinger, S.

    1976-01-01

    131 I-labeled BSP is obtained by the incorporation of one molecule of radioactive iodine in BSP. The influence of the added iodine on the hepatic extraction and biliary excretion of BSP was studied. Two types of experiments were performed. In the first, a compartmental analysis of BSP and 131 I-labeled BSP disappearance curves was performed after the simultaneous injection of 5mg per kg of BSP and 10μCi of 131 I-labeled BSP: both, the plasma to liver and liver to bile transfer rates were significantly lower for 131 I-labelled BSP than for BSP; the liver to plasma transfer rates were not significantly different. In the second series of experiments, the hepatic uptake of BSP and 131 I-labeled BSP was estimated by the multiple indicator dilution technique: the extraction of BSP (59%+-SD 5) was significantly higher that than of 131 I-labeled BSP (35%+-SD5) (P 131 I significantly modified the hepatic handling of the dye; 131 I-labeled BSP cannot therefore be used as a tracer of BSP

  1. Chemical and physical quality control of the HIPPURAN-131I

    International Nuclear Information System (INIS)

    Morin Zorilla, J.; Olive, E.; Isaac, M.; Cruz, J.

    1989-01-01

    Some physico-chemical methods for analytical control of Hippuran- 131 I are compared. The most convenient to applicate in hospitals and in more specialized quality control laboratories are recommended. The quality of Hippuran- 131 I produced by ISOTOP (USSR) is also evaluated. The product met the requirement of the International Pharmacopeia

  2. Dosimetry study of [I-131] and [I-125]- meta-iodobenz guanidine in a simulating model for neuroblastoma metastasis.

    Science.gov (United States)

    Roa, W H; Yaremko, B; McEwan, A; Amanie, J; Yee, D; Cho, J; McQuarrie, S; Riauka, T; Sloboda, R; Wiebe, L; Loebenberg, R; Janicki, C

    2013-02-01

    The physical properties of I-131 may be suboptimal for the delivery of therapeutic radiation to bone marrow metastases, which are common in the natural history of neuroblastoma. In vitro and preliminary clinical studies have implied improved efficacy of I-125 relative to I-131 in certain clinical situations, although areas of uncertainty remain regarding intratumoral dosimetry. This prompted our study using human neuroblastoma multicellular spheroids as a model of metastasis. 3D dose calculations were made using voxel-based Medical Internal Radiation Dosimetry (MIRD) and dose-point-kernel (DPK) techniques. Dose distributions for I-131 and I-125 labeled mIBG were calculated for spheroids (metastases) of various sizes from 0.01 cm to 3 cm diameter, and the relative dose delivered to the tumors was compared for the same limiting dose to the bone marrow. Based on the same data, arguments were advanced based upon the principles of tumor control probability (TCP) to emphasize the potential theoretical utility of I-125 over I-131 in specific clinical situations. I-125-mIBG can deliver a higher and more uniform dose to tumors compared to I-131 mIBG without increasing the dose to the bone marrow. Depending on the tumor size and biological half-life, the relative dose to tumors of less than 1 mm diameter can increase several-fold. TCP calculations indicate that tumor control increases with increasing administered activity, and that I-125 is more effective than I-131 for tumor diameters of 0.01 cm or less. This study suggests that I-125-mIBG is dosimetrically superior to I-131-mIBG therapy for small bone marrow metastases from neuroblastoma. It is logical to consider adding I-125-mIBG to I-131-mIBG in multi-modality therapy as these two isotopes could be complementary in terms of their cumulative dosimetry.

  3. {sup 123}I and {sup 13I} purification for biomolecules labelling; Purificacao de {sup 123}I e {sup 131}I para marcacao de biomoleculas

    Energy Technology Data Exchange (ETDEWEB)

    Catanoso, Marcela Forli

    2011-07-01

    The {sup 123}I and {sup 131}I are iodine radioisotopes widely used in Nuclear Medicine. The radioisotope {sup 123}I is used in diagnosis through the SPECT technique and is routinely produced at IPEN in cyclotron through the reaction: '1{sup 24}Xe (p, 2n) '1{sup 23}Cs -> {sup 123}Xe -> {sup 123}I. The radioisotope {sup 131}I is used both in diagnosis and therapy due to its physical characteristics of decay by {beta}{sup -} and its {gamma}-ray emissions that are softened with the use of specific collimators for diagnosis. It is routinely produced at IPEN using the nuclear reactor through the indirect reaction: {sup 130}Te (n, {gamma}) ->{sup 131}Te -> {sup 131}I, irradiating compounds containing Te. The radiopharmaceuticals prepared with these radioisotopes go through rigorous quality control tests and the chemical purity of the primary radioisotopes {sup 123}I and {sup 131}I are within the permissible limits currently defined. However, the presence of some chemical contaminants can prejudice the biomolecules labeling (monoclonal antibodies and peptides), that will produce radiopharmaceuticals of first generation to the oncology area. The aim of this work was to obtain a new purification method of these radioisotopes, allowing the labeling of biomolecules and also to established a process control on those radioisotopes. The methodology was separated on 3 steps: Evaluation of '1{sup 23}I e {sup 131}I radionuclidic purity using a hyper pure germanium detector, chemical purity using ICP-OES and the retention and elution study of {sup 131}I in several absorbers to choose the most appropriate for the purification tests analyzing the behavior of the possible contaminants. The radionuclidic analyses showed the presence of Te and Co on {sup 131}I samples and Te, Tc e Co on {sup 123}I samples. The chemical purity analyses showed the presence of Al and Mo in {sup 123}I, coming from the window material of the target holder and the presence of Al and Te in {sup

  4. Evaluation of {sup 131}I retention in several adsorbers

    Energy Technology Data Exchange (ETDEWEB)

    Catanoso, Marcela F.; Osso Junior, Joao Alberto, E-mail: marcela.forli@gmail.co, E-mail: jaosso@ipen.b [Instituto de Pesquisas Energeticas e Nucleares (IPEN/CNEN-SP), Sao Paulo, SP (Brazil). Diretoria de Radiofarmacia

    2011-07-01

    Several iodine radioisotopes are used in nuclear medicine for treatment and diagnostic purposes. The radioisotope {sup 131}I is used both in diagnosis and therapy due to its physical characteristics of decay by {beta}{sup -} and its {gamma}-ray emissions suitable for diagnosis. It is routinely produced at IPEN through the irradiation of TeO{sub 2} targets in the IEA-R1m nuclear reactor. After the irradiation, the {sup 131}I is separated by dry distillation, where the targets are put in an oven, heated at 760 deg C for 2 hours and the {sup 131}I, volatile, is carried by an O{sub 2} gas stream. The aim of this work was to evaluate the retention and elution of {sup 131}I samples produced at IPEN in several adsorbers as part of a project aiming the purification of these radioisotopes, allowing the labeling of biomolecules. Samples of {sup 131}I were used for retention and elution studies with the following adsorbers: commercial cartridges, anionic resin columns and cationic resin column. The results showed that Ag cartridges and anionic resins Dowex 1X8, Dowex 3 and IRA 400 had a great iodine retention but no elution after using specific eluents. The QMA light, acid alumina, neutral alumina and cationic resin Dowex 50WX4 showed high retention and elution and QMA plus and cationic resin Dowex 50WX8 and Dowex 50WX12 had a good retention but lower elution. Regarding to the better retention and elution, Ag cartridges and resins showed a higher percentage of iodine retention but lower elution yield and QMA light, acid and neutral alumina cartridges showed better results. (author)

  5. Occurrence of hypothyroidism after treatment of Basedow's diseases with 131I

    International Nuclear Information System (INIS)

    Torizuka, Kanji; Mori, Toru; Konishi, Junji; Ikekubo, Katsuji; Morita, Rikushi

    1975-01-01

    Description was made as to the present condition of occurrence of hypothyroidism after treatment of Basedow's disease with 131 I. It was showed that hypothyroidism was not necessarily based on numerical over-dose of 131 I, there were early stage hypothyroidism due to 131 I sensitivity of an individual and delayed hypothyroidism due to irreversible and progressive disorder of the thyroid gland, and examination of inflammatory findings before treatment and reduction of first administered dose of 131 I were effective in prevention of early stage hypothyroidism. At present, the origin of delayed hypothyroidism is not clarified and thus there is not adequate prevention method. It was suggested that it was duty of the person in charge of treatment to observe and guide treated case by careful remote-investigation and to continue efforts in prevention of hypothyroidism hereafter. (M. Tsunoda)

  6. Calibration of filters for detection of airborne I-131 in the environment of nuclear power plant; Kalibracija filtrov za detekcijo I-131 v zraku okolja jedrske elektrarne

    Energy Technology Data Exchange (ETDEWEB)

    Zupan, M; Miklavzic, U; Pucelj, B [Institut Jozef Stefan, Ljubljana (Yugoslavia)

    1982-07-01

    A simple and clean method for efficiency calibration of filters for collection of airborne I and corresponding Ge(Li) spectrometer is described. As the calibrated source of gaseous I-131 the radiopharmaceutical water solution of NaI is used. As calibration example the absolute activity distribution of I-131 measured in a charcoal filter is shown. (author)

  7. Therapeutic Effect of 131I for 230 Patients with Hyperthyroidism

    International Nuclear Information System (INIS)

    He Yujie; Zhang Chengxi; Hu Jiqing; Guo Sihui; Yuan Hui; Li Jing

    2009-01-01

    To evaluate the therapeutic effect of 131 I in treatment of patients with hyperthyroidism and analysis the factors that influence the effect, 230 cases of hyperthyroidism were treated with 131 I, and were followed-up at 1.5, 3, 6, 12 months and even longer time after 131 I radiotherapy. The serum levels of FT3, FT4 and TSH were detected in all cases. The results showed that 181 patients were cured (78.6%), 22 patients were improved (9.5%), 23 cases developed early hypothyroidism(10.0%),and 4 cases developed later hypothyroidism. 12 cases in 27 patients with hypothyroidism treated with thyroxin were recovered, but the other 15 cases need to be given permanent treatment. The factors which influence 131 I radiotherapeutic effect include the patient age, course of disease,application of ATD, size and quality of thyroid, and the level of thyroid hormone. The patients should be followed up to prevent occurrence of hypothyroidism. The early hypothyroidism should be treated in order to decrease the permanent hypothyroidism rate. (authors)

  8. Preliminary clinical experience of pulmonary scintigraphy using 131I-HIPDM

    International Nuclear Information System (INIS)

    Tian Jiahe

    1992-01-01

    The metabolic imaging of lungs using 131 I-HIPDM, a tracer known to bind to the amino-receptor in pancreas and lungs, was carried out on 44 subjects. In the normal non-smoker group (n = 8), the tracer was found to be uniformly distributed throughout the lung, with slow clearance in bi-exponential mode after peak of concentration in about 30 sec; while in the normal smoker (n = 8), patients with chronic obstructive pulmonary disease (COPD) of both smoker (n = 7) and non-smoker (n = 12), and patients with asthma (n = 5), the distribution as well as the parameters of clearance of 131 I-HIPDM were significantly different. In conclusion: (1) 131 I-HEPDM could reveal some characteristics of pulmonary metabolism of amine in various physiological as well as pathological status; (2) the washout of the tracer from lung was correlated with clinical ventilation functions; (3) smoking is one of the determinant factors of lung metabolic function; (4) the pulmonary metabolic imaging using 131 I-HIPDM was of value in detecting lung disease, especially the functional damages caused by various factors

  9. Antithyroid drugs and 131I treatment of Graves' disease: an efficacy relationship analysis

    International Nuclear Information System (INIS)

    Fang Yi; Liu Jianfeng; Zhang Xiuli; Xiao Shuping; Zhang Youren

    2004-01-01

    Objective: To investigate the influence of taking antithyroid drugs (ATD) or stopping therapy with ATD for a variable periods of time before 131 I treatment on efficacy of 131 I treatment. Methods: A total of 99 patients with Graves' disease were divided into two groups on the basis of taking antithyroid drugs (ATD) or not (the patients who had undergone operation for Graves' disease or had received 131 I therapy were excluded). The patients who had taken ATD were separated into four groups, 2 W, ∼4 W, ∼8 W, >8 W before 131 I treatment, to assess the influence on the cure rate after the 131 I treatment. Results: The cure rate of hyperthyroidism after 131 I treatment in patients not taking and taking ATD before 131 I treatment was 89.5% and 57.5%, respectively. The difference between two groups was significant. Fisher's exact test was used to compare the variable parameters (P=0.00863). The patients who had taken ATD and discontinued had no difference in the cure rate, although the duration of discontinuance of ATD was different (P=0.627). Conclusions: The cure rate will be reduced when ATD is used as initial therapy for Graves' disease even if ATD is discontinued for some period of time before the treatment. With regard to those patients having used ATD before the treatment, the cure rate of 131 I is not raised with prolonging ATD withdrawal

  10. Initial radioiodine remnant ablation success rates compared by diagnostic scan methods: I123 versus I131

    International Nuclear Information System (INIS)

    Choi, W.; Choi, E.; Yoo, I.; Kim, S.; Han, E.; Lee, S.; Lee, W.

    2015-01-01

    Full text of publication follows. Objective: to see if diagnostic whole body scan (DxWBS) performed with I-131 prior diminishes the success rate of initial radioiodine remnant ablation (RRA) compared to I-123 DxWBS in differentiated thyroid cancer patients. Material and methods: consecutive thyroid cancer patients who received total thyroidectomy for differentiated thyroid cancer and then high dose RRA (either 100 mCi or 150 mCi) within 6 months were included. DxWBSs were performed with I-123 or with I-131. Prior to the DxWBSs, all patients followed strict low iodine diet for 2 weeks and withdrew hormone to stimulate TSH above 30 mIU/l. Patients with extra-thyroidal extension of tumor, lymph node metastasis, or distant metastasis were excluded. The initial RRA was defined as successful if the next DxWBS done 6 months to 1 year later was negative and stimulated thyroglobulin level was below 2 ng/ml. Results: of 71 patients who had I-123 DxWBSs, 31 patients went on to receive RRA with 100 mCi and 40 patients received 150 mCi. Of 73 patients who had I-131 DxWBSs, 66 received 100 mCi and 7 patients received 150 mCi. The overall success rate was 79% for patients who had I-123 DxWBS prior to RRA (68% for 100 mCi and 86% for 150 mCi), and 68% for patient who had I-131 DxWBSs (68% for 100 mCi and 71% for 150 mCi). Conclusion: for patients who received 100 mCi, the RRA success rate was the same for I-123 DxWBS and I-131 DxWBS. For patients treated with 150 mCi, the success rate may be lower in patients who receive RRA following DxWBS with I-131 compared to DxWBS with I-123. (authors)

  11. Protection against {sup 131}I-induced Double Strand DNA Breaks in Thyroid Cells

    Energy Technology Data Exchange (ETDEWEB)

    Hershman, J.M.; Okunyan, A.; Cannon, S.; Hogen, V. [Endocrinology, UCLA-VA, Los Angeles (United States); Rivina, Y. [Radiation Biology, UCLA, Los Angeles (United States)

    2012-07-01

    Radioiodine-131 (I{sup 131}) released from nuclear reactor accidents has dramatically increased the incidence of papillary thyroid cancer in exposed individuals, especially young children. The accepted measure for prevention of radiation-induced thyroid cancer is potassium iodide tablets that contain 100 mg iodide taken daily to block thyroid uptake of I{sup 131}. The deposition of ionizing radiation in cells results in double-strand DNA breaks (DSB) at fragile sites, and this early event can generate oncogenic rearrangements that eventually cause the cancer. We have developed a thyroid cell model to quantify the mitogenic effect of I{sup 131}. I{sup 131} causes double strand DNA breaks in FRTL-5 cells detected by 53BP1 or gamma H2AX and had no effect on cells that do not transport iodide. Perchlorate, iodide, and thiocyanate protect against DSB induced by I{sup 131}. Preincubation with the anion or radioprotective compounds prevents DSB; delayed addition of the anion is much less effective. These data provide a basis for studies of radioprotection against DSB induced by I{sup 131} in animals in order to refine the prevention of thyroid cancer resulting from nuclear fallout

  12. Effect of successful 131I treatment on the peripheral blood picture in hyperthyroid patients

    International Nuclear Information System (INIS)

    Li Xiaoping; He Yunnan; Hu Qingwu

    2004-01-01

    Objective: To investigate the effect of successful 131 I therapy on the levels peripheral blood picture in hyperthyroid patients. Methods: Serum T 3 , T 4 , TSH (with ACCESS microparticle chemiluminescence immunoassay) and blood Hb, RBC, WBC and DC, Plt (with COULTER three assortments) counts were determined in 110 controls and 210 hyperthyroid patients both before and after 131 I therapy. Results: 131 I treatment of hyperthyroidism in this group of patients was very successful (P 131 I therapy. Conclusion: The application of 131 I to treat hyperthyroidism was very successful with no remarkable effect on peripheral blood picture. (authors)

  13. Reduction of 131I content in leafy vegetables and seaweed by cooking

    International Nuclear Information System (INIS)

    Hisamatsu, Shun-ichi; Takizawa, Yukio; Abe, Touru

    1987-01-01

    Decontamination ratios of 131 I were obtained from leafy vegetables samples and an edible seaweed sample (Papenfussiella kuromo) after cooking. Samples obtained in Akita City were contaminated with fallout 131 I from the Soviet Chernobyl reactor accident. The decontamination ratio of 131 I content in washed spinach samples to that in raw materials was 0.83 ± 0.21. The ratio of 131 I content in leafy vegetables and edible wild grass samples boiled in water to that in washed samples was 0.51 ± 0.19 on an average. The overall decontamination ratio for leafy vegetables was 0.42 ± 0.19, while the decontamination ratio after cooking was 0.68 for the seaweed sample. (author)

  14. Feasibility of in vivo thyroid {sup 131}I monitoring with an imaging plate

    Energy Technology Data Exchange (ETDEWEB)

    Hirota, Masahiro; Saze, Takuya; Ogata, Yoshimune; Nishizawa, Kunihide E-mail: nishizawa@nucc.cc.nagoya-u.ac.jp

    2001-10-01

    A new in vivo thyroid {sup 131}I monitoring method was devised by using an imaging plate (IP). A thyroid image obtained with a realistic neck-thyroid phantom showed a unique shape characteristic of the thyroid gland. A {sup 131}I thyroid imaging allows visual confirmation of thyroid accumulation of {sup 131}I. The detection limit of the IP system of 290 Bq was about ((1)/(100)) of the screening level of 30 kBq in cases of public emergencies. The IP system is applicable for thyroid {sup 131}I monitoring.

  15. 131I concentrations in air, milk and antelope thyroids in southeastern Idaho

    International Nuclear Information System (INIS)

    Markham, O.D.; Halford, D.K.; Bihl, D.E.

    1980-01-01

    Iodine-131 concentrations were determined in air, milk, and antelope (Antilocapra americana) thyroids from southeastern Idaho during 1972-77. Samples were collected in the vicinity of the Idaho National Engineering Laboratory Site which has 17 operating nuclear reactors, a fuel reprocessing plant, and a nuclear waste management facility. Samples were also collected from control areas. During the study, fallout occurred from five People's Republic of China above-ground nuclear weapon detonations. All 131 I detected in air and milk samples was attributed to fallout from the Chinese nuclear tests. 131 I was detected in low-volume air samples following only one of the five detonations while 131 I was detected in milk following four of the detonations. 131 I occurred in antelope thyroids during all five of the fallout periods and following at least one atmospheric release from facilities at the Idaho National Engineering Laboratory Site. Thyroids were the most sensitive indicators of 131 I in the environment followed by milk and then air. Maximum concentrations in thyroids, milk, and air were 400, 20 and 4 times higher respectively than their respective detection limits. (author)

  16. AgI/Ag3PO4 hybrids with highly efficient visible-light driven photocatalytic activity

    International Nuclear Information System (INIS)

    Katsumata, Hideyuki; Hayashi, Takahiro; Taniguchi, Masanao; Suzuki, Tohru; Kaneco, Satoshi

    2015-01-01

    Highlights: • AgI/Ag 3 PO 4 hybrid was prepared via an in situ anion-exchange method. • AgI/Ag 3 PO 4 displays the excellent photocatalytic activity under visible light. • AgI/Ag 3 PO 4 readily transforms to be Ag@AgI/Ag 3 PO 4 system. • h + and O 2 ·− play the major role in the AO 7 decolorization over AgI/Ag 3 PO 4 . • The activity enhancement is ascribed to a Z-scheme system composed of Ag 3 PO 4 , Ag and AgI. - Abstract: Highly efficient visible-light-driven AgI/Ag 3 PO 4 hybrid photocatalysts with different mole ratios of AgI were prepared via an in situ anion-exchange method and characterized by X-ray diffraction (XRD), scanning electron microscopy (SEM), UV–vis diffuse reflectance spectroscopy (DRS) and photoluminescence (PL) technique. Under visible light irradiation (>420 nm), the AgI/Ag 3 PO 4 photocatalysts displayed the higher photocatalytic activity than pure Ag 3 PO 4 and AgI for the decolorization of acid orange 7 (AO 7). Among the hybrid photocatalysts, AgI/Ag 3 PO 4 with 80% of AgI exhibited the highest photocatalytic activity for the decolorization of AO 7. X-ray photoelectron spectroscopy (XPS) results revealed that AgI/Ag 3 PO 4 readily transformed to be Ag@AgI/Ag 3 PO 4 system while the photocatalytic activity of AgI/Ag 3 PO 4 remained after 5 recycling runs. In addition, the quenching effects of different scavengers displayed that the reactive h + and O 2 ·− play the major role in the AO 7 decolorization. The photocatalytic activity enhancement of AgI/Ag 3 PO 4 hybrids can be ascribed to the efficient separation of electron–hole pairs through a Z-scheme system composed of Ag 3 PO 4 , Ag and AgI, in which Ag nanoparticles act as the charge separation center

  17. Synthesis and labelling of 19-iodocholesterol 131I

    International Nuclear Information System (INIS)

    Hamada, E.S.

    1979-01-01

    Considering the increasing interest in obtaining agents for vizualization of the adrenal gland with radioisotopic techniques, 19-iodocholesterol was prepared by means of chemical synthesis and radioiodine ( 131 I) introduced by isotopic exchange reaction. The reaction product was identified by determination of the melting point and elementary spectroscopic analysis (infra-red absorption and magnetic nuclear ressonance). Radiochemical analysis of the labelled compound was performed by means of then-layer cromatography in silica-gel. In order to confirm its capacity of concentration in the adrenal gland, the distribution of 19-iodocholesterol 131 I, after intravenous injection, was tested in rats. (Author) [pt

  18. I-123(131)-metyrapone for imaging of the adrenal cortex

    International Nuclear Information System (INIS)

    Zolle, I.; Bergmann, H.; Hoefer, R.; Robien, W.

    1982-01-01

    Attempts to label metyrapone with radioiodine resulted in the synthesis of 4'-bromometyrapone that is labelled with I-123(131) by halogen exchange before use. The synthesis of I-123(131)-metyrapone involves 4 intermediate compounds. 4'-bromometyrapone serves as a precursor with indefinite shelf-life that is labelled selectively in the 4'-position of ring B. Studies of the biodistribution of I-131-metyrapone indicate the highest concentration in the adrenal gland 10-20 min after injection, peak uptake in the normal adrenal corresponds to 0.2% of the administered dose. In hyperfunctioning adrenals the uptake is higher. In a patient with bilateral modular hyperplasia, 0.8% of the injected radioactivity were measured in the enlarged adrenals at 2 resp. 2.8 hrs after injection of I-123-metyrapone. We have performed the first adrenal scintigram on the same patient with 1.25 mCi of I-123-metyrapone. (Author)

  19. Determination of {sup 131}I and thorium in urine; Determinacao de iodo-131 e torio em urina

    Energy Technology Data Exchange (ETDEWEB)

    Tomida, Rute Miwa

    1978-07-01

    Methods for the determination of {sup 131}I and Thorium in urine have been developed taking into account the monitoring needs for people who handle with these radioisotopes. The method for determining {sup 131}I is based in the use of silver chloride to separate iodine by precipitation from the sample; the detection was carried out in a Nal (Tl) well type scintillator connected to a single channel analyser. This method has the following advantages; it is easy and relatively fast as well as selective, showing a separation yield higher than 80%. Thorium in urine was determined by colorimetry after the mineralization of the sample using nitric acid, and sulphuric acid, and then oxygen peroxide. The chromophore reagent used was Thoron (disodium salt of 2-(2-hydroxy-3,6-disulfo-l-naphthylazo) benzenearsonic acid).The absorbance was measured in a spectro colorimeter at a fixed wavelength (530 nm). The method proved to be simple allowing a separation yield of about 80%. The most representative sample for a monitoring program in a {sup 131}I production laboratory has been established. The {sup 131}I concentration in urine of individuals with chronic contamination have also been measured; an interpretation of these results is discussed. (author)

  20. Internal Contamination by 131I in nuclear medicine department

    International Nuclear Information System (INIS)

    Chahed, N.; Mtimet, S.; Hammami, H.; Mhiri, A.

    1998-01-01

    Therapeutic applications in nuclear medicine use high activities of 131 I in sodium iodine liquid from which is volatile at ambient temperature. Besides external exposure there is, for the nuclear medicine personnel, an internal exposure risk induced by 131 iodine inhalation. So we tried to assess this risk among the personnel in a nuclear medicine department. We used direct method for measuring 131 radioactivity in vivo by external counting. Gamma ray detector with a Nal ( TI ) probe positioned near the thyroid gland allows investigation of 131 radioactivity. We realised 34 measurements among the personnel, two times at an interval of one month. The results indicate that an 131 iodine internal contamination is found. Estimated thyroid activities were ranging from 35 to 132 Bq. The highest activities has been found in the thyroid of the technicians involved in the administration of 131 iodine therapy. Therefore this values are lower than norms. This study must lead to the implementation control of the 131 iodine internal contamination in order to optimise the personnel protection in nuclear medicine departments (author)

  1. The Relative Frequency of Persistent Hyperthyroidism After I131Therapy

    International Nuclear Information System (INIS)

    Al-EID, M.A.

    1998-01-01

    517 patients with different types of hyperthyroidism who had treated by I 131 therapy were studied. The study demonstrated that diffuse toxic goiter was the most common type of hyperthyroidism. The relative frequency of persistent hyperthyroidism in all types after the first dose of I 131 utilizing our empirical regimen in estimation of therapy doses was low (9.5%). While high frequency of persistent hyperthyroidism among diffuse toxic goiter patients (14%), probably was due to many factors discussed in this paper. Some of these factors are impossible to be estimated precisely and therefore, can not be avoided. But careful dose estimation for each case with diffuse toxic goiter may reduce the rate of retreatment by I 131 . Antithyroid medication prior to I 131 therapy might be another factor resulted in increasing of retreatment of retreatment rate diffuse toxic goiter cases. Longer time interval (more than 5 days) of ceasing antithyroid medication prior therapy is suggested to avoid the effects of these drugs. Patients with other types of hyperthyroidism were not frequently required more than one dose and the frequency of persistent hyperthyroidism was almost negligible

  2. Experimental radioimmunotherapy with I-131-antibody against a differentiation antigen

    International Nuclear Information System (INIS)

    Badger, C.C.; Krohn, K.A.; Bernstein, I.D.

    1985-01-01

    The authors have previously shown that I-131-labeled antibodies (Ab) against the Thyl.l antigen can care AKR/Cu (Thyl.2+) mice bearing the AKR/J (Thy 1l.1+) SL2 T-cell lymphoma. The authors have now extended these studies to therapy with I-131-anti-Thyl.1 of SL2 lymphoma in AKR/J mice where Ab reacts with both tumor and normal cells. A 25 μg bolus was rapidly cleared from serum by binding to spleen cells (75% with Tl/2 <60 min.) and only low concentrations of Ab(<2% ID/gm) were present in tumor after infusion. Therapy of AKR/J mice bearing established s.c. lymphoma nodules with 1500 μCi I-131-anti-Thyl.1 resulted in complete regression of the nodule in 6/6 animals although tumor eventually regrew and all animals died of metastatic lymphoma. In contrast, I-131-irrelevant Ab given to produce the same amount of whole body radiation (750 μCi) did not affect tumor growth. These studies suggest that radiolabeled-AB against differentiation antigens may be useful for therapy in spite of binding to normal cell populations

  3. Standard dose 131I therapy for toxic multinodular goiter in an endemic goiter region

    International Nuclear Information System (INIS)

    Goncalves, E.; Castro, J.A.S.; Gross, J.L.

    1986-01-01

    The effect of the standard 15 mCi dose of 131 I on the thyroid function of 25 patients from an endemic goiter region with toxic multinodular goiter of different sizes was determined. The patients were followed for 1 to 5 years and 7 months (mean: 2 years and 10 months). Eighteen patients were treated with the antithyroid drugs propylthiouracil or methimazole before 131 I and seven only received 131 I. All but three patients achieved euthyroidism after a single dose of 131 I. Two patients in the antithyroid treatment group became hypothyroid 2 months and 2 years after the isotope therapy, respectively. Pretreatment with antithyroid drugs did not significantly modify the effectiveness of 131 I treatment. This simplified dose regimen of 131 I was effective in the treatment of hyperthyroidism caused by multinodular goiter in an endemic region, and the efficacy was independent of the size of the goiter. (author)

  4. Excretion and toxicity evaluation of 131I-Sennoside A as a necrosis-avid agent.

    Science.gov (United States)

    Yin, Zhiqi; Sun, Lidan; Jin, Qiaomei; Song, Shaoli; Feng, Yuanbo; Liao, Hong; Ni, Yicheng; Zhang, Jian; Liu, Wei

    2017-11-01

    1. Sennoside A (SA) is a newly identified necrosis-avid agent that shows capability for imaging diagnosis and tumor necrosis targeted radiotherapy. As a water-soluble compound, 131 I-Sennoside A ( 131 I-SA) might be excreted predominately through the kidneys with the possibility of nephrotoxicity. 2. To further verify excretion pathway and examine nephrotoxicity of 131 I-SA, excretion and nephrotoxicity were appraised. The pharmacokinetics, hepatotoxicity and hematotoxicity of 131 I-SA were also evaluated to accelerate its possible clinical translation. All these studies were conducted in mice with ethanol-induced muscular necrosis following a single intravenous administration of 131I-SA at 18.5 MBq/kg or 370 MBq/kg. 3. Excretion data revealed that 131 I-SA was predominately (73.5% of the injected dose (% ID)) excreted via the kidneys with 69.5% ID detected in urine within 72 h post injection. Biodistribution study indicated that 131 I-SA exhibited initial high distribution in the kidneys but subsequently a fast renal clearance, which was further confirmed by the results of autoradiography and single-photon emission computed tomography-computed tomography (SPECT-CT) imaging. The maximum necrotic to normal muscle ratio reached to 7.9-fold at 48 h post injection, which further verified the necrosis avidity of 131 I-SA. Pharmacokinetic parameters showed that 131 I-SA had fast blood clearance with an elimination half-life of 6.7 h. Various functional indexes were no significant difference (p > 0.05) between before administration and 1 d, 8 d, 16 d after administration. Histopathology showed no signs of tissue damage. 4. These data suggest 131 I-SA is a safe and promising necrosis-avid agent applicable in imaging diagnosis and tumor necrosis targeted radiotherapy.

  5. The usefulness of 131I radioiodine to thyroid papillary carcinoma with extra thyroidal extension

    International Nuclear Information System (INIS)

    Shinohara, Shogo; Kikuchi, Masahiro; Naito, Yasushi; Fujiwara, Keizo; Hori, Shinya; Tona, Yosuke; Yamazaki, Hiroshi

    2009-01-01

    Extra thyroidal extension (ETE) of thyroid papillary carcinoma (PAC) is known as a risk factor of poor prognosis. The American Thyroid Association (ATA) Guideline recommends total thyroidectomy (TT) with radioiodine ablation for patients of PACs with ETE and we have been following this strategy for cases of PACs with ETE. In this paper, we retrospectively examined the patients of PACs with ETE in terms of the following two issues: Does 131 I total body scan ( 131 I-TBS) after TT enable us to detect subclinical distant metastases of PACs? and Can 131 I ablation eliminate microscopic remnants of PACs after TT? The subjects consisted of 68 patients who had PACs with ETE and underwent 131 I-TBS and/or 131 I ablation after TT in our hospital in the past 20 years. Tumor, nodes and metastasis (TNM) classifications of the patients were pT3:pT4=12:56, pN0:pN1a:pN1b=13:15:40, M0:M1=62:6. Twenty-two cases underwent only 131 I-TBS and 46 cases underwent 131 I-ablation. Fourteen cases diagnosed as M0 preoperatively had distant focus detected using 131 I-TBS. Including M1 cases, 20 out of 68 cases (29%) turned out to have clinical or subclinical distant lesions in our study. 131 I ablation eliminated thyroid bed in 18 out of 22 cases, and distant foci in 5 out of 13 cases. However, the distant lesions which had been apparent before operation (M1 cases) did not reach complete response (CR) by 131 I ablation. In 22 out of those 23 cases successfully treated with the ablation, serum-thyroglobulin level was almost undetected after therapy. The overall 10-year survival rate was 82% and the cause-specific survival rate was 91%. (author)

  6. Clinical Investigation and Treatment of Thyroid Disease with Radioactive Iodine (131I)

    International Nuclear Information System (INIS)

    Lee, Mun Ho; Koh, Chang Soon; Ro, Heung Kyu; Koo, In Seu; Suh, Whan Jo; Lee, Kyung Ja; Lee, Hong Kyu; Lee, Chung Sang

    1970-01-01

    A summary of the clinical data of the 131 I-thyroid function tests and the therapeutic results of 131 I among the 2,658 patients of various thyroid diseases treated over the past 10 years from May 1960 to Oct. 1969 at the Radioisotope Clinic and Laboratory, SNUH were presented and discussed. 1) The patients examined consisted of 929 cases (34.9%) of diffuse toxic goiter, 762 cases (28.7%) of diffuse nontoxic goiter, 699 cases (26.3%) of nodular nontoxic goiter, 58 cases (2.2%) of nodular toxic goiter and 210 cases (7.9%) of hypothyroidism. 2) There were 300 (11.4%) male and 2358 (88.6%) female, showing a ratio of 1 : 8. 3) The majority of patients (79.1%) were in the 3rd-5th decade of their lives. 3) The normal ranges, diagnostic values of 131 I uptake test, 48 hrs serum activity, BMR and main subjective symptoms of various thyroid diseases were discussed. 5) In the 579 patients among 867 cases with hyperthyroidism treated with 131 I, 47.8% were confirmed to be cured completely after single therapeutic doses. 6) The complications of 131 I therapy were discussed and myxedema had developed in 6.75% of our patients. 7) The results of 131 I thyroid function tests were analysed among the 160 cases of thyroid diseases which were confirmed the diagnosis with histopathological measures.

  7. Differentiated thyroid cancer following radioiodide 131I therapy of hyperthyroidism: a case report

    Energy Technology Data Exchange (ETDEWEB)

    Nemec, J; Soumar, J; Zeman, V; Nahodil, V; Zamrazil, V; Smejkal, V Jr

    1978-01-01

    Differentiated (papillary) thyroid cancer was detected 17 years following radioiodide 131I treatment for toxic multinodular goiter. Twenty-one cases of thyroid cancers with previous 131I therapy for hyperthyroidism were summarized. This combination is rare compared to the incidence of thyroid cancers following external irradiation. This may be due to higher absorbed dose to thyroid in 131I treatment.

  8. Design and construction of a shielded process box for the production of radiopharmaceuticals labelled with 131I

    International Nuclear Information System (INIS)

    Bonetto, O.; Goso, R.; Guerrero, G.; Huala, H.E.; Logusso, N.A.; Marques, R.; Mitta, A.E.A.

    1976-07-01

    A leakproof process box, shielded with a 5 mm lead wall, for the labelling, purification, pH adjutment and dispensing of Rose Bengal 131 I, Hippuran 131 I, Diprocon 131 I, Hipaque 131 I, Bromosuphthalein 131 I, etc. is described. (author) [es

  9. Intercomparison of 131I activity measurements in nuclear medicine

    International Nuclear Information System (INIS)

    Kim, G. Y.; Yang, H. K.; Lim, C. I.; Lee, H. K.; Jeong, H. K.

    2004-01-01

    Activity measurements in nuclear medicine using a dose calibrator have been performed for several decades and their reliability has varied. To minimise the radiation dose to patients with radionuclides, it is necessary to ensure that the sample administered is accurately assayed. Recognizing the importance of intercomparison in nuclear medicine and the need to make access to activity standards traceable to the international measurement system, the KFDA, as a national secondary standard dosimetry laboratory (SSDL), started an intercomparison program in 2002. This program was initiated by survey to all nuclear medicine centres regarding general information about their dose calibrators, radioisotopes etc. 71 nuclear medicine centres (79 dose calibrators) participated in the intercomparison program with 131 I isotope. To assess the accuracy of clinical measurements of the activity of 131 I solutions and to determine the reason for the disagreement, an intercomparison was conducted using 4 ml aliquots in 10 ml P6 vial with a total activity in the region of 10 -20 MBq. The reference time of decay for all solutions was 0:00 on 25 September 2002. The half-life used was 8.04 days. For the evaluation of solution in KFDA, a sealed, high pressure and re-entrant ionisation chamber, NPL-CRC radionuclide calibrators were used. The verification of our calibration quality was by means of a comparison with the Korea Primary Standard Laboratory (KRISS). The activity ratio of KFDA to KRISS for the 131 I solutions is 1.011. The difference between the value quoted by the clinic, A hospital and the value obtained by the KFDA, A KFDA , is expressed as a percent deviation, i.e. DEV(%) 100x(A hospital -A KFDA )/A KFDA . From the data obtained it was found that 61% of the calibrators showed a deviation within +/-5%; 23% had a deviation in the range 5% 131 I solution activity measurements, using dose calibrators in Koreas, and also to provide the participants with a traceable standard to

  10. Synthesis labeling and biological studies of 16-131I

    International Nuclear Information System (INIS)

    Sato, M.K.

    1988-01-01

    The increasing interest in obtaining radiopharmaceuticals for metabolic imaging of heart muscle led us to prepare 16-IODINE HEXADECANOIC ACID by tosilation of the corresponding hydroxy acid, following iodination with NaI and finally, introducing radioiodine (Na 131 I) by isotopic exchange reaction. The reaction products were identified by determination of melting point, elementary and spectroscopic analysis such as infra-red absortion and magnetic nuclear resonance. The radiopharmaceutical after radiochemical and other specific control procedures for injetable such as sterility and apyrogenicity, was firstly utilized in dogs: preferencial uptake by the heart, as well as by the liver was confirmed. Then, studies in patients with or without heart diseases were performed. The biodistribution of 16- 131 I-HEXADECANOIC ACID was carried out in Wistar rats. The scintigraphic images in animals and in humans demonstrated that 16- 131 -HEXADECANOIC ACID is suitable for studying viable areas as well as energetic exchange of heart muscle. (author) [pt

  11. Preparation and biodistribution of 131I labeled 3-Amino-1-hydroxypropylidene-1, 1-bisphosphonate

    International Nuclear Information System (INIS)

    Lin Rushan; Yang Yuanyou; Liu Ning; Liao Jiali; Jin Jiannan; Pu Manfei

    2008-01-01

    3-amino-1-hydroxypropylidene-1, 1-bisphosphonate (ABP) was synthesized and labeled with 131 I using N-succinimidyl-5-(tri-butylstannyl)-3-pyridinecarboxylate (SPC) as a bi-functional linker. 131 I could be coupled to ABP via a 131 I-SIPC intermediate with a labeling yield of more than 64%, and a radiochemical purity of more than 99% after HPLC purification. After 72 h at room temperature, the radiochemical purity was still more than 98.8%, implying that the 131 I-SIPC-ABP is stable in vitro. Biodistribution experiments in mice show that 131 I-SIPC-ABP has high affinity to bone and high stability in vivo as well as in vitro. (authors)

  12. Adrenal scintigraphy using 131I-Adosterol

    International Nuclear Information System (INIS)

    Fukunaga, Masao; Dokoh, Shigeharu; Yamamoto, Itsuo; Morita, Rikushi; Torizuka, Kanji

    1977-01-01

    131 I-Adosterol (6β-iodomethyl-19-norcholest-5(10)-3β-ol) was administered to evaluate adrenal grand in 20 patients including 9 patients with primary aldosteronism, 5 with Cushing's syndrome, one with pheochromocytoma, one with retroperitoneal tumor, 3 with essential hypertension and one with obesity. Standard scintigraphies were performed at 3rd day and again 6th day after administration of 131 I-adosterol (1-1.5 mCi). Suppression scintigraphies were obtained while the patients were taking dexamethasone 2 to 3 mg daily from 3 days prior to injection of the tracer until adrenal imaging. In the cases with essential hypertension and obesity, both adrenal glands were delineated equally by standard scintigraphy, and in one patient, undergone suppression scintigraphy, the uptake of 131 I-adosterol by both glands were completely inhibited by dexamethasone administration. In primary aldosteronism, six of the 9 patients demonstrated the increased radioactivity in one side, and were diagnosed as aldosteronoma. In 3 cases, failed to show the lesions on standard scintigraphy, the lesions could be detected by suppression scintigraphy, and aldosteronomas measuring 1 x 1 x 0.7, 2 x 2 x 1 and 1.7 x 1.5 x 0.8 cm were confirmed by operation. In Cushing's syndrome, standard scintigraphy could easily distinguish between adenoma (one case) and bilateral hyperplasia (4 cases). Adrenal scintigraphy was also a useful method in order to assess the effect of pituitary irradiation therapy in the case of hyperplasia. In pheochromocytoma and retroperitoneal tumor, the side of the lesion was identified by the absence of a functioning gland. Suppression scintigraphy was particularly useful in detecting the localization of the small tumor in primary aldosteronism. (auth.)

  13. Delayed results of therapy of thyrotoxicosis with sup(131)I and posttherapeutic hypothyrosis

    Energy Technology Data Exchange (ETDEWEB)

    Khelds, A O; Ozols, V K; Shtelmane, I A

    1986-03-01

    A total of 1587 patients with thyrotoxicosis (1387 women and 266 men) were examined over time after /sup 131/I therapy. The radioactive drug was given once to 808 patients, two times to 337 patients, 3 times to 198 and 4 times to 82 patients. 669 patients received 74-185 MBq of /sup 131/I. 649 patients 222-370 MBq, 128 patients 407-555 MBq and 94 patients 592-740 MBq. The other 47 patients received /sup 131/I of higher activity. Posttherapeutic hypothyrosis was revealed in 5.4% of the cases. In half of the patients hypothyrosis developed after a single administration of /sup 131/I. In all the patients with posttherapeutic hypothyrosis, i.v. administration of thyroliberin resulted in a significant rise of the thyrotropin level indicating to great importance of this test. A follow up of such patients is necessary as hypothyrosis can develop at different time after treatment of thyrotoxicosis patients with /sup 131/I.

  14. A new method activation analysis of 131I in charcoal cartridge sampler

    International Nuclear Information System (INIS)

    Lai Caifeng; Xu Jiayun; Qin Jianguo; Wang Dalun

    2011-01-01

    Instead of the traditional method for measuring 1311 activation by calibrating the detecting efficiency, MCNP5 calculation and ill-posed equation solution were used in a new method for analysing 131 I activation and depth distribution in sample box. Because of no necessary to prepare for standard sample and calibrate the efficiency, it makes the survey of 131 I more quickly and accurately and is able to take into account the physics processes of 131 I in the sample box. (authors)

  15. Clinical study of 1003 cases with Graves' disease treated with 131I

    International Nuclear Information System (INIS)

    Wang Qinfen; Zhang Chenggang; Zhao Xiaobin; Shi Longbao

    2005-01-01

    Objective: To explore the treatment effects of individual 131 I dose treatment of Graves' disease. Methods: Graves' disease patients were given individual 131 I dose ( 131 I MBq/per gram thyroid tissue), which ranged at 1.48-4.07 MBq/g. A total of 1003 cases (76.9%) were successfully followed up. The mean administered dose of 131 I was (329.3 ± 307.1, 44.4-3700) MBq. The term of follow-up was (16.4 ± 10.0, 3.0-44.7) months. Results: After one dose 131 I treatment, 593 patients (59.1%) were with euthyroid, 200 patients (19.9%) hypothyroidism, 190 patients (18.9%) were partially remitted, 20 patients (2.0%) showed no changes; 259 patients (25.8%) suffered from early hypothyroidism, 88 patients were with transient hypothyroidism. Logistic stepwise regression analysis revealed that hard thyroid texture was a risk factor for developing early hypothyroidism, whereas large goiter was a protective factor for developing permanent hypothyroidism. Partial-correlations analysis showed that curative effects correlated negatively with the weight of goiter mass, the course of disease and the use of antithyroid drugs (ATD). After 131 I treatment, for 195 patients (41.7%) the ophthalmopathy was cured, 155 patients (33.1%) were partially remitted, 105 patients (22.4%) showed no effects, 13 patients (2.8%)were deteriorated. For 56 patients (77.8%) their hyperthyroid heart disease was cured, 10 patients(13.9%) were partially remitted, 6 patients (8.3%) were of no effects. For 60 patients (85.7%) periodic paralysis associated with thyrotoxicosis were cured, 2 patients (2.9%) were partially remitted, 8 patients (11.4%) were of no effects. Of 249 patients with large goiter (≥90 g), 219 cases (88.0%) were completely remitted. Conclusions: The individual 131 I dose treatment for Graves' disease exerts good therapeutic efficiencies. 131 I treatment for ophthalmopathy, hyperthyroid heart disease and Graves' disease with lager goiter is effective and safe. (authors)

  16. Detection and tracing of the medical radioisotope 131I in the Canberra environment

    Directory of Open Access Journals (Sweden)

    Gilfillan Nathan R.

    2012-10-01

    Full Text Available The transport and radioecology of the therapeutical radioisotope 131I has been studied in Canberra, Australia. The isotope has been detected in water samples and its activity quantified via characteristic J-ray photo peaks. A comparison of measurements on samples from upstream and downstream of the Canberra waste water treatment plant shows that 131I is discharged from the plant outflow into the local Molonglo river. This is consistent with observations in other urban environments. A time-correlation between the measured activities in the outflow and the therapeutical treatment cycle at the hospital identifies the medical treatment as the source of the isotope. Enhanced activity levels of 131I have been measured for fish samples. This may permit conclusions on 131I uptake by the biosphere. Due to the well-defined and intermittent input of 131I into the sewage, the Canberra situation is ideally suited for radioecological studies. Furthermore, the 131I activity may be applied in tracer studies of sewage transport to and through the treatment plant and as an indicator of outflow dilution following discharge to the environment.

  17. An experimental study on the antitumor effect of 131I-17-AAG in vitro and in vivo

    International Nuclear Information System (INIS)

    Tu Wenyong; Liu Lu; Chen Daozhen; Huang Ying; Yin Weidong

    2009-01-01

    The objective of this study was to observe the antitumor effect of 131 I-17-allylamino-17-demethoxygeldanamycin ( 131 I-17-AAG) in vitro/in vivo and explore its antitumor mechanism with a view to its potential therapeutic application. 131 I-17-AAG was prepared by the reaction of 17-AAG with Na [ 131 I] in the presence of hydrogen peroxide. The effects of 131 17-AAG on cell growth inhibition and cell cycle distribution in vitro were studied in BEL-7402 cells lines. Following BEL-7402 tumor implantation by subcutaneous xenografts into nude mice, the reagents were injected through the tail vein, and the tumor volume was measured and analyzed. At the end of the experiment, tumor specimens were processed for histopathological analysis. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) was used to investigate apoptosis. The expression change of Akt2 was tested by Western-blot analysis. Methyl-thiazolyl-tetrazolium assay showed inhibition rates of 27.7±5.3%, 57.3±4.3%, and 63.7±3.1%, in Na 131 I group, 17-AAG group, and 131 I-17-AAG group, respectively. The inhibition rate in the 131 I-17-AAG group differed significantly between Na 131 I group and 17-AAG group (F=229.49, P 131 I group, 17-AAG group, and 131 I-17-AAG group, respectively. Following infusion for 32 days, the tumor volumes in the 131 I-17-AAG group were significantly smaller than those in the DMSO group (F=24.18, P 131 I group (F=20.68, P 131 I-17-AAG inhibited the proliferation of tumor cells and induced apoptosis. The expression of Akt2 in 131 I-17-AAG was significantly lower than that in the DMSO group or 131 I group. 131 I-17-AAG can effectively inhibit the growth of BEL-7402 tumor cells in vitro and in vivo. 131 I-17-AAG is a promising agent for the treatment of BEL-7402 cell tumor. (author)

  18. Preparation of [[sup 131]I]lipiodol as a hepatoma therapeutic agent

    Energy Technology Data Exchange (ETDEWEB)

    Jiunnguang Lo; Aiyih Wang; Yuanyaw Wei (National Tsinghua Univ., Hsinchu (Taiwan). Inst. of Nuclear Science); Wingyiu Lui; Chinwen Chi (Taipei Veterans General Hospital, Taipei (Taiwan)); Wingkai Chan (Academia Sinica, Taipei (Taiwan). Inst. of Biomedical Sciences)

    1992-12-01

    An isotopic exchange method was used to label lipiodol with [sup 131]I. The labelling efficiency was > 92.5%, and the radiochemical purity of [[sup 131]I]lipiodol was above 98% as determined by ITLC. The influencing factors e.g. the heating temperature, reaction, pH and storage conditions were studied and the optimum conditions were determined. In a pilot study injecting [[sup 131]I]lipiodol for the treatment of hepatoma, about 70% of hepatoma patients had a response to the treatment with a reduction of [alpha]-fetoprotein and decrease of hepatoma sizes. The overall median survival was 9 months (range 2-17 months). (author).

  19. Diagnosis of Constitutional Hyperbilirubinemias by Sequential Scanning with 131I-BSP

    International Nuclear Information System (INIS)

    Ueda, Hideo; Lio, Masahiro; Yamada, Hideo; Kamada, Haruo; Luchi, Masahiko; Ishiwa, Mamoru

    1971-01-01

    Sequential liver scanning was introduced for the diagnosis of medical and surgical jaundices by Yamada and Taplin (1) using 131 I-Rose Bengal. Following this trial authors have reevaluated the 131 I-BSP (monoiodide) (2) and applied this dye successfully for the same purpose as well as for hepatic function study (2). In this paper, taking note of the fact that 131 I-BSP sequential scanning method makes visible the mechanism of liver uptake, intrahepatic transport and biliary excretion of this dye, the authors aimed to make clear the classification of constitutional hyperbilirubinemias and the pathophysiology of this disease subjects, which are still controversial among researchers.

  20. Calculation of the activity incorporated in the therapy with I 131

    International Nuclear Information System (INIS)

    Chica, L.G.; Puerta, J.A.

    1998-01-01

    By means of the product S(T--S). A-s-(T-e-). the absorbed dose to thyroid delivered by I-131 incorporated is calculated. Where S(T--S) is the absorbed dose in the thyroid per nuclear transformations (tn.) of I-131 localized in the thyroid and as a potential function of the mass is expressed. A-s-(T-e-) is the number of tn. of I-131 in the thyroid since the moment of the incorporation until the time T-e- (the effective middle time); to find A-s-(T-e-) to normal as different pathological conditions, the metabolic model of the iodo proposed by the ICRP is used. Of the expression of the doses, the incorporated activity, I-o- is obtained

  1. The use of lithium carbonate in the treatment of Graves' disease with 131I

    International Nuclear Information System (INIS)

    Kang Yuguo; Chen Miao; Kuang Anren

    2004-01-01

    Lithium carbonate involving radioactive iodine uptake, goiter volume, thyroid hormone and applying range is reviewed briefly. Lithium may elongate the T 1/2 of iodine in thyroid gland, decrease 131 I dosage and enhance curative effect. Lithium carbonate inhibit iodine uptake and thyroid hormone synthesize, blocks the release of iodine and thyroid hormone from the thyroid gland, which lead to reduce the 131 I dosage the patients need and to decrease the surge of serum FT 3 and FT 4 levels caused by 131 I therapy. so lithium carbonate can alleviate the symptoms caused by 131 I treatment. For lithium carbonate can increase leucocyte amount, there are some merits with lithium carbonate in treating Graves' disease by 131 I. (authors)

  2. Multiple factor analysis of the therapeutic effect of 131I in treating 783 cases of Graves disease

    International Nuclear Information System (INIS)

    Cai Min; Li Xianfeng; Li Sijin; Chen Haibin

    2008-01-01

    Objective: To study the factors influencing therapeutic effect of 131 I in treating 783 cases of Graves disease. Methods: The values of various indexes were quantized on influencing factors such as age, sex, course of disease, mass of thyroid gland, the absorbed dose of 131 I per gram of thryoid gland, the given dose of 131 I, thyroid 24 h 131 I uptaking percentage, thyroid hormone and thyroid autoantibodys. The assessment of the therapeutic effect was made according to complete remission (including hypothyroidism) and partial remission after 131 I therapy. CMH χ 2 , Wilcoxon signed-rank test and Logistic regression were used to analyze the variable parameters before the treatment. Results: The therapeutic effect of 131 I is significant in the follow-up period (CMH χ 2 =69.21, P 131 I therapy for 12 months. The therapeutic effect was related to such factors as age thyroid mass, the absorbed dose of 131 I per gram of thryoid gland, thyroid 24 h 131 I uptaking percentage, etc (all the values of P 131 I uptaking percentage is higher, thyroid mass is bigger, thyroid gland is with noduses, the given dose of 131 I should be increased. Conversely decreased. (authors)

  3. Determination of 131I as contaminant in samples of fission 99Mo

    International Nuclear Information System (INIS)

    Aghazarian, V.P.; Nunez, O.J.; Duran, Adrian P.; Mondino, Angel V.

    2003-01-01

    A method for 99 Mo production from fission products was developed at the Ezeiza Atomic Center 15 years ago. A complete quality control of the product, preceding its use in nuclear medicine, is a basic requirement. One of the main purposes of this work was to improve the resolution of the 364.5 keV and 366.4 keV peaks, from respectively 131 I and 99 Mo, due to the fact that the former could not be detected in the presence of high activities of the later. A new procedure is described for determination of 131 I impurity contents present in the 99 Mo samples. A highly specific 131 I separation from an alkaline solution has been developed, which utilizes porous metallic silver. Elemental silver was prepared by reduction of Ag + with ascorbic acid. The isotopes of iodine were fixed as Ag 131 I and then, the iodide ion was eluted from the column with a Na 2 S solution. Finally, the 131 I activity could be quantitatively determined. All the parameters were fitted in order to obtain a suitable statistic in counting times within 2000-5000 seconds, short enough for on-line controls. (author)

  4. Radiological protection guidance for radioactive patients -new data for therapeutic 131I

    International Nuclear Information System (INIS)

    Hilditch, T.E.; Watson, W.S.; Connell, J.M.C.; Davies, D.L.; Alexander, W.D.

    1991-01-01

    Thyroidal retention of 131 I was measured in 77 thyrotoxic patients over a period of 1-50 days after a first therapeutic administration of the radionuclide. Mean 131 I activity in the gland (± S.D.) at 1 day was 56.1 ± 11.1% of the administered dose activity and thereafter retention followed a single exponential decay pattern with a mean effective half-life (± S.E.M.) of 6.35 ± 0.14 days. In patients who required further 131 I therapy, there was evidence that retention could be markedly reduced if there was virtual ablation of thyroid tissue. It is proposed that these retention data can be used to determine body radioactivity at any interval after the administration of 131 I for treatment of thyrotoxicosis, thus obviating the need for serial measurements in every individual patient. (author)

  5. Radioimmunoimaging of nude mice bearing human lung adenocarcinoma xenografts after injecting 131I-McAbs

    International Nuclear Information System (INIS)

    Liu Liang

    1992-01-01

    Monoclonal antibodies (Lc86a-C5, Lc86a-H8) directed against human lung adenocarcinoma cell line LTEP-a-2 and normal BALB/c IgG were labelled with iodine-131 by chloramine T. The 131 I-McAbs and 131 I-IgG were respectively injected into the peritoneal cavities of nude mice bearing transplanted human lung adenocarcinoma cell line LTEP-a-2. After 72 h, the tumor tissue in nude mice injected with 131 I-McAbs was distinguishable from normal tissues as a very clear image obtained during gamma scintigraphy. No difference was found between tumor and normal tissues in the nude mice injected with 131 I-IgG. The tumor: blood ration was 3.1:1 in nude injected with 131 I McAb(H8) and 0.9:1 in nude mice injected with 131 I-IgG respectively. This indicates that the tumor tissue image was the result of specific binding of the 131 I-McAbs, which have high specificity and affinity both in vitro and in vivo, to tumor cells, and these monoclonal antibodies may serve as potential agents in tumor diagnosis and treatment

  6. Computer-aided pathophysiological analysis of 131I rose bengal hepatogram

    International Nuclear Information System (INIS)

    Matsumoto, Akira

    1976-01-01

    The author analysed 131 I-rose bengal (R.B.) hepatograms over the liver region using digital simulation technique to determine the hepatobiliary functions separately and to compare the rate constants obtained from the kinetic model and the results obtained from conventional liver function tests. A total of 112 cases were observed including various liver and gallbladder diseases and 8 normal subjects. Fasting patients were given intravenous injections of 300 μCi of 131 I-R.B. Hepatic uptake and excretion of radioactivity were measured for 120 minutes using a gamma camera. Two regions, one over the right lobe and the other over the gallbladder, were studied. The author applied a 3 compartment analysis to the 131 I-R.B. hepatogram. Measured 131 I-R.B. hepatogram was printed out on a line printer with curve pattern indices. Assumed rate constants and relative volume indices were placed on punch cards. Computer-aided simulation curves were printed on a line printer with curve pattern indices. The measured hepatogram and the simulated hepatogram were compared. The blood flow index (K 21 ), the hepatocellular function index (K 32 ) and the intrahepatic biliary excretion index (K 03 ) were obtained with the schematic presentation of the curves. Rate constants from the kinetic model correlated well with conventional liver function tests. In normal liver and hepatobiliary diseases, there were high statistical correlations between K 21 and Ksub(L) 131 I-R.B. Retention (%), between K 32 and Cholinesterase, and between K 03 and Alkaliphosphatase. However, there was a low statistical correlation between the results of the simulation study and the results of liver function tests in the cases of obstructive jaundice and intrahepatic cholestasis. (Evans, J.)

  7. Three cases of respiratory failure after I-131 radioiodine therapy

    International Nuclear Information System (INIS)

    Watanabe, Ken; Uchiyama, Masayuki; Fukuda, Kunihiko

    2016-01-01

    We report three cases of respiratory failure after I-131 radioiodine therapy. All cases involved relapsed cervical lesions, and two showed edema of the larynx. Emergency tracheostomy was performed to treat the respiratory failure in one case while the others were treated conservatively. All patients showed improvements without after-effects. Patients who undergo I-131 radioiodine therapy, especially those with cervical lesions, should be carefully monitored for this rare complication after treatment. (author)

  8. Comparison of {sup 131}I whole-body imaging, {sup 131}I SPECT/CT, and {sup 18}F-FDG PET/CT in the detection of metastatic thyroid cancer

    Energy Technology Data Exchange (ETDEWEB)

    Oh, Jong-Ryool; Chong, Ari; Kim, Jahae; Kang, Sae-Ryung; Song, Ho-Chun; Bom, Hee-Seung [Chonnam National University Hospital, Department of Nuclear Medicine, Clinical Medicine Research Center, Gwangju (Korea, Republic of); Byun, Byung-Hyun; Hong, Sun-Pyo; Yoo, Su-Woong [Chonnam National University Hwasun Hospital, Department of Nuclear Medicine, Clinical Medicine Research Center, Hwasun, Jeonnam (Korea, Republic of); Kim, Dong-Yeon [Dongguk University, Department of Chemistry, Seoul (Korea, Republic of); Chonnam National University Hospital, Department of Nuclear Medicine, Clinical Medicine Research Center, Gwangju (Korea, Republic of); Min, Jung-Joon [Chonnam National University Hwasun Hospital, Department of Nuclear Medicine, Clinical Medicine Research Center, Hwasun, Jeonnam (Korea, Republic of); Center for Biomedical Human Resources at Chonnam National University, Brain Korea 21 Project, Gwangju (Korea, Republic of)

    2011-08-15

    The aim of this study was to compare {sup 131}I whole-body scintigraphy (WBS), WBS with {sup 131}I single photon emission computed tomography/computed tomography (SPECT/CT), and {sup 18}F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in the detection of distant metastases of differentiated thyroid cancer (DTC). A total of 140 patients with 258 foci of suspected distant metastases were evaluated. {sup 131}I WBS, {sup 131}I SPECT/CT, and {sup 18}F-FDG PET/CT images were interpreted separately. The final diagnosis was obtained from histopathologic study, serum thyroglobulin level, other imaging modalities, and/or clinical follow-up. Of the 140 patients with 258 foci, 46 patients with 166 foci were diagnosed as positive for distant metastasis. The sensitivity, specificity, and diagnostic accuracy of each imaging modality were 65, 55, and 59%, respectively, for {sup 131}I WBS; 65, 95, and 85% for {sup 131}I SPECT/CT, respectively; and 61, 98, and 86%, respectively, for {sup 18}F-FDG PET/CT in patient-based analyses. Lesion-based analyses demonstrated that both SPECT/CT and PET/CT were superior to WBS (p<0.001) in all patient groups. SPECT/CT was superior to WBS and PET/CT (p<0.001) in patients who received a single challenge of radioiodine therapy, whereas PET/CT was superior to WBS (p=0.005) and SPECT/CT (p=0.013) in patients who received multiple challenges. Both SPECT/CT and PET/CT demonstrated high diagnostic performance in detecting metastatic thyroid cancer. SPECT/CT was highly accurate in patients who underwent a single challenge of radioiodine therapy. In contrast, {sup 18}F-FDG PET/CT presented the highest diagnostic performance in patients who underwent multiple challenges of radioiodine therapy. (orig.)

  9. Radioimmunotherapy in refractory b-cell nonhodgkins lymphoma with I-131-labeled chimeric anti cd-20 c2b8 (I-131 rituximab): preliminary result

    International Nuclear Information System (INIS)

    Kang, Hye Jin; Park, Yeon Hee; Kim, Sung Eun and others

    2005-01-01

    Recently, the native chimeric human-mouse anti CD-20 antibody IDEC-C2B8 (Rituximab) has been widely applied in NHL. This ongoing phase study was to evaluate whether radioimmunotherapy (RIT) with I-131 rituximab is effective in refractory B-cell NHL. Inclusion criteria were as follows: B-cell NHL with relapsed or refractory to primary standard therapy, measurable disease, adequate hematologic, renal, and hepatic function, informed consent. The rituximab (Mabthera, Roach) was radiolabeled with iodine-131(I-131) using a modified chloramine T method with high radiochemical purity (95%) and preservation of immuno-reactivity. All patients received loading doses of unlabeled rituximab (median, 40 mg: range, 20∼70 mg) immediately prior to administration of therapeutic dose (51.4∼152.2 MBq/kg), and then underwent gamma camera scan. 11 patients were enrolled (4 low-grade B-cell NHL, 7 DLBCL, median age 63 years). Patients had received a median of three prior chemotherapy regimens. The objective response rate was 36.4% (1 CR, 3 PRs). These all responses were observed in low-grade B-cell NHL, except one with DLBCL. Adverse events were primarily hematologic toxicities; the incidence of grade 3/4 neutropenia, thrombocytopenia, and anemia was 27.3%, 45.5%, and 18.2%, respectively. The treatment-related mortality was observed in one patient, who had been previously treated with high-dose chemotherapy plus TBI with autologous stem cell transplantation. RIT with I-131 rituximab seems to be effective tolerable in refractory low-grade B-cell NHL, although modest activity in refractory DLBCL. Further studies to define the efficacy of I-131 rituximab in DLBCL are warranted

  10. Radioimmunotherapy in refractory b-cell nonhodgkins lymphoma with I-131-labeled chimeric anti cd-20 c2b8 (I-131 rituximab): preliminary result

    Energy Technology Data Exchange (ETDEWEB)

    Kang, Hye Jin; Park, Yeon Hee; Kim, Sung Eun and others [Korea University Medical School, Seoul (Korea, Republic of)

    2005-07-01

    Recently, the native chimeric human-mouse anti CD-20 antibody IDEC-C2B8 (Rituximab) has been widely applied in NHL. This ongoing phase study was to evaluate whether radioimmunotherapy (RIT) with I-131 rituximab is effective in refractory B-cell NHL. Inclusion criteria were as follows: B-cell NHL with relapsed or refractory to primary standard therapy, measurable disease, adequate hematologic, renal, and hepatic function, informed consent. The rituximab (Mabthera, Roach) was radiolabeled with iodine-131(I-131) using a modified chloramine T method with high radiochemical purity (95%) and preservation of immuno-reactivity. All patients received loading doses of unlabeled rituximab (median, 40 mg: range, 20{approx}70 mg) immediately prior to administration of therapeutic dose (51.4{approx}152.2 MBq/kg), and then underwent gamma camera scan. 11 patients were enrolled (4 low-grade B-cell NHL, 7 DLBCL, median age 63 years). Patients had received a median of three prior chemotherapy regimens. The objective response rate was 36.4% (1 CR, 3 PRs). These all responses were observed in low-grade B-cell NHL, except one with DLBCL. Adverse events were primarily hematologic toxicities; the incidence of grade 3/4 neutropenia, thrombocytopenia, and anemia was 27.3%, 45.5%, and 18.2%, respectively. The treatment-related mortality was observed in one patient, who had been previously treated with high-dose chemotherapy plus TBI with autologous stem cell transplantation. RIT with I-131 rituximab seems to be effective tolerable in refractory low-grade B-cell NHL, although modest activity in refractory DLBCL. Further studies to define the efficacy of I-131 rituximab in DLBCL are warranted.

  11. The comprehensive assessment of 131I and ATD therapy for the patients with hyperthyroidism

    International Nuclear Information System (INIS)

    Deng Haoyu; Xiao Min; Liang Changhua; Li Xinhui

    2002-01-01

    Objective: To comprehensively mark the treatment of hyperthyroidism with 131 I and antithyroid drugs (ATD) and to quantitatively assess the advantages and the disadvantages of them. Methods: In two therapeutic methods of hyperthyroidism those being cured were marked 0, those getting better were marked 1, those remaining unchanged were marked 2. After treatment the patients demonstrated ophthalmopathy or more severe ophthalmopathy, hyperthyroid heart disease, liver function damage and leukopenia were marked 2, those showed temporary hypothyroidism and permanent hypothyroidism were marked 1,2, respectively. Those who had a relapse of the disease after being cured were marked 2. Both individual kinds of marks and total marks were compared. Results: The total mark of group treated with 131 I was 319, and the average mark was 1.39; the total mark of group treated with ATD was 569, and the average mark was 2.20, the difference between the two groups was significant (P 131 I (P 131 I contracted hypothyroidism more often than those treated with ATD ( P = 0.001). The patients cured with 131 I their hyperthyroidism relapse obviously less occurred than in those cured with ATD. In the patients treated with 131 I the incidences of hyperthyroid heart disease, liver function damage, leukopenia and so on were less than in those treated with ATD (P 131 I therapy excels the ATD in treatment of the patients with hyperthyroidism. Although there is certain incidence of hypothyroidism, ophthalmopathy and so on after 131 I treatment, its total curative effect is better than that of ATD

  12. Influence of prilocaine in the interchange of 131I between aqueous humour and blood

    International Nuclear Information System (INIS)

    Arbex, S.T.; Neder, A.C.; Mattos Filho, T.R. de; Ramos, A.O.; Nascimento Filho, V.F. do

    1981-01-01

    The experiment had two groups: Group I - (six dogs) - 131 I was injected into the aqueous humour and the radioactivity was measured in the blood at 1,2,4,8,16,32,64 and 128 minutes after the administration. Group II - (eight animals) - 131 I was injected intravenously and the radioactivity was measured in the aqueous humour at 5 and 10 minutes after the administration. Each group was subdivided in two sub-groups, one of them besides the 131 I received 5 mg/Kg of prilocaine. 131 I in the iodite form was always injected in 0.1 ml volumes, corresponding to 312.5 μCi. The radioactivity was measured and the results were as follows: a) Group I - the prilocaine markedly decreased the radioactivity in the blood, suggesting a smaller passage of 131 I from the aqueous humour to the blood. b) Group II - the prilocaine increased the radioactivity in the aqueous humour, suggesting an accumulation of iodite in that compartment. (Author) [pt

  13. I131-MIBG in early diagnose of neuroblastoma in symptomatic children

    International Nuclear Information System (INIS)

    Saddadi, F.S.; Kargarzadeh, F.K.; Yaghoobi, N.Y.

    2002-01-01

    Aim: Neuroblastoma is the second most common solid tumors in childhood which derivates from neural crest. It is very malignant and almost always patient comes with metastasis. However there are some diagnostic tools to detection of lesion in the early stage of tumor. We decided to have a review with using I-131 MIBG in patients suspected and/or proved to have neuroblastoma. Material and Methods: 300-500 μci I 131 MIBG was injected intravenously in patients (5 patients with age range 4 years old) referred for their bone pain and pelvic mass(detected with anatomical tools). Images were obtained 24 to 72 hours throughout the body with ADAC gamma camera and SPECT was performed in each local abnormal uptake. Each patient has already had a WBBS with TcMDP. Results: All abnormal tracer uptakes were seen in bone scan were revealed clearly in I131 MIBG. However, three to five other abnormal tracer activities were only seen in MIBG scan. The main tumoral lesions were showed perfectly in pelvic,that was not seen in WBBS. With a statistical analysis, I131 MIBG has 94% sensitivity 85-100% specificity, compare to Tc99m-MDP that was 78% and 51% respectively. Conclusions: We found that I131 MIBG is the most useful method to diagnose of patients with neuroblastoma and reproved that it has a competitive role in management, follow-up of these tumors especially in detection of metastasis

  14. [131I therapy in hyperthyroidism. Results of treatment from 1960-1974].

    Science.gov (United States)

    Heinze, H G; Schenk, F

    1977-02-01

    488 PATIENTS WITH Graves' disease were treated by 131Iodine between 1960 and 1974. 427 (87,5%) of these patients were reexamined several times (clinically, 131I-uptake, PB127I, T4 (CPB-A), T3-uptake, and since 1973 TRH-test). The 131I was given as an individually calculated single dose treatment, using 7 000 -- 10 000 rd before 1965 and 6 000 rd thereafter. Two thirds of the patients became euthyroid after a single 131I-dose. In 20% the treatment had to be repeated. These patients show evidently a different biological behaviour of their disease, since multiple treatments revealed a higher rate of failure (33--35%). There is no principal difference between the out-come after 131I-therapy and surgery concerning the rate of failure, respectively relapse (3--4%) and hypothyroidism. Early incidence of hypothyrodism is dose--dependent, as could be shown in patients treated with higher doses before 1965. The reduction of the irradiation dose to 6 000 rd was followed by a drop of hypothyroidism from 18% to 7%. The reasons of late incidence of hypothyroidism are discussed. The incidence of hypothroidism was calculated by three different methods (over-all incidence, incidence within the observed interval after therapy, life-table method). All three methods revealed different results. This has to be taken into account comparing results after radioiodine as well as after surgery. Radioiodine therapy for hyperthyroidism offers a true alternative to surgery.

  15. Adrenal imaging with 131I-Adosterol (NCL-6-131I) by diverging and pinhole methods, 2

    International Nuclear Information System (INIS)

    Nakajo, Masayuki

    1982-01-01

    The analysis of the adrenal diverging and pinhole images with 131 I-Adosterol was made to establish adrenal imaging patterns, in 43 patients with various adrenal disorders, 4 with adrenal adjacent tumors and one with arrhenoblastoma of the ovary whose images were also included. From this analysis and review of literature, three principles (1. Accumulation in cortical tumors, 2. Relation to endogenous ACTH and 3. Nonaccumulation in noncortical tumors) and several additional factors to make various adrenal imaging patterns with 131 I-iodocholesterols could be induced. The accuracy of locating the adrenal tumor-bearing glands was 97% (28/29) with pinhole images and 70% (21/30) with diverging images in baseline conditions. Various adrenal high/low ratios could not be used as confidential indicators to locate the tumorbearing glands, especially in primary aldosteronism, although the left higher ratios on both views showed high discrepancy between normal and abnormal subjects. The ''Pinhole method'' is recommended as a simple technique of adrenal imaging, because it provides a high-resolution adrenal image which results in a high diagnostic value. A pinhole collimator is available in any institute which has a gamma camera. (author)

  16. The early development of hypothyroidism after 131I treatment for hyperthyroid Graves' disease

    International Nuclear Information System (INIS)

    Kang Zengshou; Zhou Qian; Liu Shizhen

    1995-01-01

    827 patients with Graves' hyperthyroidism following 131 I treatment were followed up at 3 monthly intervals for 12∼36 months from 1985 to 1991. Physical examination and serum total T 3 , T 4 , TSH measurements were made at each visit. According to the authors data, 90% early hypothyroidism occurred within 2∼3 months after 131 I treatment, thereby, careful follow-up study is very important during this period. T 4 was much more sensitive than T 3 in diagnosing early hypothyroidism, while the TSH level shows thyroid reservation function, and is less sensitive than T 4 in diagnosing 131 I induced hypothyroidism. The study confirmed the view that the early incidence of post 131 I therapy hypothyroidism was strongly dose dependent

  17. 131I therapy of teen-age hyperthyroidism: the primary results in 46 patients

    International Nuclear Information System (INIS)

    Wang Kaiming

    2001-01-01

    Objective: To explore various conditions of teen-age hyperthyroidism with 131 I therapy. Methods: 46 patients were administrated with 131 I, the changes of T 3 and T 4 level of serum were tested by radioimmunoassay. The improvement of clinical symptoms has been observed in 46 cases with teen-age hyperthyroidism by 131 I before and after treatment. Results: 39 of 46 (84%) has been proved complete responses (CR), partial responses (PR) 7 cases. 3 months later; we found that 39 patients have hypothyroidism symptoms, T 3 and T 4 level of serum decreased. There are significance increases of TSH 23 percent patients. Conclusion: It has been proved that treatment of teen-age hyperthyroidism by 131 I is effective and safe

  18. The dose analysis of 131I treatment in pediatric patients with Graves hyperthyroidism

    International Nuclear Information System (INIS)

    Zheng Yan; Zhao Deshan; Fu Songhai; Feng Fei; Geng Huixia; Sun Qiting; Lu Keyi; Li Baojun; Li Sijin

    2013-01-01

    Objective: To analyze the radioactive 131 I dose of treatment in pediatric patients with Graves hyperthyroidism. Method: Fifty one pediatric patients with hyperthyroidism and 150 adult patients with hyperthyroidism were retrospectively analyzed, who were contraindicated or refractory for medical therapy and treated with 131 I in this study. All pediatric and adult patients treated with 131 I were divided into five groups according to the thyroid weight. Group 1: ≤30 g,Group 2: 31∼50 g, Group 3: 51∼70 g, Group 4: 71 ∼90 g and Group 5: >90 g. The pediatric patients were comparable to the adult patients in data distribution of the thyroid weight. All pediatric patients who were either contraindicated or refractory to antithyroid drugs treatment and adult patients received radioactive 131 I treatment with a dose of (2.41±0.71), (3.27±0.97) MBq/g thyroid tissue respectively. The total administrated doses of 131 I in all pediatric and adult patients were (224.36±130.10) MBq and (354.88 ±308.04) MBq respectively. All the pediatric and adult patients treated with 131 I were followed-up (median 32 months, range 24 to 83 months; median 23 months,range 15 to 62 months, respectively). The treatment results were divided into euthyroid, hyperthyroidism, late-onset hypothyroidism and relapsed. Results: The results by followed-up found that 16 and 65 patients became euthyroid, 22 and 56 patients developed late-onset hypothyroidism, 12 and 25 patients still had hyperthyroidism, 1 and 4 patients relapsed after radioiodine therapy in pediatric group and adult group who were treated with 131 I, respectively. The total efficiency was 98% and 97.3%, respectively. There were no statistical significance of treatment effect between pediatric and adult patients (χ 2 =0.058, P>0.05). Conclusion: When the radioactive 131 I dose was administrated in pediatric patients with hyperthyroidism, who were contraindicated or refractory for medical therapy, it is recommended that the

  19. Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma

    International Nuclear Information System (INIS)

    Kosmin, Michael A.; Cork, Nicholas J.; Gaze, Mark N.; Bomanji, Jamshed B.; Shankar, Ananth

    2012-01-01

    Radiolabelled meta-iodobenzylguanidine (mIBG), used as targeted therapy for neuroblastoma, is known to have effects on blood pressure (BP). In this study we audited BP changes in patients receiving 131 I-mIBG therapy for neuroblastoma to identify BP-related adverse events (AE) and possible predictive factors. Between 2003 and 2010, 50 patients with neuroblastoma received 110 131 I-mIBG administrations. BP measurements before and after administration were compared with age- and sex-matched centile values. AE were analysed, and possible predisposing factors identified. This population had a baseline BP distribution higher than that of their age- and sex-matched peers, with 16% of preadministration systolic BP values above the 95th centile. Changes in BP after administration showed an approximately normal distribution with similar numbers of reduced and increased values. Four AE, all related to hypertension, occurred with one patient having generalized seizures. One AE was immediate, others occurred between 20 and 25 h after administration. No significant association between AE and patient age or sex was demonstrated. However, a significant association between AE and high preadministration BP was shown, both above the 90th centile (p = 0.0022) and above the 95th centile (p = 0.0135). Clinically relevant hypertension following 131 I-mIBG therapy affected less than 5% of administrations, but was more common in those patients with preexisting hypertension. As hypertensive episodes may occur many hours after treatment, close monitoring of BP needs to be continued for at least 48 h after administration of 131 I-mIBG. (orig.)

  20. Hypothyroidism caused by 131I treatment for Graves disease

    International Nuclear Information System (INIS)

    Deng Shouzhen; Lin Xiangtong; He Wanting; Zhang Kaili; Zhang Jinming; Kuai Dayu

    1991-01-01

    The refollow-up has been carried out in hypothyroidism caused by 131 I treatment for Graves disease. The serum HS-TSH(IRMA), FT3, TSH(RIA), TT3, TT4, FT4I, MCA, TGA, Cholesterol and Triglyceride has been measured in 26 patient after 131 I treatment for 9.5 years in average. At the same time TRH stimulation test was also performed, and the clinical symptoms and signs assessed. The results showed that TSH is the most sensitive criterion for hypothyroidism, followed by Cholesterol and FT 4 I. The occurence of hypothyroidism may be related to the presence of thyroid antibody as demonstrated by the elevation of serum MCA, TGA. Therefore measurement of serum TSH, FT 4 I and Cholesterol during long term follow-up is beneficial for early diagnosis of hypothyroidism and evaluating the effect of substitution treatment

  1. Comparison of thyroid uptake of 131I capsule and solution in rabbits and graves disease patients

    International Nuclear Information System (INIS)

    Zhou Xinjian; Li Fang; Lu Jingqiao; Chen Daming; Zhang Ruilin

    2002-01-01

    Objective: To observe the difference between thyroid uptake rates (TUR) of 131 I capsule and solution in rabbits and Graves disease patients. Methods: Part one: 6 rabbits randomized into two groups received capsule or solution of 131 I 7.4 MBq. Then with SPECT scintigraphy 2,4,6 and 24 h thyroid pure counts in percentage of stomach counts (first frame) were determined. Part two: 1) Measured 131 I capsule standard. 2) 104 patients with Graves disease were administered tracing and therapeutic dose of 131 I capsule (capsule group), 118 of 131 I solution (solution group). Compared the tracing and therapeutic 131 I TUR at 24 h. Results: Part one: There were no significant difference at 2,4,6,24 h TUR between capsule and solution group. For 1 case the maximum TUR was at 6 h in capsule group and 2 cases in solution groups. Part two: 1) For the 131 I capsule administered immediately after being dissolved in 30 mL of water, the activity counts measured were higher by (13.8 +- 2.8)% than it was administered directly, t8.97, P 0.05) and in solution group were (71.3 +- 12.3)% and (65.1 +- 13.0)% (t = 3.82, P 131 I capsule standard should be dissolved before being measured. 3) 131 I capsules can be used as a standard formulation for Graves disease patients. 4) The dose of 131 I should be increased as tracer TUR is larger than 80.0%

  2. Radioiodine (131I) in animal thyroids during nuclear tests in both hemispheres

    International Nuclear Information System (INIS)

    Van Middlesworth, L.

    1975-01-01

    In mid-1974 a small increase of 131 I was observed in animal thyroids following a nuclear test in China. In late 1974 there was no public announcement of an atmospheric nuclear test in the Northern Hemisphere, but 131 I was readily measured in animal thyroids. This latter increase occurred while animals in the Southern Hemisphere accumulated 131 I from nuclear tests in the Southern Hemisphere. It is suggested that in late 1974 the Northern Hemisphere was contaminated by either late fallout from tests in June or by interhemispheric mixing or by a combination of these sources. (author)

  3. Radiation exposure estimation from patient treated by I-131

    International Nuclear Information System (INIS)

    Lahfi, Y.; Anjak, O.

    2012-09-01

    Radioactive iodine is the main radiopharmaceutical substance in the nuclear medicine field which used in diagnosis and treatment of patients suffering from thyroid cancer; thus it can be considered as the main source of the public and patient relative exposure. In this study, 192 patients were selected randomly and their radiation dose rate was measured at different levels of the patient's body (thyroid, knee, bladder) after one, twenty four and forty eight hours from availing the prescript quantity of the I-131. The collected data may serve in estimating the worker and public exposure related to the patient treated by I-131. (authors)

  4. 131I-19-iodocholesterol adrenal scanning in Cushing's syndrome

    International Nuclear Information System (INIS)

    Charbonnel, B.; Chatal, J.F.; Chupin, M.; Guillon, J.

    1976-01-01

    7 patients were investigated: 2 bilateral hyperplasia due to pituitary ACTH excess showed bilateral adrenal activity. 1 post-surgical remnant with recurrent Cushing's syndrome was detected. 1 adenoma showed unilateral intense activity and absent activity in the controlateral gland, even after ACTH treatment. 2 carcinomas were weakly imaged. In 1 case, hepatic metastasis showed 131 I-19-iodocholesterol uptake. Adrenal imaging with 131 I-19-iodocholesterol is not a good procedure for assessing hormonal function. It is a valuable and safe tool in the localization and diagnosis of adrenal lesions causing Cushing's syndrome, perhaps better than radiologic procedures. Radiation dosimetry is acceptable [fr

  5. An experimental study on the antitumor effect of 131I-17-AAG in vitro and in vivo.

    Science.gov (United States)

    Wenyong, Tu; Lu, Liu; Daozhen, Chen; Weidong, Yin; Ying, Huang

    2009-02-01

    To observe the antitumor effect of (131)I-17-allylamino-17-demethoxygeldanamycin ((131)I-17-AAG) in vitro/in vivo and explore its antitumor mechanism with a view to its potential therapeutic application. (131)I-17-AAG was prepared by the reaction of 17-AAG with Na [(131)I] in the presence of hydrogen peroxide. The effects of (131)17-AAG on cell growth inhibition and cell cycle distribution in vitro were studied in BEL-7402 cells lines. Following BEL-7402 tumor implantation by subcutaneous xenografts into nude mice, the reagents were injected through the tail vein, and the tumor volume was measured and analyzed. At the end of the experiment, tumor specimens were processed for histopathological analysis. Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) was used to investigate apoptosis. The expression change of Akt2 was tested by Western-blot analysis. Methyl-thiazolyl-tetrazolium assay showed inhibition rates of 27.7 +/- 5.3%, 57.3 +/- 4.3%, and 63.7 +/- 3.1%, in Na(131)I group, 17-AAG group, and (131)I-17-AAG group, respectively. The inhibition rate in the (131)I-17-AAG group differed significantly between N(a131)I group and 17-AAG group (F = 229.49, P AAG group, and (131)I-17-AAG group, respectively. Following infusion for 32 days, the tumor volumes in the (131)I-17-AAG group were significantly smaller than those in the DMSO group (F = 24.18, P AAG inhibited the proliferation of tumor cells and induced apoptosis. The expression of Akt2 in (131)I-17-AAG was significantly lower than that in the DMSO group or (131)I group. (131)I-17-AAG can effectively inhibit the growth of BEL-7402 tumor cells in vitro and in vivo. (131)I-17-AAG is a promising agent for the treatment of BEL-7402 cell tumor.

  6. Investigation of therapeutic efficiency of phenytoin (PHT) labeled with radioactive 131I in the cancer cell lines

    International Nuclear Information System (INIS)

    Cansu Uzaras; Ugur Avcibasi; Hasan Demiroglu; Emin Ilker Medine; Ayfer Yurt KiIcar; Fazilet Zuemruet Biber Mueftueler; Perihan Uenak

    2016-01-01

    The aim of this study is to determine the incorporations of PHT radiolabeled with 131 I ( 131 I-PHT) on U-87 MG, Daoy and A549 cancerous cell lines. For this, cold and radio-labeling studies were carried out. The radiolabeling yield of 131 I-PHT was obtained about 95 %. Subsequently, cell culture studies were carried out and radio-labeling yields of 131 I, 131 I-PHT on U-87 MG, Daoy and A549 cancerous cells were investigated. Cell culture studies demonstrated that the incorporation values of 131 IPHT on the three cell lines decreased with increasing radioactivity. Consequently, 131 I-PHT may be a good radiopharmaceutical for targeting radionuclide therapy of Central Nervous System Tumors. (author)

  7. The curative effect analysis of 131I-therapy on patients with Graves' disease

    International Nuclear Information System (INIS)

    Cui Qin; Lu Shujun; Lu Tianhe

    2002-01-01

    To investigate the curative effect of 131 I-therapy on Graves' disease, the authors analyse conditions of patients who have received 131 I-therapy (n -674). These results showed that the incidence of fully recover, improve, Graves' disease and invalid is 80.11%, 7.28%, 11.87% and 0.74% respectively. Therefore, 131 I-therapy on Graves' disease is convenient. It has little side effect, low cost and better curative effect, it is one of the best therapeutic methods to treat hyperthyroidism

  8. Consecutive Renal Scanning with {sup 131}I And {sup 203}Hg in Obstructive Uropathy

    Energy Technology Data Exchange (ETDEWEB)

    Poshyachinda, V. [Chulalongkorn Hospital, Bangkok (Thailand)

    1969-05-15

    Two patients with obstructive uropathy were scanned after injections of {sup 131}I sodium orthoiodohippurate (OlH) and {sup 203}Hg chlormerodrin. The {sup 131}I OIH scan was performed 30 min after the injection with the patient in the prone position. The {sup 203}Hg chlormerodrin was injected as soon as a negligible amount of {sup 131}I OIH was detected over the kidney, and the patient was scanned again 30 min later. A third patient and a normal subject were scanned 20 min after the simultaneous injection of {sup 131}I OIH and {sup 203}Hg chlormerodrin. Three scans with different analyser settings were done in sequence. The first scan was done with a window setting for {sup 131}I, and the second scan included both {sup 131}I and {sup 203}Hg; in the third scan, the analyser was set for {sup 203}Hg only. Evidence of hydronephroses, hydroureter and the residual functioning renal tissue were demonstrated by this scanning technique. The intravenous pyelograms in all three cases had failed to give satisfactory results. The simultaneous injection technique was found advantageous over the separate injection technique. (author)

  9. The observation of the therapeutic effectiveness of 131I on 260 youngster with Grave's hyperthyroidism

    International Nuclear Information System (INIS)

    Liu Binwen; Gao Xiusheng; Zhang Yahua; Pu Dongli

    2003-01-01

    Objective: To study the therapeutic effect and find new ways on treatment of Grave's hyperthyroidism in youngsters. Methods: 260 Grave's hyperthyroidism patients (age under 21 years) treated with 131 I were followed up 1-16 years later. Results: 118 of all patients were cured and 55 cases improved, failed treatment 2 cases, subclinical hypothyroidism 9 cases, clinical hypothyroidism 6 cases. 35 cases were treated with 131 I two or three times. All the patients with subclinical hypothyroidism and clinical hypothyroidism caused by 131 I were cured with medicine. 131 I treatment had no effect on growth and mentality and didn't cause leukemia nor thyroid cancer. Conclusions: The therapy of youngsters with Grave's hyperthyroidism with 131 I has the same effectiveness as adult. To the youngster Grave's patients who failed medical treatment, therapy with 131 I is safe and effective. It leads to temporary hypothyroidism which can be cured with medicine, no delayed hypothyroidism has been found

  10. Thyroid uptake of I-131 during anti-thyroid drug treatment

    International Nuclear Information System (INIS)

    Hoque, M.; Alam, F.; Haque, F.S.; Karim, M.A.; Fariduddin, M.

    2004-01-01

    Hyperthyroidism is a global ailment and its treatment is very promising either by ant-thyroid drug or by radioiodine. Iodine-131 uptake test is very important for evaluation of hyperthyroid in respect to its therapy and to exclude thyroiditis. This study was performed to observe the thyroid uptake pattern during intake of anti-thyroid medicine and workout the possibility to start I-131 therapy just after withdraw of antithyroid drug without waiting few days. In this study total 252 patient's I-131 uptake test is performed. Among the patient 135 (53.57%) were female, 117 (64.43%) were male. All this patients were hyperthyroid both clinically and biochemically. Thyroid uptake was taken to all patients at 24 hours after oral administration of 5 to 10 micro-curie of I -131. Uptake was taken by an uptake system and recorded as percentage uptake. These patients are grouped into three categories. Group-A-newly diagnosed cases, who have not taken antithyroid drug or I-131 therapy, there were 82 patients in this group, and their mean uptake was 37.12 ±18.5%. Group B - this group of patients were studied during intake of antithyroid medicine, there were 130 patients in this group and their mean uptake was 34.34±16.0%. Group-B patients were further divided in two sub-groups, patients having antithyroid drug for 1 to 3 weeks (group-B 1), group B1 have mean uptake 37±21% and those were taking antithyroid for 3 weeks to 2 years (group-B2), group B2 have uptake 34.34±20%. Group C- these patients are taken from those patients who had withdrawn antithyroid drug for 3 days to 3 months, there were 40 such patients. Group C further divided into two sub-group, group-C1 (stopped for 3-10 days) and group C2 (stopped for 11 days to 3 months). Group C1 had mean uptake 38±16% and group C2 had mean uptake 35±19%. From this study it is observed that Iodine-131 uptake percentage of untreated hyperthyroid; during antithyroid drug treatment and after withdraw of antithyroid drug almost

  11. Preliminary clinical experience of pulmonary scintigraphy using [sup 131]I-HIPDM

    Energy Technology Data Exchange (ETDEWEB)

    Jiahe, Tian [Department of Medicine, The Chinese PLA General Hospital, Beijing (China); and others

    1992-02-01

    The metabolic imaging of lungs using [sup 131]I-HIPDM, a tracer known to bind to the amino-receptor in pancreas and lungs, was carried out on 44 subjects. In the normal non-smoker group (n = 8), the tracer was found to be uniformly distributed throughout the lung, with slow clearance in bi-exponential mode after peak of concentration in about 30 sec; while in the normal smoker (n = 8), patients with chronic obstructive pulmonary disease (COPD) of both smoker (n = 7) and non-smoker (n = 12), and patients with asthma (n = 5), the distribution as well as the parameters of clearance of [sup 131]I-HIPDM were significantly different. In conclusion: (1) [sup 131]I-HEPDM could reveal some characteristics of pulmonary metabolism of amine in various physiological as well as pathological status; (2) the washout of the tracer from lung was correlated with clinical ventilation functions; (3) smoking is one of the determinant factors of lung metabolic function; (4) the pulmonary metabolic imaging using [sup 131]I-HIPDM was of value in detecting lung disease, especially the functional damages caused by various factors.

  12. Usefulness of {sup 131}I-SPECT/CT and {sup 18}F-FDG PET/CT in evaluating successful {sup 131}I and retinoic acid combined therapy in a patient with metastatics struma ovarii

    Energy Technology Data Exchange (ETDEWEB)

    Seo, Hyo Jung; Lee, In Ki; Kang, Keon Wook; Lee, Dong Soo; Chung, June Key [Dept. of Nuclear Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul (Korea, Republic of); Ryu, Young Hoon [Dept. of Nuclear Medicine, Yonsei University College of Medicine, Seoul (Korea, Republic of); Min, Hye Sook [Dept. of Pathology, Seoul National University Hospital, Seoul (Korea, Republic of); Lee, Dae Hee [Dept. of Oncology, GSAM Hosptial, Gunpo (Korea, Republic of)

    2015-03-15

    Metastatic struma ovarii is an extremely rare disease, and the treatment of choice has not been established. Here, we introduce the case of a 36-year-old female pregnant patient with metastatic struma ovarii. Initial treatment was an exploratory laparotomy to remove multiple peritoneal masses. After delivery, a total thyroidectomy was done for the further {sup 131}I-therapy. {sup 131}I-SPECT/CT and {sup 18}F-FDG PET/CT showed multiple hepatic metastases and extensive peritoneal seeding nodules. Multiple {sup 131}I and retinoic acid combination therapies were performed, resulting in marked improvement. {sup 131}I-SPECT/CT and {sup 18}F-FDG PET/CT were quite useful for evaluating the biologic characteristics of the metastase.

  13. Nose swabs and urinalysis as indicators of exposure to I-131

    Energy Technology Data Exchange (ETDEWEB)

    Barrall, R. C.

    1963-06-15

    During a maintenance operation on the Aromour Research Reactor, a heat lamp, which was drying a valve, caused a small quantity of I/sup 131/ become airborne. A continuous air monitor sampling in the area gave the alarm and the area ntified by the use of a 256 channel analyzer. Nose swabs of the personnel involved were taken and 24 hour urine samples were obtained. A single channel analyzer was set up, calibrated for I/sup 131/ and thyroid counts were started several hours after the incident. The thyroid count rose during the first 24 hour period and then declined closely following the 8 day half life of I/sup 131/. The urine Samples were analyzed by two different gamma counting techniques. Portions of the 24 hour urine sample were also sent to a commercial urinalysis service and analysis for I/sup 131/specifically requested. The results of the commercial service in this instance appeared to be poor. Nose swabs taken immediately after the incident were analyzed using a NaI well crystal. The average value of the ratio mu c on nose swabs to mu c in thyroid was found to be 2.6 x 1-/sup -1/ with all values within a factor of 6. The average value of the ratio mu c in 24 hour urine sample to mu c in thyroid was 5.7 with all values within a factor of 2. It would appear that at short times after a suspected exposure to I/sup 131/ nose swabs and urine samples are both useful in making a rapid assessment of exposure. The data presented are based on 10 subjects. (auth)

  14. The effect of 131I on apoptosis of thyrocytes in patients with Graves disease

    International Nuclear Information System (INIS)

    Cai Min; Li Xianfeng; Feng Xiaoyan; Chen Haibin; Liu Jianzhong; Zhao Deshan; Li Sijin; He Zouxiang

    2011-01-01

    Objective: To investigate the effect of 131 I on apoptosis of thyrocytes in patients with Graves disease. Methods: Forty-seven patients with Graves disease were divided into two groups, two week group (G 2w ) and four week group (G 4w ). All patients underwent thyroid needle biopsy before 131 I treatment and the repeated biopsy at two weeks (G 2w ) or four weeks (G 4w ) after 131 I treatment. The positive units of pro-apoptotic proteins (Fas, FasL) and anti-apoptotic protein (Bcl-2) were studied with immunohistochemistry staining. The differences of the two groups were compared with t-test. Liner correlation analysis was applied to study the correlation between 131 I dose and apoptosis-related proteins and that between serum sTSH after 131 I treatment and apoptosis-related proteins. Results: Fas, FasL and Bcl-2 expression (positive units) were significantly increased in both groups after 131 I treatment, G 2w :22.84±9.31 vs 16.20±6.75, 21.13±6.29 vs 14.56±4.06, 21.69±7.83 vs 15.22±5.94, t=-3.08, -3.73, -4.05 (all P 4w : 21.69±4.52 vs 15.83±5.03, 19.11±3.75 vs 14.02±4.98, 19.06±3.44 vs 16.63±4.73, t =-5.26, -5.00, -2.41 (all P 2w and G 4w (t =0.53, 0.82, 1.46, all P>0.05). Significant correlation was found between 131 I 0.727, r FasL =0.763 (both P Bcl-2 =- 0.094, 0.102(both P > 0.05). There were significant correlation between serum sTSH three months after 131 I treatment and apoptosis-related proteins, r Fas = 0.433, r FasL = 0. 601, r Bcln2 = - 0.397, (all P 131 I can induce thyrocytes to express the pro-apoptotic proteins in patients with Graves disease. (authors)

  15. Clinical comparison of I-131 orthoiodohippurate and the kit formulation of Tc-99m mercaptoacetyltriglycine

    International Nuclear Information System (INIS)

    Taylor, A. Jr.; Ziffer, J.A.; Steves, A.; Eshima, D.; Delaney, V.B.; Welchel, J.D.

    1989-01-01

    Previous studies in animals and humans have shown that technetium-99m mercaptoacetyltriglycine (MAG3) purified by high-performance liquid chromatography is a renal tubular agent with characteristics similar to those of iodine-131 orthoiodohippurate (OIH). A kit formulation for Tc-99m MAG3 has been developed and compared with I-131 OIH in 17 patients with suspected renal dysfunction and three potential kidney donors. There were no adverse reactions. Tc-99m MAG3 images were of good quality and consistently better than I-131 OIH images. There was no significant difference in the relative renal uptake of Tc-99m MAG3 and I-131 OIH. The 30-minute urinary excretion of Tc-99m MAG3 was 36.4%, versus 40.4% for I-131 OIH. The average plasma clearance of Tc-99m MAG3 (138 mL/min +/- 117) was less than that of I-131 OIH (272 mL/min +/- 205) (P less than .001); however, there was good correlation between the Tc-99m MAG3 and I-131 OIH clearances (r = .87). The volume of distribution of Tc-99m MAG3 (5.96 L +/- 1.94) was less than that of I-131 OIH (9.41 L +/- 3.73) (P less than .001). These characteristics and the advantages of a simple kit formulation should lead to widespread clinical use

  16. 131I-therapy of graves' disease and non-immunogenic thyrotoxicosis

    International Nuclear Information System (INIS)

    Hoeschel, M.; Heinze, H.G.

    1984-01-01

    From 1977 to 1982, 315 patients suffering from thyrotoxicosis with diffuse and/or nodular goitre or Graves' disease were treated with 131 I. In 246 patients, the results of treatment after 7 months to 5 1/2 years could be evaluated. After a single treatment with 131 I, 72% of the patients with hyperthyroid nodular goitre and 61% of those with diffuse goitre, but only 36% of the patients with Graves' disease showed normal thyroid function. By repeated 131 I treatments - as many as 5 for those with Graves' disease - normal thyroid function could be achieved in nearly all patients examined. Patients with immune thyrotoxicosis, type Graves' disease, showed a high resistance to therapy. A dependence was found between the results of these treatments and previous antithyroidal drug therapy or surgery. The rate of hypothyroidism varied between 4 and 15%. The highest rate of hypothyroidism was observed in operated patients with persistent or recurring thyrotoxicosis. (orig.) [de

  17. 131I-metaiodobenzylguanidine in the treatment of neuroblastoma at diagnosis

    International Nuclear Information System (INIS)

    Mastrangelo, R.; Troncone, L.; Lasorella, A.; Riccardi, R.; Montemaggi, P.; Rufini, V.

    1989-01-01

    Radioactive metaiodobenzylguanidine ( 131 I-MIBG) is taken up specifically by neuroblastoma cells and appears to represent a new treatment modality in patients with advanced neuroblastoma. Taking into account the fact that all patients so far treated were heavily pretreated and resistant to chemotherapy, the results obtained appear encouraging. In order to explore further the potential role of this new drug in untreated patients, we treated with 131 I-MIBG a child with stage III neuroblastoma at diagnosis. We observed the complete disappearance of a large abdominal tumor mass after a relatively low dosage of 131 I-MIBG, with minimal hematologic toxicity. No further treatment was given and, at present, the patient is alive with no evidence of disease 18 months from diagnosis. This child represents, to our knowledge, the only case of neuroblastoma thus far treated at diagnosis and the excellent response obtained suggests the need for further investigations of this therapy in untreated patients

  18. The treatment of hyperthyroidism in adolescents and children with 131I

    International Nuclear Information System (INIS)

    Feng Fei; Zhao Deshan

    2009-01-01

    Hyperthyroidism in adolescents and children is a common endocrinium disorder, which disturbs the development of diverse body systems, especially of skeletal and central nervous systems. The patients with hyperthyroidism have a lower long-term, spontaneous remission of the disease. The majority of adolescents and children patients with hyperthyroidism have to receive an effective, safe therapy. Currently, there are three methods for treating hyperthyroidism. They include in antithyroid drugs (ATD), surgery and radioactive iodine ( 131 I) therapy. ATD always is the first line way to these patients with hyperthyroidism for endocrinologist yet. But the remission rate of hyperthyroidism for ATD is lower, the remission of hyperthyroidism also need spend longer time, and side effects of ATD are more common in adolescents and children than in adult. The success ratio and complications of surgery are mainly depended on the technic of surgeons, 131 I has been used as the treatment of hyperthyroidism for more than six decades. So far, there are still no enough evidences to show that the incidence of thyroid cancer and other malignant diseases, the patients fertility rate, rate of abortion and malformation of descendants in hyperthyroidism patients following 131 I were marked difference with that in other people. The remission rate of hyperthyroidism following 131 I was higher and its side effects were less. 131 I therapy can be the first choice to adolescents and children with hyperthyroidism who are no suitable to ATD therapy. Hypothyroidism is most often one outcome of pediatric patients with hyperthyroidism after 131 I therapy. Hence, the patients with hypothyroidism have to receive the replacement treatment of thyroxine. Since the development of adolescents and children are more dependent on thyroxine and adolescents and children are more sensitive to the radioactive rays than adults, it is more suitable to get ideal control with a relative lower dosage of mi to

  19. Preparation of a radioactive boron compound (B-I-131-lipiodol) for neutron capture therapy of hepatoma

    International Nuclear Information System (INIS)

    Chou, F.I.; Chung, H.P.; Chung, R.J.; Wen, H.W.; Wei, Y.Y.; Kai, J.J.; Lui, W.Y.; Chi, C.W.

    2000-01-01

    In our research, a radioactive boron compound, B-I-131-lipiodol, that can be selectively retained in hepatoma cells was prepared. Combining the effect of α particles produced by boron neutron capture reaction with the β particles released by radionuclides in the radioactive boron compounds will produce a synergistic killing effect on cancer cells. Human hepatoma HepG2 cell cultures were used to examine the stability and the intracellular distribution of the radioactive boron drug. Microscopes were used to examine the interaction and retention of B-I-131-lipiodol globules in the individual hepatoma cell. Moreover, ICP-AES and NaI scintillation counter were performed to determine boron concentrations and I-131 radioactivity, respectively. Results showed that B-I-131-lipiodol with a boron concentration and a specific radioactivity ranged from 500-2000 ppm and 0.05-10 mCi/mL respectively was stably retained in serum. The radiochemical purity of B-I-131-lipiodol was 98%. After supplement with a medium containing B-I-131-lipiodol, the HepG2 cells had intracellular B-I-131-lipiodol globules in the cytoplasm as seen by inverted light microscope, the I-131 and boron can be stably retained in HepG2 cells. (author)

  20. Optimization of the therapeutic dose of {sup 131}I for thyroid differentiated carcinoma; Otimizacao da dose terapeutica com {sup 131}I para carcinoma diferenciado da tiroide

    Energy Technology Data Exchange (ETDEWEB)

    Lima, Fabiana Farias de

    2002-09-01

    I-131 thyroid cancer therapy is based on the strategy of concentrating radioactive iodine in the thyroid tissue, to completetly eliminate thyroid tissue and functioning thyroid cancer metastases remaining after thyroidectomy. In Brazil, fixed activities of {sup 131} I generally are given, sometimes either delivering insufficient activities to ablate all of the remnants, or unnecessarily high activities, with patients remaining in the hospital for some period of time. This investigation proposes a protocol of individualized planning of ablative doses, based on individual patients metabolisms and measured thyroid remnant masses. Simulated thyroid remnants were fabricated in various forms, volumes and activities, and optimum image acquisition parameters were determined using Single-Photon Emission Computed Tomography 9SPECT). Resultant images were evaluated, to determine the apparent volumes and the {sup 131} I concentrations. I-131 metabolism was studied in 9 patients who had undergone thyroidectomies. Their thyroid remnant masses were determined applying the same parameters used in SPECT simulation studies, and the optimum activity for their therapy was calculated and compared to the established fixed activity of 3.7 GBq (100 mCi), which would have normally been assigned. Background subtraction using the method of percent maximum counts, using a value of 67.5%, combined with scatter correction (triple energy window method), was shown to be optimum for SPECT quantification of volumes between 3-10 ml. Errors in the method were below 9% for sources with regular geometries and around 11% for sources with irregular geometries. In the patient studies, it was observed that 78% of patients could have received reduced activities of {sup 131} (from 0.8-3-2. GBq (20-87 nCi). In addition, 33% of these patients could have received low enough activities to have discharged from the hospital, using an individualized administration scheme. This could also have resulted in a dose

  1. Comparative study between 131I-MIBG scintigraphy and other tumor markers in diagnosis of neuroblastoma

    International Nuclear Information System (INIS)

    Ohsawa, Yoshihiro; Iwafuchi, Makoto; Odano, Ikuo; Yamagiwa, Iwao.

    1989-01-01

    In order to prove the clinical usefulness in diagnosis of neuroblastoma, comparative studies between iodine-131 metaiodobenzylguanidine ( 131 I-MIBG) scintigraphy and other related tumor markers were attempted. Sixteen children diagnosed as having a neuroblastoma in recent 2 years were examined. In 5 postoperative patients in complete remission, who were negative to other tumor markers, showed no pathological accumulation of 131 I-MIBG (specificity 100%). In other 11 patients with remains of neuroblastoma, 131 I-MIBG was negative only in 2 patients (sensitivity 82%) and these 2 patients showed negative urinary excretion of catecholamine metabolites (VMA). (Negative urinary VMA was proved in 3 of 11 patients). Serum neuron-specific enolase (NSE) was elevated in all 8 preoperative patients, but only in 2 of 11 postoperative patients. On the other hand 131 I-MIBG was positive in 9 among these 11 postoperative patients in whom neuroblastoma remained. Similar relationship was obtained between 131 I-MIBG scintigraphy and serum LDH. On the basis of our present experience, we like to regard 131 I-MIBG scintigraphy as one of the most sensitive parameters for neuroblastoma during a follow-up period after treatment. (author)

  2. Clinical investigation of 131I therapy combined with low-dose lithium carbonate for Graves disease

    International Nuclear Information System (INIS)

    Xu Haiqing; Wu Bian

    2006-01-01

    Objective: To investigate the clinical curative effects of 131 I therapy combined with low-dose lithium carbonate for Graves disease. Methods: Patients with Graves disease took lithium carbonate (250 mg, once per day) orally for 5 weeks. Then they were treated with 131 I (doses=3.15 MBq(80 uCi)/g, based on 60%-70% of the thyroid size). We kept track from 6 to 24 months (averaging 14 months) and classified the results into three: cured, improved or no effect. Results: After a single cycle of 131 I therapy combined with low-dose lithium carbonate, 106 patients with Graves disease were cured, 28 were improved and 8 saw no effects, respectively 74.6%, 19.7% and 5.6% among the 142 patients. We then treated 23 of them with another 131 I therapy (without lithium carbonate). 10 of such were cured (43.5%), 8 were improved (34.8%) and the other 5 saw no effects. Among all patients, hypothyroidism was observed from 25(17.6%), 6 months after the first 131 I therapy. Conclusions: Notable curative results were observed from 131 I therapy combined with low-dose lithium carbonate for Graves disease. Moreover, the dosage of 131 I was therefore decreased, which also lowered the toxicity response. (authors)

  3. Indication of doxorubicin cardiotoxicity by impairment of pIPPA I 131 utilization

    International Nuclear Information System (INIS)

    Lenzhofer, R.; Dudczak, R.

    1986-01-01

    The present study was designed to evaluate if doxorubicin (D) can impair myocardial fatty acid utilization. To this end we studied the myocardial utilization of pIPPA I 131 in untreated (Co, n=6) and D (20 mg/kg intraperitoneal) treated rats. D was given 24 h (24 D, n=6) and 48 hours (48 D, n=6) before tracer administration. One min after i.v. pIPPA I 131 (50 μCi) injection, the hearts were rapidly removed, frozen in liquid nitrogen, weighed, and counted. Following lipid extraction of homogenized heart extracts 131 I radioactivity distribution was analyzed by thin-layer chromatographity (TLC). In additional rat experiments, high energy phosphates (12 rats/group) and carnitine (20 rats/group) were determined enzymatically in heart extracts. The mean pIPPA uptake in rat heart (%dose/g) was 2.49 in Co, 1.74 in 24 D, and 2.36 in 48 D rats. Usually five peaks were separated by TLC, that with a mean Rf value of 0.92 corresponding to pIPPA I 131, the remaining four representing catabolites of pIPPA metabolism. The mean relative amount of unmetabolized pIPPA I 131 as compared to the sum of pIPPA I 131 catabolites was less in Co than in 24 D or 48 D rats (P<0.05) (anti x: 46.5% vs 72.4% vs 59.4%, respectively). The mean carnitine content of H extracts was higher in Co (0.55 μM/g) than in D treated rats (24 D, 0.42 μM/g; 48 D, 0.46 μM/g) (P<0.05). The total amount of higher energy phosphates was not different between the groups. However the mean ATP/AMP ratio was higher in Co (35.9) than in 24 D (22.3) or 48 D (27.1) rats (P<0.05). We conclude that D therapy is accompanied by a partial reversible impairment in myocardial pIPPA utilization, possibly mediated by carnitine deficiency. Thus, pIPPA I 131 might be useful in patients on D therapy to evaluate eventual D-induced effects on myocardial fatty acid utilization. (orig.)

  4. Early change of thyroid hormone concentration after 131I treatment in patients with solitary toxic adenoma

    International Nuclear Information System (INIS)

    Pirnat, E.; Fidler, V.; Zaletel, K.; Gaberscek, S.; Hojker, S.

    2002-01-01

    Aim: In spite of extensive use of 131 I for treatment of hyperthyroidism, the results of early outcome are variable. In our prospective clinical study we tested whether 131 I induced necrosis causing clinical aggravation of hyperthyroidism and increasing the free thyroid hormone concentration in the serum of patients with solitary toxic adenoma not pretreated with antithyroid drugs. Patients and methods: 30 consecutive patients were treated with 925 MBq 131 I. Serum concentration of thyrotropin (TSH), free thyroxine (fT 4 ), free triiodothyronine (fT 3 ), thyroglobulin (Tg), and interleukin-6 (IL-6) were measured before and after application of 131 I. Results: After application of 131 I no clinical worsening was observed. FT 4 and fT 3 concentration did not change significantly within the first five days, whereas both of them significantly decreased after 12 days (p 131 I induced necrosis of thyroid cells was found. Therefore, the application of 131 I may be considered as a safe and effective treatment for patients with hyperthyroidism due to toxic adenoma. (orig.)

  5. Thyroidal uptake and retention of 131I by pregnant and fetal guinea pigs

    International Nuclear Information System (INIS)

    Book, S.A.; McNeill, D.A.

    1975-01-01

    Preliminary studies on thyroidal 131 I concentration by fetal guinea pigs indicate a peak uptake approximately 7 times that of the maternal gland, with an effective half-life of less than 2 days. The resultant dose was estimated to be 37 rads for the maternal gland and from 60 to 81 rads for the fetal gland per microcurie administered. From 1 to 11 days after maternal injection of 131 I, amniotic fluid contained more 131 I per liter than did fetal blood which in turn had a greater concentration than did maternal blood

  6. 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study

    International Nuclear Information System (INIS)

    Lin, Chien-Mu; Doyle, Pat; Tsan, Yu-Tse; Lee, Chang-Hsing; Wang, Jung-Der; Chen, Pau-Chung

    2014-01-01

    To evaluate the association between 131 I therapy for thyroid cancer and risk of developing primary hyperparathyroidism. This was a nationwide population-based cohort study of patients with thyroid cancer diagnosed during the period 1997-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative 131 I dose in each patient was calculated. Hazard ratios (HRs) were calculated using a proportional hazards model to estimate the effect of 131 I therapy on the risk of developing primary hyperparathyroidism in the cohort. A total of 8,946 patients with thyroid cancer were eligible for the final analysis. Among these patients, 8 developed primary hyperparathyroidism during the follow-up period that represented 38,248 person-years giving an incidence rate of 20.9 per 10 5 person-years. 131 I was used in the treatment of 6,153 patients (68.8 %) with a median cumulative dose of 3.7 GBq. The adjusted HRs were 0.21 (95% CI 0.02-1.86) and 0.46 (95% CI 0.10-2.10) for those receiving a cumulative 131 I dose of 0.1-3.6 GBq and ≥3.7 GBq, respectively, compared to no therapy. The risk of developing primary hyperparathyroidism did not increase with increasing 131 I dose (test for trend p = 0.51). No interaction was found between 131 I dose and age (p = 0.94) or 131 I dose and sex (p = 0.99). 131 I treatment for thyroid cancer did not increase risk of primary hyperparathyroidism during a 10-year follow-up in this study population. Further research with a longer follow-up period is needed to assess late adverse effects beyond 10 years. (orig.)

  7. 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study.

    Science.gov (United States)

    Lin, Chien-Mu; Doyle, Pat; Tsan, Yu-Tse; Lee, Chang-Hsing; Wang, Jung-Der; Chen, Pau-Chung

    2014-02-01

    To evaluate the association between (131)I therapy for thyroid cancer and risk of developing primary hyperparathyroidism. This was a nationwide population-based cohort study of patients with thyroid cancer diagnosed during the period 1997-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative (131)I dose in each patient was calculated. Hazard ratios (HRs) were calculated using a proportional hazards model to estimate the effect of (131)I therapy on the risk of developing primary hyperparathyroidism in the cohort. A total of 8,946 patients with thyroid cancer were eligible for the final analysis. Among these patients, 8 developed primary hyperparathyroidism during the follow-up period that represented 38,248 person-years giving an incidence rate of 20.9 per 10(5) person-years. (131)I was used in the treatment of 6,153 patients (68.8%) with a median cumulative dose of 3.7 GBq. The adjusted HRs were 0.21 (95% CI 0.02-1.86) and 0.46 (95% CI 0.10-2.10) for those receiving a cumulative (131)I dose of 0.1-3.6 GBq and ≥3.7 GBq, respectively, compared to no therapy. The risk of developing primary hyperparathyroidism did not increase with increasing (131)I dose (test for trend p = 0.51). No interaction was found between (131)I dose and age (p = 0.94) or (131)I dose and sex (p = 0.99). (131)I treatment for thyroid cancer did not increase risk of primary hyperparathyroidism during a 10-year follow-up in this study population. Further research with a longer follow-up period is needed to assess late adverse effects beyond 10 years.

  8. Localization of 131I-chTNT in a nude mice model with human hepatoma

    International Nuclear Information System (INIS)

    Chen Shaoliang; Sun Xiaoguang; Xiu Yan; Zhong Gaoren; Qiao Weiwei; Xu Lanwen; Li Wenzheng

    1998-01-01

    Purpose: In order to evaluate the targeting activity in the animal model with human hepatoma, the 131 I-chTNT radioimmunoimaging was explored. Methods: Radioimmunoimages were taken on different intervals after injection of 131 I-chTNT 5.55 MBq to the nude mice, and tissue distribution was measured. The results of 131 I-chTNT monoclonal antibody group were compared with that of 131 I control group. Results: The experimental group developed tumor positive images after one day of radio-labelled monoclonal antibodies injection and held on until the end of the experiment. The radioactivity in tumor mass was stable, and the half life of 131 I-chTNT in hepatoma mass was 6.0 +- 1.6 days. there was no special radioactivity accumulation in normal liver tissue in the nude mice and the radioactivity in it disappeared rapidly. Statistics indicated the tumor/liver ratio in 1, 2, 3, 5, 7 days were 1.03, 2.43, 5.71, 7.96, 10.67, respectively. Conclusions: The results suggest that 131 I-chTNT monoclonal antibody has a considerable targeting activity, and provide an evidence for that it can be used as a new radiopharmaceutical agent for the imaging and radio therapy of hepatoma

  9. Multimodality imaging of 131I uptake in nude mice thyroid based on Cerenkov radiation

    International Nuclear Information System (INIS)

    Hu Zhenhua; Liang Jimin; Qu Xiaochao; Yang Weidong; Ma Xiaowei; Wang Jing; Tian Jie

    2012-01-01

    Objective: To perform the multimodality 131 I thyroid imaging using Cerenkov luminescence tomography (CLT) and gamma imaging, and to compare the results of CLT and gamma imaging. Methods The nude mice (n=4, mass: (21 ±3) g) were injected with 1.67 ×10 7 Bq 131 I. CLT and gamma imaging were acquired at 0.5, 3, 12 and 24 h after the injection. Three-dimensional biodistribution of 131 I uptake in thyroid was reconstructed using Cerenkov source reconstruction method based on the diffusion equation (DE), and the reconstructed power of 131 I in different acquisition time points was obtained. Additionally, the ROIs were drawn over the gamma images of the mouse neck, and the counts were read. The correlation between the reconstructed power of CLT and gamma ray counts of gamma imaging was analyzed. Results: The power of 131 I uptake in thyroid at 0.5, 3, 12 and 24 h were 7.80 ×10 -13 , 1.62×10 -12 , 2.20×10 -12 and 2.68 × 10 -12 W, respectively. CLT results showed that reconstructed power increased with the increasing of acquisition time. Gamma imaging results indicated that 131 I uptake decreased in abdomen and increased in thyroid with the collection time. The results of CLT were consistent with that of gamma imaging (r 2 =0.7620, P<0.05). Conclusion: CLT has the potential to identify and monitor functioning thyroid tissue at before and (or) after 131 I treatment. (authors)

  10. Evaluation of systematic I-131 thyroid measurements for nuclear medicine workers

    International Nuclear Information System (INIS)

    Puscalau, M.A.

    2002-01-01

    In Nuclear Medicine, I-131 is used intensively for the diagnosis and for the treatment of the different severities maladies of the thyroid. This radionuclide generates an important internal contamination to the patients, because of its oral administration, and, also, through inhalation, to the workers involved in the radiopharmaceuticals production , to the nursing staff and to the physicians that care and treat the patients in the hospitals. The paper presents the data obtained by systematically thyroid monitoring of the physicians and nurses from the Endocrinology Hospital, that are contaminated by I-131 inhalation because of their permanent relation with the patients treated with 3.7 MBq I-131 for investigation and with activities in the range 1100 MBq - 4000 MBq for therapy. The measurements were carried out with our Body Counter equipped with a NaI(Tl) scintillation detector, 50 mm thickness and 40mm diameter. Values of the estimated committed equivalent doses are, also, reported

  11. Experience by the use of /sup 131/I-19-iodocholesterol

    Energy Technology Data Exchange (ETDEWEB)

    Kinoshita, H; Tsuru, Y; Inazuki, S; Fujimoto, S; Futagawa, S [Nagasaki Univ. (Japan). School of Medicine

    1975-01-01

    Clinical application of /sup 131/I-iodocholesterol to adrenal scintigraphy of the total 50 times was made in 36 patients suggestive of adrenal disease. The index and ratio of bilateral adrenal alands were calculated by ROI processing on the computer scintigram, which was assumed useful for diagnosis of adrenocortical hypofunction as well as its hyperfunction as formerly said. Adrenal scintigraphy with /sup 131/I-iodocholesterol is routine examination which should be positively applied to patients with adrenal cortex disease, because its exposure dose is as small as it matters little except for repeating frequently.

  12. 131I-MIBG in Neuroblastoma, is Not Simply the Uptake in the Primary Mass

    International Nuclear Information System (INIS)

    El-Maghraby, T.A.; Nasr, H.A.; Hassan, M.

    2003-01-01

    Neuroblastoma is the third most common malignancy of childhood. Nowadays. MlBG has become a central procedure for staging and defining extent and location of neuroblastoma tumors. The recommendations of the International Neuroblastoma Staging System (INSS) indicate that MlBG scintigraphy must be performed in patients with neuroblastoma at the time of initial staging and as a followup tool during therapy. Purpose: Of this study is to identify the role of 131 I M lBG scintigraphy in neuroblastoma patients and to correlate it with other diagnostic modalities for staging and follow up of neuroblastoma. Methods: The study was conducted on 26 patients provisionally diagnosed to have neuroblastoma. On histopathologic verification 5 of these 26 patients were re diagnosed as non-neuroblastoma. Since the study aims at assessing the diagnostic power of 131 I M IBG scan, these 5 cases were not excluded. The 21 histopathologically diagnosed as neuroblastoma were 11 patients in stage IV, 7 in stage III and 1 patient in each of stages I, 11 and IVS. Each. patient underwent a standard comprehensive diagnostic work up, Radiological imaging by conventional X-ray. ultrasound. CT and/or MRI was carried out. In all patients I3II M IBG scintigraphy was performed, among them 15 patients underwent additional 99m Tc-MDP bone scan as well. The 21 neuroblastoma patients were studied according to the results obtained from CT, MRI and 131 I M lBG scanning. The outcome demonstrated that CT and MR1 were able to detect lesions in 19 out of 2] patients; while in 2 patients no lesions were detected. 131 I M IBG scan showed actively functioning lesions in ] 6 out of the above] 9 patients. while in 3 patients MIBG scan was negative. There was no false positive result by 131 I M IBG scan. Accordingly. 131 1 M IBG is able to detect neuroblastoma lesions with an overall sensitivity of 84.2%. specificity of 100% and an accuracy of 85.7%. Detection of primary lesions by 131 I M lBG was significantly

  13. Structure determination of AgPO3 and (AgPO3)0.5(AgI)0.5 glasses by neutron diffraction and small angle neutron scattering

    International Nuclear Information System (INIS)

    Tachez, M.; Mercier, R.; Malugani, J.P.; Chieux, P.

    1987-01-01

    Neutron diffraction and small angle neutron scattering (SANS) were performed on AgPO 3 and (AgPO 3 ) 0.5 (AgI) 0.5 glasses. AgPO 3 glass is made up of long chains of PO 4 tetrahedra joined together by Ag atoms. When silver iodide is added, the radial distribution function shows a large peak at 2.83 A, due to Ag-I interactions. AgI does not modify the network forming unit. The existence of small clusters is confirmed by analysing the coordination number of Ag-I pairs obtained by subtracting the experimental structure function of the AgPO 3 glass from that of the corresponding AgI-doped glasses. A rough estimation of their size is given by SANS experiments. Not all the AgI pairs are involved in AgI cluster units. The compatibility of the results obtained with recent structural investigations by non diffractometric techniques is examined. 23 refs.; 5 figs.; 3 tabs

  14. Comparative Analysis of Direct and Indirect 131I Measurement Methods from the Stack to Outdoor

    Directory of Open Access Journals (Sweden)

    G. Suhariyono

    2017-11-01

    Full Text Available The radioisotope production facility at PUSPIPTEK Serpong produces and processes 131I that can disperse to the settlements (community and the environment around the Serpong Nuclear Area (SNA. 131I is produced routinely for medical uses in hospitals and pharmacies, for both domestic uses and export. 131I is a beta and gamma emitting radioactive material and can cause thyroid cancer. The problem was that there was so far no research and in-depth assessment of the aerial dispersion of 131I radioactivity emitted from the radioisotope production stack to the environment at actual conditions. The research was conducted through simultaneous measurement of 131I radioactivity in the stack of the 131I radioisotope production facility, Serpong, and outdoor in house courtyards around SNA in normal condition (no accident based on the variations of the distance and wind direction. Direct measurements were carried out with a portable in-situ NaI(Tl detector at outdoor, and with a LaBr3 detector in the stack. Indirect measurements were carried out by using charcoal filter and vacuum pump in the stack and outdoor. The direct measurement method has many advantages over the indirect measurement. The direct measurement method was found to be more accurate, less expensive, easier to operate, needing just one operator in its implementation, portable, and can be operated continuously and for long durations. The overall activity concentrations of 131I on average obtained by either direct or indirect method were still below the upper limit of 131I activity concentration in the air (530 Bq/m3 stipulated by the Regulation of the Chairman of BAPETEN (Perka BAPETEN No. 7/2013. 

  15. Synthesis and 131I labelling of epidepride as a dopamine D2 receptor imaging agent

    International Nuclear Information System (INIS)

    Yang Min; Hu Mingyang; Pei Zhuguo; Wang Bocheng; Zhou Xingqin

    2001-01-01

    S-(-)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2, 3-dimethoxybenzamide (Epidepride) and its iodine labeling precursor S-(-)-N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-tributyltin-2, 3-dimethoxybenzamide are synthesized from 3-methoxy salicylic acid. The labeling precursor is labeled with 131 I by hydrogen peroxide method, and 131 I-epidepride is gained, its radiolabelling yield (RLY) and the radiochemical purity (RCP) are all over 95%. The RCP of 131 I-epidepride is over 90% under 4 degree C after 15 days. 131 I-epidepride has high affinity to dopamine D 2 receptor. The striatal uptake can be blocked completely by spiperone. The striatum and cerebellum uptake ratio can reach 237 at 320 min in rats. The results show that 131 I-epidepride may be used as a dopamine D 2 receptor imaging agent for SPECT

  16. Differential diagnosis of thyroid diseases with 131I and 201TlCl scintigraphy

    International Nuclear Information System (INIS)

    Kumano, Machiko; Ishida, Osamu

    1979-01-01

    Scintigraphic study with 131 I and 201 TlCl was performed on the differential diagnosis of various kinds of thyroid disease. When thyroid nodules are cold by scintigraphy with 131 I and hot with 201 TlCl, the lesions were proved to be solid tumor, that is, mostly follicular adenoma and carcinoma, and also most probably chronic thyroiditis. Accumulation of 201 TlCl, however, is not observed in cystic lesions, and is very high with high frequency in metastatic lesion of the lymph nodes as well as the thyroid cancer, especially in well differentiated follicular carcinoma. Therefore 201 TlCl was very useful to confirm the metastatic tumors from the thyroid cancer. These features in accumulation of 131 I and 201 TlCl in thyroid disease suggest the imaging technique with 201 TlCl combined with 131 I seem to provide more pathological information on the thyroid and metastatic lesions. (author)

  17. A pioneer experience in Malaysia on In-house Radio-labelling of (131)I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose (131)I-rituximab-BEAM conditioning autologous transplant.

    Science.gov (United States)

    Kuan, Jew Win; Law, Chiong Soon; Wong, Xiang Qi; Ko, Ching Tiong; Awang, Zool Hilmi; Chew, Lee Ping; Chang, Kian Meng

    2016-10-01

    Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies - (90)Y-ibritumomab tiuxetan is expensive and (131)I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling (131)I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling (131)I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose (131)I-rituximab (6000MBq/163mCi) combined with BEAM conditioning for autologous HSCT. Copyright © 2016 Elsevier Ltd. All rights reserved.

  18. Labeling of - N-Isopropil - p - I-Anphetamine (IMP-131I) and its biological distribution in rats

    International Nuclear Information System (INIS)

    Barboza, M.F. de; Goncalves, R.S.V.; Muramoto, E.

    1988-09-01

    The described labeling and purification preparation of N-Isopropil-p 131 I-anphetamine ( 131 I-IMP) represents a fast and efficient method to obtains a compound that fullfills all criterions of purity for its application 'IN VIVO'. The labeling yield was 68-78% and the radiochemical purity performed by paper chromatography and electrophorese was 97-99%. As demostrated in animal experiments, the cerebral affinity offers a possibility to study brain diseases in clinical studies when the product will be labelled with 123 I. (author) [pt

  19. Histological changes in the thyroid gland after treatment of hyperthyroidism with 131I, 2

    International Nuclear Information System (INIS)

    Takeichi, Nobuo; Inoue, Shozo; Hirose, Fumio; Nagata, Nobuo; Niimoto, Minoru

    1976-01-01

    At first, degeneration and destruction of follicular epithelium appears and its regeneration occurred after the first time administration of 131 I to hyperthyroidism. This regenerated follicule was tidy and could be called regeneration with low grade atypism. The second time administration of 131 I was made in the most active regeneration period, that is, 3.5 - 5 months after the first administration of 131 I. Degeneration and destruction of follicular epithelium were occurred strongly again, and after that, regeneration was occurred again. Regenerated folliculer epitherium in this case shaped comparatively distortion, and it could be called 'regereration with high grade atypism'. In the groups administered 131 I two or three time, the regenerated figure which is highly atypical remained for a long time, and at the same time, many adenoma-like proliferation figures were found in cases taking long clinical course of this group. It was thought that this process would give a lead to clarify the cause of occurrence of thyroid gland tumors following treatment with 131 I. (Tsunoda, M.)

  20. Microwave assistance of labeling hippuric acid by I-131

    International Nuclear Information System (INIS)

    Sherlock Huang, Lin-Chiang; Wu, Kou-Hung; Ko, Pi-Wen; Hsieh, Cheng-Ying; Pao, Kuan-Chuan; Chou, Shih-Ching; Shieh, Fa-Kuen; Sureshbabu, Radhakrishnan; Hsu, Ming-Hua

    2014-01-01

    This work presents a novel approach for labeling hippuric acid with I-131 using microwaves. It utilizes copper(II) acetate as a catalyst of the labeling. The process involves the use of this catalytic copper(II) acetate at low dilutions that were nevertheless sufficient to produce labeled hippuric acid with high radiochemical purity in a short time. Therefore, the novel technique overcomes the limitations of previously reported conventional methods that involve heating. - Highlights: • We report the microwave assisted radiochemical labeling of hippuric acid by I-131. • Cu(OAc) 2 can be used as catalyst to get labeled product in lower dilution condition. • Advantages of our method are lesser time scale and high radiochemical purity.

  1. The chromatography plant in Wuerzburg for the decontamination of sewage containing 131I

    International Nuclear Information System (INIS)

    Lassmann, M.; Haenscheid, H.; Alt, P.; Boerner, W.

    1994-01-01

    The effluents of the radioiodine therapy ward of the Klinik und Poliklinik fuer Nuklearmedizin der Universitaet Wuerzburg are decontaminated by a new plant working by the chromatography principle. The decontamination effect is caused by adsorption of 131 I to activated coal. From January 1992 to September 1993 1280 GBq 131 I were administered to patients. During this period 1028 m 3 of sewage was gathered in the plant corresponding to an input of 0.15 m 3 per patient and day. The water leaving the chromatography plant was contaminated with less than 7 kBq/m 3 131 I. (orig.) [de

  2. Effect of thyroid auto-antibodies on hypothyroidism of adolescents with graves disease after 131I treatment

    International Nuclear Information System (INIS)

    Feng Xuemin; Wang Junqi; Qin Lan

    2011-01-01

    To investigate the effect of TSH receptor antibody (TRAb) and thyroid peroxidase antibody (TPOAb) levels in adolescents with Graves disease (GD) before 131 I treatment on the incidence of hypothyroidism after 131 I therapy. The total 264 adolescent with GD were treated with 131 I. All patients before the treatment were divided into A, B, C, D, E and F groups in accordance with the levels of TRAb and TPOAb in various combinations. The serum TSH, FT 3 , FT 4 , TRAb and TPOAb levels in all patients were measured after 131 I treatment. The incidence of hypothyroidism within three years were observed in each group. The results showed that the incidence of hypothyroidism in TRAb negative group was higher than that of positive group (χ 2 =4.67, P 2 =4.10, 4.34, 5.66, P 131 I therapy. It could be cautious in treatment of GD adolescents of TRAb negative and TPOAb positive with 131 I. (authors)

  3. The present status of I-131 therapy for Graves' hyperthyroidism in Japan. Survey by questionnaire

    International Nuclear Information System (INIS)

    Ikekubo, Katsuji; Kusakabe, Kiyoko; Kanaya, Shinichi; Nakada, Kunihiro; Mori, Yutaka

    2003-01-01

    A survey on the I-131 therapy of Graves' hyperthyroidism was undertaken by questionnaire in 1,246 hospitals of Japan. One thousand and ninety seven of them (88.0%) responded to the questionnaire. In this paper, we report the results and analysis of the replies to the questionnaire. In the 121 hospitals (11.03%) of the respondents, I-131 therapy is being performed for Graves' hyperthyroidism. A gradual increase was observed in the annual number of I-131 treated Graves' disease patients during the period of 1998-2001, from 1,740 to 2,484. I-131 treatment was selected mainly for the cases with side effects from antithyroid drug (ATD) therapy, followed by the cases with complication of heart or hepatic diseases, recurrences of hyperthyroidism after surgery, radioiodine treatment, and long-term ATD treatment. The 41% of respondents used I-131 in order to restore euthyroidism, 34% aimed for hyperthyroidism and 41% used the dose properly between the two according to the patients. Administration dosage of I-131 was estimated mainly on the basis of thyroid uptake and volume in 93% of the respondents and 48% calculated the radiation dose by also determining the effective half-life in the thyroid gland. Thyroid size was estimated by scintigram (51%), ultrasonography (US) (33%), CT (22%) and palpation (12%). ATD treatment was used before I-131 administration by 70% of the respondents and 34% after radioiodine therapy. A low-iodine diet was given to the patients for a week (46%) or two weeks (47%) before I-131 administration. However, after treatment only 46% of the respondents continued low-iodine diet for a week. (author)

  4. Treatment of Graves' disease with I131: Case Report

    International Nuclear Information System (INIS)

    Sanchez Povis, J.E.; Sandoval Okuma, J.C.; Contreras Carreno, S.E.; Cabello Morales, E.

    2006-01-01

    Objective: To describe the response and complications in children and teenagers suffering Graves' disease who received radioactive iodine therapy. Material and Methods: The clinical records of the patients attended at Paediatric Endocrinology Unit of Hospital Nacional Cayetano Heredia who received therapy with I 131 were reviewed. Demographic characteristics, thyroid weight, radioactive iodine uptake, I 131 dose and clinical and thyroid function evolution were registered. Results: We include thirteen patients: 1 male and 12 females. The mean thyroid weight obtained was 47.56 ± 10.70 gr. Initial calculated dose was 3.92 ± 0.95 mCi, with a total dose of 4.47 ± 1.66 mCi, and mean following period of 2.76 years. Ten patients received only one dose, 2 patients received two doses and one patient received three doses; all cases remitted. Patients who received only 1 dose showed disease remission at 13.13 weeks and mean remission period of the population was 24.62 weeks. Hypothyroidism prevalence up to six months from initiating treatment was 66.66%, and up to 257 weeks 83.33%. Conclusions: We conclude that I 131 was 100% effective in the treatment of children and adolescents suffering Graves' disease in this small series. (author)

  5. Theoretical calibration of a NaI(Tl) detector for the measurement of {sup 131}I in a thyroid phantom; Calibracao teorica de um detetor NaI(Tl) para a determinacao de {sup 131}I em um simulador de tireoide

    Energy Technology Data Exchange (ETDEWEB)

    Venturini, Luzia [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil). Dept. de Metrologia das Radiacoes]. E-mail: lventur@net.ipen.br

    2002-07-01

    This paper describes the theoretical calibration of a NaI(Tl) detector using Monte Carlo Method, for the measurement of {sup 131} I in a thyroid phantom. The thyroid is represented by the region between two concentric cylinders, where the inner one represents the trachea and the outer one represents the neck. {sup 133} Ba was used for experimental calibration. The results shows that the calibration procedure is suitable for {sup 131} I measurements. (author)

  6. Estimation of foetal brain dose from I-131 in the foetal thyroid

    International Nuclear Information System (INIS)

    O'Hare, N.J.; Murphy, D.; Malone, J.F.; Gilligan, P.

    1997-01-01

    The ingestion of I-131 by pregnant women can have consequences for the developing foetus, in particular brain function. As the foetal thyroid accumulates iodine from the twelfth week of gestation onwards, the determination of foetal brain dose resulting from such I-131 accumulation is essential. Normal dosimetric methods fail to treat the case of the foetus. Using an approximation method based on the MIRD approach, a foetal dose estimation scheme is developed to allow the determination of foetal brain dose from foetal thyroid irradiation. Dose values are obtained for the foetus based on the maternal intake of I-131. It was found that the choice of biokinetic model for the mother/foetus has a large impact on the determined dose estimate. (author)

  7. Air-to-vegetation transport of /sup 131/I as hypoiodous acid (HOI)

    Energy Technology Data Exchange (ETDEWEB)

    Voilleque, P G [Science Applications, Inc., Idaho Falls, ID (USA); Keller, J H [Exxon Nuclear Idaho Co., Inc., Idaho Falls, ID (USA)

    1981-01-01

    A significant fraction of the /sup 131/I in ventilation air in both BWRs and PWRs is present as hypoiodous acid (HOI). While HOI has been observed in the atmosphere its transport through the critical pathway has not been studied in detail. Of particular importance and interest is the deposition velocity used to characterize air-to-vegetation transport. This note describes the measurement of air-to-vegetation transport of HOI in a laboratory environmental chamber. The deposition velocity for HOI is compared with those for elemental I/sub 2/, methyl iodide and iodine associated with airborne particulates to show the relative importance of HOI in transport of /sup 131/I through the air-grass-cow-milk food chain. The data can be used to estimate relative contributions of the four /sup 131/I species to doses via the critical pathway.

  8. Hypertension complicating {sup 131}I-meta-iodobenzylguanidine therapy for neuroblastoma

    Energy Technology Data Exchange (ETDEWEB)

    Kosmin, Michael A.; Cork, Nicholas J.; Gaze, Mark N. [University College London Hospitals NHS Foundation Trust, Department of Oncology, London (United Kingdom); Bomanji, Jamshed B. [University College London Hospitals NHS Foundation Trust, Department of Nuclear Medicine, London (United Kingdom); Shankar, Ananth [University College London Hospitals NHS Foundation Trust, Department of Paediatric Oncology, London (United Kingdom)

    2012-04-15

    Radiolabelled meta-iodobenzylguanidine (mIBG), used as targeted therapy for neuroblastoma, is known to have effects on blood pressure (BP). In this study we audited BP changes in patients receiving {sup 131}I-mIBG therapy for neuroblastoma to identify BP-related adverse events (AE) and possible predictive factors. Between 2003 and 2010, 50 patients with neuroblastoma received 110 {sup 131}I-mIBG administrations. BP measurements before and after administration were compared with age- and sex-matched centile values. AE were analysed, and possible predisposing factors identified. This population had a baseline BP distribution higher than that of their age- and sex-matched peers, with 16% of preadministration systolic BP values above the 95th centile. Changes in BP after administration showed an approximately normal distribution with similar numbers of reduced and increased values. Four AE, all related to hypertension, occurred with one patient having generalized seizures. One AE was immediate, others occurred between 20 and 25 h after administration. No significant association between AE and patient age or sex was demonstrated. However, a significant association between AE and high preadministration BP was shown, both above the 90th centile (p = 0.0022) and above the 95th centile (p = 0.0135). Clinically relevant hypertension following {sup 131}I-mIBG therapy affected less than 5% of administrations, but was more common in those patients with preexisting hypertension. As hypertensive episodes may occur many hours after treatment, close monitoring of BP needs to be continued for at least 48 h after administration of {sup 131}I-mIBG. (orig.)

  9. Computer-aided pathophysiological analysis of /sup 131/I rose bengal hepatogram

    Energy Technology Data Exchange (ETDEWEB)

    Matsumoto, A [Kobe Univ. (Japan). School of Medicine

    1976-06-01

    The author analysed /sup 131/I-rose bengal (R.B.) hepatograms over the liver region using digital simulation technique to determine the hepatobiliary functions separately and to compare the rate constants obtained from the kinetic model and the results obtained from conventional liver function tests. A total of 112 cases were observed including various liver and gallbladder diseases and 8 normal subjects. Fasting patients were given intravenous injections of 300 ..mu..Ci of /sup 131/I-R.B. Hepatic uptake and excretion of radioactivity were measured for 120 minutes using a gamma camera. Two regions, one over the right lobe and the other over the gallbladder, were studied. The author applied a 3 compartment analysis to the /sup 131/I-R.B. hepatogram. Measured /sup 131/I-R.B. hepatogram was printed out on a line printer with curve pattern indices. Assumed rate constants and relative volume indices were placed on punch cards. Computer-aided simulation curves were printed on a line printer with curve pattern indices. The measured hepatogram and the simulated hepatogram were compared. The blood flow index (K/sub 21/), the hepatocellular function index (K/sub 32/) and the intrahepatic biliary excretion index (K/sub 03/) were obtained with the schematic presentation of the curves. Rate constants from the kinetic model correlated well with conventional liver function tests. In normal liver and hepatobiliary diseases, there were high statistical correlations between K/sub 21/ and Ksub(L) /sup 131/I-R.B. Retention (%), between K/sub 32/ and Cholinesterase, and between K/sub 03/ and Alkaliphosphatase. However, there was a low statistical correlation between the results of the simulation study and the results of liver function tests in the cases of obstructive jaundice and intrahepatic cholestasis.

  10. Evaluation of results of more than 20 years treating hyperthyroidism by I-131

    International Nuclear Information System (INIS)

    Phan, S.A.; Mai, T.K.; Tran, D.H.

    2001-01-01

    The authors have summarized their works of more than 20 years using I-131 for treatment and close observation of 723 patients with hyperthyroidism in 1000 ones in the Nuclear Medicine Department, Bach Mai University Hospital in Hanoi to collect data and draw experience for the report. Patient selection for the treatment is based on clinical features and laboratory tests results by the Nuclear Medicine Department such as thyroid uptake, scintigraphy and RIA determinations of thyroid hormones. I-131 dose is determined in compliance with a prevailing formula. The average dose is 6.2 ± 1.1 mCi (that is 233.1 ± 40.7 MBq). The average number of times is 1.3 time for one patient. The results are as follows: Euthyroid status after 4- year following- up from date of I-131 dose administration: 72.3%; Persistent or recurrent hyperthyroidism: 20.0%; Hypothyroid complications: appear 4 to 12 months after date of I-131 administration: 3.0%; appear 4 years after date of I-131 administration: 7.7%; appear 6 years after date of I-131 administration. 14.0%; so the cumulative hypothyroid rate is 2.3% per year. No occurrence of other serious complications by all the observed patients. This is therefore a safe, efficient treatment method to be applied on a large scale including adolescents and children. However, much more study has still to be made on the dose due to high rate of recurrence of the therapeutic method although the hypothyroid complications cases are not serious. Hyperthyroidism is a common health problem in Viet Nam. Previously, only anti-thyroid drugs and surgery were used. Use of I-131 was firstly introduced to Viet Nam in the Nuclear Medicine Department in Bach Mai in 1974 and afterwards applied larger nationwide. Initial therapeutic results have been published in national medical magazines. This is a general study aiming at analyzing the way to carry out the work and get experience and recommendation from gained results for further work in the future. (author)

  11. The change of serum TRAb after 131I radiotherapy in patients of Graves' hyperthyroidism

    International Nuclear Information System (INIS)

    Cui Bangping; Jiang Changbin; Hu Wei; Yang Jianhua; Guo Zugao

    2007-01-01

    Objective: The clinical value of thyrotrophin receptor antibody (TRAb) in patients with Graves' hyperthyroidism was investigated during 131 I radiotherapy. Methods: A total of 130 patients with Graves' hyperthyroidism and 50 normal controls were included in the study. Serum concentration of TRAb was measured by radioreceptor assay (RRA) before and at 3, 6, 12 and 24 months after 131 I radiotherapy. Results: Abnormally higher TRAb level [(92.93±68.99)U/L] was noted in patients before treatment(P 131 I radiotherapy, the TRAb [(12.99±5.52) U/L] was back to normal with no difference to that of controls (P>0.05). Conclusion: Serum concentration of TRAb was of clinical significance in the diagnosis of Graves' hyperthyroidism and in the monitoring of 131 I radiotherapy. (authors)

  12. 131I-MIBG Scintigraphy in the Evaluation of Suspected Pheochromocytoma

    International Nuclear Information System (INIS)

    Oh, Sei Jung; Yoo, Hyung Sik; Park, Chang Yun; Lee, So Jin

    1992-01-01

    Pheochromocytomas are catecholamine producing tumors of neuroectodermal origin. Diagnosis of pheochromocytoma is significant due to potentially curable hypertension. But they have a significant associated morbidity due to uncontrolled hypertension and mortality since 10% are malignant. From Aug. 1989 to Jul. 1992, 12 patients of our institution had 131 I-MIBG scan during work up of suspected primary or recurrent pheochromocytoma. In our studies conclude that 131 I-MIBG scan is recommended as the initial localizing study of choice (especially for the detection of extraadrenal disease and postoperative recurrence) as a guide for CT and/or MR and specific functional confirmation of their findings.

  13. Benign oral pathology as a cause of false positive 131I uptake in thyroid carcinoma

    International Nuclear Information System (INIS)

    Mansberg, R.; Wadhwa, S.S.; Fernandes, V.B.

    1997-01-01

    Full text: We present three thyroidectomised patients with a history of thyroid carcinoma who had non-metastatic 131 I uptake due to benign oral pathology. A salivary gland study suggested impaired function but no obstruction was demonstrated on a sialogram. The symptoms resolved on antibiotic therapy and a subsequent 131 I study was normal. A subsequent thallium study demonstrated physiological tracer distribution. A 35-year-old female with papillary cell carcinoma of the thyroid demonstrated a focus of uptake on the right hemi-mandible following both a diagnostic and a therapeutic dose of 131 I. This area was tender and an OPG confirmed an area of liquefaction at this site. A 53-year-old female with medullary cell carcinoma of the thyroid demonstrated a focus of uptake in the right side of the maxilla following a diagnostic administration of 131 I. An OPG confirmed an area of liquefaction around the apex of the right upper centre. These three cases illustrate salivary gland and dental inflammation as causes of false positive 131 I uptake. It is important to differentiate non-metastatic 131 I uptake from that due to functioning metastatic thyroid carcinoma in order to avoid inappropriate treatment with large additional doses of 131 I. As in these patients, clinical assessment and the use of anatomical imaging or other isotopes such as thallium or technetium can be helpful in ruling out a mistaken diagnosis of metastasis

  14. The {sup 131}I cytogenetic effect preceded by the REC-HTSH administration in Wistar rats; Efeito citogenetico do {sup 131}I precedido por administracao de Rec-hTSH em ratos Wistar

    Energy Technology Data Exchange (ETDEWEB)

    Silva, Marcia Augusta da [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil)]|[Centro Universitario Sao Camilo, Sao Paulo, SP (Brazil); Ribela, Maria Teresa Carvalho Pinto; Suzuki, Miriam Fussae; Bartolini, Paolo; Okazaki, Kayo [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil)]. E-mail: kokazaki@ipen.br; Guimaraes, Maria Ines Calil Cury; Buchpiguel, Carlos Alberto [Sao Paulo Univ., SP (Brazil). Centro de Medicina Nuclear]. E-mail: maria.ins@hcnet.usp.br

    2005-07-01

    In nuclear medicine, the {sup 131}I is one of the most used radionuclides in thyroid disorders, for both diagnostic and therapeutic purposes. The target of the present study was to analyze the cytogenetic effects of the {sup 131}I, precede by stimulus with rec-hTSH, produced at IPEN/CNEN-SP, in an animal model by means of the chromosome aberration technique. The rec-hTSH is a glycoprotein administered in patients submitted to thyroidectomy as an alternative to the suspension of the hormone therapy for increasing the TSH level and, consequently, the {sup 131}I collection by the metastatic tissue, thus maintaining the euthyroid state. For this aim, Wistar rats were used (SPF, females, 200 g heavy), divided in 2 groups: animals treated only with {sup 131}I (G1) (11.1 MBq gastric gavage) and animals submitted to rec-hTSH-IPEN (1.2 {mu}g by intramuscular injection), 24 hours before the {sup 131}I (G2) administration. The blood samples were collected before (basal), 24 hours, 1 week and 1 month after the treatment, for cytogenetic evaluation. The cytogenetic data obtained showed an increase un the frequency of cells with chromosome aberration as well as the number of chromosome/cell aberrations, 24 hours after the {sup 131}I administration, when compared with the basal values, both for animals in group G1 and for in group G2. After 7 and 30 days of the radioiodine administration, a slight fall in the frequency of the chromosome aberrations was verified. The animals pre-treated with rec-hTSH-IPEN showed higher percentage of cells with chromosome aberration and chromosome/cell aberrations than the animals of group G1, in both de 24 hour-after administration of {sup 131}I samples and 7 day-sample, although the difference is not statistically significant (p>0,05). The results obtained allow the extrapolation for humans, in the more accurate evaluation of the biological risks involved by people exposed to the radioiodine, and also for the optimizations of a therapeutic

  15. The therapeutic use of I-131 meta-iodobenzylguanidine (MIBG) in neuroblastoma

    International Nuclear Information System (INIS)

    Hartmann, O.; Lumbroso, J.D.; Lemerle, J.; Schlumberger, M.; Parmentier, C.; Ricard, M.; Aubert, B.; Coornaert, S.; Merlin, L.

    1988-01-01

    Despite the use of intensified conventional chemotherapy the complete response rate of advanced neuroblastoma remains low. The use of high-dose chemo-radiotherapy followed by bone marrow transplantation (BMT) improved the duration of disease free survival but, even after these high-dose regimens the relapse rate remains high. Metaiodobenzylguanidine (MIBG) labelled with I-131 or I-123 can be used for scintigraphic imaging of neuroblastoma. In order to evaluate the therapeutic role of I-131-MIBG in the treatment of neuroblastoma patients, a phase II study was performed in 12 patients. Results are presented in this paper

  16. Diagnostic I-131 scintigraphy in patients with differentiated thyroid cancer. No additional value of higher scan dose

    International Nuclear Information System (INIS)

    Phan, T.T.H.; Tol, K.M. van; Links, T.P.; Piers, D.A.; Vries, E.G.E. de; Dullaart, R.P.F.; Jager, P.L.

    2004-01-01

    After initial treatment with total thyroidectomy and radio iodine ablation, most follow-up protocols for patients with differentiated thyroid carcinoma contain cyclic diagnostic I-131 imaging and serum thyroglobulin (Tg) measurements. The applied diagnostic I-131 doses vary between 37 and 370 MBq. The aim of this study was to determine the yield of a diagnostic scan with 370 MBq I-131 in patients with a negative diagnostic scan with 74 MBq I-131. Retrospective evaluation of 158 patients who received a high-dose diagnostic scan with 370 MBq I-131 because of a negative low-dose diagnostic scan with 74 MBq I-131. Special attention was paid to the patients with positive high-dose diagnostic scanning and undetectable serum Tg levels after thyroid hormone withdrawal. In 127 (80%) of patients the 370 MBq I-131 scan was negative, just like the preceding low-dose scan. In 31 (20%) of patients abnormal uptake was present on the 370 MBq diagnostic scan. In 19 of these 31 patients serum Tg was undetectable. In 15/19 the high-dose diagnostic scan proved either false positive or demonstrated clinically irrelevant minor ablation rests. In only four patients (2.5%) did the high-dose diagnostic scans reveal possibly relevant uptake caused by residual differentiated thyroid cancer. In 98% of patients a 370 MBq dose of I-131 for diagnostic whole-body scintigraphy (WBS) had no additional value. The combination of a low-dose diagnostic I-131 scan using only 74 MBq combined with a serum Tg level measurement proved sufficient for correct clinical decision making regarding whether the patient requires additional I-131 therapy. (authors)

  17. Experimental transmission of M. leprae in the testis of mice, born from 131I-injected females

    International Nuclear Information System (INIS)

    Sushida, Kiyo

    1974-01-01

    Six strains of M. leprae taken from lepromatous leprosy patients were inoculated into the testes of '' 131 I-F 1 '' mice, which were divided into two groups. The first group was born of females which had been subcutaneously injected with 131 I-100 μc during pregnancy; the second group was born of females which had been injected before pregnancy. The '' 131 I-F 1 '' mice which were born of females injected with 131 I-100 μc, during pregnancy were then inoculated with leprous bacilli described above, showed the presence of the so-called ''globi'' in the testes. When samples of leprous bacilli (LL28, LL32, LL33) taken from patients who had not been receiving anti-leprous drug treatments were injected into the 131 I-F 1 mice, globi were also found. When leprous bacilli from leproma removed from patients under treatment were injected into mice born from females which had been injected with 131 I-100 μc either during or before their pregnancy, no globi were found. Even though bacilli (LL32, LL33, LL34) from untreated patients were injected into mice born of females who were injected with 131 I-100 μc before pregnancy, no globi were found. (auth.)

  18. Experimental study on 131I-labelled anti-alpha-fetoprotein antibodies in the diagnosis of rat hepatoma

    International Nuclear Information System (INIS)

    Terashima, Hiromi

    1980-01-01

    The tumor-specificity of 131 I-labelled anti-α-fetoprotein antibodies was evaluated in rats using α-fetoprotein-producing AH66C4 rat hepatoma as a model. 1) Following the 12 hour incubation of 125 I-labelled anti-α-fetoprotein antibodies and tumor cells, microautoradiography revealed marked radioactivity in and around the tumor cells. This suggested that the labelled antibodies accumulated around the cells and were combined with the α-fetoprotein secreted from the cells. 2) The tumor was transplanted subcutaneously into the thighs of rats. There was marked accumulation of 131 I-antibodies in the tumor with cyst formation, but there was none in the tumor without cyst formation. The accumulation was enhanced by the administration of non-labelled antibodies to the rats before the administration of 131 I-antibodies. The α-fetoprotein level was higher in the cyst than in any other organ. 131 I-labelled horse-γ-globulins administered as a control, also accumulated in the tumor with cyst but the degree of accumulation did not exceed that of the 131 I-antibodies. The amount of 131 I-antibodies accumulated increased, while that of 131 I-horse-γ-globulins decreased with time. This indicated that the accumulation of the γ-globulins in the tumor was nonspecific and that it was related to the blood pool. These results strongly suggest that the accumulation of 131 I-antibodies in the tumor with cyst formation was a specific antigen-antibody reaction, and the present procedure reported is applicable in the specific diagnosis of such kinds of α-fetoprotein secreting tumor. (author)

  19. Physico-chemical quality control 131I-sodium 2-iodohippurate

    International Nuclear Information System (INIS)

    Morin, J.; Olive, E.; Issac, M.; Cruz, J.

    1992-01-01

    Some physico-chemical methods for analytical control 131 I-sodium 2-iodohippurate are compared. The most convenient to applicate in hospital and in more especialized quality control laboratories are recommended

  20. Hypothyroidism in patients after thyroid elimination by 131I

    International Nuclear Information System (INIS)

    Vana, S.; Nemec, J.; Reisenauer, R.

    1979-01-01

    Patients after elimination of the thyroid gland with radioiodine 131 I develop hypothyroidism only slowly, the peripheral parameters lagging behind the protein bound iodine especially till the fiftieth day after elimination. In young patients the Achilles tendon reflex and the preejection period lag behind symmetrically, in older patients the effect of the supply of thyroid hormones to the skeletal muscles disappear faster, whereas the heart retains the reserves of the thyroid hormones or systems dependent on thyroid hormones affecting the rapidity of myocardial contraction for a relatively longer period of time. Thus, in older patients after elimination of the thyroid gland with radioiodine 131 I the Achilles tendon reflex is a better criterion of hypothyroidism than the preejection period of heart contraction. (author)

  1. Cost-utility analysis of antithyroid drug therapy versus 131I therapy for Graves' disease

    International Nuclear Information System (INIS)

    Hayashi, Katsumi; Abe, Katsumi; Sakata, Ikuko; Sakaguchi, Chiharu; Yamamoto, Kentaro; Kosuda, Shigeru

    2005-01-01

    There is no comparative cost-utility study between 131 I therapy and antithyroid drugs (ATD) therapy for Graves' disease, though 131 I therapy has higher remission rate and less side effects. The objective of the study was to analyze the cost-utility of ATD therapy versus 131 I therapy by calculating life-long medical costs and utility, based on the responses of Graves' disease patients to questionnaires. To determine the expected cost and expected utility, a decision tree analysis was designed on the basis of the 2 competing strategies of ATD therapy versus 131 I therapy. A simulation of 1,000 female patients weighing≥50 kg who assumed to experience the onset of Graves' disease at the age of 30, to first complain of thyrotoxic symptoms and moderate goiter 2-3 mo. previously, and to undergo a 40-years-long cohort study, was created for each strategy using a decision tree and baselines of other relevant variables. The variables and costs were based on the literature and hospital bills. The maximum and minimum values of utility were defined as 1.0 and 0.0, respectively. Future costs and utilities were discounted 5%. The medical costs and utilities were 85,739-88,650 yen/patient/40 years and 16.47-16.56/patient/40 years, respectively, for the ATD therapy strategy, and 81,842 yen/patient/40 years and 17.41/patient/40 years, respectively, for the 131 I therapy strategy. These results quantitatively demonstrated that the 131 I therapy strategy was superior to the ATD therapy strategy in terms of both cost and utility. 131 I therapy should be used more widely in Japan because of its greater utility and lower cost. (author)

  2. The calculation of 131I dose in second treatment for Graves' disease and the selection of patients

    International Nuclear Information System (INIS)

    Yang Jisheng; Wang Qiang; Hu Mingzao; Zuo Lei; Peng Xiaoyan

    2001-01-01

    Objective: To improve the method of 131 I dose calculation in second treatment for Graves' disease (GD) and to make a criterion for selection of patients. Methods: From 87 GD patients not recovered more than half a year after 131 I treatment, authors selected 41 cases (group A) whose thyroid weight were ≥30 g and gave them second 131 I treatment. The absorbed dose (d 2 ) of 131 I was calculated by the formula we designed: (m 1 /m 2 ):d 1 =(m 2 /m 3 ): d 2 ; i.e. d 2 (Gy) = d 1 m 2 2 /m 1 m 3 . The total dose (D) was calculated by the classical formula: D(37 KBq or μ Ci)= d 2 x 8 x m 2 (g)/1.6 x max. uptake % of 131 I x T 1/2eff (days). m 1 and m 2 was the thyroid weight before and after the first 131 I treatment respectively, m 3 was the pre-estimated thyroid weight after the second treatment, d 1 was the unit dose of the first treatment. Results were compared with 97 patients (group B) who had received second 131 I treatment before using this calculation method. The resting 46 cases (group C) whose thyroid weight were 131 I treatment of group A was 73.2% (30/41 cases), it was remarkably higher than that of group B (19.6%), but the early-permanent hypothyroidism rate was lower in group A. The recovery rate of group C was 91.3% (42/46 case) in two years (averaged 8.8 months). Conclusion: The calculating method can make the dose of second 131 I treatment for GD relatively optimal. Thyroid weight ≥30 g can be used as the main criterion for selection of patients 131 I treatment. Patients whose thyroid weight 131 I treatment and the therapeutic effect was poor

  3. {sup 131}I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study

    Energy Technology Data Exchange (ETDEWEB)

    Lin, Chien-Mu [Taipei Medical University - Shuang Ho Hospital, Department of Nuclear Medicine, Taipei (China); Taipei Medical University, Department of Radiology, College of Medicine, Taipei (China); Doyle, Pat [London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, London (United Kingdom); Tsan, Yu-Tse [National Taiwan University College of Public Health, Institute of Occupational Medicine and Industrial Hygiene, Taipei (China); Taichung Veterans General Hospital, Department of Emergency Medicine, Taichung (China); Chung Shan Medical University, School of Medicine, Taichung (China); Lee, Chang-Hsing [Ton Yen General Hospital, Department of Occupational Medicine, Hsinchu County (China); Wang, Jung-Der [National Taiwan University College of Public Health, Institute of Occupational Medicine and Industrial Hygiene, Taipei (China); National Cheng Kung University College of Medicine, Department of Public Health, Tainan (China); Chen, Pau-Chung [National Taiwan University College of Public Health, Institute of Occupational Medicine and Industrial Hygiene, Taipei (China); National Taiwan University College of Public Health, Department of Public Health, Taipei (China); National Taiwan University College of Medicine and Hospital, Department of Environmental and Occupational Medicine, Taipei (China); Collaboration: Health Data Analysis in Taiwan (hDATa) Research Group

    2014-02-15

    To evaluate the association between {sup 131}I therapy for thyroid cancer and risk of developing primary hyperparathyroidism. This was a nationwide population-based cohort study of patients with thyroid cancer diagnosed during the period 1997-2008. The data were obtained from the Taiwan National Health Insurance Research dataset. The cumulative {sup 131}I dose in each patient was calculated. Hazard ratios (HRs) were calculated using a proportional hazards model to estimate the effect of {sup 131}I therapy on the risk of developing primary hyperparathyroidism in the cohort. A total of 8,946 patients with thyroid cancer were eligible for the final analysis. Among these patients, 8 developed primary hyperparathyroidism during the follow-up period that represented 38,248 person-years giving an incidence rate of 20.9 per 10{sup 5} person-years. {sup 131}I was used in the treatment of 6,153 patients (68.8 %) with a median cumulative dose of 3.7 GBq. The adjusted HRs were 0.21 (95% CI 0.02-1.86) and 0.46 (95% CI 0.10-2.10) for those receiving a cumulative {sup 131}I dose of 0.1-3.6 GBq and ≥3.7 GBq, respectively, compared to no therapy. The risk of developing primary hyperparathyroidism did not increase with increasing {sup 131}I dose (test for trend p = 0.51). No interaction was found between {sup 131}I dose and age (p = 0.94) or {sup 131}I dose and sex (p = 0.99). {sup 131}I treatment for thyroid cancer did not increase risk of primary hyperparathyroidism during a 10-year follow-up in this study population. Further research with a longer follow-up period is needed to assess late adverse effects beyond 10 years. (orig.)

  4. False-positive I-131 scan by contaminated muffler in a patient with thyroid carcinoma

    Energy Technology Data Exchange (ETDEWEB)

    Seo, Han Kyung; Kim, Min Woo; Jeong, Hwan Jeong; Sohn, Myung Hee [Chonbuk National University Hospital, Chonju (Korea, Republic of)

    2006-02-15

    A 39-year-old female patient who had undergone a total thyroidectomy for a papillary thyroid carcinoma underwent a whole body scan with I-131. The I-131 scan was performed 72 hours after administering 185 MBq (5 mGi) of an I-131 solution. The anterior image of head, neck, and upper chest showed multiple areas of increased uptake in the mediastinal area considering of functional metastasis. However, radioactivity was not evident in the image taken after removing her clothes and muffler. The image obtained after placing the muffler on the pallet showed that the radioactivity was still present. It is well known that artifacts on an I-131 scan can be produced by styling hair sputum, drooling during sleep, chewing gum, and paper or a cloth handkerchief that is contaminated with the radioactive iodine from either perspiration or saliva. This activity might be mistaken for a functional metastasis. Therefore, it is essential that an image be obtained after removing the patient's clothes. In this study, artifacts due to a contaminated muffler on the I-131 scan were found. These mimicked a functional metastasis of the mediastinal area in a patient with a papillary thyroid carcinoma.

  5. A pioneer experience in Malaysia on In-house Radio-labelling of "1"3"1I-rituximab in the treatment of Non-Hodgkin's Lymphoma and a case report of high dose "1"3"1I-rituximab-BEAM conditioning autologous transplant

    International Nuclear Information System (INIS)

    Kuan, Jew Win; Law, Chiong Soon; Wong, Xiang Qi; Ko, Ching Tiong; Awang, Zool Hilmi; Chew, Lee Ping; Chang, Kian Meng

    2016-01-01

    Radioimmunotherapy is an established treatment modality in Non-Hodgkin's lymphoma. The only two commercially available radioimmunotherapies – "9"0Y-ibritumomab tiuxetan is expensive and "1"3"1I-tositumomab has been discontinued from commercial production. In resource limited environment, self-labelling "1"3"1I-rituximab might be the only viable practical option. We reported our pioneer experience in Malaysia on self-labelling "1"3"1I-rituximab, substituting autologous haematopoietic stem cell transplantation (HSCT) and a patient, the first reported case, received high dose "1"3"1I-rituximab (6000 MBq/163 mCi) combined with BEAM conditioning for autologous HSCT. - Highlights: • Usual dose: Day 0 (dosimetry) – 5 mCi, Day 7 (therapeutic) 0.75 Gy to whole body. • High dose: 6000 MBq (163 mCi) on Day − 18, BEAM conditioning starts on Day − 8. • Self-labelled "1"3"1I-rituximab is a viable treatment in resource limited environment. • "1"3"1I-rituximab may substitute autologous transplant. • High dose "1"3"1I-rituximab-BEAM is a feasible conditioning regime.

  6. Long-term follow-up of autonomous hyperfunctioning thyroid nodules treated with 131I

    International Nuclear Information System (INIS)

    Zhou Qian

    1990-01-01

    30 cases of hyperthyroidism caused by solitary autonomous functioning thyroid nodules (AFTN) and treated with 131 I 4 to 24 years earlier (mean, 14.13 years) were studied. In comparison, a control group of 15 cases with AFTN, trated surgically 4 to 22 years ago (mean, 8.66 years), was also examined. The results showed that: (1) Thyroid scintigraphy is not only the determinant criterion for the diagnosis of AFTN, but also the most reliable measure for evaluating the effect of treatment and prognosis. Disappearance of the hot nodule and restoration of the function of suppressed thyroid tissue indicate cure of the disease. (2) Solitary toxic thyroid nodules are frequently polyclonal and occur in nodular goiters with scattered small multifocal hot areas. Therefore, recurrence of the disease is unavoidable either after 131 I therapy or partial thyroidectomy. (3) After treatment of this disease, an absent or low response to TRH test dose not indicate ineffective cure, and an exaggerated response also dose not predict hypothyroidims. (4) Use 131 I and surgery are almost equally effective for the treatment of this disease. All the patients are clinically euthyroid. According to the scintigraphic pattern, all the surgically treated patients are cured, but there are 1 recurrent and 1 with persistent hot nodule in the 131 I therapy group. (5) The 131 I dose calculated individually is more reasonable than a standard does

  7. Measurements of iodine uptake in thyroid after diagnostic administration of 131I

    International Nuclear Information System (INIS)

    Osko, J.; Pliszczynski, T.

    2003-01-01

    The measurements performed up to now, showed that the spectrometric measurements can be useful in selection of the patients who need special consideration during the 131 I diagnostics and treatment. The next step of the work will include the measurements of the real activity of 131 I in thyroid gland, after the therapeutic administration of radioiodine. A special collimator was designed for this purpose and the thyroid counter was calibrated using a phantom with inserts simulating different shapes of pathologically changed thyroid glands. It can be expected that the improvement of accuracy of the diagnostic measurements and better control of real activity of 131 I in thyroid gland after the therapeutic administration will contribute to the process of optimisation of radiation doses to the patients and medical personnel. (authors)

  8. Tc-99m imaging in thyroidectomized differentiated thyroid cancer patients immediately before I-131 treatment.

    Science.gov (United States)

    Tsai, Chi-Jung; Cheng, Cheng-Yi; Shen, Daniel Hueng-Yuan; Kuo, Shou Jen; Wang, Lien-Yen; Lee, Chiang-Hsuan; Wang, Jhi-Joung; Chang, Ming-Che; Huang, Wen-Sheng

    2016-02-01

    The aim of this study was to evaluate the clinical role of technetium-99m pertechnetate (Tc-99m) imaging in thyroidectomized differentiated thyroid cancer patients immediately before radioiodine-131 (I-131) treatment (Tx). Eighty-six consecutive post-total-thyroidectomy patients (15 men, 71 women; mean age: 46.8 years) with pathologically diagnosed differentiated thyroid cancer were retrospectively studied. Tc-99m imaging immediately before I-131 Tx using both patient-based and lesion-based measurements were analyzed and were further compared with those of post-Tx I-131 whole-body scans. For patients with unequivocally positive Tc-99m uptake, the sensitivity was 77% (patient-based) and 59% (site-based). The positive predictive value (PPV) was 100% for both patient-based and site-based measurements. If equivocal Tc-99m uptake was counted as positive, the sensitivity was 83 and 67%, and the PPV was 100 and 99% for patient-based and site-based measurements, respectively. (a) To increase sensitivity yet maintaining high PPV, equivocal Tc-99m uptake should be considered a positive finding. (b) The nearly 100% PPV of Tc-99m imaging immediately before I-131 Tx for remnant detection suggests that Tc-99m imaging not only serves as an alternative to low-dose I-131 scanning in the low-risk post-thyroidectomy patients but also provides a clue for the subsequent I-131 therapeutic dosage and even for the outcome prediction.

  9. Evaluation of absorbed dose in studies of renal function due to 123I/131I (hippuran) e 111In (DPTA)

    International Nuclear Information System (INIS)

    Vasquez, M.V.; Castillo, C.E.; Rojas, R.; Cabrera, C.; Abanto, D.; Morgan, A.; Diaz, E.E.

    2015-01-01

    The absorbed dose of the kidneys during renal function studies of adult patients is estimated through biokinetics of radiopharmaceuticals containing the 123 I/ 131 I (hippuran) e 111 In (DPTA). Using the methodology MIRD and representation Cristy-Eckerman for adult kidneys, it is shown that dosimetric contributions of organs of biokinetics 123 I/ 131 I (hippuran) e 111 In (DPTA) are significant, in estimative of dose for renal function studies. Dosimetric contributions (body and whole bladder, kidneys excluding) are given by 11.90% (for 123 I), 4.97% (for 131 I) and 28.32% (for 111 In). In all cases, the dosimetric contributions are mainly due to photons issued by the whole body

  10. Post-laryngectomy localization of I-131 at tracheostomy site on a total body scan

    International Nuclear Information System (INIS)

    Kirk, G.A.; Schulz, E.E.

    1984-01-01

    A post-thyroidectomy, post-I-131-therapy patient had a laryngectomy and neck dissection for recurrent papillary thyroid carcinoma. A subsequent I-131 total body scan revealed persistent anterior neck activity, which disappeared upon removal of the tracheostomy tube and dressings

  11. Retention of elemental 131I by activated carbons under accident conditions

    International Nuclear Information System (INIS)

    Deuber, H.

    1984-09-01

    Under simulated accident conditions (maximum temperature: 130 0 C) no significant difference was found in the retention of I-131 loaded as elemental iodine, by various fresh and aged commercial activated carbons. In all the cases, the I-131 passing through deep beds of activated carbon was in a non-elemental form. It is concluded that a minimum retention of 99.99% for elemental radioiodine, as required by the RSK guidelines for PWR accident filters, can be equally well achieved with various commercial activated carbons. (orig.) [de

  12. Radiolabeling and Preclinical Evaluation of 131I-anti-CD20 for Non-Hodgkin's Lymphomas Therapy

    International Nuclear Information System (INIS)

    Kullaprawittaya, Usa; Khongpetch, Pranom; Ngamprayad, Tippanan; Nuanchuen, Suphatphong

    2007-08-01

    Full text: In this study, a monoclonal anti-CD20 was developed for radioimmunotherapy of non-Hodgkin's B-cell lymphoma by reacting anti-CD20 with iodine-131 using iodogen procedure. It was found that radiochemical yield was > 95 % independently of incubation time and the antibody could be conjugated with iodine-131 up to 10 mCi/mg. The radiolabeled antibody exhibited excellent retention of immunoreactivity with radio incorporations >95% for 6 hr at 4 o C. In vitro stability tests showed minimal loss of iodine-131 from the conjugate in the presence of cysteine and in human serum at 37 o C. Biodistribution study in normal ICR mice showed higher uptake by the liver, kidney and intestines but lower thyroid uptake compared to 131 I -MIBG. Biodistribution studies confirmed the in vitro stability of 131 I -anti-CD20. In particular, excellent in vivo retention of iodine-131 was demonstrated by lower thyroid accumulation over 48 hr. A favorable biological distribution of 131 I -anti-CD20 suggests this radiopharmaceutical may be effectively used in the therapy of non-Hodgkin's lymphoma

  13. Dose-specific transcriptional responses in thyroid tissue in mice after 131I administration

    International Nuclear Information System (INIS)

    Rudqvist, Nils; Schüler, Emil; Parris, Toshima Z.; Langen, Britta; Helou, Khalil; Forssell-Aronsson, Eva

    2015-01-01

    Introduction: In the present investigation, microarray analysis was used to monitor transcriptional activity in thyroids in mice 24 h after 131 I exposure. The aims of this study were to 1) assess the transcriptional patterns associated with 131 I exposure in normal mouse thyroid tissue and 2) propose biomarkers for 131 I exposure of the thyroid. Methods: Adult BALB/c nude mice were i.v. injected with 13, 130 or 260 kBq of 131 I and killed 24 h after injection (absorbed dose to thyroid: 0.85, 8.5, or 17 Gy). Mock-treated mice were used as controls. Total RNA was extracted from thyroids and processed using the Illumina platform. Results: In total, 497, 546, and 90 transcripts were regulated (fold change ≥ 1.5) in the thyroid after 0.85, 8.5, and 17 Gy, respectively. These were involved in several biological functions, e.g. oxygen access, inflammation and immune response, and apoptosis/anti-apoptosis. Approximately 50% of the involved transcripts at each absorbed dose level were dose-specific, and 18 transcripts were commonly detected at all absorbed dose levels. The Agpat9, Plau, Prf1, and S100a8 gene expression displayed a monotone decrease in regulation with absorbed dose, and further studies need to be performed to evaluate if they may be useful as dose-related biomarkers for 131I exposure. Conclusion: Distinct and substantial differences in gene expression and affected biological functions were detected at the different absorbed dose levels. The transcriptional profiles were specific for the different absorbed dose levels. We propose that the Agpat9, Plau, Prf1, and S100a8 genes might be novel potential absorbed dose-related biomarkers to 131 I exposure of thyroid. Advances in knowledge: During the recent years, genomic techniques have been developed; however, they have not been fully utilized in nuclear medicine and radiation biology. We have used RNA microarrays to investigate genome-wide transcriptional regulations in thyroid tissue in mice after low

  14. Efficacy of different I-131 doses for thyroid remnant ablation

    International Nuclear Information System (INIS)

    Nguyen, X.C.; Thiep, T.V.; Hung, N.C.

    2007-01-01

    Full text: Radioactive iodine 131 I has been widely used as a treatment modality of differentiated thyroid carcinoma. The need for high dose radioiodine ablation of thyroid remnant is still in question. The aim of this prospective study was to assess the efficacy of 131 I different single and fractionated doses in ablation of post-operative thyroid remnant. Patients and methods: One hundred-twelve patients were included in this study. Sixty-one patients with TSH≥30 μU/ml were treated 30 mCi in group 1 (36 patients) or 100 mCi in group 2 (25 patients). Fifty one patients with TSH 131 I high dose of 100 mCi and no severe adverse effect in the other groups. Conclusion: Single high dose (100 mCi) may be more efficient than single low dose (30 mCi) for post-operative remnant ablation with serum TSH≥30 μU/ml and the efficacy of low fractionated doses (30+30 mCi) was comparable with high-fractionated dose (30+100 mCi) for post-operative remnant ablation with low serum TSH in differentiated thyroid carcinoma. (author)

  15. 131I-m IBG preparation and clinical applications

    International Nuclear Information System (INIS)

    Yassine, T.; Bakeir, M. A.; Al-Shnan, S.; Al-Asad, M.

    2001-12-01

    The factors affecting the preparation of 131 I-mIBG were studied and the optimal labelling and preparation conditions were determined in a manner that the requirements of GRP and GMP are satisfied. The m-IBG was labeled by isotopic exchange method where in situ produced Cu (II) was used as a catalyst. The Cu (II) was in situ produced by the effect of thiosulfate on Cu(II) ions in the presence of acetic acid. The optimal conditions were determined as: (The ratio of acetic acid to the iodide-131 solution is 0.5-1.5, the reaction temperature is (160 Centigrade), the reaction period is 60 minutes, and the quantity of m-IBG must be more than 1mg). At these conditions, high labelling yield of 98% was obtained. Further purification lead to an increase in the RCP to more than 99%. All preparations produced sterile and Pyrogen free solutions. The biodistribution studies in rats showed random distribution, which were slightly higher than that were shown in literature. These differences were attributed to the absence of stable iodine saturation of the rats prior to the injection of 131 I-mIBG in this study. Clinical studies using our products showed high localization in the tumors in case of neuroblastoma patients and in adrenal gland in case of pheochromocytoma patients. (author)

  16. Long-term radiobiological effects in rats after exposure of 131I in utero

    Directory of Open Access Journals (Sweden)

    V. V. Talko

    2017-12-01

    Full Text Available Remote radiobiological effects in male rats prenatally exposed by 131I in different periods of gestation were studied. It was established that the negative effects of irradiation of 131I in utero in the distant period are manifested by disorders of the functioning of the pituitary-thyroid link of endocrine regulation, pro-antioxidant equilibrium, changes in the lipid-lipoprotein spectrum of blood serum. As a result of irradiation of 131I in utero throughout the period of gestation, discoordination in the functioning of the pituitary-thyroid link of endocrine regulation, a violation of the pro-antioxidant balance by increasing the intensity of lipoperoxidation processes and the activity reducing of enzymes of antioxidant defense, the atherogenic orientation of changes in the lipid-lipoprotein spectrum was established. As a result of irradiation by 131I in utero during the third trimester of gestation, the development of hypothyroidism, changes in pro-antioxidant balance due to the activation of antioxidant defense, and the reduction of the concentration of the main classes of lipids have been established.

  17. Studies on the airborne radioiodine-contamination in thyroid therapy with /sup 131/I doses of approx 370 MBq

    Energy Technology Data Exchange (ETDEWEB)

    Krzesniak, J W; Czerminska, M [Centralne Lab. Ochrony Radiologicznej, Warsaw (Poland); Chomicki, O A [Centrum Medyczne Ksztalcenia Podyplomowego, Warsaw (Poland)

    1979-01-01

    The equipment and methods are described and the results presented of /sup 131/I levels in various physical and chemical forms measured at the Endocrinology Clinic of the Center for Postgraduate Medical Training in Warsaw. The analysis was made of the radiation hazards to the personnel and ''nonradioisotope'' patient from /sup 131/I inhaled. Even though the /sup 131/I levels in the air exceeded the permissible levels by a factor 2-5, when the time spent in corresponding areas was taken into consideration, the /sup 131/I uptake in the above persons constituted only between 1 and 10% of the maximum permissible level of the /sup 131/I inhaled. The dynamics of radioiodine exhalation in the euthyroid and hyperthyroid patients treated with /sup 131/I is discussed. No statistical difference was found between the exhalation curves when /sup 131/I was administered as a liquid or in the form of closed capsules.

  18. Internal dosimetry of nuclear medicine workers through the analysis of 131I in aerosols

    International Nuclear Information System (INIS)

    Gomes C, L.; Lucena, E. A.; Da Silva S, C.; Almeida D, A. L.; Oliveira S, W.; Souza S, M.; Maranhao D, B.

    2014-08-01

    131 I is widely used in nuclear medicine for diagnostic and therapy of thyroid diseases. Depending of workplace safety conditions, routine handling of this radionuclide may result in a significant risk of exposure of the workers subject to chronic intake by inhalation of aerosols. A previous study including in vivo and in vitro measurements performed recently among nuclear medicine personnel in Brazil showed the occurrence of 131 I incorporation by workers involved in the handling of solutions used for radioiodine therapy. The present work describes the development, optimization and application of a methodology to collect and analyze aerosol samples aiming to assess internal doses based on the activity of 131 I present in a radiopharmacy laboratory. Portable samplers were positioned at one meter distant from the place where non-sealed liquid sources of 131 I are handled. Samples were collected over one hour using high-efficiency filters containing activated carbon and analyzed by gamma spectrometry with a high purity germanium detection system. Results have shown that, although a fume hood is available in the laboratory, 131 I in the form of vapor was detected in the workplace. The average activity concentration was found to be of 7.4 Bq /m 3 . This value is about three orders of magnitude below the Derived Air Concentration (Dac) of 8.4 kBq/m 3 . Assuming that the worker is exposed by inhalation of iodine vapor during one hour, 131 I concentration detected corresponds to an intake of 3.6 Bq which results in a committed effective dose of 7.13 x 10 -5 mSv. These results show that the radiopharmacy laboratory evaluated is safe in terms of internal exposure of the workers. However it is recommended that the presence of 131 I should be periodically re-assessed since it may increase individual effective doses. It should also be pointed out that the results obtained so far reflect a survey carried out in a specific workplace. Thus, it is suggested to apply the

  19. The therapy for huge goiter together with hyperthyroidism through 131I case studies

    International Nuclear Information System (INIS)

    He Jianhua; Yu Wencai; Zeng Qingwen; Wu Congjun

    2001-01-01

    Objective: 214 cases of the treatment of huge goiter with hyperthyroidism are revised to collect clinic material for the improvement of therapy to hyperthyroidism indications through 131 I. Methods: In all of these cases, patients take a full dose of 131 I based on MC Garack's formula for one time. Results: Among them, 154 resolved, accounting for 72%, 139 of the cases were reduced to normal size, which accounted for 64.9% of the patients. Only 114 cases of patients had side-effect, and during one year 12.1% of them have symptoms of hypothyroidism. Conclusion: The statistics shows that 131 I is convenient, safe, well and with reduces suffering from treating huge goiter with hyperthyroidism

  20. Determination of thephysico-chemical 131I species in the exhausts and stack effluent of a PWR power plant

    International Nuclear Information System (INIS)

    Deuber, H.; Wilhelm, J.G.

    1979-01-01

    To quantify the credit that can be granted in the assessment of the 131 I ingestion doses and the improvement that can be achieved in the ventilation systems if differences of the physico-chemical 131 I species with respect to the environmental impact are taken into account, the fractions of the 131 I species were determined in the stack effluent and in various exhausts of a 1300 MW/sub e/ PWR power plant during a period of 3 months. Based on these measurements, calculations for different cases of filtration of the main exhausts for iodine were carried out. The average fractions of elemental and organic 131 I were about 70 and 30% respectively in the stack effluent during the time indicated. Elem. 131 I orginated mainly from the hoods in which samples of the primary coolant are taken and processed. Org. 131 I was mainly contributed by the equipment compartments. If the hood exhaust had been filtered, as was the case with the equipment compartment exhaust, the fractions of elem. and org. 131 I would have been on the order of 50% each and the calculated 131 I ingestion doses would have been a factor of 3 lower

  1. Theoretical calibration of a NaI(Tl) detector for the measurement of 131I in a thyroid phantom

    International Nuclear Information System (INIS)

    Venturini, Luzia

    2002-01-01

    This paper describes the theoretical calibration of a NaI(Tl) detector using Monte Carlo Method, for the measurement of 131 I in a thyroid phantom. The thyroid is represented by the region between two concentric cylinders, where the inner one represents the trachea and the outer one represents the neck. 133 Ba was used for experimental calibration. The results shows that the calibration procedure is suitable for 131 I measurements. (author)

  2. Assessment of exposures to 131I in the continental United States resulting from the Nevada atmospheric nuclear tests

    International Nuclear Information System (INIS)

    Bouville, A.; Wachholz, B.W.; Dreicer, M.

    1991-01-01

    The National Cancer Institute (NCI) is conducting an assessment of the exposure to 131 I that the American people received from the fallout resulting from the atmospheric bomb tests carried out at the Nevada Test Site (NTS). It is estimated that about 5 EBq of 131 I were released into the atmosphere as a result of approximately 100 tests carried out mainly in the 1950s. The most important source of human exposure from fallout 131 I was due to the ingestion of cows' milk but other routes of exposure (ingestion of goats' milk, leafy vegetables, eggs, and cottage cheese as well as inhalation) are also considered. The exposure to 131 I are assessed on a test-by-test and county-by-county basis. In order to make these estimates for locations throughout the United States, it is necessary to determine: The activities of 131 I deposited on soil and vegetation, the amount of 131 I consumed by dairy cows and the resulting 131 I concentrations in cow's milk, and the 131 I ingested by people. The overall methodology currently used in the assessment of the 131 I exposures is presented. Particular attention is devoted to the methodology developed to estimate the intake of contaminated pasture by dairy cows, milk production, and milk distribution for each county of the continental United States during the 1950s

  3. Radiochemical analysis of a wide range of 131I activities in water and milk using well-type germanium detector

    International Nuclear Information System (INIS)

    Xin Li; Bradt, C.J.; Umme-Farzana Syed; Abdul Bari; Torres, M.A.; Kimi Nishikawa; Khan, A.J.; Menia, T.A.; Semkow, T.M.; University at Albany, State University of New York, Rensselaer, NY

    2017-01-01

    We report a study of a fast radiochemical method to determine the activity of 131 I via the radiochemical recovery obtained with a 129 I tracer. Previous methods were valid for low levels of 131 I activities. In the new method, we developed a correction using the 29.7-keV X-ray peak from Xe, taking into consideration that this peak originates from both and 131 I decay. This enables quantitation of high levels of 131 I activity. Furthermore, for a very high 131 I activity, one can use the 39.6-keV gamma peak which is unique to 129 I. Combining both approaches enables quantitation of 131 I activities up to 200 times that of the 129 I recovery tracer. (author)

  4. The curative effect of 131I therapy on Re-hyperthyroidism treated with ATD

    International Nuclear Information System (INIS)

    Yuan Wuhong; Guo Yayun; Lian Qiufang

    2002-01-01

    68 cases of re-hyperthyroidism patients treated with ATD are treated with 131 I, and the results are analyzed carefully. It indicates that the re-hyperthyroidism patients with 131 I treating could receive good effect. It is necessary to monitor the thyroid hormone level and to be supplemented with ATD or thyroxine agent when the thyroid function is abnormal

  5. Optimization of the therapeutic dose of 131I for thyroid differentiated carcinoma

    International Nuclear Information System (INIS)

    Lima, Fabiana Farias de

    2002-09-01

    I-131 thyroid cancer therapy is based on the strategy of concentrating radioactive iodine in the thyroid tissue, to completetly eliminate thyroid tissue and functioning thyroid cancer metastases remaining after thyroidectomy. In Brazil, fixed activities of 131 I generally are given, sometimes either delivering insufficient activities to ablate all of the remnants, or unnecessarily high activities, with patients remaining in the hospital for some period of time. This investigation proposes a protocol of individualized planning of ablative doses, based on individual patients metabolisms and measured thyroid remnant masses. Simulated thyroid remnants were fabricated in various forms, volumes and activities, and optimum image acquisition parameters were determined using Single-Photon Emission Computed Tomography 9SPECT). Resultant images were evaluated, to determine the apparent volumes and the 131 I concentrations. I-131 metabolism was studied in 9 patients who had undergone thyroidectomies. Their thyroid remnant masses were determined applying the same parameters used in SPECT simulation studies, and the optimum activity for their therapy was calculated and compared to the established fixed activity of 3.7 GBq (100 mCi), which would have normally been assigned. Background subtraction using the method of percent maximum counts, using a value of 67.5%, combined with scatter correction (triple energy window method), was shown to be optimum for SPECT quantification of volumes between 3-10 ml. Errors in the method were below 9% for sources with regular geometries and around 11% for sources with irregular geometries. In the patient studies, it was observed that 78% of patients could have received reduced activities of 131 (from 0.8-3-2. GBq (20-87 nCi). In addition, 33% of these patients could have received low enough activities to have discharged from the hospital, using an individualized administration scheme. This could also have resulted in a dose reduction for many

  6. Radioiodinated (I{sup 131} and I{sup 125}) Fibrinogen for the Detection of Malignant Tumours in Man; Emploi de Fibrinogene Marque avec {sup 131}I ou {sup 125}I pour la Detection de Tumeurs Malignes chez l'Homme; Primenenie mechennogo radioaktivnym Jodom-131 i Jodom-125 fibrinogena dlya obnaruzheniya zlokachestvennykh opukholej u cheloveka; Empleo el Fibrinogeno Radioyodado ({sup 131}I y {sup 125}I) para la Deteccion de Tumores Malignos en el Hombre

    Energy Technology Data Exchange (ETDEWEB)

    Monasterio, G.; Becchini, M. F.; Riccioni, N. [Centre of Nuclear Medicine, Medical Clinic, University of Pisa (Italy)

    1964-10-15

    A high fibrin content has been shown in a large number of malignant tumours, both experimental and human; this finding has been referred to the high thromboplastin content within the tumour, inducing the polymerization of fibrinogen into fibrin. On the basis of these data, human fibrinogen labelled with I{sup 131} and I{sup 125} has been tested as a possible agent for detecting malignant tumours in man. The uptake of radioiodinate fibrinogen has been studied in malignant and benign tumours, as well as non-neoplastic space-occupying lesions. Seventy-three cases have been so far examined; 53 of these were represented by malignant tumours localized in the skeleton, lungs, brain, abdominal organs etc. The I{sup 131}- fibrinogen uptake test gave correct results in 79% of the cases examined; no false positive results were obtained in the whole series. The technique and the results are briefly discussed. From the data obtained, it seems that fibrinogen-I{sup 131} may be usefully applied for the early detection of malignancies in man; possible improvements of the detection technique may markedly increase the diagnostic value of the method. (author) [French] Une teneur elevee en fibrine a ete mise en evidence dans un grand nombre de tumeurs malignes, tant chez l'homme que chez des animaux de laboratoire; on a impute ce phenomene au fait que la tumeur contient une forte proportion de thromboplastine qui provoque la formation de fibrine par polymerisation du fibrinogene. Sur cette base, les auteurs ont utilise du fibrinogene humain marque avec {sup 1}'3{sup 1}I ou {sup 125}I pour la detection de tumeurs malignes chez l'homme. Ils ont etudie la fixation du fibrinogene marque dans des tumeurs malignes et des tumeurs benignes, ainsi que dans des lesions en volume non-neoplastiques. Sur les 73 cas examines jusqu'a present, 53 etaient constitues par des tumeurs malignes localisees dans le squelette, les poumons, le cerveau, les organes abdominaux, etc. Le test de fixation du

  7. Factors predlisposing to developing early hypothyroidism after 131I therapy in patients with Graves' disease

    International Nuclear Information System (INIS)

    Zhu Mingfeng; Wen Chijun; Qian Hong

    2006-01-01

    Objective: To explore the clinical meanings of changes of serum TRAb, TGA, TMA contents during treatment of Graves' disease with 131 I, especially in those patients developing early hypothyroidism. Methods: Serum levels of TRAb, TGA, TMA, TSH, T 3 , T 4 were measured in 167 patients with Graves' disease both before and six months after mi therapy. Results: Six months after 131 I treatment, the original 167 patients could be divided into three groups based apon their thyroid ruction statas: Group A, improved but remained hyperthyroid, n=91, Group B, enthyroid, n=48, Group C, developing early hypothyroidism, n=28. Average age in Group C (hypothyroid) was significantly lower than that in Group A (hyperthyroid) (P 131 I treatment in younger patients. (2) Patients with high TRAb levels before 131 I therapy were less likely to be rendered enthyroid after a single course of treatment while those with low TRAb levels were easily rendered hypothyroid. (3) Development of hypothyroidism after 131 I treatment was closely related to the increase of TGA, TMA levels. (authors)

  8. Outcome analysis of 250 cases of Graves disease with large goiter treated with 131I

    International Nuclear Information System (INIS)

    Wang Qinfen; Zhang Chenggang; Zhao Xiaobin; Shi Longbao

    2003-01-01

    Objective: To evaluate the treatment effects of Graves disease with large goiter treated with 131 I and the method of 131 I individualized estimated dose. Methods: Two hundred and fifty patients with Graves disease with large goiter (mean of thyroid weight 113.0 ± 39.2 g; range 90-450 g) were studied according to patient individual factors, the dose per g thyroid tissue ranging from 2. 775-5.18 MBq/g was determined, then the administered dose was calculated using the special formula. The follow-up was for 15.9 ± 9.9 (range 3-44.7) months. Results: After one dose of 131 I, 154 patients (61.6%) became euthyroid, 53 patients (21.2%) remained to be hyperthyroidism, 43 patients (17.2%) became hypothyroidism. Large goiter in 219 patients (87.6%) was normalized. Conclusions: Treatment with 131 I is an effective method for Graves disease with large goiter; According to factors affecting outcome, employing the method of individualized radioiodine therapy can improve the efficacy of 131 I treatment

  9. Labeling method of 17-allylamino, 17-demethoxygeldanamycin with 131I and its biodistribution in experimental animals

    International Nuclear Information System (INIS)

    Jiang Xinyu; Liu Lu; Gao Wen; Chen Daozhen; Huang Ying; Yang Min; Luo Shineng

    2008-01-01

    Objective: The aims of the study were to find out the optimal 131 I labeling method with 17-allylamino, 17-demethoxygeldanamycin (17-AAG) and also to study its biodistribution in animals. Methods: 131 I-17-AAG was prepared by the reaction of 17-AAG with Na 131 I in the presence of hydrogen peroxide. The labeling efficiency and the stability of 131 I-17-AAG were measured by paper chromatograph. The biodistribution in the ICR normal mice was observed by the blood samplings and major organs that were taken out from mice at 0.5, 1, 4, 8, 24 h after 131 I-17-AAG injection through tail veins. VX2 tumor was also implanted in rabbit liver for in vivo imaging with SPECT. Results: The optimal labeling conditions of 17-AAG with mi were determined. The labeling efficiency was 85.65%. The radiochemical purity of 131 I- 17-AAG in acetoacetate solution was (96.51 ± 0.80)% after purification and its radiochemical purity in normal saline solution was (95.57 ± 0.09)%. The radiochemical purity could keep to 90% in normal saline after 5 d at 4 degree C. The biodistribution study in normal mice showed that the uptake (percentage activity of injection dose per gram of tissue, % ID/g) in liver and kidney was less than that in cholecyst [(3.0963 ± 1.3394) %ID/g] at 0.5 h post-injection, and the uptake in stomach and intestine reached to the highest level at 4 h post-injection. The SPECT images showed that the 131 I-17-AAG was obviously concentrated in the tumor after injection at 2 h and 4 d, 6 d, 14 d with the highest tumor to non-tumor (T/NT) radioactivity ratio of 10.36. Conclusions: The labeling method of 17-AAG with 131 I was successfully established. The 131 I-17-AAG in normal saline had a good stability. The main biodistribution in mice was in digestive system and was excreted through the intestinal tract. The SPECT images showed that 131 I-17-AAG might be a potential target-directed agent to the tumor. (authors)

  10. Get the Facts About Exposure to I-131 Radiation

    Science.gov (United States)

    ... Data Conducting Clinical Trials Statistical Tools and Data Terminology Resources NCI Data Catalog Cryo-EM NCI's Role ... affected by I-131 fallout from nuclear testing. Medical signs —A lump or nodule that an individual ...

  11. Diagnostic value of β amyloid plaques imaging agent 131I-IMPY brain imaging in early Alzheimer's disease

    International Nuclear Information System (INIS)

    Ye Wanzhong; Lu Chunxiong; Yang Min; Bao Jiandong; Cheng Zhaohuo; Cai Deliang; Wang Zhiqiang; Yang Bixiu

    2012-01-01

    Objective: To evaluate the diagnostic value of β-amyloid plaques imaging agent [ 131 I] 2( 4-dimethylaminop henyl)-6-iodoimidazo [1, 2-α] pyridine ( 131 I-IMPY) SPECT imaging in early Alzheimer's Disease. Methods: 24 cases of AD (7 males, 17 females, aged 48∼79 years) and 14 normal (6 males, 8 females, aged 42∼67 years) control subjects were selected for this study. 131 I-IMPY SPECT imaging was carried out 2-3 h post injection. 131 I-IMPY uptake defined as the ratio of each brain gyrus and cerebellum uptake on fixed region of interest (ROI) (Rcl/cb) was calculated. Comparative analysis between the two groups was carried out using t-test. Results: In patients with early AD (MCI), 131 I-IMPY was increased in parietal gyrus, temporal gyrus and frontal gyrus compared with normal control group and it were found to be statistically significant (t = 1.3967∼2.8757, all P 0.05). In patients with AD, increase in 131 I-IMPY were observed in parietal, temporal, occipital lobes and basal ganglia compared with normal control group and it were found to be statistically significant (t=2.1001∼6.2789, all P 0.05), and 131 I-IMPY was increased in occipital lobes and basal ganglia compared with MCI group and it were found to be statistically significant (t=2.0850∼3.6772, all P 131 I-IMPY was lightly increased in each brain of left side gyrus compared with right but without statistically significant difference (t=0.1273∼0.5571, all P>0.05). Conclusions: 131 I-IMPY SPECT Imaging was helpful for early diagnosis of AD. (authors)

  12. Radiation exposure in I-131 iodine therapy

    International Nuclear Information System (INIS)

    Friedrich, W.

    1985-01-01

    In the past five years, the applied I-131 radioactivity quantity has doubled with a constant number of beds. In 1984, it was 925 GBq (25 Ci). Despite this development, no changes in the professional radiation exposure were made out. The evaluation shows a dose smaller than 0.04 man Sv/TBq (0.16 man rem/Ci) of I-131 applied. This value is below the traceability limit of the film badges. The incorporation load of the personnel (27 members) was determined by monthly body counter measurements. Only in one measurement thyroid gland activity of 5 kBq (140 nCi) was detected. Most measurements did not show any incorporation; and the few positive results were below 0.74 kBq (20 nCi). The environmental load due to unfiltered release from patients' rooms was determined at the fence of the nuclear research plant. The maximum was 0.24 mSv/a thyroid gland dose of a small child in 1982 taking into account the measured 90% partion of organic compound iodine. The waste water is decayed following chemical treatment in storage tanks. (orig./HP) [de

  13. Investigations on the retention of 131I by an iodine filter of a pressurized water reactor

    International Nuclear Information System (INIS)

    Deuber, H.; Gerlach, K.

    1983-09-01

    The retention of 131 I by an equipment room exhaust filter of a German pressurized water reactor was determined by various methods to particularly obtain reliable results. Moreover, investigations were performed to clarify the reason for aging of the carbon contained in the iodine filter mentioned. The actual retention of the organic 131 I, corresponding to a value of 99.9%, was limited by 131 I in the form of penetrating iodine compounds. It was lower than the retention of CH 3 131 I under layout conditions by more than one order of magnitude. The aging was essentially caused by the adsorption of low-volatile organic compounds. (orig.) [de

  14. Investigations on the retention of I-131 by an iodine filter of a pressurized water reactor

    International Nuclear Information System (INIS)

    Deuber, H.; Gerlach, K.

    1984-01-01

    The retention of I-131 by an equipment room exhaust filter of a German pressurized water reactor was determined by various methods to particularly obtain reliable results. Moreover, investigations were performed to clarify the reason for aging of the carbon contained in the iodine filter mentioned. The actual retention of the organic I-131, corresponding to a value of 99.9%, was limited by I-131 in the form of penetrating iodine compounds. It was lower than the retention of CH 3 I-131 under layout conditions by more than one order of magnitude. The aging was essentially caused by the adsorption of low-volatile organic compounds. (orig.) [de

  15. Synthesis and labelling of 131-I 19-iodocholesterol

    International Nuclear Information System (INIS)

    Barberio, J.C.

    1978-10-01

    The technique for the preparation of ( 131 I)-19-Iodocholesterol is described. The identification of the synthesized compound was made by spectroscopic, chemical and radiochemical techniques. Biological distribution studies in mice demonstrate that the compound can be used for the diagnosis of tumours and hyperplasia of suprarenal glands

  16. The research on biodistribution of 131I-iodosennoside A in normal mice and to evaluate myocardial activity

    International Nuclear Information System (INIS)

    Wang Junhu; Yin Zhiqi; Jiang Cuihua; Jiang Xiao; Li Yue; Zhang Jian; Sun Ziping; Ni Yicheng

    2013-01-01

    Purpose: The objective of this project is to evaluate biodistribution of [ 131 I]-Iodosennoside A in normal mice and explore the feasibility on the diagnosis of myocardial infarction. Methods: Iodogen method was used to radioiodinate sennoside A with 131 I. [ 131 I] Iodosennoside A was intravenously injected into mice. Three groups of mice were killed at 4 h, 24 h and 48 h post injection respectively and the radioactive uptake in major organs were calculated. Rats were subjected to left anterior descending (LAD) coronary artery ligation to induce acute myocardial infarction. Rat models of myocardial infarction were intravenously injected [ 131 I] iodosennoside A. 24 h after injection of [ 131 I] iodosennoside A, the regional distribution of radioiodinated sennoside A was determined by radioactivity counting technique. 2, 3, 5-triphenyl tetrazolium chloride (TTC) staining and autoradiography were per- formed with 2 mm thick sections of hearts for postmortem verifications. Results: The study showed high uptake of [ 131 I] iodosennoside A in kidneys and fast blood clearance. At 24 h post injection, radioactivity concentration in infarcted myocardium was over 11.9 times higher than in normal myocardium. Preferential uptake of the [ 131 I] iodosennoside A in necrotic tissue was confirmed by perfect match of images from TTC staining and autoradiography. Conclusion: The result proved that [ 131 I] iodosennoside A has myocardial necrosis affinity and may serve as a marker on the diagnosis of myocardial infarction. (authors)

  17. Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2

    International Nuclear Information System (INIS)

    Li Ling; Xu Huiyun; Mi Li; Bian Huijie; Qin Jun; Xiong Hua; Feng Qiang; Wen Ning; Tian Rong; Xu Liqing; Shen Xiaomei; Tang Hao; Chen Zhinan

    2006-01-01

    Purpose: Therapeutic efficacy, suitable dose, and administration times of 131 I-CAb 1 F(ab') 2 , a new monoclonal antibody therapeutics specifically directed against a cell surface-associated glycoprotein of colon cancer, were investigated in this article. Methods and Materials: In human colon cancer xenografts, 131 I-CAb 1 F(ab') 2 at the dose of 125 μCi, 375 μCi, and 1125 μCi were administrated intraperitoneally on Days 6 and 18 after implantation of HR8348 cells with CAb 1 high reactivity. Survival time and tumor growth inhibition rate were used to evaluate the efficacy and safety of 131 I-CAb 1 F(ab') 2 in treatment of colon cancer xenografts. Results: Treatment of 125, 375, and 1125 μCi 131 I-CAb1 F(ab') 2 did not significantly decrease the mean survival time of nude mice when compared with nontreated groups (p = 0.276, 0.865, 0.582, respectively). Moreover, the mean survival times of nude mice receiving 375 μCi and 1125 μCi 131 I-CAb1 F(ab') 2 were significantly longer than that of 5-FU-treated groups (p 0.018 and 0.042). Tumor growth inhibition rates of the first therapy were 35.67% and 41.37%, with corresponding 131 I-labeled antibody dosage of 375 μCi and 1125 μCi. After single attack dosage, second reinforcement therapy may rise efficacy significantly. Tumor growth inhibition rates of 125 μCi, 375 μCi, and 1125 μCi 131 I-labeled antibody on Day 20 posttherapy were 42.65%, 56.56%, and 84.41%, respectively. Histopathology examination revealed that tissue necrosis of various degrees was found in 131 I-CAb1 F(ab') 2 -treated groups. Conclusion: 131 I-CAb 1 F(ab') 2 is safe and effective for colon cancer. It may be a novel and potentially adjuvant therapeutics for colon cancer

  18. Inhibitory effects of 131I labeled 17-allylamino-17-demethoxygeldanamycin on breast cancer cell line

    International Nuclear Information System (INIS)

    Chen Daozhen; Liu Lu; Jiang Xinyu; Huang Ying; Yang Min; Yu Huixin; Luo Shineng; Lin Xiufeng

    2007-01-01

    Objective: 17-allylamino-17-demethoxygeldanamycin(17-AAG) is a less toxic analogue of geldanamycin (GA) that retains the tumoricidal features of GA. Same as its parent compound, 17-AAG inhibits several signaling pathways through binding to heat shock protein (HSP) 90, which results in destabilization of signaling complexes and degradation of client proteins in a variety of tumor cell growth. Treatment with 17-AAG was effective to inhibit tumor growth and induce apoptosis in colon cancer, glioblastoma, and breast cancer cell lines. This study aimed at exploring the anti-proliferation effects and mechanism of 131 I labeled 17-AAG on human breast cancer cell line MCF-7. Methods: 131 I-17-AAG was prepared by the reaction of 17-AAG with Na 131 I in the presence of hydrogen peroxide. The MCF-7 cells were divided into 5 groups with different additional drugs: group A, dimethyl sulfoxide (DMSO); group B, 370 kBq Na 131 I; group C, 2.5 mg/L 17-AAG; group D, 370 kBq 131 I-17-AAG; group E, 370 kBq 131 I-17-AAG + 2.5 mg/L 17-AAG. 3- (4,5-dimethylthiazol-2-yl)-2,5, diphenylte-trazolium bromide (MTT) assay was used to evaluate the effect of growth inhibition of MCF-7 cells. Cell cycle and apoptosis were analyzed by flow cytometry. The change of the expression of Akt2 mRNA in MCF-7 cells was examined by RT-PCR. Results: The labeling yield of 131 I-17-AAG was 83%. The radiochemical purity of 131 I-17-AAG after purification was 96.6%. The specific activity was 1.48 x 10 5 MBq/μmol. All drugs could significantly inhibit the growth of MCF-7 cells in vitro as the duration lasts longer, especially for group E. After 48 h, sub-G1 peaks detected by flow cytometry were(1.54±0.13)%, (5.72±1.05)%, (12.97±1.44)%, (20.65±1.36)%, (35.39±4.15)% for group A, B, C, D and E, respectively. The experimental groups (B-E) were all significantly higher than the control group (A, all P 131 I-17-AAG could suppress the growth of human breast cancer cell line MCF-7 and hasten the apoptosis. It could

  19. Radiation protection recommendations for I-131 thyrotoxicosis, thyroid cancer and phaeochromocytoma patients

    International Nuclear Information System (INIS)

    Woodings, S.

    2004-01-01

    Iodine-131 patients pose a radiation risk to their family members, carers and colleagues. Doses from thyrotoxicosis and thyroid cancer patients undergoing standard treatments have been well characterised in the literature. However the resulting precautions cannot be easily adapted to circumstances where the patient has an unusual affliction, or an atypical family or occupational environment. In this study, a model for calculating dose from an I-131 patient is derived from first principles. The model is combined with existing results from the literature to determine a distance weighting factor between patients and family members. This technique reduces the uncertainty in the dose calculations by removing the need to guess the unknown patterns of close contact, a problem common to all previous dose calculation techniques. Data is presented for four unusual I-131 treatments; a child thyroid cancer patient, two thyroid cancer dialysis patients and a phaeochromocytoma patient. The model is used to calculate appropriate periods of restricted contact for these patients. The recommendations provide a useful guide for future unusual I-131 treatments. Copyright (2004) Australasian College of Physical Scientists and Engineers in Medicine

  20. Iodobell in vivo kits for labelling with 123I or 131I

    International Nuclear Information System (INIS)

    Koernyei, J.; Horvath, M.; Pszota, A.; Lakatos, M.; Szirtes, L.

    1988-01-01

    Iodobell in vivo kits provide an easy and fast method for 'on the spot' radioiodination with 123 I (or 131 I). Until now three kits have been developed in the Institute of Isotopes Budapest, the heptadecanoic acid, the hippurate and the MIBG kits. From these, the heptadecanoic acid kit is being tested in humans in Hungary, the other two are under the registration procedure. The Iodobell in vivo kits may contribute to the application of 123 I radioisotope in Hungary. (orig.)

  1. Use of I-131- CRTX for targeting malignant adenocarcinoma in mice: biodistribution and radiation dosimetry

    International Nuclear Information System (INIS)

    Santos, Raquel Gouvea dos; Soares, Marcella Araugio; Andrade, Henrique Martins de; Santos, Marcos Antonio da Cunha

    2008-01-01

    Snake venoms molecules have been shown to play a role not only in the survival and proliferation of tumour cells but also in the processes of tumour cell adhesion, migration and angiogenesis. We have shown that 125 I-Crtx, a radiolabeled version of a protein derived from Crotalus durissus terrificus snake venom (Cdt), specifically binds to tumor and triggers apoptotic death. This study reports the biokinetic profile of 99m Tc-Cdt and 125/131 I-Crtx in Swiss mice bearing Ehrlich solid tumor and MIRD formulation was applied to calculate the absorbed radiation doses for various organs and tumor site. Biokinetic evaluations were performed up to 24 h after intravenous (i.v) or intratumor (i.tu.) injection of 99m Tc-Cdt or 125/131 I-Crtx. Time-activity curves were generated for the main organs by fitting the organ specific mass mean counts. The radiation dose from 131 I-Crtx was calculated based on non penetrating radiation in the mouse model. Biokinetics data from 99m Tc-Cdt after i.v. injection in mice tumor model showed rapid blood clearance (T 1/2 = 36.1 ± 2.4 min.), slow tumor clearance (T 1/2 : 108.3 ± 19.5 min.) and indicated the kidneys as the main excretion pathway. Interaction studies in vitro demonstrated that 125 I-Crtx recognize specific sites on Erlich tumor cell membrane. Upon intravenous and intratumor administration of 131 I-Crtx in mice bearing Erlich tumor, it was observed high uptake in tumor site in vivo (Ã =72kBq x h/g) resulting in a high absorbed dose radiation to tumor site. Distributions of 125/131 I-Crtx i.v. were only significant in tumor, stomach, liver and kidneys, reflecting non-specific uptake of Crtx in normal excretion tissues in vivo. Intratumoral administration reduced significantly the radiation dose to the kidneys (42-fold lower) and increased the uptake by the tumor site (128- fold higher). 131 I control was run in a parallel experiment and showed no significant tumor uptake. In conclusion, 131 I-Crtx had a high concentration in

  2. Clinical research and long-term follow-up of early hypothyroidism after 131I treatment for hyperthyroidism

    International Nuclear Information System (INIS)

    Liu Jianfeng; Zhang Youren; Xing Jialiu; Ye Genyao

    2004-01-01

    Objective: To evaluate the clinical research and long-term follow-up results of early hypothyroidism after 131 I treatment for hyperthyroidism. Methods: One hundred and forty-five patients with hyperthyroidism who developed hypothyroidism within 12 months after 131 I therapy were evaluated by clinical symptoms and plasma T 3 , T 4 , thyroid-stimulating hormone (TSH). One year after treatment, 121 of 145 patients were divided into two groups according to the occurrence of hypothyroidism. Results: 1) Group 1: transient hypothyroidism (n=33), 64%(21/33) of the patients developed euthyroidism and 36%(12/33) patients had recurrent hyperthyroidism within 1 year after being diagnosed with hypothyroidism after 131 I treatment. The long-term follow-up showed 2 patients were with euthyroidism and 2 patients who were previously with hyperthyroidism developed permanent hypothyroidism after 3 months ∼6 years. Three patients who were previously with hyperthyroidism developed euthyroidism after 3 months ∼5 years. Group 2: permanent hypothyroidism (n=88), 82.95% (73/88) patients of group 2 were treated with low-dose 131 I, 86.36% (76/88) cases of this group were found with clinical hypothyroidism. Conclusions: 72.73% (88/121) patients of early hypothyroidism after 131 I therapy developed permanent hypothyroidism. The incidence of permanent hypothyroidism in the patients treated with low-dose 131 I was higher. Recovery of transient hypothyroidism after 131 I therapy did not predict future thyroid function. (authors)

  3. The discriminatory analysis about factors correlative with the early hypothyroidism after 131I therapy for hyperthyroidism

    International Nuclear Information System (INIS)

    Xiong Lingjing; Liang Changhua; Deng Haoyu; Li Xinhui; Hu Shuo

    2002-01-01

    Objective: To explore the factors correlative with the early hypothyroidism after 131 I therapy for Graves' hyperthyroidism so as to cure it and decrease the early hypothyroidism occurring and prevent it from becoming irreversible hypothyroidism. Methods: Logistic regression discriminatory analysis by introducing multiple factors from group data and forward stepwise selection of 11 independent variables of 240 hyperthyroidism patients from clinical data and 1 dependent variable from follow-up data after 131 I therapy was conducted. Univariate analysis of each observed factor was performed, too. Results: (1)The results of multivariate analysis showed that the age of patients, the weight of thyroid, the suffering situation, the curve of 131 I absorption rate and the giving 131 I dosage/g thyroid tissue were correlated to early hypothyroidism. The results of univariate analysis showed that the weight of thyroid, the highest absorption of 131 I, the total treatment dosage of 131 I were correlated to early hypothyroidism. (2) The logistic regression equation was statistically significant. (3) The positive and negative predicting accuracy of the early hypothyroidism occurring was 64.08 %, 78.83 %, respectively, the overall predicting accuracy was 72.50%. Conclusions: The dosage of 131 I for treatment of hyperthyroid is the key factor according to the five correlative factors which are relating to the early hypothyroidism and the discriminatory classification. Enhanced follow-up and in time supplement of thyroid hormone are important measures for preventing the early hypothyroidism from becoming irreversible hypothyroidism

  4. Treatment of hyperthyroidism: use of 131I and 125I

    International Nuclear Information System (INIS)

    Atkins, H.L.

    1977-01-01

    Factors related to late hypothyroidism following the use of 131 I for treatment of hyperthyroidism are discussed with regard to age of patient, size of dose, previous surgery, immune status, and others. Possible reasons for the post-therapeutic hypothyroidism are discussed with regard to effects of radiation on the reproductive capacity of thyroid cells, effects of radiation on blood vessels, and dose distribution of radioiodine. The following therapeutic strategies are discussed: reduction of initial dose; multiple small doses; high dose radioiodine followed by replacement therapy; the use of external beam irradiation; and the use of 125 I

  5. Validation of a technique of measurement in vivo of 131I in thyroids

    International Nuclear Information System (INIS)

    Villella, A.M.; Puerta Yepes, N.; Gossio, S.; Papadopulos, S.

    2010-01-01

    The Total Body Counter (TBC) Laboratory of the Nuclear Regulatory Authority, following the institutional initiative of quality assurance in its measurement techniques, has been involved in an accreditation process based on the ISO/IEC 17205:2005 norm. In vivo measurement of 131 I in thyroid has been selected as the first technique in this process, and it is described in this paper. The TBC Laboratory uses for this technique a gamma spectrometry system with a NaI(Tl) detector, calibrated with a neck simulator of the IRD and a certified plane source of 131 I with thyroid form. It has been carried out a validation plan that has permitted the characterization of the 131 I measurement technique, and its uncertainty evaluation. Measurement parameters that affect the uncertainty are discussed and recommendations for the technique optimization are proposed. (authors) [es

  6. 131I release from a HTGR during the LOFC accident

    International Nuclear Information System (INIS)

    Foley, J.E.

    1975-03-01

    The time-dependent release of 131 I from both the core and the containment building of a high temperature gas-cooled (HTGR) reactor during the loss of forced coolant (LOFC) accident is studied. A simplified core release model is combined with a containment building release model so that the total amount of the isotope released to the environment can be calculated. The time-dependent release of 131 I from the core during the LOFC accident is primarily a function of the time-dependent core temperatures and the failed fuel release constants. The most important factor in calculating the amount of the isotope released to the environment is the total amount released into the containment building. (U.S.)

  7. Synthesis, labelling and biodistribution of N-isopropyl 131I-p-iodoamhetamine (131IAMP)

    International Nuclear Information System (INIS)

    Godoy, N.; Reveco, P.; Mena, P.; Gil, M.C.

    1986-01-01

    It is possible to synthesize N-isopropyl-p-iodoamphetamine (IAMP) through differents schemes, being the most feasible the iodination of phenylacetic acid. The labelling of this compound with radioidine, by isotope exchange in presence or absence of Cu (II) as catalyst, presents less activity concentration in brain than using Cu (II) with an excess of ascorbic acid as reducing agent of Cu (II). The use of ascorbic acid in excess allow the formation of Cu (I) in-situ, which may form an Ar-Cu-I complex, favouring the isotope nucleophilic substitution reaction, obtaining 131 IAMP higher radiochemical purity and better cerebral uptake. (Author)

  8. Measurement Of I-131 In Air Using A Portable Gamma Spectrometer

    International Nuclear Information System (INIS)

    Bunawas; Dadong Iskandar; Wahyudi; U, Wiwik

    2000-01-01

    Aerosol contamination of I-131, radioactive emitting gamma radiation, can be directly measured by using a portable gamma spectrometer which used GC2020 Canberra HPGe detector. Assuming constant concentration of I-131 in the infinite space of semi spherical, calibration factor, and detection limits determined using standard CH 3 I gas. The results showed that the detection limits for 1 hour counting period was 3.06 Bq/m exp.3 for confidence level of 95% (2σ). Field measurements are conducted on several rooms with uncertainties variation between 0.34 and 60.11% compare with true values. Qualitative discussion of the factors contributing to the uncertainty in the in situ result is included

  9. 131I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment

    Science.gov (United States)

    Xing, Jialiu; Fang, Yi; Wang, Yong; Zhang, Youren; Long, Yahong

    2015-01-01

    The aim of this study is to evaluate the safety and long-term results of 131I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment. From January 2002 to December 2012, 408 patients with refractory severe hyperthyroidism were treated with 131I alone. Among them, 345 were followed up for 1 to 10 years for physical examination, thyroid function, and thyroid ultrasound. Complete Blood Count (CBC) liver function, electrocardiogram, echocardiogram, and Emission Computed Tomography (ECT) thyroid imaging were performed as indicated. The 345 patients had concomitant conditions including thyrotoxic heart disease, severe liver dysfunction, enlarged thyroid weighing 80 to 400 g, severe cytopenia, and vasculitis. One to two weeks prior to 131I therapy, all patients were given low-iodine diet. The dose of 131I therapy was 2.59 to 6.66 MBq (70 to180 µCi) per gram of thyroid with an average of 3.83 ± 0.6 MBq (103.6 ± 16.4 µCi); and the total 131I activity administrated for the individuals was 111 to 3507.6 MBq (3.0 to 94.8 mCi, mean 444 ± 336.7 MBq (12.0 ± 9.1 mCi)). Out of the 408 patients, 283 were cured, 15 with complete remission, and 47 with incomplete remission. No treatment failure or significant clinical worsening was noted in these patients. Our data indicated that 131I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment is safe and effective. PMID:26341470

  10. 131I therapy for 345 patients with refractory severe hyperthyroidism: Without antithyroid drug pretreatment.

    Science.gov (United States)

    Ding, Yong; Xing, Jialiu; Fang, Yi; Wang, Yong; Zhang, Youren; Long, Yahong

    2016-02-01

    The aim of this study is to evaluate the safety and long-term results of (131)I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment. From January 2002 to December 2012, 408 patients with refractory severe hyperthyroidism were treated with (131)I alone. Among them, 345 were followed up for 1 to 10 years for physical examination, thyroid function, and thyroid ultrasound. Complete Blood Count (CBC) liver function, electrocardiogram, echocardiogram, and Emission Computed Tomography (ECT) thyroid imaging were performed as indicated. The 345 patients had concomitant conditions including thyrotoxic heart disease, severe liver dysfunction, enlarged thyroid weighing 80 to 400 g, severe cytopenia, and vasculitis. One to two weeks prior to (131)I therapy, all patients were given low-iodine diet. The dose of (131)I therapy was 2.59 to 6.66 MBq (70 to180 µCi) per gram of thyroid with an average of 3.83 ± 0.6 MBq (103.6 ± 16.4 µCi); and the total (131)I activity administrated for the individuals was 111 to 3507.6 MBq (3.0 to 94.8 mCi, mean 444 ± 336.7 MBq (12.0 ± 9.1 mCi)). Out of the 408 patients, 283 were cured, 15 with complete remission, and 47 with incomplete remission. No treatment failure or significant clinical worsening was noted in these patients. Our data indicated that (131)I therapy alone for patients with refractory severe hyperthyroidism without antithyroid drug pretreatment is safe and effective. © 2015 by the Society for Experimental Biology and Medicine.

  11. Clearance of 131I-labeled murine monoclonal antibody from patients' blood by intravenous human anti-murine immunoglobulin antibody

    International Nuclear Information System (INIS)

    Stewart, J.S.; Sivolapenko, G.B.; Hird, V.; Davies, K.A.; Walport, M.; Ritter, M.A.; Epenetos, A.A.

    1990-01-01

    Five patients treated with intraperitoneal 131I-labeled mouse monoclonal antibody for ovarian cancer also received i.v. exogenous polyclonal human anti-murine immunoglobulin antibody. The pharmacokinetics of 131I-labeled monoclonal antibody in these patients were compared with those of 28 other patients receiving i.p.-radiolabeled monoclonal antibody for the first time without exogenous human anti-murine immunoglobulin, and who had no preexisting endogenous human anti-murine immunoglobulin antibody. Patients receiving i.v. human anti-murine immunoglobulin antibody demonstrated a rapid clearance of 131I-labeled monoclonal antibody from their circulation. The (mean) maximum 131I blood content was 11.4% of the injected activity in patients receiving human anti-murine immunoglobulin antibody compared to 23.3% in patients not given human anti-murine immunoglobulin antibody. Intravenous human anti-murine immunoglobulin antibody decreased the radiation dose to bone marrow (from 131I-labeled monoclonal antibody in the vascular compartment) 4-fold. Following the injection of human anti-murine immunoglobulin antibody, 131I-monoclonal/human anti-murine immunoglobulin antibody immune complexes were rapidly transported to the liver. Antibody dehalogenation in the liver was rapid, with 87% of the injected 131I excreted in 5 days. Despite the efficient hepatic uptake of immune complexes, dehalogenation of monoclonal antibody was so rapid that the radiation dose to liver parenchyma from circulating 131I was decreased 4-fold rather than increased. All patients developed endogenous human anti-murine immunoglobulin antibody 2 to 3 weeks after treatment

  12. The behavior of 131I in polymetatelluric acid irradiated in the nuclear reactor

    International Nuclear Information System (INIS)

    Teofilovski, C.

    1966-01-01

    Polymetarelluric acid, whose composition is (H 2 TeO 4 ) n , is successfully used at he Institute as a target for obtaining 131 I in the reactor. It is prepared by hearing orthotelluric acid in air at 160 deg C of in a steam of water vapor at 208 deg C. Analysis of the valency states of 131 I in irradiated (H 2 TeO 4 ) n prepared in either of the above ways shows a variable ratio of reduced and oxidized forms. A considerable increase of the reduced forms with increasing integral thermal neutron flux during irradiation in the reactor in the given interval has also been observed. In order to explain the above phenomenon (H 2 TeO 4 ) n was irradiated in the reactor under different conditions, with measurement of the wall temperature of the quartz ampoules containing the target material. Yields of reduced and oxidized form of 131 I were determined immediately after irradiation and after annealing of the target at temperatures from 60 deg C to 150 deg C. A considerable decrease in the yield of the reduced forms of 131 I on target annealing above 100 deg C was observed (author)

  13. 131I metabolism in the study of antithyroid drug

    International Nuclear Information System (INIS)

    Gagliardi, R.P.; Santalla de Pirovano, M. del C.; Kramar de Valmaggia, E.P.; Valsecchi, R.; Pisarev, Mario; Altschuler, Noe

    1977-11-01

    The main purpose of the present report was to study the action of antithyroid drugs on different parameters of thyroid activity utilizing 131 I, in the offsprings of rats treated during pregnancy and the perinatal period. Both PTU and MMI caused alterations in growth and thyroid activity, but they were more dramatic with the former. A significative increase in 131 I thyroid uptake and in circulating radioactivity was observed. When % uptake was expressed as a function of thyroidal and body weights, a significative decrease was noticed. The ratio T/S and the percentage of labelled iodothyronines in pancreatin digests were also decreased. Neuromuscular maturation was evaluated, by means of the test of Schapiro. A group of animals treated with PTU plus T 4 had a significant delay, reaching normal developement later than the controls or those treated with MMI. (author) [es

  14. The value of recombinant human TSH-aided 131I treatment in differentiated thyroid carcinoma patients

    International Nuclear Information System (INIS)

    Ding Yong; Long Yahong; Tian Jiahe; Xu Baixuan; Xing Jialiu; Fang Yi; Wei Lijing; Zong Zhaoyi

    2013-01-01

    Objective: To evaluate the efficacy and safety of recombinant human TSH(rhTSH)-aided 131 I treatment for DTC. Methods: A total of 144 patients with DTC who underwent total or near total thyroidectomy were retrospectively analyzed. The rhTSH-aided 131 I treatment of 3.7 GBq was performed in 72 cases (Group Ⅰ: euthyroid). Another 72 cases received radioiodine ablation treatment of 3.7 GBq after 4 to 6 weeks of thyroxine withdrawal (Group Ⅱ: hypothyroidism). Serum endogenous TSH, FT 3 , FT 4 and Tg were measured. The life qualities of both groups were observed, such as intolerance to cold, weight gain, constipation, motor retardation, skin dryness, periorbital edema and bone pain. Absence of visible uptake or uptake rate less than 1% was taken as complete ablation. The efficacy of 131 I treatment was evaluated. The life quality of both groups was evaluated by χ 2 test, and the effect of 131 I treatment was analyzed by t test. Results: Serum TSH was effectively improved in both groups before 131 I treatment. In group Ⅰ, TSH was higher than that of group Ⅱ ((141.26 ± 27.30) mU/L vs (70.57 ± 51.13) mU/L; t=2.435, P<0.05), and FT 3 , FT 4 were not significantly different before or after the injection of rhTSH. Tg was well stimulated in both groups with no statistical difference. Group Ⅱ exhibited more side effects, which included intolerance to cold 80.56% (58/72), weight gain 86.11% (62/72), constipation 15.28% (11/72), motor retardation 22.22% (16/72), skin dryness 56.94% (41/72), bone pain 2.78% (2/72), and no periorbital edema was found. Group Ⅰ had a higher quality of life than group Ⅱ, only few side effects were observed including dizziness and nausea 2.78% (2/72), bone pain 2.78% (2/72), and transient tachycardia 1.39% (1/72). The effect of 131 I treatment was evaluated by whole body scans with a diagnostic dose of 131 I. The complete ablation rate was 70.83% (51/72) in group Ⅰ and 66.67% (48/72) in group Ⅱ (χ 2 =0.58, P>0.05). Conclusion: The

  15. The physico-chemical 131I species in the exhaust air of a boiling water reactor (BWR 4)

    International Nuclear Information System (INIS)

    Deuber, H.

    1982-12-01

    In a German boiling water reactor, the physico-chemical 131 I species were determined in the plant exhaust and in the individual exhausts during 12 months. These measurements aimed in particular at determining the percentage and the source of the radiologically decisive elemental 131 I released to the environment. The retention of the 131 I species by iodine filters was also investigated. On an average, 45% of the 131 I discharged with the plant exhaust consisted of elemental iodine. This was largely released with the exhaust from the reactor building and from the turbine building. The other 55% consisted almost entirely of organic I. (orig./HP) [de

  16. 131I Treatment of differentiated thyroid carcinoma in children and adolescents

    International Nuclear Information System (INIS)

    Qu Yuan; Huang Rui; Li Lin

    2014-01-01

    The occurrence rate of DTC in children and adolescents is not high. However, DTC in these patients has some distinct characteristics different from those in adult, such as larger tumor volume at diagnosis, early invasion of neck lymph nodes and early distant metastases, high NIS expression, high recurrence but higher overall survival rate. 131 I ablation is still one of the important treatment methods after surgery. Currently, there are 3 major dosage regimens adopted for 131 I treatment: prescribed dose without causing bone marrow suppression/toxicity, dose aiming at tumor ablation, and empirically fixed dose. (authors)

  17. Medically-derived I-131: a potential tool for understanding the fate of wastewater nitrogen in aquatic systems

    Science.gov (United States)

    Rose, P. S.; Smith, J. P.; Aller, R. C.; Cochran, J. K.; Swanson, R. L.; Murthy, S. N.; Coffin, R. B.

    2010-12-01

    Iodine-131(t1/2 = 8 days) has been measured in Potomac River water and sediments in the vicinity of the Blue Plains Water Pollution Control Plant (WPCP), Washington, DC. The source of I-131 is medical, where it is commonly used to treat thyroid cancer and hyperthyroidism. Iodine is metabolized by patients and eliminated primarily in urine. While other medical radioisotopes may enter the environment via sewage effluent, the nature and quantity of treatments using I-131 cause it to account for much of the radioactivity in sewage effluent. Natural iodine in aquatic systems is biologically cycled similar to other nutrients, such as nitrogen. Iodine-131 concentrations measured in sewage effluent from Blue Plains WPCP and in the Potomac River suggest a relatively continuous discharge of this isotope. Dissolved I-131 shows a strong, positive correlation with δ15N values of nitrate in the river. The range of I-131 concentrations detected in surface waters is 0.18 ± 0.01 to 0.68 ± 0.02 Bq/L. Surface water δ15NO3 values ranged from 8.7 ± 0.3 to 33.4 ± 7.3 ‰ with NO3+NO2 concentrations between 0.38 ± 0.02 and 2.79 ± 0.13 mgN/L. Sediment profiles of particulate I-131 and δ15N indicate rapid mixing or sedimentation and in many cases remineralization of a heavy nitrogen source consistent with wastewater nitrogen. Iodine-131 concentrations in sediments ranged from 1.31 ± 0.8 to 117 ± 2 Bq/kg dry weight. Values of δ15N in sediments ranged from 4.7 ± 0.1 ‰ to 9.3 ± 0.1 ‰. We propose that I-131 coupled with δ15N can be an excellent tracer for the short-term fate of wastewater nitrogen in this system. However, the utility of I-131 as a tracer is not limited to use in the Potomac River. Other studies have documented the presence of I-131 in several aquatic systems and continuous discharges of this radioisotope in sewage effluent are likely to be widespread in urban environments.

  18. 131I-CRTX internal dosimetry: animal model and human extrapolation

    International Nuclear Information System (INIS)

    Andrade, Henrique Martins de; Ferreira, Andrea Vidal; Soares, Marcella Araugio; Silveira, Marina Bicalho; Santos, Raquel Gouvea dos

    2009-01-01

    Snake venoms molecules have been shown to play a role not only in the survival and proliferation of tumor cells but also in the processes of tumor cell adhesion, migration and angiogenesis. 125 I-Crtx, a radiolabeled version of a peptide derived from Crotalus durissus terrificus snake venom, specifically binds to tumor and triggers apoptotic signalling. At the present work, 125 I-Crtx biokinetic data (evaluated in mice bearing Erlich tumor) were treated by MIRD formalism to perform Internal Dosimetry studies. Doses in several organs of mice were determinate, as well as in implanted tumor, for 131 I-Crtx. Doses results obtained for animal model were extrapolated to humans assuming a similar concentration ratio among various tissues between mouse and human. In the extrapolation, it was used human organ masses from Cristy/Eckerman phantom. Both penetrating and non-penetrating radiation from 131 I in the tissue were considered in dose calculations. (author)

  19. Bioaccumulation factor for I-131 in aquatic biota II fish - tilapia (Tilapia Mossambica)

    International Nuclear Information System (INIS)

    Garcia, G.F.; Casyao, J.M.; Bautista, E.Rb.

    1982-01-01

    The study was undertaken to provide local values for an essential parameter in the estimation of the dose contribution of I-131 through ingestion of fresh water fish. The result showed that the tilapia used in the experiment did not vary significantly in weight and no definite conclusion can be derived as to the effect of body size to bioaccumulation of I-131. (ELC)

  20. Comparative evaluation of 131I-hippuran and sup(99m)Tc-DTPA for renal function test

    International Nuclear Information System (INIS)

    Kempi, V.; Persson, R.B.R.; Svensson, L.

    1975-07-01

    131 I-labelled Hippuran and sup(99m)Tc-labelled DTPA have been compared as substances used for renal function tests. The radiation absorbed dose for 131 I-Hippuran and sup(99m)Tc-DTPA to different organs of an adult standard man is given i a table, showing considerably lower doses for sup(99m)Tc-DTPA. Good agreement was found between the renographic curves obtained with 131 I-Hippuran and sup(99m)Tc-DTPA compared to 131 I-Hippuran excellent scintiphotos of the kidney and also of the upper urinary ways were obtained with sup(99m)Tc-DTPA. With sup(99m)Tc-DTPA, repeated examinations make it possible to follow the development of a disease without great radiation risk to the patient (K.K.)

  1. A simple low-cost of liquid I-131 dispenser for routine radiopharmaceutical dispensing at nuclear medicine department, Institut Kanser Negara

    Energy Technology Data Exchange (ETDEWEB)

    Said, M. A.; Suhaimi, N. E. F. [Fakulti Sains dan Teknologi, Universiti Kebangsaan Malaysia, 43600 UKM, Bangi Selangor (Malaysia); Ashhar, Z. N., E-mail: aminhpj@gmail.com [Institut Kanser Negara, No 4, Jalan P7, Presint 7, 62250 Putrajaya (Malaysia); Zainon, R. [Advanced Medical & Dental Institute, Universiti Sains Malaysia, Bertam, 13200, Kepala Batas, Pulau Pinang (Malaysia)

    2016-01-22

    In routine radiopharmaceutical Iodine-131 ({sup 131}I) dispensing, the amount of radiation dose received by the personnel depends on the distance between the personnel and the source, the time spent manipulating the source and the amount of shielding used to reduce the dose rate from the source. The novel iRAD-I131 dispenser using recycle {sup 131}I liquid lead pot will lead into low cost production, less maintenance and low dose received by the personnel that prepared the {sup 131}I. The new fabricated of low cost {sup 131}I dispenser was tested and the dose received by personnel were evaluated. The body of lead material is made from 2.5 cm lead shielded coated with epoxy paint to absorb the radiation dose up to 7.4 GBq of {sup 131} I. The lead pot was supported with two stainless steel rod. The Optically Stimulated Luminescence (OSL) nanodot was used in this study to measure the dose rate at both extremities for every personnel who prepared the {sup 131}I. Each OSL nanodot was attached at the fingertip. Three different personnel (experienced between one to ten years above in preparing the radiopharmaceuticals) were participated in this study. The average equivalent dose at right and left hand were 122.694 ± 121.637 µSv/GBq and 77.281 ± 62.146 µSv/GBq respectively. This study found that the dose exposure received using iRAD-I131 was less up to seven times compared to the conventional method. The comparison of experimental data using iRAD-I131 and established radiopharmaceutical dispenser was also discussed. The innovation of {sup 131}I dispenser is highly recommended in a small radiopharmaceutical facility with limited budget. The novel iRAD-I131 enables implementation of higher output liquid dispensing with low radiation dose to the personnel.

  2. Prediction of thyroidal 131I effective half-life in patients with Graves' disease.

    Science.gov (United States)

    Zhang, Ruiguo; Zhang, Guizhi; Wang, Renfei; Tan, Jian; He, Yajing; Meng, Zhaowei

    2017-10-06

    Calculation of effective thyroidal half-life (Teff) of iodine-131( 131 I) is cumbersome and tedious. The aim of this study was to investigate factors that could be used to predict Teff and to develop a Teff prediction model in Graves' disease patients. A total of 256 patients with GD were involved in this study. We investigated the influences of age, gender, disease duration, thyroid weight, antithyroid drugs, antithyroid drugs discontinuation period (ADP), thyroid function indexes, thyroid autoantibodies, thyroid-stimulating hormone receptor antibody (TRAb) level and radioactive iodine uptake (RAIU) values before 131 I therapy on Teff, applying univariate and multivariate analyses. Teff correlated negatively with thyroid peroxidase antibody, TRAb and thyroid weight, as well as positively with 24-hour, 48-hour, and 72-hour RAIU. Additionally, a longer ADP (especially≥ 14d) or without antithyroid drugs before 131 I therapy led to a longer Teff. Stepwise multiple linear regression analysis showed that 24-hour and 72-hour RAIU were statistically significant predictors of Teff ( P Graves' disease, with high prediction accuracy.

  3. Experience in treatment of hyperthyroidism with I-131 diagnosis, patient preparation and therapeutic procedure

    International Nuclear Information System (INIS)

    Zhongyun, Pan

    2003-01-01

    Treatment of hyperthyroidism with I-131 diagnosis is being performed after clinical diagnosis of thyrotoxicosis based on clinical manifestations of hypermetabolic state, serumT3 and T4 determination; medical preparation of patients and therapeutic procedure is obtained for better efficacy, relieve symptoms and prevent aggravation of thyrotoxicosis after I-131 treatment

  4. Euthyroid goiter with autonomy: Results of treatment with radioiodine (131I) and by surgery

    International Nuclear Information System (INIS)

    Emrich, D.; Reinhardt, M.

    1989-01-01

    In order to evaluate the efficacy of, and the risk associated with, the definite treatment of euthyroid goiter with autonomy, the data of 88 patients treated between 1982 and 1986 (50 by subtotal thyroidectomy; 38 by 131 I-treatment, mean radiation dose 200 Gy without protection by thyroxine) were analyzed in a retrospective study. The following criteria were used before and after treatment: the results of scintigraphy under suppression qualitatively (in focal autonomy) and quantitatively (global thyroid uptake) (TcU s ), the means of FT 4 I, FT 3 I and ΔTSH after TRH, the improvement of mechanical signs and symptoms and the decrease of thyroid volume. Measured by TcU s and ΔTSH, autonomy could be removed completely in 85-90% of all patients. Surgery was slightly more successful (100%) compared to treatment by 131 I (75-80%). This was also true for removal of mechanical symptoms and reduction of the goiter. The incidence of manifest hypothyroidism was greater after surgery (16%) than after 131 I treatment (3%). At a higher grade of autonomy (TcU s > 3.2%) surgery was more effective (95-100%) than treatment with 131 I (60-70%) but at a higher risk of hypothyroidism (24 vs 0%). It is imperative to improve the methods of estimating the amount of 131 I to be administered in euthyroid goiter with autonomy. Selection of patients with autonomy in euthyroid goiter for definite treatment is difficult, since until now their risk to become hyperthyroid cannot be predicted properly. (orig.) [de

  5. I-131 therapy for thyroid diseases: Doses, new regulations and patient advice

    International Nuclear Information System (INIS)

    Amaral, H.; Michaud, P.

    2001-01-01

    I-131 therapy has been widely used in the past 50 years. Its main applications are hyperthyroidism and functioning thyroid cancer. The indications, doses, regulations, precautions and guidelines differ in various centers. The following are recommended: 1. I-131 should be indicated in agreement of the endocrinologist and the nuclear physician with the patient consent; 2. Pre-treatment I-131 thyroid uptake must be performed; 3. The only contraindication for treatment is pregnancy, in children it might be used with caution; 4. For thyrotoxicosis both a calculated or an ablative dose (555 MBq) criteria are acceptable In this case secondary hypothyroidism must be considered an objective rather than a complication; 5. In uninodular toxic goiter a 1110 MBq dose is recommended; 6. Iodine free diet is indicated only for cancer patients; 7. Propylthiouracil (PTU) must be discontinued 5 days before treatment, it should be reinitiated 5 days later; 8. Prophylactic use of corticoid in Graves' disease still require more clinical data to support its use; 9. In treatment failure, wait six months for a new dose; 10. In intrathyroid cancer disease an ablative dose of 3700 MBq should be administered 4 weeks post-thyroidectomy or with a TSH level above 30 μUI/mL; 11. A whole body scan should be done one week later; 12. Follow-up whole body scan should be used only if there is clinical suspicion of metastasis. Thyroid hormone replacement must be discontinued for 30 days or with TSH value above 30 I/mL. For follow-up scan 185 MBq of I-131 are recommended to ovoid thyroid tissue stunning; 13. For metastases, 5700 to 7400 MBq dose is recommended if there are cervical lymphatic nodes or distant metastases. We recommended to adopt the criteria proposed by the United States Nuclear Regulatory Commission (NRC) published as 10 CFR 35.75 and the Regulatory Guide 8.39 for patients release after I-131 administration. (author)

  6. Histopathological Studies of Mice after Administration of Radioactive Iodine ({sup 131}I)

    Energy Technology Data Exchange (ETDEWEB)

    Ro, Chae Song; Lee, Mun Ho [Seoul National University College of Medicine, Seoul (Korea, Republic of)

    1967-09-15

    Histopathological changes of various organs of the mice after intra-peritoneal injections of radioactive iodine ({sup 131}I) were experimentally observed. Sixty healthy female mice, weighing average 25 gm, divided into 6 groups, were used. The various doses of {sup 131}I were injected intraperitoneally at different intervals. The histopathological changes after these treatments were observed in organs such as thyroids, parathyroids, livers, kidneys and gonads. Following were the results; 1) Thyroid: In the group A given {sup 131}I with a single dose of 10{mu}C per gm body weight, it was observed that the protoplasms of follicular epithelial cells were destroyed, the nuclei were expanded or dissoluted, showing pyknotic changes of nuclei and vacuolizations of protoplasms. In the group B given {sup 131}I with a single dose of 5{mu}C per gm body weight, hyperemias, hemorrhages and hyaline degenerations in the whole area were observed. In the group C given {sup 131}I with 3 doses of 2.5{mu}C per gm body weight every week, the thyroid parenchyma were destroyed and epithelial cells of varing size were observed in the filbrinous tissues. In the group D given {sup 131}I with 6 doses of 0.5{mu}C per gm body weight every week, some destroyed follicles and new borne follicles were observed. But the histopathological changes resemble the follicles of the normal thyroid gland. In the group E and F given {sup 131}I with 8 and 10 doses of 0.2{mu}C and 0.01{mu}C for each group per gm body weight every two days, both pyknotic changes of nuclei and cytoplasmic vacuolizations of the follicular epithelia, hypertrophies of follicles and abnormal irregular follicular structures were observed, and in the group F, lymphocytes appeared around the thyroid glands. 2) Parathyroid: In the group A, hyperemia, proliferations of connective tissues, karyorrhexes and vacuolizations were observed. In other experimental groups, no particular pathological change was observed. 3) Liver: The degenerative

  7. I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse

    International Nuclear Information System (INIS)

    Heyman, S.; Evans, A.E.; D'Angio, G.J.

    1988-01-01

    Metaiodobenzylguanidine (MIBG) has been used for the detection and treatment of neuroectodermal tumors, including neuroblastoma. We report our experience with 131 I-MIBG used diagnostically in neuroblastoma patients with relapse. Thirty-eight studies were performed in 26 patients. There were 24 children (range 3 months-14 years) and two adults. While the study was found to be both sensitive and specific for the presence of disease, there are instances of discordance. False-negative studies were found with a markedly anaplastic tumor and with two mature ganglioneuromas. A bone lesion was negative with 131 I-MIBG, but positive on bone scan. A biopsy confirmed the presence of neuroblastoma. Caution should be exercised when scanning pretreated patients, and perhaps with newly diagnosed patients as well

  8. Diagnosis of pheochromocytome by 131-I-MIBG

    International Nuclear Information System (INIS)

    Kerik Rotenberg, N.E.

    1985-01-01

    The purpose of this project is to evaluate the specificity and sensitivity of 131-I-metaiodobenzylguanidine (MIBG), a newly developed radiopharmaceutical which accumulated in the neuro transmitter adrenergic sacs, in diagnosing pheochromocytomes, which originate from well-differentiated cells in the adrenergic region of the autonomous nervous system. A sizeable number of these cells appear in the adrenal medulla, the para-spinal ganglion and the para-aortic (Organ of Zuckerkandl), however, a certain number of pheochromocytomes are found in other sites including the bladder, heart and vagus nerves. Adrenergic tumors which are located outside the adrenal medulla and which secrete both norepinephrine and epinephrine are called pheochromocytomes. Scintigraphic distribution of 131-I-MIBG, an imaging agent for the adrenal medulla, was studied to determine the uptake in patients suspected of harboring pheochromocytomes. Normal distribution of the radiotracer includes: the salivary glands, liver, spleen, gall-bladder, kidneys and heart. Accumulations in the thyroids are detected only in cases of inadequate thyroid blocking. Injected were 0.5 mCi/1.7 m 2 and scans taken 24, 48 and 72 hours afterward. The five patients investigated showed high levels of epinephrine and norepinephrine and revealed abnormal accumulations of radioactive material. These data were surgically verified. (author)

  9. Recurrence rates following I-131 therapy of differentiated thyroid carcinoma: results of meta-analysis

    International Nuclear Information System (INIS)

    Obaldo, J.M.

    1990-01-01

    To examine the efficacy of I-131 therapy in decreasing recurrence rates after surgery for differentiated thyroid carcinoma, a research tool called meta-analysis was used. Data were pooled from five published studies which evaluated recurrences following at least sub-total thyroidectomy with or without I-131 ablation of remnants. Of 1332 patients managed surgically only 202 (15%) developed recurrences compared to 36 of 339 (11%) treated with radioiodine. This difference was statistically significant at p<.05. When a separate analysis of only those studies which directly compared the two modes of management was conducted, recurrence rates for patients treated by surgery alone was higher at 18% (185 of 1034) compared with those who had subsequent I-131 therapy with a rate of 9% (27 of 297). This difference was again significant at p <.001. This meta-analysis strongly suggests that the use of I-131 for ablation of post-surgical thyroid remnants significantly reduces recurrence rates in patients with differentiated thyroid carcinoma. (Auth.). 34 refs., 1 tab.; 1 fig

  10. The determination and monitoring of 131I activity in sewage treatment plants based on A2/O processes

    International Nuclear Information System (INIS)

    Jimenez, Fernando; Lopez, Raul; Pardo, Rafael; Deban, Luis; Garcia-Talavera, Marta

    2011-01-01

    131 I, a radionuclide used in nuclear medicine facilities, is habitually dumped into domestic sewer systems, which causes its control in municipal sewage treatment plants (STP) to become necessary. In this paper, we describe a procedure for the determination of the 131 I activity based on its precipitation as silver (I) iodide, its dissolution with cyanide in ammonia medium and its measurement by the liquid scintillation counting technique (LSC). After optimization, this LSC procedure allows the determination of 131 I activities with a limit of detection (CCβ) of 11 mBq kg -1 . The procedure was successfully validated by comparison with the normative and requires both less sample volume and measurement time than the standard procedure. The method has been applied to the monitoring of 131 I in the STP of Valladolid (Spain), which found activities below the maximum allowed by legislation and showed a near constant background 131 I activity in the influents with punctual increases corresponding to authorized spills. The mean 131 I removing efficiency of the STP was 52%.

  11. Determination of the sources of the airborne physico-chemical 131I species in a PWR power plant

    International Nuclear Information System (INIS)

    Deuber, H.; Wilhelm, J.G.

    1978-01-01

    In a 1300 MWE PWR power plant the sources of the airborne 131 I species were determined over a period of 5 months. During power operation the main source of the radiologically decisive elemental 131 I was the exhaust from the hoods in which samples from the primary coolant are taken and processed. During refueling outage elemental 131 I was mainly contributed by the containment purge air. By efficient filtration of these exhausts, a reduction of the ingestion dose, caused by the total 131 I stack release, by a factor of nearly 4 during power operation and of possibly 10 during refueling outage can be accomplished. (author)

  12. SPECT imaging of 131I (364 keV): importance of collimation

    International Nuclear Information System (INIS)

    Clarke, L.P.; Saw, C.B.; Leong, L.K.; Serafini, A.N.

    1985-01-01

    A low sensitivity medium energy collimator (LSMEC) designed with thick septa and long bore (theoretical leakage 131 I for a SPECT system operated in both planar and tomographic imaging modes. The collimator was designed to minimize the influence of photon penetration on spatial resolution, in particular the resolution index FWTM. Overall spatial resolution for the planar imaging mode at 10 cm from the collimator face was found to be 11.6 mm FWHM and 21.6 mm FWTM. The corresponding transverse plane and slice thickness resolution was of the order of 17 mm FWHM and 31 mm FWTM, for a radius of rotation of 16 cm. A SPECT resolution phantom was imaged. Two quadrants of cold rods were well resolved, with rod dimensions of 16 and 12.7 mm respectively, the resolution being comparable to that obtained using 99 Tcsup(m) (140 keV) and a low-energy high-resolution collimator. NEMA sensitivity obtained was 75 cpm/μCi 131 I. The resolution measurements obtained suggest that this collimator should be useful for SPECT imaging with 131 I in either radioimmunoimaging or radioimmunotherapy. (author)

  13. Occupational exposure to 99mTc and 131I in a radiopharmacy room

    International Nuclear Information System (INIS)

    Valle, Bruna P.; Cunha, Kenya Dias da; Sa, Lidia Vasconcellos de; Souza, Wanderson; Santos, Maristela; Medeiras, Geiza; Conceicao, Cirilo S.

    2009-01-01

    Brazil has about 310 nuclear medicine services and 90% of these services use Molybdenum/Technetium generators to prepare several radiopharmaceuticals to diagnostics; about 70% use also 131 I for diagnosis and therapy. These radionuclides are associated to compounds in liquid form and during the manipulation to prepare and administer the patient dose some radioactive airborne particle can be generated. As consequence the workers can be exposed to airborne particles in the respirable fraction containing 99m Tc and 131 I. The aim of this study is develop a simple and rapid method to verify if the exhaust systems installed in the SMN are efficient in preventing the inhalation of radionuclides airborne particles by workers. In order to estimate the occupational exposure a nuclear medicine service was selected and aerosol samples were collected using personal air sampler with a cyclone. The samples were analyzed using a germanium detector system and the 99m Tc and 131 I average concentrations were obtained as 16,6 ± 14,34 mBq/m 3 and 0.72 ± 0.36 mBq/m 3 , respectively. It was not observed a correlation among air concentration and total activity processed in laboratory. These results show that the worker inhales airborne particles containing 99m Tc and 131 I. (author)

  14. Early changes of thyroid hormone concentrations after {sup 131}I therapy in Graves' patient pretreated or not with methimazole

    Energy Technology Data Exchange (ETDEWEB)

    Pirnat, E.; Zaletel, K.; Gabercsek, S.; Fidler, V.; Hojker, S. [University Medical Centre, Ljubljana (Slovenia). Dept. of Nuclear Medicine

    2004-08-01

    Aim: Despite extensive use of {sup 131}I therapy for Graves' hyperthyroidism the treatment regimen with {sup 131}I and antithyroid drugs remain under discussion. In our prospective clinical study we followed acute thyroid hormone changes after {sup 131}I in patients not pretreated with methimazole (MMI) and in patients with different MMI pretreatment regimes. Patients, methods: 187 patients were treated with fixed activity of 550 or 740 MBq of {sup 131}I. First group (71 patients) received {sup 131}I alone. In the second group (57 patients) MMI was stopped seven days before {sup 131}I. The third group (59 patients) received MMI until {sup 131}I application. Initial free triodothyronin and free thyroxin were measured in the second group 7 and 2 days before {sup 131}I therapy and in all three groups on the day of {sup 131}I application as well as 2, 5, 12, and 30 days afterwards. Absorbed dose was measured in each patient. Results: In the non-pretreated group {sup 131}I application was followed by a significant decrease of fT{sub 4} in 5 days and of fT{sub 3} in 2 days, higher reduction was detected in patients with higher baseline values. In MMI pretreated patients significant but clinically irrelevant increase of both thyroid hormones was detected with maximum value 7 days after discontinuation in the second group and 5 days after discontinuation in the third group. Additionally, in patients of the third group absorbed dose of {sup 131}I was significantly lower relative to other two groups. We found no correlation between absorbed dose of {sup 131}I and thyroid hormone changes. Conclusion: Our study demonstrates that {sup 131}I application alone does not result in exacerbation of hyperthyroidism and therefore it may be considered as safe. Additionally, MMI withdrawal causes significant but clinically irrelevant elevation of thyroid hormones. (orig.)

  15. A case report of hyperfunctioning metastatic thyroid cancer and rare I-131 avid liver metastasis

    International Nuclear Information System (INIS)

    Kunawudhi, Anchisa; Promteangtrong, Chetsadaporn; Chotipanich, Chanisa

    2016-01-01

    Thyroid cancer is usually, relatively hypofunctional; most patients with thyroid cancer are clinically euthyroid. The combination of thyroid cancer and thyrotoxicosis is not common. We herein, report a case of follicular thyroid cancer with hyperfunctioning metastasis in a 43-year-old woman who presented with thyrotoxicosis, a cold right thyroid nodule, and low I-131 uptake at the thyroid bed. An additional total body scan with I-131 revealed a large radioiodine avid osteolytic bone metastasis with soft tissue masses and liver metastasis. The patient received treatment with total thyroidectomy, methimazole, and I-131 at a cumulative dose of 600 mCi along with recombinant human thyroid-stimulating hormone before the first I-131 treatment and palliative radiation. The patient had normal liver function test and experienced a mild degree of bone marrow suppression after I-131. At the 2-year follow-up, the patient was still alive with the progression of bone metastases but was doing well with less severe thyrotoxicosis, good ambulation, and an Eastern Cooperative Oncology Group performance status of 2. Clinicians should be aware of the unusual concurrent presentation of thyrotoxicosis and thyroid cancer, a differential diagnosis in patients with thyrotoxicosis and low or normal radioiodine uptake over the neck and also potential pitfalls during radionuclide treatment

  16. A pancreas imaging agent-131I-HIPDM: the animal experiment and preliminary clinical application

    International Nuclear Information System (INIS)

    Shao Hesheng

    1988-01-01

    131 I-HIPDM has been used clinically for studying regional cerebral perfusion. The [ 131 I] HIPDM was prepared in a kit. The labelling yields were consistently more than 95%, as analyzed by the TLC-Silica gel. The labelled compound is stable in vitro and in vivo. S D Strain rats (170-220 g) and mice (18-22 g) were used. The pancreatic uptake of [ 131 I] HIPDM is rather slow in mice and rats. At 8 hr after iv, the pancreas activity and the pancreas to liver (P/L) ratio are highest in mice and rats. The effect of carrier loading dose from 0.010 to 6.0 mg/kg on blodistribution in mice has been studied. The liver uptake was increased by adding carrier HIPDM. The result indicates that administration between 0.010 and 0.05 mg/kg carrier dose is most suitable for the pancreas imaging. Gamma camera imaging of dog at 6 hr after iv with 300 μCi [ 131 I] HIPMD, 0.05 mg/kg body weight showed clear pancreas image. The P/L ratio of the dog is 0.40. Preliminary clinical tests were satisfactory. Using 1 to 1.5 mCi of [ 131 I] HIPDM, 0.05 mg/kg, the pancreas imaging was operated in 4 cases of volunteers and pancreas cyst respectively with the good diagnostic quality. The authors are of the opinion that this pancreas imaging agent may have potential value for routine use

  17. Bone metastases of differentiated thyroid cancer: the importance of early diagnosis and 131I therapy on prognosis

    International Nuclear Information System (INIS)

    Zanotti-Fregonara, P.; Rubello, D.; Hindie, E.

    2008-01-01

    Complete text of publication follows: Distant metastases are found at diagnosis or during follow-up in 10%-15% of patients with differentiated thyroid cancer. Bone is the second most commonly involved site. Patients with bone metastases, whether isolated or associated with lung metastases, have a markedly poor prognosis. Ten-year survival rates range from 13% to 21%. Given such poor prognosis, the use of 131 I therapy has been questioned. However, it might well be that poor prognosis of bone metastases can be overcome if 131 I therapy is delivered at an early stage, when tumor burden is small, as previously demonstrated for pulmonary metastases. A review of a large series of patients showed that only rarely were bone metastases diagnosed at an early stage. Among 109 patients with bone metastases reported by Bernier et al., only 4 had both radioiodine uptake and a negative standard radiography examination. Similarly, Durante et al. reported that only 8 of 115 patients had negative radiography findings at presentation. Prognosis may improve if bone metastases are detected earlier. In a recent study, bone metastases were first detected by 131 I scanning in 8 of 16 patients, when complementary radiologic studies were negative. Six of these patients showed an excellent response to 131 I therapy. Today, the nuclear medicine community is well armed for this challenge toward earlier diagnosis. Postsurgery thyroid remnant ablation is more widely used. The 131 I whole body scan associated with thyroid remnant ablation after thyroidectomy has a major role in early diagnosis of functioning distant metastases at a time when complementary imaging techniques (CT, MRI, bone scanning) are often still showing negative findings. Early diagnosis of specific 131 I-avid bone foci will be improved with the advent and generalization of SPECT/CT. When early diagnosis is achieved, repeated 131 I therapy can be effective by targeting not only visible metastases but also those still too small

  18. Early change of thyroid hormone concentration after {sup 131}I treatment in patients with solitary toxic adenoma

    Energy Technology Data Exchange (ETDEWEB)

    Pirnat, E.; Fidler, V.; Zaletel, K.; Gaberscek, S.; Hojker, S. [Univ. Medical Centre Ljubljana, Dept. of Nuclear Medicine (Slovenia)

    2002-08-01

    Aim: In spite of extensive use of {sup 131}I for treatment of hyperthyroidism, the results of early outcome are variable. In our prospective clinical study we tested whether {sup 131}I induced necrosis causing clinical aggravation of hyperthyroidism and increasing the free thyroid hormone concentration in the serum of patients with solitary toxic adenoma not pretreated with antithyroid drugs. Patients and methods: 30 consecutive patients were treated with 925 MBq {sup 131}I. Serum concentration of thyrotropin (TSH), free thyroxine (fT{sub 4}), free triiodothyronine (fT{sub 3}), thyroglobulin (Tg), and interleukin-6 (IL-6) were measured before and after application of {sup 131}I. Results: After application of {sup 131}I no clinical worsening was observed. FT{sub 4} and fT{sub 3} concentration did not change significantly within the first five days, whereas both of them significantly decreased after 12 days (p<0.0001). Slight and clinically irrelevant increase in the level of the two thyroid hormones was observed in 9 patients. Furthermore, we observed a prolonged increase in Tg concentration and a transient increase in IL-6 concentration. Conclusion: Neither evidence of any clinical aggravation of hyperthyroidism nor any significant increase in thyroid hormone concentration by {sup 131}I induced necrosis of thyroid cells was found. Therefore, the application of {sup 131}I may be considered as a safe and effective treatment for patients with hyperthyroidism due to toxic adenoma. (orig.)

  19. Methimazole, but not betamethasone, prevents 131I treatment-induced rises in thyrotropin receptor autoantibodies in hyperthyroid Graves' disease

    International Nuclear Information System (INIS)

    Gamstedt, A.; Wadman, B.; Karlsson, A.

    1986-01-01

    The effects of methimazole or betamethasone therapy on the TSH receptor antibody response to radioiodine therapy were compared in a prospective randomized study of 60 patients with hyperthyroidism due to Graves' disease. The patients were followed for 1 yr after treatment with 131I. Twenty-three patients received 131I alone, 17 were treated with methimazole for 2 months before and 3 months after 131I therapy, and 20 patients were treated with betamethasone for 3 weeks before and 4 weeks after 131I therapy. 131I induced a transient rise in the mean serum level of TSH receptor autoantibodies, measured as TSH binding inhibitory immunoglobulin (TBII), but in patients receiving methimazole treatment, no such rise occurred. In the betamethasone-treated patients, TBII increased similarly to that in patients treated with 131I alone. In addition, in patients given betamethasone, there was an early decrease in total serum immunoglobulin G, which persisted throughout the follow-up period. In the other 2 groups, no changes in total immunoglobulin G were found. The results demonstrate that in hyperthyroid Graves' disease, TBII production is influenced by therapy. Methimazole abolished the 131I-induced increase in TBII, whereas betamethasone did not have such an inhibitory effect

  20. Synthesis and preliminary biodistribution studies of [131I]SIB-PEG4-CHC in tumor-bearing mice

    International Nuclear Information System (INIS)

    Xiaobei Zheng; Jing Yang; Xiaojiang Duan; Tingting Niu; Wangsuo Wu; Jianjun Wang; Feng Dong

    2011-01-01

    This work reports the synthesis and preliminary biodistribution results of [ 131 I]SIB-PEG 4 -CHC in tumor-bearing mice. The tributylstannyl precursor ATE-PEG 4 -CHC was synthesized by conjugation of ATE to amino pegylated colchicine NH 2 -PEG 4 -CHC. [ 131 I]SIB-PEG 4 -CHC was radiosynthesized by electrophilic destannylation of the precursor with a yield of ∼44%. The radiochemical purity (RCP) appeared to be >95% by a Sep-Pak cartridge purification. [ 131 I]SIB-PEG 4 -CHC was lipophilic and was stable at room temperature. Biodistribution studies in tumor-bearing mice showed that [ 131 I]SIB-PEG 4 -CHC cleared from background rapidly, and didn't deiodinate in vivo. However, the poor tumor localization excluded it from further investigations as a tumor-targeted radiopharmaceuticals. (author)

  1. SU-F-T-222: Dose of Fetus and Infant Following Accidental Intakes of I-131 by the Mother

    Energy Technology Data Exchange (ETDEWEB)

    Wang, Y [The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan (China); Hu, P [Fudan University Shanghai Cancer Center, Shanghai, Shanghai (China)

    2016-06-15

    Purpose: To estimate the calculation of absorbed dose to the fetus and infants from intakes of I-131 by the mother. Thus provide some advice to the radioprotection of radioactive accident. Methods: In this clinical case, a staff of nuclear medicine accidently intake I-131 during (10–12 weeks) and after pregnancy. The infant was born at full term, but both lobes of the thyroid gland were found to be absent (bilobar thyroid agenesis). It was suspected that the fetal thyroid agenesis may be related with mother’s contamination of I-131 during pregnancy. Urine samples for 24h were collected at different times after administered and radioactivity were measured to calculate the dose of intake I-131. Calculate the intake I-131 by the results of personal TLD dosimeter. We adopted the mean of two calculated results as the I-131 intake. According to the dose of intake I-131 by the mother, effective dose and absorbed dose of thyroid for mother, fetus and infant were calculated. Results: The intake of I-131 was estimated for 8.18 mCi. I-131 intake was calculated for 7.9 mCi based on data of TLD dosimeter. We adopted the mean of two results as the I-131 intake. The final result was 8.0 mCi. Effective dose and absorbed dose of thyroid for mother were 7.3Sv and 164 Gy, effective dose and absorbed dose of thyroid for fetus were 2.035 Sv and 40.7 Gy, effective dose and absorbed dose of thyroid for infant were 16.25 Sv and 355Gy. Conclusion: The intake during pregnancy was about 1mCi. The absorbed dose of thyroid of the mother was 19.5Gy, whereas the effective of infant was estimated for 40.7Gy. The function of the mother’s thyroid was normal after diagnosis. But the infant was diagnosed as bilobar thyroid agenesis.

  2. 131I-recombinant human EGF has antitumor effects against MCF-7 human breast cancer xenografts with low levels of EGFR

    International Nuclear Information System (INIS)

    Li Y.-C.; Xu, W.-Y.; Tan, T.-Z.; He Sheng

    2004-01-01

    This study investigated the inhibitory action of 131 I-recombinant human EGF ( 131 I-rhEGF) on MCF-7 human breast cancer tumor development in nude mice. The activity and tumor uptake of 131 I-rhEGF was measured by tissue distribution assay, and its effect on tumor growth was measured by monitoring tumor size after treatment with 131 I-rhEGF. Changes in tumor cell ultrastructure were observed by transmission electron microscopy (TEM), and pathological changes in tumor tissue were observed by light microscopy. The tissue distribution assay revealed that 131 I-rhEGF was markedly absorbed by the tumor and reached its maximal uptake rate (16.73%ID · g -1 ) at 120 hours at which point the drug concentration in the tumor was 11.1-fold, 8.1-fold, and 6.6-fold higher than that in blood, liver, and kidneys, respectively. Tumor size measurements showed that tumor development was significantly inhibited by intravenously and intratumorally injected 131 I-rhEGF. Tumor inhibition rates (82.0% and 80.7%, respectively) were significantly higher than those of tumors treated with 131 I (7.49%) and 131 I-HSA (6.91%; P 131 I-rhEGF could significantly damage and ultimately kill tumor cells. Our results suggest that 131 I-rhEGF suppresses development of xenografted breast cancer cells in nude mice, providing a novel candidate for receptor-mediated targeted radiotherapy

  3. Roles of TgAb and TPOAb in the development of hypothyroidism after 131I treatment in hyperthyroid patients with Graves' disease

    International Nuclear Information System (INIS)

    Han Yunfeng; Tong Liangqian; Lan Qiong; Zhu Xiaohua; Chen Jing; Zhao Ming

    2012-01-01

    To evaluate the roles of antithyroid peroxidase antibodies (TPOAb) and antithyroglobulin antibodies (TbAb) in the development of hypothyroidism after 131 I treatment in hyperthyroid patients with Graves' disease (GD), data were collected from 160 GD patients who were treated with 131 I in the department of nuclear medicine of Tongji Hospital between January 2008 and February 2011. Patients were divided into four groups: group A (TgAb 131 I. The incidence of hypothyroidism after 131 I treatment was different for each group(P=0.034 131 I treatment. In conclusion, because TgAb and TPOAb play important roles in the occurrence of hypothyroidism after 131 I therapy, in patients with positive levels of TgAb and TPOAb, lower doses of 131 I might prevent hypothyroidism. (authors)

  4. The early changes of thyroid hormone concentrations after 131I therapy for graves' hyperthyroidism - the role of pretreatment with methimazole

    International Nuclear Information System (INIS)

    Pirnat, E.; Fidler, V.; Zaletel, K.; Gaberscek, S.; Hojker, S.

    2002-01-01

    Full text: 131 I therapy may cause exacerbation of hyperthyroidism due to leakage of previously formed thyroid hormones from damaged thyroid cells in Graves' patients. To avoid this complication pretreatment with antithyroid drugs is recommended. Otherwise, the use of antithyroid drugs prior to 131 I therapy may diminish the success of 131 I therapy and should therefore be discontinued. The aim of our prospective clinical study was to compare early changes of thyroid hormone concentrations after 131 I therapy in Graves' patients, pretreated or not pretreated with methimazole. 92 consecutive Graves' patients, 84 females and 8 males, aged 17 to 80 were treated with 555 MBq of 131 I. Absorbed dose of 131 I was calculated. In the first group of 22 patients treatment with methimazole (20 mg/day) was discontinued 7 days before 131 I therapy, the second group of 33 patients received methimazole until the day of 131 I therapy and the third group of 37 patients was not pretreated with methimazole before 131 I therapy. 7 and 2 days before 131 I therapy and 2, 5, 12 and 30 days after serum free T 4 (fT 4 ) and free T 3 (fT 3 ) concentrations were measured. In the first group a significant increase of fT 4 and fT 3 was observed 7 days after discontinuation of methimazole (fT 4 14.60 ± 4.10 vs. 18.25 ± 7.16; fT 3 5.45 ± 1.44 vs. 7.79 ± 5.27 pmol/l), while gradual decrease of fT 4 and fT 3 was observed after 131 I therapy. In the second group a significant increase of fT 4 and fT 3 after 131 I therapy peaking on day 5 was observed (fT 4 20.91 ± 13.70 vs. 27.85 ± 18.17; fT 3 7.81 ± 5.21 vs. 9.42 ± 6.21 pmol/l). In the third group significant decrease of fT 4 and fT 3 concentrations was observed after 131 I therapy (fT 4 36.12 ± 18.55 vs. on day 12th 27.49 ± 15.20; fT 3 12.66 ± 7.04 vs. on day 12th 8.31 ± 4.92 pmol/l). No correlation between absorbed dose of 131 I and changes of fT 4 and fT 3 concentrations was observed. Therefore, our results indicate that not 131 I

  5. National comparison of activity measurements of 131I, 60Co, and 133Ba in Indonesia

    International Nuclear Information System (INIS)

    Wurdiyanto, Gatot; Marsoem, Pujadi; Widodo, Susilo; Iskandar, Dadong; Muhayatun; Hartoyo, Unggul; Sugino; Gede Sutresna, I.; Hutabarat, Tommy; Suparman, Ibon; Purwanto, Setyo

    2014-01-01

    National comparisons of radioactivity measurements of 131 I and 60 Co (in 2010) and of 133 Ba (in 2011) were carried out within the framework of the National Radiation Metrology Laboratory Program of Indonesia, coordinated by PTKMR-BATAN. Eleven laboratories took part in the comparison, and all measurements were made using gamma spectrometry, on point sources with an activity between 2000 Bq and 6000 Bq. Several laboratories reported values which were more than 10% different from the reference value for 131 I and 133 Ba. Possible reasons for these differences are discussed. This program will be continued with other radionuclides to maintain and control quality assurance for the local laboratories. - Highlights: • PTKMR-BATAN coordinated national comparison of 131 I, 60 Co and 133 Ba. • Eleven laboratories took part in the comparison. • All measurements were done using gamma spectrometry methods. • For 131 I and 133 Ba, 3 laboratories have more than 10% difference from reference laboratory value

  6. Absorbed Dose in the Uterus of a Three Months Pregnant Woman Due to 131I

    International Nuclear Information System (INIS)

    Vega-Carrillo, Hector Rene; Manzanares-Acuna, Eduardo; Hernandez-Davila, Victor Martin; Arcos-Pichardo, Areli; Barquero, Raquel; Iniguez, M. Pilar

    2006-01-01

    The use of 131I is widely used in diagnostic and treatment of patients. If the patient is pregnant the 131I presence in the thyroid it becomes a source of constant exposition to other organs and the fetus. In this study the absorbed dose in the uterus of a 3 months pregnant woman with 131I in her thyroid gland has been calculated. The dose was determined using Monte Carlo methods in which a detailed model of the woman has been developed. The dose was also calculated using a simple procedure that was refined including the photons' attenuation in the woman organs and body. To verify these results an experiment was carried out using a neck phantom with 131I. Comparing the results it was found that the simple calculation tend to overestimate the absorbed dose, by doing the corrections due to body and organs photon attenuation the dose is 0.14 times the Monte Carlo estimation

  7. Evaluation of absorbed dose in studies of renal function due to {sup 123}I/{sup 131}I (hippuran) e {sup 111}In (DPTA); Evaluacion de la dosis absorbida durante estudios de la funcion renal debido al {sup 123}I/{sup 131}I (hippuran) e {sup 111}In (DPTA)

    Energy Technology Data Exchange (ETDEWEB)

    Vasquez, M.V.; Castillo, C.E.; Rojas, R.; Cabrera, C.; Abanto, D.; Morgan, A. [Universidad Nacional de Trujillo (UNT), Area de Fisica Medica, Trujillo (Peru); Diaz, E.E., E-mail: marvva@hotmail.com [Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre (Brazil)

    2015-07-01

    The absorbed dose of the kidneys during renal function studies of adult patients is estimated through biokinetics of radiopharmaceuticals containing the {sup 123}I/{sup 131}I (hippuran) e {sup 111}In (DPTA). Using the methodology MIRD and representation Cristy-Eckerman for adult kidneys, it is shown that dosimetric contributions of organs of biokinetics {sup 123}I/{sup 131}I (hippuran) e {sup 111}In (DPTA) are significant, in estimative of dose for renal function studies. Dosimetric contributions (body and whole bladder, kidneys excluding) are given by 11.90% (for {sup 123}I), 4.97% (for {sup 131}I) and 28.32% (for {sup 111}In). In all cases, the dosimetric contributions are mainly due to photons issued by the whole body.

  8. Analysis of influence of dosimetric factors on the outcome of I-131 therapy in patients with hyperthyroidism

    International Nuclear Information System (INIS)

    Knapska-Kucharska, M.; Oszukowska, L.; Makarewicz, J.; Lewinski, A.

    2012-01-01

    The influence of dosimetric factors on the outcome of 131 I therapy has been examined in hyperthyroid patients submitted to 131 I treatment. The following factors - which could have influence on the effects of therapy with radioiodine - were analysed: the goitre volume, the thyroid radioiodine uptake after 24 h, and the effective half-life time of 131 I (EHL). Five hundred (500) randomly selected patients with hyperthyroidism, treated with 131 I, were studied. They were divided into three groups (based on clinical examination, hormonal and immunological tests, thyroid scintigraphy and ultrasound imaging). The study shows that the effectiveness of 131 I therapy depends on the thyroid volume and absorbed dose in all the groups of patients and on the thyroid radioiodine uptake and EHL in patients with a single autonomously functioning thyroid nodule. We have failed to determine the borderline D, distinguishing between effective and ineffective therapy. The treatment outcome can be predicted with approximately 70% accuracy, based on minimal absorbed dose

  9. Analysis of influence of dosimetric factors on the outcome of I-131 therapy in patients with hyperthyroidism

    Energy Technology Data Exchange (ETDEWEB)

    Knapska-Kucharska, M.; Oszukowska, L.; Makarewicz, J. [Department of Nuclear Medecine and Oncological Endocrinology, Province Hospital, Zgierz (Poland); Lewinski, A. [Chair and Department of Endocrinology and Metabolic Diseases, Medical University, Lodz (Poland)

    2012-07-01

    The influence of dosimetric factors on the outcome of {sup 131}I therapy has been examined in hyperthyroid patients submitted to {sup 131}I treatment. The following factors - which could have influence on the effects of therapy with radioiodine - were analysed: the goitre volume, the thyroid radioiodine uptake after 24 h, and the effective half-life time of {sup 131}I (EHL). Five hundred (500) randomly selected patients with hyperthyroidism, treated with {sup 131}I, were studied. They were divided into three groups (based on clinical examination, hormonal and immunological tests, thyroid scintigraphy and ultrasound imaging). The study shows that the effectiveness of {sup 131}I therapy depends on the thyroid volume and absorbed dose in all the groups of patients and on the thyroid radioiodine uptake and EHL in patients with a single autonomously functioning thyroid nodule. We have failed to determine the borderline D, distinguishing between effective and ineffective therapy. The treatment outcome can be predicted with approximately 70% accuracy, based on minimal absorbed dose

  10. Therapeutic administration of 131I for differentiated thyroid cancer, radiation dose to ovaries and outcome of pregnancies

    International Nuclear Information System (INIS)

    Garsi, Jerome-Philippe; Rubino, Carole; Labbe, Martine; Vathaire, Florent de; Schlumberger, Martin; Ricard, Marcel; Ceccarelli, Claudia; Schvartz, Claire; Henri- Amar, Michel; Bardet, Stephane

    2008-01-01

    Full text: Background: Radiation is known to be mutagenic. In thyroid cancer treatment, 131 I is usually administered, for the first treatment, at a 3.7 GMBq activity, corresponding to an estimated mean radiation dose of 140 mGy to the ovaries. However data on the effects of 131 I therapy on pregnancy outcomes, especially untoward, are scarce. Methods: Data on 2673 pregnancies were obtained by interviewing female patients treated for thyroid carcinoma who had not received external radiation to the ovaries, in three French hospitals and one Italian hospital. Results: The incidence of miscarriages was 10 % before any treatment for thyroid cancer; this percentage increased after surgery for thyroid cancer, both before (20 %) and after (19 %) 131 I treatment, with no variation according to the cumulative dose. Miscarriages were not significantly more frequent in women treated with 131 I during the year before conception, even in subjects who had received more than 370 MBq during that year, as compared to women never treated with 131 I. The incidence of stillbirths, preterm births, a low birth weight, congenital malformation and death during the first year of life was not significantly different before or after 131 I therapy. The incidence of thyroid and non thyroidal cancers was similar in children born either before or after the mother's exposure to 131 I. Conclusion: In our data, we found no evidence that exposure to 131 I affects the outcome of subsequent pregnancies and offspring. Whether the number of malformations, or thyroid and non thyroidal cancers are related to gonadal irradiation remains to be established. Our findings allowed us to fuel the debate on the doubling dose: the concept is still heatedly debated and the value of 1 Gy as the doubling dose in humans should be rediscussed. (author)

  11. Transfer of 131I and /sup 95m/Tc from pasture to goat milk

    International Nuclear Information System (INIS)

    Bondietti, E.A.; Garten, C.T. Jr.

    1984-01-01

    Field measurements were made in 1983 on the transfer of 131 I and /sup 95m/Tc from spray-contaminated pasture to goat's milk. The transfer of 131 I to milk was similar to that used for mathematical models in US Nuclear Regulatory Commission Regulatory Guide 1.109, which was derived from stall-feeding experiments using capsulized doses. Compared to 131 I, the /sup 95m/Tc transferred to milk was about 5600 times less. The lower transfer resulted from both immobilization of technetium on pasture prior to ingestion as well as reduced gastrointestinal absorption. The results show that the food chain transfer of technetium to milk is much less than that previously expected based on inferences made from metabolism studies. 6 references, 4 figures, 1 table

  12. Cancer of the thyroid and 131I fallout in Norway

    International Nuclear Information System (INIS)

    Oftedal, P.; Lund, E.

    1983-01-01

    From 1953 to 1962 Norway received relatively high levels of radioactive fallout. On the basis of extensive measurements in air, precipitation, food and humans, the dose to the thyroid due to 131 I has been calculated. Cancer registration in Norway is practically completely efficient because of obligatory notification of the Cancer Registry by physicians, pathology laboratories, and the Central Bureau of Statistics of all cases or death certificates concerning cancer. Analysis of the Cancer Registry data from 1953 to 1980 concerning birth cohorts 1936 to 1961 indicates an overall increasing trend in thyroid cancer morbidity, most pronounced in female cohorts born 1930-50. The highest, most abrupt irregularities reveal a coincidence of high numbers with high 131 I content in milk consumed during the years of prepuberty and puberty. Possible interpretations are discussed. (author)

  13. Comparison of F-18 FDG PET and I-131 whole body scan in diagnosis of suspicious metastatic thyroid carcinoma

    International Nuclear Information System (INIS)

    Seok, Ju Won; Chung, June Key

    2005-01-01

    There are several reports about the usefulness of F-18 FDG PET in thyroid cancer. The aim of this study was to evaluate the effectiveness of F-18 FDG PET and I-131 whole body scan in suspicious metastatic thyroid cancer. There were 46 patients (11 men, 35 women; age range, 18-74yr; mean age, 47.3yr) with suspicious metastatic thyroid cancer after total thyroidectomy who performed FDG PET and I-131 scan. The interval of FDG PET and I-131 scan was within 6 months. An overall clinical evaluation was performed including cytology, thyroglobulin level, sonography, MRI and CT. Metastatic regions were divided into four areas: neck, mediastinum, lung and bone. Among 46 patients, the number of patients, metastatic lesions were detected, totaled 36 (78.3%). Twenty-nine patients (63.0%) were detected by FDG PET and 18 patients (39.1%) were detected by I-131 scan. Twenty-one patients were detected in neck by two methods. Nineteen patients (90.5%) were detected by FDG PET and 7 patients (33.3%) were detected by I-131 scan. Eighteen patients were detected in mediastinum by two methods. Ten patients (55.5%) were detected by FDG PET and 10 patients (55.5%) were detected by I-131 scan. Ten patients were detected in lung by two methods. Nine patients (90.0%) were detected by FDG PET and 3 patients (30.0%) were detected by I-131 scan. Three patients were detected in bone by two methods. Three patients (100%) were detected by FDG PET and 0 patients (0%) were detected by I-131 scan. These data indicate that for detecting metastatic lesions, F-18 FDG PET and I-131 whole body scan may provide complementary information. Thus, the combination of FDG PET and I-131 scan is the method of choice for detecting suspicious metastatic thyroid cancer after total thyroidectomy

  14. Development of a recovery method of 131I in the 99Mo process through the fission of 235U

    International Nuclear Information System (INIS)

    Bignardi, Aline Moraes Teixeira

    2013-01-01

    13 1 I is an iodine radioisotope widely used in nuclear medicine that can be used either for diagnostic or for treatment due to its physical decay by β - and its high emission of y-rays. It is produced at IPEN using the indirect reaction: 130 Te(n,y) 131m Te → 131 Te → 131 I where TeO 2 targets are irradiated in a Nuclear Reactor. There is also the possibility of producing 131 I by the fission of 235 U, where about 300 different elements are produced together with 131 I. The 131 I produced through this method presents high specific activity and radioactive concentration suitable for the labeling of molecules. The aim of this work was to develop a recovery method of 131 I with the required quality to be used in Nuclear Medicine in the 99 Mo production process through the route of acid dissolution of metallic 235 U targets. 131 I can appear in two phases of the process, both in the gaseous phase produced during the dissolution of metallic U targets and in the dissolution solution. This work studied the recovery of 131 I in these two phases. Several materials were used for the capture and recovery of 131 I at the two phases of the process, the gaseous one and the solution of dissolution of U targets. Columns of alumina with Cu, acid alumina with Cu, Ag microspheres, Cu microspheres, Ag nanospheres, anionic cartridges, Ag cartridges, anion exchange resin and activated charcoal columns were tested. Solutions containing 131 I in 0.1 mol.L -1 NaOH were percolated through the materials and the eluted solutions were analyzed in a dose calibrator. The precipitation of AgI was also studied wth further dissolution of this precipitate with 0.1 mol L -1 NH 4 OH and 5% Na 2 S 2 O 3 . The recovery results varied according to the material, activated charcoal showed recovery yields between 42% and 83% but the recovery yield of the alumina column with Cu ranged from 20% to 85%. Tests with Ag nanospheres showed recovery yield of 26% using 0.1 mol L -1 NaOH and 72% for Na 2 S 2 O

  15. Meta[{sup 131}I]iodobenzylguanidine therapy for patients with metastatic and unresectable pheochromocytoma and paraganglioma

    Energy Technology Data Exchange (ETDEWEB)

    Goldsby, Robert E. [Division of Pediatric Oncology, Department of Pediatrics, University of California, San Francisco, CA 94143-0106 (United States); Fitzgerald, Paul A. [Division of Endocrinology, Department of Medicine, University of California, San Francisco, CA 94143-1222 (United States)], E-mail: paul.fitzgerald@ucsf.edu

    2008-08-15

    Introduction: Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are tumors that can exhibit a malignant behavior. Targeted radiotherapy with {sup 131}I-metaiodobenzylguanidine ({sup 131}I-MIBG) has proven useful in patients with unresectable, metastatic and/or relapsed disease. Methods: We review the literature and our experience at UCSF to highlight important characteristics of PHEO/PGL and the use of {sup 131}I-MIBG in the treatment of this disease. Results: These tumors are rare, with a diagnosed incidence of only two to four cases per million annually; 40% are discovered at autopsy. Clinical manifestations are caused by excess secretion of catecholamines, although some PGLs are nonsecretory. Approximately 25% of patients with PHEO/PGLs have an underlying genetic predisposition. The risk of a germline mutation is higher in children. Diagnostic evaluation should include serial determinations of fractionated metanephrines and serum chromogranin A. Staging requires both {sup 123}I-MIBG and full-body magnetic resonance imaging or {sup 18}FDG-PET scanning. The primary treatment for PHEO/PGL is resection. Patients may be candidates for treatment with {sup 131}I-MIBG if they have unresectable or metastatic tumors that are avid for MIBG. Such patients usually respond to this targeted radioisotope therapy and many achieve a durable remission. Myelosuppression is a dose-related side effect that can be treated with transfusions or autologous hematopoietic stem cells. Late side effects can include infertility, myelodysplasia and second cancers. Conclusions: Treatment with {sup 131}I-MIBG can be considered for patients if surgery is not feasible. There are significant risks associated with this treatment, but the majority of patients will respond. Treatment with {sup 131}I-MIBG should be done at institutions with experience in delivering targeted radiotherapeutics.

  16. Dosimetry prior to I-131-therapy of benign thyroid disease

    International Nuclear Information System (INIS)

    Haenscheid, Heribert; Lassmann, Michael; Reiners, Christoph

    2011-01-01

    The activity to be administered in I-131 therapy of benign thyroid disease is determined by the radiation absorbed dose necessary to cure the disease, the target mass, and the residence time of the I-131 in the target volume. Data from 73 patients with complete sets of uptake measurements 2, 6, 24, 48, and 96 (n = 53) or 120 (n = 20) hours after oral administration of 1 MBq I-131 were used to deduce residence times from subsets of 3, 2, or only 1 measurement for each individual. The values were compared to those obtained with the reference method, i.e. a fit of an uptake function based on a 2-compartment model to all 5 measurements, to quantify the errors introduced by the less demanding assessments. Deviations are less than 10% if the 2- compartment uptake function is fitted to only 3 values measured after 6, 24, and 96-120 h. Use of 2, 24, and 96-120 h data results in errors > 20% in individual patients. The effective half-lives as determined from 2 measurements after 24 and 96-120 h correlate well with those deduced from the reference method with larger deviations in individuals with slow iodine kinetics and late maximal uptake. Residence times determined from the 24 h uptake, assuming linear increase during the first day, and the effective half-life limited to maximum 8 days underestimate the actual values systematically in patients with long and short half-lives. These errors can be eliminated by a modification of the calculation method resulting in deviations less than 14% in all but one individual for this procedure. The accuracy of methods based on only one retention value increases with the time of measurement after the administration of I-131. While systematic errors up to a factor of two occur if the 24 h uptake is used for the estimate, deviations are less than 18% for measurements after 120 h. The results suggest that only one late uptake assessment warrants residence time estimates with an acceptable error. Given the high inherent uncertainties in the

  17. Internal dosimetry of nuclear medicine workers through the analysis of {sup 131}I in aerosols

    Energy Technology Data Exchange (ETDEWEB)

    Gomes C, L.; Lucena, E. A.; Da Silva S, C.; Almeida D, A. L.; Oliveira S, W.; Souza S, M.; Maranhao D, B., E-mail: carneiro@ird.gov.br [Instituto de Radioprotecao e Dosimetria - CNEN, Av. Salvador Allende s/n, 22783-127 Rio de Janeiro (Brazil)

    2014-08-15

    {sup 131}I is widely used in nuclear medicine for diagnostic and therapy of thyroid diseases. Depending of workplace safety conditions, routine handling of this radionuclide may result in a significant risk of exposure of the workers subject to chronic intake by inhalation of aerosols. A previous study including in vivo and in vitro measurements performed recently among nuclear medicine personnel in Brazil showed the occurrence of {sup 131}I incorporation by workers involved in the handling of solutions used for radioiodine therapy. The present work describes the development, optimization and application of a methodology to collect and analyze aerosol samples aiming to assess internal doses based on the activity of {sup 131}I present in a radiopharmacy laboratory. Portable samplers were positioned at one meter distant from the place where non-sealed liquid sources of {sup 131}I are handled. Samples were collected over one hour using high-efficiency filters containing activated carbon and analyzed by gamma spectrometry with a high purity germanium detection system. Results have shown that, although a fume hood is available in the laboratory, {sup 131}I in the form of vapor was detected in the workplace. The average activity concentration was found to be of 7.4 Bq /m{sup 3}. This value is about three orders of magnitude below the Derived Air Concentration (Dac) of 8.4 kBq/m{sup 3}. Assuming that the worker is exposed by inhalation of iodine vapor during one hour, {sup 131}I concentration detected corresponds to an intake of 3.6 Bq which results in a committed effective dose of 7.13 x 10{sup -5} mSv. These results show that the radiopharmacy laboratory evaluated is safe in terms of internal exposure of the workers. However it is recommended that the presence of {sup 131}I should be periodically re-assessed since it may increase individual effective doses. It should also be pointed out that the results obtained so far reflect a survey carried out in a specific

  18. Comparison of curative effect of 131I and antithyroid drugs in Graves' disease: a meta analysis.

    Science.gov (United States)

    Yuan, Ju; Lu, Xiuqing; Yue, Yan

    2017-03-01

    Radioactive 131I is currently reported to be a potential effective intervention for Graves' Disease treatment in China. Whether 131I treatment was associated with effective outcome or reduced risk of side effects, reccurence rate remained unknown. Eligible studies were selected from Chinese VIP, Wangfang, CNKI databases using the keywords "Iodine" and "Graves Disease". Finally, 13 clinical trials met the inclusion criterion and were included this meta-analysis. Our meta-analysis included 1355 patients diagnosed of Graves' Disease with regular anti-thyroid drugs oral administration and 1320 patients with 131I therapy. The results showed that there was significant symptom improvement with radioactive iodine intervention (Odd Ratio (OR)=4.50, 95% CI [3.55, 5.71], PGraves' Disease. Treatment with 131I was associated with better clinical outcome; it reduced side effects and reccurence rate but increased hypothyroidism in Graves' Disease.

  19. I-131 attraction by thyroid during first hours following its oral administration

    International Nuclear Information System (INIS)

    Franquiz, J.M.; Cardenas, R.; Blanco, J.; Garcia, M.

    1982-01-01

    From radioisotopic investigations used to study thyroid function, that of I-131 attraction results to be one of the most known and used in medical practice. In the authors' laboratory measurement of I-131 activity upon the gland has been for long adopted at 24 hours after administration; however, current needs compel to look for an early time (within the first six hours) for measuring it. In the paper results of I-131 attraction by thyroid in a group with more than 200 patients at 2,4 and 24 hours following its administration are presented in order to assess a 24 hours attraction representativeness by an early attraction. Results demonstrate early attraction is representative of an attraction at 24 hours and with the same diagnostic usefulness. Normal and doubtful ranks for attraction in our medium are determined at 2 and 6 hours, being adopted as proceeding for those cases whose value should be found within doubtful rank, a measurement at 24 hours in order to determine functional condition of the gland. (author)

  20. Analysis of factors affecting the early hypothyroidism following 131I treatment of Graves' disease

    International Nuclear Information System (INIS)

    Tian Rong; Kuang Anren; Qin Weishi

    2001-01-01

    Objective: It is a retrospective study designed to evaluate the early therapeutic outcome of radioiodine therapy in patients with Graves' disease and determine whether the outcome of radioiodine therapy in Graves' disease depends on thyroid volume, function, thyreo-stasis, therapeutic dosage, 131 I uptake, age, sex, and absorbed doses by per gram of thyroid tissue. Methods: One year after treatment, 342 patients were divided into two groups according to whether there was hypothyroidism, t test and x 2 test were used to compare the variable parameters between the two groups. Results: 92.1% were cured with a single dose of 131 I, and 21.2% contracted hypothyroidism at 12 months after treatment. The outcome of treatment at 12 months depended on the volume of thyroid and the absorbed doses by per gram of thyroid tissue. And pretreatment with thyreo-stasis did not reduce the therapeutic efficacy of 131 I in hyperthyroidism if antithyroid drugs were discontinued at least 3 days before 131 I treatment. Conclusions: Since most hypothyroidism occurred in patients whose thyroid volume is small, appropriate reduction of target dose is recommended here for those patients

  1. The fate of 131I-17-iodoheptadecanoic acid during lactate loading: Its oxidation is strongly inhibited in favor of its esterification

    International Nuclear Information System (INIS)

    Duwel, C.M.B.; Visser, F.C.; Eenige, M.J. van; Roos, J.P.; Hollander, W. den

    1990-01-01

    The influence of lactate loading on fatty acid metabolism (pH = 7.4) by the normal canine heart was investigated radiochemically using the radioiodinated fatty acid 131 I-17-iodoheptadecanoic acid ( 131 I-17-HDA). Fatty acid metabolism was studied during control conditions (n = 8) and after lactate loading (n = 7). In the canine heart total myocardial 131 I-17-HDA radioactivity (uptake) was not changed during the lactate intervention. The oxidation decreased fivefold (measured as free 131 I-iodide ion) from 70% to 14% (p 131 I-17-HDA was mainly stored in the triglycerides and phosphoglycerides. These results suggest that lactate inhibits cardiac 131 I-HDA oxidation. (orig.) [de

  2. Superparamagnetic iron oxide nanoparticles mediated 131I-hVEGF siRNA inhibits hepatocellular carcinoma tumor growth in nude mice

    International Nuclear Information System (INIS)

    Chen, Jing; Zhu, Shu; Tong, Liangqian; Li, Jiansha; Chen, Fei; Han, Yunfeng; Zhao, Ming; Xiong, Wei

    2014-01-01

    Hepatocellular carcinoma (HCC) is a primary liver tumor and is the most difficult human malignancy to treat. In this study, we sought to develop an integrative approach in which real-time tumor monitoring, gene therapy, and internal radiotherapy can be performed simultaneously. This was achieved through targeting HCC with superparamagnetic iron oxide nanoparticles (SPIOs) carrying small interfering RNA with radiolabled iodine 131 ( 131 I) against the human vascular endothelial growth factor (hVEGF). hVEGF siRNA was labeled with 131 I by the Bolton-Hunter method and conjugated to SilenceMag, a type of SPIOs. 131 I-hVEGF siRNA/SilenceMag was then subcutaneously injected into nude mice with HCC tumors exposed to an external magnetic field (EMF). The biodistribution and cytotoxicity of 131 I-hVEGF siRNA/SilenceMag was assessed by SPECT (Single-Photon Emission Computed Tomography) and MRI (Magnetic Resonance Imaging) studies and blood kinetics analysis. The body weight and tumor size of nude mice bearing HCC were measured daily for the 4-week duration of the experiment. 131 I-hVEGF siRNA/SilenceMag was successfully labeled; with a satisfactory radiochemical purity (>80%) and biological activity in vitro. External application of an EMF successfully attracted and retained more 131 I-hVEGF siRNA/SilenceMag in HCC tumors as shown by SPECT, MRI and biodistribution studies. The tumors treated with 131 I-hVEGF siRNA/SilenceMag grew nearly 50% slower in the presence of EMF than those without EMF and the control. Immunohistochemical assay confirmed that the tumor targeted by 131 I-hVEGF siRNA/SilenceMag guided by an EMF had a lower VEGF protein level compared to that without EMF exposure and the control. EMF-guided 131 I-hVEGF siRNA/SilenceMag exhibited an antitumor effect. The synergic therapy of 131 I-hVEGF siRNA/SilenceMag might be a promising future treatment option against HCC with the dual functional properties of tumor therapy and imaging

  3. 131I-Recombinant human EGF has anti-tumor effects against MCF-7 human breast cancer xenografts with low levels of EGFR

    International Nuclear Information System (INIS)

    Li Yunchun; Tan Tianzhi; Xu Weiyun; He Sheng

    2004-01-01

    Purpose: This study investigated the inhibitory action of 131 I-recombinant human EGF ( 131 I-rhEGF) on MCF-7 human breast cancer tumor development in nude mice. Methods: The activity and tumor uptake of 131 I-rhEGF was measured by tissue distribution assay, and its effect on tumor growth was measured by monitoring tumor size after treatment with 131 I-rhEGF, Changes in tumor cell ultrastructure were observed by transmission electron microscopy (TEM), and pathological changes in tumor tissue were observed by light microscopy. Results: The tissue distribution assay revealed that 131 I-rhEGF was markedly absorbed by the tumor and reached its maximal uptake rate (16.73% ID·g-l) at 120 h, at which point the drug concentration in the tumor was 11.1-fold, 8.1-fold, 6.6-fold higher than that in blood, liver, kidneys, respectively. The tumor size measurements showed that tumor development was significantly inhibited by intravenously and intratumorally injected 131 I-rhEGF. The extent of tumor inhibition rates (82.0% and 80.7%, respectively) were significantly higher than those of tumors treated with 131 I (7.49%) and 131 I-HSA (6.91%; P 131 I-rhEGF could significantly damage and ultimately kill tumor cells. Conclusions: Our results suggest that 131 I-rhEGF suppresses development of xenografted breast cancer cells in nude mice, providing a novel candidate for receptor-mediated targeted radiotherapy. Key words. Iodine-131 rhEGF Breast cancer Therapy. (authors)

  4. Imaging the primate adrenal medulla with [123I] and [131I] metaiodobenzylguanidine: concise communication

    International Nuclear Information System (INIS)

    Wieland, D.M.; Brown, L.E.; Tobes, M.C.; Rogers, W.L.; Marsh, D.D.; Mangner, T.J.; Swanson, D.P.; Beierwaltes, W.H.

    1981-01-01

    An evaluation of radioiodinated meta-iodobenzylguanidine (m-IBG) as an adrenomedullary imaging agent is reported in 15 rhesus monkeys. Scintiscans of the monkey adrenal medulla have been obtained with [ 123 I]- and [m- 131 ]IBG at 2 to 6 days after injection. The imaging superiority of m-IBG over its positional isomer, para-iodobenzylguanidine (p-IBG), is documented in both dogs and monkeys. Administration of reserpine, a depletor of catecholamine stores, markedly lowers the [m- 131 I]-IBG content of the dog adrenal medulla, but the adrenergic blocking agents phenoxybenzamine and propanolol have no effect. Subcellular fractionation of the dog's adrenal medullae reveals that m-IBG is sequestered mainly in the chromaffin storage granules. The results of this study suggest that radioiodinated m-IBG, previously reported to image the primate myocardium, also merits evaluation as a clinical radiopharmaceutical for the adrenal medulla

  5. Measurements of Actual Effective Half - Life in 131I Therapy for Graves' Hyperthyroidism

    International Nuclear Information System (INIS)

    So, Yong Seon; Kim, Myung Seon; Kwon, Ki Hyun; Kim, Seok Whan; Kim, Tae Hyung; Han, Sang Woong; Kim, Eun Sil; Kim, Chong Soon

    1996-01-01

    Radioiodine[131I] has been used for the treatment of Graves' hyperthyroidism since the late 1940's and is now generally regarded as the treatment of choice for Graves' hyperthyroidism who does not remit following a course of antithyroid drugs. But for the dose given, several different protocols have been described by different centers, each attempting to reduce the incidence of long-term hypothyroidism while maintaining an acceptable rate control of Graves' hyperthyroidism. Our goals were to evaluate effective half-life and predict absorbed dose in Graves' hyperthyroidism patients, therefore, to calculate and read minister radioiodine activity needed to achieve aimed radiation dose. Our data showed that the mean effective 131I half-life for Graves' disease is 5.3 days(S.D=0.88) and mean biologic half-life is 21 days, range 9.5-67.2 days. The mean administered activity and the mean values of absorbed doses wet: 532 MBq(S.D.=254), 112 Gy (S.D.=50.9), respectively. The mean activity needed to achieve aimed radiation dose were 51 MBq and marked differences of 131I thyroidal uptake between tracer and therapy occurred in our study. We are sure that the dose calculation method that uses 5 days thyroidal 131I uptake measurements after tracer and therapy dose, provides sufficient data about the effective treatment in Graves' hyperthyroidism.

  6. ALARA implementation in 131I therapeutic capsule production facility

    International Nuclear Information System (INIS)

    Kumawat, Lalit; Swaminathan, N.; Sudheer, T.S.; Sachdev, S.S.; Arora, S.S.; Vairalkar, K.G.

    2005-01-01

    Sodium iodide 131 I solution had been invariably administered to patients for both diagnosis and therapy of thyrotoxicosis. The undue exposure to non-target organs has been over come by introducing NaI ( 131 I) in a gelatin capsule. BRIT has set up experimental facility for the preparation and the production volume has augmented into four fold due to increase in demand and the same facility is being used to cater the need. However, the adequately shielded facility (fume hood) used for (manual) dispensing activity in capsules, capsules and product vial capping, transfer of the vials into lead pots and activity measurement of each vial has resulted in significant increase in the personnel exposure. The sources had been identified and efforts were made to reduce the exposure in these operations. An annular shield was introduced around the dispenser, resulted in the reduction of radiation field at wrist level by a factor of three. Introduction of shielded automated dispenser and usage of longer tools for transfer and capping of vials has effected in two times reduction of collective wrist dose. Currently, the relocated capping station two meters away from the source certainly will bring down further exposure. (author)

  7. The bioconcentration of 131I in fresh water fish

    International Nuclear Information System (INIS)

    Yu, K.N.; Cheung, T.; Young, E.C.M.; Luo, D.L.

    1996-01-01

    The dynamic characteristics of the radionuclide concentration process in fresh water fish have been studied. The experimental data for the tilapias were fitted using a simple compartment model to get characteristics parameters such as concentration factors, elimination rate constants, and initial concentration rates, which are 3.08 Bq kg -1 /Bq L -1 , 0.00573 h -1 , and 12.42 Bq kg -1 h -1 , respectively. The relative concentrations of 131 I in different parts, i.e., head, gills, flesh, bone and internal organs, of the tilapias are also determined, which are found to be 10.8, 15.4, 26.1, 11.0, and 37.0%, respectively. The effects of different factors on the transfer of radionuclides in fresh water fishes are also discussed. Experiments on the tilapias and the common carp show that the variation of concentration factors for different species may be significant even for the same radionuclide and the same ecological system. On the other hand, the variation in the concentration factors for the flesh of the tilapias is not significant for a certain range of 131 I concentrations in the water. 12 refs., 1 fig., 1 tab

  8. Influence of antithyroid medication on effective half-life and uptake of {sup 131}I following radioiodine therapy; Einfluss thyreostatischer Medikation beim Morbus Basedow auf die Kinetik von 131-Iod waehrend einer Radiotherapie

    Energy Technology Data Exchange (ETDEWEB)

    Moka, D.; Voth, E.; Schicha, H. [Koeln Univ. (Germany). Klinik und Poliklinik fuer Nuklearmedizin

    1997-12-01

    Aim of this study was to assess the influence of antithyroid drugs (ADT) on the kinetics of {sup 131}I. Therefore, 56 patients with Graves` disease and with shortened effective half-life of {sup 131}I were examined under stationary conditionary conditions. In 38 patients ATD was stopped three days after radioiodine therapy (RIT). The progress of the first RIT and of a second RIT, which still was necessary in 12 patients, was compared to 18 patients receiving ATD continuously. Values of effective half-life for {sup 131}I rose significantly from 3.4 to 5.7 days 2-3 days after stopping ATD. There was an increase of the {sup 131}I-uptake of a second RIT after stopping ATD from 29.0 to 38.4%. In contrast, {sup 131}I-uptake of a second RIT decreased significantly in patients receiving ATD continuously. Effective half-life and uptake of {sup 131}I were affected significantly by ATD. Interrupting ATD after RIT is useful to improve an apparantly insufficient RIT in thyrotoxic patients receiving ATD. (orig.) [Deutsch] Ziel dieser Studie war es, beim M. Basedow die Kinetik von {sup 131}I unter dem Einfluss thyreostatischer Medikation (tM) zu untersuchen. Dazu wurden die 56 Patienten mit immunogener Hyperthyreose M. Basedow (MB) und mit einem erhoehten `turn over` von {sup 131}I unter tM untersucht. Bei 38 Patienten wurde die tM am 3. Tag nach RITh abgesetzt. Der Verlauf der 1. RITh bzw. einer Nachtherapie wurde mit 18 Patienten unter fortlaufender tM verglichen. 2-3 Tage nach Absetzen der tM stieg die effektive Halbwertzeit (HWZ{sub eff.}) von {sup 131}I signifikant von 3,4 auf 5,7 Tage und der {sup 131}I-Uptake bei der Nachtherapie von 29,0 auf 38,4% an, waehrend er unter fortlaufender tM signifikant abfiel. Beide Effekte zeigen, dass tM die {sup 131}I-Kinetik der Schilddruese sehr schnell beeinflussen kann. Gezieltes Absetzen der tM eignet sich deshalb, um bei ausgewaehlten Patienten eine primaer unzureichende RITh noch waehrend des stationaeren Aufenthaltes zu steuern und

  9. Development of gamma-photon/Cerenkov-light hybrid system for simultaneous imaging of I-131 radionuclide

    Energy Technology Data Exchange (ETDEWEB)

    Yamamoto, Seiichi; Suzuki, Mayumi; Kato, Katsuhiko [Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine (Japan); Watabe, Tadashi; Ikeda, Hayato; Kanai, Yasukazu [Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine (Japan); Ogata, Yoshimune [Radiological and Medical Laboratory Sciences, Nagoya University Graduate School of Medicine (Japan); Hatazawa, Jun [Department of Molecular Imaging in Medicine, Osaka University Graduate School of Medicine (Japan)

    2016-09-11

    Although iodine 131 (I-131) is used for radionuclide therapy, high resolution images are difficult to obtain with conventional gamma cameras because of the high energy of I-131 gamma photons (364 keV). Cerenkov-light imaging is a possible method for beta emitting radionuclides, and I-131 (606 MeV maximum beta energy) is a candidate to obtain high resolution images. We developed a high energy gamma camera system for I-131 radionuclide and combined it with a Cerenkov-light imaging system to form a gamma-photon/Cerenkov-light hybrid imaging system to compare the simultaneously measured images of these two modalities. The high energy gamma imaging detector used 0.85-mm×0.85-mm×10-mm thick GAGG scintillator pixels arranged in a 44×44 matrix with a 0.1-mm thick reflector and optical coupled to a Hamamatsu 2 in. square position sensitive photomultiplier tube (PSPMT: H12700 MOD). The gamma imaging detector was encased in a 2 cm thick tungsten shield, and a pinhole collimator was mounted on its top to form a gamma camera system. The Cerenkov-light imaging system was made of a high sensitivity cooled CCD camera. The Cerenkov-light imaging system was combined with the gamma camera using optical mirrors to image the same area of the subject. With this configuration, we simultaneously imaged the gamma photons and the Cerenkov-light from I-131 in the subjects. The spatial resolution and sensitivity of the gamma camera system for I-131 were respectively ~3 mm FWHM and ~10 cps/MBq for the high sensitivity collimator at 10 cm from the collimator surface. The spatial resolution of the Cerenkov-light imaging system was 0.64 mm FWHM at 10 cm from the system surface. Thyroid phantom and rat images were successfully obtained with the developed gamma-photon/Cerenkov-light hybrid imaging system, allowing direct comparison of these two modalities. Our developed gamma-photon/Cerenkov-light hybrid imaging system will be useful to evaluate the advantages and disadvantages of these two

  10. Euthyroid goiter with autonomy: Results of treatment with radioiodine (/sup 131/I) and by surgery

    Energy Technology Data Exchange (ETDEWEB)

    Emrich, D.; Reinhardt, M.

    1989-02-01

    In order to evaluate the efficacy of, and the risk associated with, the definite treatment of euthyroid goiter with autonomy, the data of 88 patients treated between 1982 and 1986 (50 by subtotal thyroidectomy; 38 by /sup 131/I-treatment, mean radiation dose 200 Gy without protection by thyroxine) were analyzed in a retrospective study. The following criteria were used before and after treatment: the results of scintigraphy under suppression qualitatively (in focal autonomy) and quantitatively (global thyroid uptake) (TcU/sub s/), the means of FT/sub 4/I, FT/sub 3/I and ..delta..TSH after TRH, the improvement of mechanical signs and symptoms and the decrease of thyroid volume. Measured by TcU/sub s/ and ..delta..TSH, autonomy could be removed completely in 85-90% of all patients. Surgery was slightly more successful (100%) compared to treatment by /sup 131/I (75-80%). This was also true for removal of mechanical symptoms and reduction of the goiter. The incidence of manifest hypothyroidism was greater after surgery (16%) than after /sup 131/I treatment (3%). At a higher grade of autonomy (TcU/sub s/ > 3.2%) surgery was more effective (95-100%) than treatment with /sup 131/I (60-70%) but at a higher risk of hypothyroidism (24 vs 0%). It is imperative to improve the methods of estimating the amount of /sup 131/I to be administered in euthyroid goiter with autonomy. Selection of patients with autonomy in euthyroid goiter for definite treatment is difficult, since until now their risk to become hyperthyroid cannot be predicted properly.

  11. Radioimmunoimaging of ovarian cancer with 131I labelled CEA monoclonal antibody

    International Nuclear Information System (INIS)

    Hu Likuan; Li Zhen; Huo Zhenguo; Jiang Sen; Jia Shiquan

    2001-01-01

    Objective: To investigate radioimmunoimaging with 131 I labelled CEA McAb and its value in diagnosis and treatment of ovarian cancer. Methods: CEA McAb was labelled with 131 I by standard chloramine T procedure. The radiolabeled McAb was given intravenously to the patients. The scintigraphy was performed at different time. Results: In 105 patients with histopathology proved ovarian cancers, for 96 patients the lesions were well located with RII (true positives), for the remaining 9 patients, the results were false negative. 22/23 cases with RII diagnosed benign ovarian tumors were proved to be true negative by surgical pathology in RII. Of 96 ovarian cancers 87 were stratified into identical stages by surgical pathology all RII. 141/151 metastatic tumors were found in RII and the positive rate was as high as 93.4%. The smallest tumor defected by RII was of 1 cm in diameter. Conclusions: RII is as good as ultrasonography and CT in distinguishing benignancy and malignancy. The location, size and number of the lesions can also be determined with RII. RII of ovarian cancer with 131 I-CEA McAb is valuable and helpful in early detection of ovarian cancer. It is also helpful for clinical staging, treatment programing and prognosticating

  12. Comprehensive analysis of the related factors of early hypothyroidism occurring in patients with Graves' disease after 131I treatment

    International Nuclear Information System (INIS)

    Tan Jian; Wang Peng; Zhang Lijuan; He Yajing; Wang Renfei

    2005-01-01

    Objective: To make a comprehensive analysis of the related factors of early hypothyroidism occurring in patients with Graves' disease after 131 I treatment. Methods: The information of 131 I treated Graves' disease was collected including general data, clinical observation, laboratory data, thyroid function test, etc. Then a retrospective statistical analysis was carried out, using cluster analysis, factor analysis, discriminant analysis, multivariate regression analysis, etc. Results: 1) Cluster analysis and factor analysis showed that among clinical observation such as clinical course, treatment course, patients' state and disease occurrance, the first three factors correlated highly; among laboratory data such as thyrotrophin receptor antibody (TRAb), thyroid-stimulating immunoglobulins (TSI), thyroglobulin antibody (TgAb) and thyroid microsomal antibody (TMAb), both the first two and the last two correlated highly, each two factors had the similar effect. 2) Fsher discriminant analysis showed that among the thyroid weight, the effective half life, the maximum 131 I uptake percentage, total dose of 131 I and the average dose of 131 I per gram of thyroid, the last one had the most predicting value for incidence of early hypothyroidism. 3) Logistic regression analysis showed that among all the related factors of early hypothyroidism occurred after 131 I treated Graves' disease, thyroid weight, average dose of 131 I per gram of thyroid, the maximum 131 I uptake percentage and the level of TSI were effective factors. Conclusions: The occurrence of early hypothyroidism for 131 I-treated Graves' disease is probably affected by many factors. If more factors are taken into consideration before therapy and the theraputic dose is well adjusted accordingly, it can reduce the incidence of early hypothroidism to a certain extent. (authors)

  13. Negative predictive value of 124I-PET/CT imaging in patients affected by metastatic thyroid cancer and treated with 131I

    International Nuclear Information System (INIS)

    Pettinato, C.; Civollani, S.; Nanni, C.; Celli, M.; Allegri, V.; Zagni, P.; Fanti, S.; Monari, F.; Cima, S.; Mazzarotto, R.; Spezi, E.

    2015-01-01

    Full text of publication follows. Aim: patients affected by metastatic Differentiated Thyroid Cancer (mDTC) are treated with 131 I even in presence of negative diagnostic 131 I whole body (WB) scan. Actually, very often, these patients present positive post therapy 131 I whole body scan, showing iodine avid metastases that were not seen with the diagnostic imaging. The aim of this work was the evaluation of the feasibility to use 124 I PET/CT images to predict patients who will not benefit from the iodine therapy, because of the absence of avidity, avoiding useless treatments. Material and methods: 25 patients affected by mDTC were enrolled in the study approved by the ethical Committee of our Institution, with the aim to evaluate the usefulness of 124 I PET/CT sequential scans to predict absorbed doses to metastatic thyroid cancer patients undergoing 131 I therapy. Patients (pts) were divided into 4 groups, based on their histology: group A, 4 pts with follicular cancer; group B, 13 pts with papillary cancer; group C, 2 pts with papillary tall cells cancer; group D, 6 patients with papillary cancer with follicular variant. Patients showing negative 124 I-PET/CT were treated with a reduced dose of 131 I (3700 MBq) and post treatment WB scans were acquired 96 hours after the therapeutic administration. Results: 12 patients showed at least one metastatic lesion at 124 I PET/CT imaging, and most of the lesions were visible at the 24 hours scan (4 pts group A, 3 pts group B, 5 pts group D). The remaining 13 patients did not show any uptake of all known metastatic lesions at each PET/CT time points (10 pts group B, 2 pts group C, 1 pt group D). Negative PET/CT findings were confirmed by post therapy WB scan. Discussion and Conclusion: 124 I-PET/CT scan is a useful diagnostic tool to discriminate patients with iodine avid metastases. Actually, when they are present, the superiority of PET/CT resolution and sensitivity, compared to standard 131 I planar imaging, allow the

  14. Serum thyroid auto-antibody contents in GD patients developing hypothyroidism after 131I treatment

    International Nuclear Information System (INIS)

    Cao Huiling; Sun Lijuan; Ji Xiaopeng; Zhao Ming

    2004-01-01

    Objective: To explore the auto-immune factors predisposing to developing hypothyroidism after 131 I treatment in patients with Graves' disease (GD). Methods: Eighty-eight GD patients treated with 131 I were followed for three years. These patients were of two groups: Group A (n=35), serum TGA, TMA, TRAb all positive before treatment; Group B (n=53) serum TGA, TMA negative but TRAb positive. Results: In Group A, 31.40% (n=11) of all the patients were hypothyroid three years after treatment. The result was much better in Group B, with only 3.8% (n=2) being hypothyroid. The difference was significant. Conclusion: GD patients with positive TGA, TMA were liable to develop hypothyroidism after 131 I treatment. Those patients should be treated with lesser amount of the drug accordingly

  15. The physico-chemical I-131 species in the exhaust air of a boiling water reactor (BWR 5)

    International Nuclear Information System (INIS)

    Deuber, H.

    1984-02-01

    In a German boiling water reactor, the pysico-chemical I-131 species were determined in the plant exhaust and in the individual exhausts during four months. These measurements aimed in particular at determining the percentage and the source of the radiologically decisive elemental I-131 released to the environment. On an average 13% of the I-131 discharged with the plant exhaust consisted of elemental iodine. This was largely released with the exhausts from the reactor building and from the turbine building. The main component was organic-bound I. (orig./HP) [de

  16. Effect of fallout on measurement of 131I around nuclear reactors

    International Nuclear Information System (INIS)

    Paperiello, C.J.; Matuszek, J.M.

    1976-01-01

    In early July 1974, 131 I produced by detonaion of a nuclear device by the People's Republic of China appeared in fallout over New York State. Radioiodine levels in milk were measured using a β-γ coincidence system with a sensitivity of 0.02 pCi/liter. Peak levels of 1.6 pCi/liter of milk in early July tapered off to approx.0.1 pCi/liter by early October. When fresh pasture growth ceased and supplemental feed was provided, radioiodine was no longer detectable. This episode shows that operators of light-water power reactors must analyze background samples collected some distance from the reactor site to meet the present U.S. Nuclear Regulatory Commission analytical requirements for 131 I as expressed in Appendix I to 10CFR50 and Regulatory Guide 1.42

  17. Response of monitors of surface contamination to internal exposition control from 131I in the 'nuclear medicine services'

    International Nuclear Information System (INIS)

    Puerta, Nancy; Rojo, Ana M.; Villella, Adrian; Gossio, Sebastian; Parada, Ines Gomez; Acosta, Norma; Arenas, German

    2013-01-01

    The IAEA, in its publication RS-G-1.2, proposes individual control of workers occupationally exposed with risk of internal exposure when the potential exposure provided by incorporation leads to a value of annual committed effective dose equal to or greater than 1 mSv. Because the radionuclide 131 I is the most important to control internal exposure in Nuclear Medicine Services, it is evaluated if the surface contamination monitors, commonly used in nuclear medicine centers of Argentina, would implement individual control of internal exposure to 131 I. Selected detectors were calibrated with a dummy neck and thyroid with calibrated sources of 131 I and 133 Ba reference. For each detector is was estimated the detection efficiency for 131 I and its detection limit. Each instrument was evaluated for the lowest effective dose possible to detect compromised by individual routine monitoring with different measurement intervals . We analyzed the response of each team for determining conditions that may be effective for the control of internal exposure of 131 I. Finally , we conclude that the daily individual monitoring surface contamination detectors available in the Nuclear Medicine Services is feasible to implement and ensures detection of significant additions of 131 I

  18. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: Clinical Phase I/II trials

    International Nuclear Information System (INIS)

    Chen Zhinan; Mi Li; Xu Jing

    2006-01-01

    Purpose: HAb18G/CD147 is a hepatocellular carcinoma (HCC)-associated antigen. We developed iodine ( 131 I) metuximab injection (Licartin), a novel 131 I-labeled HAb18G/CD147-specific monoclonal antibody F(ab') 2 fragment, and evaluated its safety, pharmacokinetics, and clinical efficacy on HCC in Phase I/II trials. Methods and Materials: In a Phase I trial, 28 patients were randomly assigned to receive the injection in 9.25-, 18.5-, 27.75-, or 37-MBq/kg doses by hepatic artery infusion. In a multicenter Phase II trial, 106 patients received the injection (27.75 MBq/kg) on Day 1 of a 28-day cycle. Response rate and survival rate were the endpoints. Results: No life-threatening toxic effects were found. The safe dosage was 27.75 MBq/kg. The blood clearance fitted a biphasic model, and its half-life was 90.56-63.93 h. In the Phase II trial, the injection was found to be targeted and concentrated to tumor tissues. Of the 73 patients completing two cycles, 6 (8.22%) had a partial response, 14 (19.18%) minor response, and 43 (58.90%) stable disease. The 21-month survival rate was 44.54%. The survival rate of progression-free patients was significantly higher than that of patients with progressive disease after either one or two cycles (p 131 I) metuximab injection is safe and active for HCC patients

  19. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism

    International Nuclear Information System (INIS)

    Safa, A.M.; Schumacher, O.P.; Rodriguez-Antunez, A.

    1975-01-01

    To evaluate the long-term results of 131 I therapy for children, the course of 87 patients (three to 18 years old, 24 boys and 63 girls) treated from 1949 through 1968, for hyperthyroidism due to Graves's disease was studied. Dose of 131 I per patient ranged from 2.9 to 31 mCi (mean +- S. D., 9.75 +- 6.5). Patients were followed for five to 24 years (mean, 12.3 +- 3.5). Hyperthyroidism was controlled in 85 within one to 14 months (mean, 3.3 +- 2.6). Recurrence of thyrotoxicosis due to toxic diffuse goiter, observed in only one case after 11 years, was successfully re-treated with 131 I. Reproductive history and health status of the progeny of 131 I-treated patients were not different from those of the general population. No deaths and no cancer or leukemia were observed in patients or their offspring. The major cause of goiter regrowth was Hashimoto's thyroiditis. Hypothyroidism developed in 35 of 76 patients (46 percent). 131 I deserves further use in treatment of hyperthyroid children with Graves's disease

  20. Aplicaciones clínicas del radioyodo 131 (I131 en las enfermedades del tiroides Clinical applications of radioiodine 131 (I131 in the thyroid diseases

    Directory of Open Access Journals (Sweden)

    Levi González Rivero

    2012-12-01

    Full Text Available El radioyodo 131 es un isótopo radioactivo que se emplea exitosamente en el diagnóstico y tratamiento de las enfermedades benignas y malignas del tiroides. Su propiedad de integrarse selectivamente al metabolismo del tiroides y emitir una señal, le permite describir el funcionamiento glandular mediante estudios de captación, y delimitar la morfología y localización de los tejidos que capten yodo, a través de la gammagrafía. Es además una radioterapia sencilla, segura y coste-efectiva, usada como primera línea terapéutica en el control del hipertiroidismo, cuya dosis y momento de aplicación debería individualizarse según la etiología y la clínica de cada paciente. El radioyodo 131 ofrece una alternativa eficaz para reducir el tamaño del bocio no tóxico; además, respalda el tratamiento quirúrgico del carcinoma diferenciado del tiroides, y destruye a dosis ablativa los restos tisulares y las lesiones metastásicas que puede identificar durante el seguimiento gammagráfico. El empleo de radioyodo 131 está sujeto al cumplimiento de regulaciones de protección contra la radioactividad.Radioiodine 131 is a radioactive isotope that is successfully used for the diagnosis and the treatment of benign and malignant thyroid diseases. Its quality of selectively integrating to the thyroid metabolism and emitting a signal allows it to describe the gland functioning through capture studies, and to delimit the morphology and location of the tissues that capture iodine by means of gammagraphy. It is also a simple, safe and cost-effective radiotherapy used as first-line therapeutics in the control of hyperthyroidism. The dose and right time of application should be individualized according to the etiology and the clinic of each patient. Radioiodine 131 offers an efficient alternative to reduce the size of non-toxic goiter in addition to supporting the surgical treatment of the differentiated thyroid carcinoma and destroying with ablative doses

  1. The clinical summary of 312 cases of differentiated thyroid cancer metastases with 131I treatment

    International Nuclear Information System (INIS)

    Zhu, R.S.; Yongli, Y.L.; Hankui, H.K.

    2002-01-01

    Objective: Three hundred and twelve thyroid carcinoma patients with metastasis treated by the multiple 'high dose' program were followed up for 10 years. The result of 131I adverse effect were accessed. Method 1 Treatment protocol: In case of lung and bone metastasis. 200mCi 131 I was administered each time. For patient with lymphatic metastasis, 150mCi 131 I was given each time. The interval between 2 doses was 4 month. 2 Assessment of results, 131 I scanning of negative 131 I scanning denotes cure. Lesion size decrease, reduction of number of foci or reductions of iodine uptake by the lesion, normal blood Tg indicated effective treatment. Treatment failure shows higher blood Tg, appearance of new lesions with ensuing death. 3 Adverse events - marrow inhibition pulmonary function affected ; parathyroid function affected; salivary glands affected; chromosome aberration. Result 1: of the 312 patients, 112 were cured (35.9%),effective 118 patients (60.2%). Treatment failed in 12 cases(3.8%).2 adverse events bone marrow inhibition. accumulation dose of 131I could produce temporary reversible inhibition of bone marrow, no aplastic anemia was evident. Effect of salivary gland function, reversible changes were seen. Sub maxilla glandular function was least affected. Effect of parathyroid function: PTH showed temporary change, without a single case of hypoparathyroidism. Effect of pulmonary function: no change what so ever without a single case of pulmonary fibrosis. Effect on chromosome: After treatment lymphocytes in peripheral blood showed aberration, in part of the patients radioaction tolerability increased. Conclusion: Multiple high dose therapy with treatment of metastatic thyroid carcinoma is an effective method. Indication can be extended to patients showing pathological lesion on operation. Adverse events was almost negligible percent and treatment was discussed. Good results were obtained no aplastic anemia. hypoparathyroidism, decrease of pulmonary function

  2. {sup 131}I-CRTX internal dosimetry: animal model and human extrapolation

    Energy Technology Data Exchange (ETDEWEB)

    Andrade, Henrique Martins de; Ferreira, Andrea Vidal; Soares, Marcella Araugio; Silveira, Marina Bicalho; Santos, Raquel Gouvea dos [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN-CNEN-MG), Belo Horizonte, MG (Brazil)], e-mail: hma@cdtn.br

    2009-07-01

    Snake venoms molecules have been shown to play a role not only in the survival and proliferation of tumor cells but also in the processes of tumor cell adhesion, migration and angiogenesis. {sup 125}I-Crtx, a radiolabeled version of a peptide derived from Crotalus durissus terrificus snake venom, specifically binds to tumor and triggers apoptotic signalling. At the present work, {sup 125}I-Crtx biokinetic data (evaluated in mice bearing Erlich tumor) were treated by MIRD formalism to perform Internal Dosimetry studies. Doses in several organs of mice were determinate, as well as in implanted tumor, for {sup 131}I-Crtx. Doses results obtained for animal model were extrapolated to humans assuming a similar concentration ratio among various tissues between mouse and human. In the extrapolation, it was used human organ masses from Cristy/Eckerman phantom. Both penetrating and non-penetrating radiation from {sup 131}I in the tissue were considered in dose calculations. (author)

  3. Incidence of hypothyroidism following small doses of 131I in the treatment of Graves' disease

    International Nuclear Information System (INIS)

    McCullagh, F.P.; Jelden, G.L.; Rodriguez-Antunez, A.

    1976-01-01

    In a group of 147 patients treated with 131 I in doses of 3.0 millicuries or less for Graves' disease, the incidence of hypothyroidism was calculated 10 to 17 years after treatment. This paper emphasizes the frequency of hypothyroidism after treatment with 131 I in small doses, if sufficient time lapse is considered

  4. Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease

    International Nuclear Information System (INIS)

    Sridama, V.; McCormick, M.; Kaplan, E.L.; Fauchet, R.; DeGroot, L.J.

    1984-01-01

    We treated 187 patients who had Graves' disease with low-dose radioactive iodide ( 131 I), using a protocol that included a compensation for thyroid size. The incidence of early hypothyroidism (12 per cent) was acceptably low in the first year after 131 I treatment, but we found a cumulative high incidence (up to 76 per cent) at the end of the 11th year. In contrast, the incidence of permanent hypothyroidism was relatively stable in 166 surgically treated patients, increasing from 19 to 27 per cent at the end of 11 years. Among 122 medically treated patients, only 40 per cent entered remission, and hypothyroidism developed in 2 per cent during the same period of follow-up. The long-term incidence of hypothyroidism in our patients treated with low-dose 131 I therapy was much higher than that found in earlier studies using a comparable dose. Our study suggests that it will be difficult to modify therapy with 131 I alone to produce both early control of thyrotoxicosis and a low incidence of hypothyroidism

  5. Evaluation of absorbed dosis during studies of renal function due AI 123I / 131I (Hippuran) and 111 In (DPTA)

    International Nuclear Information System (INIS)

    Arteaga, Marcial V.V.; Diestra, Carlos E.C.; Villanueva, Raul A.S.; Alegria, Roberto R.; Salvatierra, Carlos C.; Rosales, Jorge M.; Gonzalez, Denis A.; Cruz, Carlos A.M.

    2014-01-01

    Using the MIRD methodology and Cristy-Eckerman representation for for adult kidneys, it proves that the dosimetric contributions of bodies of the biokinetics of 123 I / 131 I (Hippuran) and 111 In (DTPA) are significant, in the estimated of dose, during studies of renal function. Dosimetric contributions (whole body and urinary bladder, kidney excluding) are given by 11.90% (for 123 I), 4.97% (for 131 I) and 28.32% (for 111 In). In all cases, the dosimetric contributions are mainly due to photons emitted by the entire body

  6. Dosimetry-guided high-activity 131I therapy in patients with advanced differentiated thyroid carcinoma: initial experience

    International Nuclear Information System (INIS)

    Verburg, Frederik A.; Haenscheid, Heribert; Biko, Johannes; Hategan, Maria C.; Lassmann, Michael; Kreissl, Michael C.; Reiners, Christoph; Luster, Markus

    2010-01-01

    In patients with advanced differentiated thyroid carcinoma (DTC), therapy with the highest safe 131 I activity is desirable to maximize the tumour radiation dose yet avoid severe myelotoxicity. Recently, the European Association of Nuclear Medicine (EANM) published a standard operational procedure (SOP) for pre-therapeutic dosimetry in DTC patients incorporating a safety threshold of a 2 Gy absorbed dose to the blood as a surrogate for the red marrow. We sought to evaluate the safety and effectiveness in everyday tertiary referral centre practice of treating advanced DTC with high 131 I activities chosen primarily based on the results of dosimetry following this SOP. We retrospectively assessed toxicity as well as biochemical and scintigraphic response in our first ten patients receiving such therapy for advanced DTC. The 10 patients received a total of 13 dosimetrically guided treatments with a median administered activity of 14.0 GBq (range: 7.0-21.4 GBq) 131 I. After 6 of 13 treatments in 6 of 10 patients, short-term side effects of 131 I therapy, namely nausea, vomiting or sialadenitis, were observed. Leukocyte and platelet counts dropped significantly in the weeks after 131 I treatment, but returned to pre-treatment levels by 3 months post-therapy. Serum thyroglobulin levels decreased after 12 of 13 treatments (median reduction: 58%) in 9 of 10 patients. In our initial patient cohort, high-activity 131 I therapy for advanced DTC based on pre-therapeutic blood dosimetry following the EANM SOP was safe and well tolerated. Such treatment almost always produced a partial biochemical tumour response. (orig.)

  7. Post-Irradiation Behaviour of I131 in TeO2

    International Nuclear Information System (INIS)

    Jaćimović, Lj.; Stevović, J.; Veljković, S.R.

    1965-01-01

    The system I 131 in TeO 2 is interesting because little is known about thermal chemical changes in this target. Radioiodine was produced by neutron irradiation of TeO 2 in the reactor. Irradiated TeO 2 was dissolved in diluted NaOH. The analysis of the iodine valency forms was made by ion exchange techniques. The thermal and radiation stability of TeO 2 was studied by using the spectrophotometric method for the determination of tellurium. Post-irradiation annealing of I 131 in TeO 2 was studied in dependence on the time and temperature of the heating. The main tendency of annealing was the reduction of radioiodine. The time dependence of this process indicates a fast change at high temperatures. The curves are more complex at lower temperatures. The annealing may appear complex because of the variety of thermal reactions of iodine intermediary. It may react with products of the following processes: tellurium recoil and corresponding hot zone, beta transition of Te 131 and TeO 2 itself. The kinetics of these changes was considered and an estimation of the processes during annealing was made. The influence of the neutron flux on the kinetics of annealing was also studied. (author) [fr

  8. Study on the damage effect of 131I-iodinated oil internal radiation in SMMC-7721 hepatoma model in rat

    International Nuclear Information System (INIS)

    Wu Shuyan; Zhang Xuguang; Wang Xiangying; Li Su'an; Mao Dihua

    2004-01-01

    Objective: To investigate the damage effect of 131 I-iodinated oil internal radiation in hepatoma. Methods: SMMC-7721 rat hepatoma model was used to evaluate the damage of 131 I-iodinated oil internal radiation in carcinoma. 131 I-iodinated oil was injected sector-shapely into tumor model of SMMC-7721 hepatoma with arc-needle, matched with routine straight-needle injection. Tumor damage induced by 131 I-iodinated oil intralesion radiation in the carcinoma models are recorded through survival time, weight of rat, local carcinoma, pathology, electron microscopy. Results: Arc-needle injection 131 I-iodinated oil in SMMC-7721 hepatoma at subcutis could increase rat's survival time, the body weight kept less descent, the lumps necrosed wholly. Pathology and ultrastructure detection revealed cell necrosis and collapse, sever nuclear damage was observed in the death cells. The early characteristics of necrosis such as margination of heterochromatin was also found in some tumor cells. Besides, well differentiated tumor cells, degenerative tumor cells and some lymphocytes were seen. Conclusion: Arc-needle injection 131 I-iodinated oil step-by step sector-shapely into tumor is a better method and necrosis is the major effect of 131 I-iodinated oil internal radiation in carcinoma at the level of treated dosage

  9. 99mTc-HYNIC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma.

    Science.gov (United States)

    Chen, Libo; Li, Fang; Zhuang, Hongming; Jing, Hongli; Du, Yanrong; Zeng, Zhengpei

    2009-03-01

    In this investigation, the efficacy of scintigraphy using (99m)Tc-labeled hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) in the evaluation of extraadrenal pheochromocytoma was assessed and compared with (131)I-labeled metaiodobenzylguanidine (MIBG) imaging. Ninety-seven patients who were suspected of having pheochromocytoma but showed no definite adrenal abnormalities on CT were evaluated by both (99m)Tc-HYNIC-TOC scintigraphy and (131)I-MIBG imaging. The results were compared with pathology findings or clinical follow-up. Of 58 patients proven to be without pheochromocytoma, (99m)Tc-HYNIC-TOC and (131)I-MIBG imaging excluded 56 and 58 patients, respectively, rendering a specificity of 96.6% for (99m)Tc-HYNIC-TOC imaging and 100% for (131)I-MIBG imaging. In the evaluation of adrenal pheochromocytoma (14 patients), the sensitivity of (99m)Tc-HYNIC-TOC scintigraphy and (131)I-MIBG imaging was 50% and 85.7%, respectively. However, in the evaluation of extraadrenal pheochromocytomas (25 patients), the sensitivity of (99m)Tc-HYNIC-TOC scintigraphy and (131)I-MIBG imaging was 96.0% and 72.0%, respectively. (99m)Tc-HYNIC-TOC scintigraphy is more sensitive than (131)I-MIBG imaging in the detection of extraadrenal pheochromocytomas.

  10. Bone metastases of differentiated thyroid cancer: the importance of early diagnosis and {sup 131}I therapy on prognosis

    Energy Technology Data Exchange (ETDEWEB)

    Zanotti-Fregonara, P. [CEA, DSV, I2BM, SHFJ, UMNRC, Orsay (France); Rubello, D. [Santa Maria Misericordia Hosp, Rovigo (Italy); Hindie, E. [Hop StLouis, Paris (France)

    2008-07-01

    Complete text of publication follows: Distant metastases are found at diagnosis or during follow-up in 10%-15% of patients with differentiated thyroid cancer. Bone is the second most commonly involved site. Patients with bone metastases, whether isolated or associated with lung metastases, have a markedly poor prognosis. Ten-year survival rates range from 13% to 21%. Given such poor prognosis, the use of {sup 131}I therapy has been questioned. However, it might well be that poor prognosis of bone metastases can be overcome if {sup 131}I therapy is delivered at an early stage, when tumor burden is small, as previously demonstrated for pulmonary metastases. A review of a large series of patients showed that only rarely were bone metastases diagnosed at an early stage. Among 109 patients with bone metastases reported by Bernier et al., only 4 had both radioiodine uptake and a negative standard radiography examination. Similarly, Durante et al. reported that only 8 of 115 patients had negative radiography findings at presentation. Prognosis may improve if bone metastases are detected earlier. In a recent study, bone metastases were first detected by {sup 131}I scanning in 8 of 16 patients, when complementary radiologic studies were negative. Six of these patients showed an excellent response to {sup 131}I therapy. Today, the nuclear medicine community is well armed for this challenge toward earlier diagnosis. Postsurgery thyroid remnant ablation is more widely used. The {sup 131}I whole body scan associated with thyroid remnant ablation after thyroidectomy has a major role in early diagnosis of functioning distant metastases at a time when complementary imaging techniques (CT, MRI, bone scanning) are often still showing negative findings. Early diagnosis of specific {sup 131}I-avid bone foci will be improved with the advent and generalization of SPECT/CT. When early diagnosis is achieved, repeated {sup 131}I therapy can be effective by targeting not only visible

  11. Summary of current radiation dose estimates to humans from 123I, 124I, 126I, 130I, and 131I as sodium rose bengal

    International Nuclear Information System (INIS)

    Anon.

    1975-01-01

    Estimated absorbed doses to human gall bladder, gastrointestinal tract, liver, ovaries, bone marrow, and testes from 123 I, 124 I, 126 I, 130 I, and 131 I after a single intravenous administration as sodium rose bengal are summarized. The greatest uncertainty in these dose estimates is due to the variability in time for the movement of radioiodine through the biliary tract, gall bladder, and gastrointestinal tract

  12. Brachytherapy Using Elastin-Like Polypeptides with (131)I Inhibit Tumor Growth in Rabbits with VX2 Liver Tumor.

    Science.gov (United States)

    Liu, Xinpei; Shen, Yiming; Zhang, Xuqian; Lin, Rui; Jia, Qiang; Chang, Yixiang; Liu, Wenge; Liu, Wentian

    2016-10-01

    Brachytherapy is a targeted type of radiotherapy utilized in the treatment of cancers. Elastin-like polypeptides are a unique class of genetically engineered peptide polymers that have several attractive properties for brachytherapy. To explore the feasibility and application of brachytherapy for VX2 liver tumor using elastin-like polypeptides with (131)I so as to provide reliable experimental evidence for a new promising treatment of liver cancer. Elastin-like polypeptide as carrier was labeled with (131)I using the iodogen method. Ten eligible rabbits with VX2 liver tumor were randomly divided into the treatment group (n = 5) and control group (n = 5). The treatment group received brachytherapy using elastin-like polypeptide with (131)I, and in the control group, elastin-like polypeptide was injected into the VX2 liver tumor as a control. Periodic biochemical and imaging surveillances were required to assess treatment efficacy. The stability of elastin-like polypeptide with (131)I in vitro was maintained at over 96.8 % for 96 h. Biochemistry and imaging indicated brachytherapy using elastin-like polypeptide with (131)I for liver tumor can improve liver function and inhibit tumor growth (P Elastin-like polypeptide can be an ideal carrier of (131)I and have high labeling efficiency, radiochemical purity and stability. Brachytherapy using elastin-like polypeptide with (131)I for liver tumor is a useful therapy that possesses high antitumor efficacy advantages.

  13. Systemic Endoradiotherapy with Carrier Added 4 [131I] Iodo LPhenylalanine: Clinical Proof of principle in Refractory Glioma

    International Nuclear Information System (INIS)

    Baum, Richard P.; Schuchardt, Christiane; Senftleben, Stephan; Gildehaus, Franz Josef; Samnick, Samuel; Kluge, Andreas; Bronzel, Marcus; Schmidt, Karl

    2011-01-01

    To explore feasibility, tolerability, dosimetry and probable efficacy of intravenous endoradiotherapy with carrier added 4 [ 131I ]iodo Lp henylalanine (c.a. 131I IPA) in refractory high grade glioma. Two male patients (45 and 50 years), with long standing, extensively pretreated gliomas and evidence of progression underwent single intravenous injections of 2 and 4 GBq of c.a. 131I IPA, respectively. Tumor targeting was verified by 131I IPA single photon emission computed tomography (SPECT). Metabolic and morphological changes indicative of tumour response were assessed by sequential [ 18F ] fluoroethyltyrosine ( 18F FET) positron emission tomography (PET) and contrast enhanced magnetic resonance imaging (MRI) following therapy. Further monitoring included clinical state, safety laboratory, quality of life and dosimetry. Absorbed mean organ and whole body doses were determined according to the Medical Internal Radiation Dose (MIRD) scheme using OLINDAEXM based on serial planar scintigraphy. Both patients tolerated the treatment well. No evidence of acute of delayed organ toxicity was observed. 131I IPA accumulated in the tumour recurrences identified by MRI/ 18F FET. In patient 1, PET showed progressively decreasing maximum standardised uptake values (SUVmax) over 10 months, indicating metabolic response, paralleled by reduced contrast enhancement and tumour volume on MRI. Progression occurred 18 months after therapy. Treatment was repeated using 6.6 GBq of 131I IPA, to which no response was observed. Patient 2, followed up for 3 months after therapy, showed stable disease on MRI and PET. Mean absorbed whole body doses ranged from 0.13 to 0.17 mSv/MBq, with the highest absorbed organ doses to kidneys, bladder and heart (0.86-1.23; 0.49-0.6 and 0.45-0.56 mSv/MBq). Systemic endoradiotherapy using up to 6.6 GBq of c.a. 131I IPA is not associated with clinically detectable toxicity. Measurable anti tumour effects in gliomas were observed. 131I IPA warrants further

  14. Guide-line of the radio-iodine (131I) therapy in Graves' disease and thyroid cancer

    International Nuclear Information System (INIS)

    Mori, Yutaka; Ikekubo, Katsuji

    2005-01-01

    Radio-iodine ( 131 I) therapy has been using in Graves' disease and well differentiated thyroid cancer. The rules of control in the discharge from radio-isotope hospital were notified in 1999 in Japan. Guideline of the 131 I therapy in Graves' disease and thyroid cancer were prepared by sub-group of Japanese Society of Nuclear Medicine. (author)

  15. Is it safe to treat hyperthyroid patients with I-131 without fear of thyroid storm?

    International Nuclear Information System (INIS)

    Vijayakumar, V.; Nusynowitz, M.L.; Ali, S.

    2006-01-01

    Thyroid storm is extremely rare. However, hyperthyroid patients with severe thyrotoxicosis are frequently not treated immediately with I-131 for fear of thyroid storm but are placed on thiouracil drugs for varying periods of time. We demonstrate herein that it is safe to treat these patients with I-131, without pretreatment with thiouracil drugs, provided they do not have complicating intercurrent disease. Our definition of severe hyperthyroidism includes marked signs and symptoms of thyrotoxicosis, suppressed thyroid stimulating hormone (TSH), markedly elevated free T4 and/or free T3 and elevated radioactive iodine uptake (RAIU) (>30%) at 4 or 24 hours. Our diagnostic criteria for thyroid storm include two or more findings of fever (>38 deg C, 100 deg F), severe tachycardia, high pulse pressure, agitation with tremors, flushing, sweating, heart failure, nausea, vomiting, diarrhea, jaundice associated with high free T4 and/or free T3. Patients were selected retrospectively for the period between August 2003 and December 2004. One hundred and twenty-two patient visits were identified. These patients were treated with 370-740 MBq (10-20 mCi) of I-131 and were evaluated for any evidence of thyroid storm. Most of the patients were placed on beta blocker drugs at the time of initial I-131 therapy; these were continued for at least two months, when the first follow-up visit occurred. At the time of I-131 therapy, it is our policy to educate the patients to seek immediate medical attention for exacerbation of symptoms of thyrotoxicosis. Not one of these patients developed thyroid storm. A subset of 25% of these cases with higher potential for thyroid storm (RAIU more than 65%, very marked signs and symptoms, and very markedly elevated free T4 and/or free T3) also tolerated the I-131 therapy well with marked clinical improvement and no exacerbation of the thyrotoxic state. It is safe to administer I-131 to patients who are severely hyperthyroid without fear of thyroid

  16. Radiation Dose-rate Reduction Pattern in Well-differentiated Thyroid Cancer Treated with I-131.

    Science.gov (United States)

    Khan, Shahbaz Ahmad; Khan, Muhammad Saqib; Arif, Muhammad; Durr-e-Sabih; Rahim, Muhammad Kashif; Ahmad, Israr

    2015-07-01

    To determine the patterns of dose rate reduction in single and multiple radioiodine (I-131) therapies in cases of well differentiated thyroid cancer patients. Analytical series. Department of Nuclear Medicine and Radiation Physics, Multan Institute of Nuclear Medicine and Radiotherapy (MINAR), Multan, Pakistan, from December 2006 to December 2013. Ninety three patients (167 therapies) with well differentiated thyroid cancer treated with different doses of I-131 as an in-patient were inducted. Fifty four patients were given only single I-131 therapy dose ranging from 70 mCi (2590 MBq) to 150 mCi (5550 MBq). Thirty nine patients were treated with multiple I-131 radioisotope therapy doses ranging from 80 mCi (2960 MBq) to 250 mCi (9250 MBq). T-test was applied on the sample data showed statistically significant difference between the two groups with p-value (p < 0.01) less than 0.05 taken as significant. There were 68 females and 25 males with an age range of 15 to 80 years. Mean age of the patients were 36 years. Among the 93 cases of first time Radio Active Iodine (RAI) therapy, 59 cases (63%) were discharged after 48 hours. Among 39 patients who received RAI therapy second time or more, most were discharged earlier after achieving acceptable discharge dose rate i.e 25 µSv/hour; 2 out of 39 (5%) were discharged after 48 hours. In 58% patients, given single I-131 therapy dose, majority of these were discharged after 48 hours without any major complications. For well differentiated thyroid cancer patients, rapid dose rate reduction is seen in patients receiving second or subsequent radioiodine (RAI) therapy, as compared to first time receiving RAI therapy.

  17. Effects of 40 K on 131 I in vivo monitoring of thyroid

    International Nuclear Information System (INIS)

    Venturini, Luzia; Berti, Eduardo A.R.; Campos, Vicente P.; Rodrigues, Leticia L.C.

    1999-01-01

    This paper investigates how the detection limit for 131 I in vivo monitoring is affected by the 40 K body content. Gamma spectral data of 32 non-contaminated subjects were analyzed. The detection limit is determined for each case and the mean value is compared to the detection limit calculated for the shielded room. The detector used was a 3 x 3 NaI(TI) shielded with 3.2 cm lead and 0.7 cm aluminium. The results show that the interference of 40 K is very important in the determination of the activity of 131 I but it can be disregarded, in the occupational routine measurements, if the record level (Bq) is several times greater than the measured activity. (author)

  18. Krwotok położniczy – zasady współpracy położnika i anestezjologa

    Directory of Open Access Journals (Sweden)

    Elżbieta Nowacka

    2012-04-01

    Full Text Available Krwotok położniczy wciąż jest jedną z najczęstszych przyczyn zgonów ciężarnych irodzących. Prawie 88% kobiet umiera w ciągu pierwszych czterech godzin od momentu jego wystąpienia. Znajomość mechanizmów regulują‑ cych homeostazę ustroju ciężarnej ma ogromne znaczenie w postępowaniu terapeutycznym w przypadku wystą‑ pienia krwotoku okołoporodowego. O tym, jak trudno rozpoznać i zdefiniować krwotok położniczy, dowodzi obecność kilkunastu różnych jego definicji. Z punktu widzenia zmian hemodynamicznych, następstw ogólno‑ ustrojowych i konieczności podjęcia określonych decyzji terapeutycznych bardzo użyteczne wydają się pojęcia oceniające szybkość utraty wokreślonym przedziale czasowym: skumulowana utrata krwi wynosząca 150 ml/min lub 1,5 ml/kg m.c./min oraz utrata 50% objętości krwi krążącej w ciągu 3 godzin. Rokowanie w krwotoku położ‑ niczym zależy od wielu elementów, do których zaliczamy: szybkie rozpoznanie, powiadomienie i wdrożenie algo‑ rytmu postępowania terapeutycznego oraz efektywne działanie interdyscyplinarne różnych zespołów biorących udział w procesie diagnostyczno‑leczniczym. Niezbędna jest jednoczasowa, efektywna współpraca doświadczo‑ nego zespołu anestezjologicznego, ginekologiczno‑położniczego, bloku operacyjnego, zespołów pracowni dia‑ gnostyczno‑laboratoryjnych oraz regionalnego centrum krwiodawstwa. Skoordynowanie pracy dużej liczby ludzi, często „rozrzuconych” w strukturach organizacyjnych szpitala na różnych piętrach lub w oddzielnych budyn‑ kach, jest niezmiernie trudne. Opracowanie algorytmu postępowania uwzględniającego kolejność i sposób powiadamiania oraz wdrażanie określonych procedur w poszczególnych jednostkach organizacyjnych decydu‑ ją o przeżyciu pacjentki i późniejszej jakości życia. Większość czynności w ciężkim krwotoku położniczym (resu‑ scytacja, monitorowanie, opanowywanie

  19. Dose {sup 131}I radioactivity interfere with thyroglobulin measurement in patients undergoing radioactive iodine therapy with recombinant human TSH?

    Energy Technology Data Exchange (ETDEWEB)

    Park, So Hyun; Bang, Ji In; Lee, Ho Young; Kim, Sang Eun [Dept. of Nuclear Medicine, Seoul National University College of Medicine, Seoul (Korea, Republic of)

    2015-06-15

    Recombinant human thyroid-stimulating hormone (rhTSH) is widely used in radioactive iodine therapy (RIT) to avoid side effects caused by hypothyroidism during the therapy. Owing to RIT with rhTSH, serum thyroglobulin (Tg) is measured with high 131I concentrations. It is of concern that the relatively high energy of 131I could interfere with Tg measurement using the immunoradiometric assay (IRMA). We investigated the effect of 131I administration on Tg measurement with IRMA after RIT. A total of 67 patients with thyroid cancer were analysed retrospectively. All patients had undergone rhTSH stimulation for RIT. The patients’ sera were sampled 2 days after 131I administration and divided into two portions: for Tg measurements on days 2 and 32 after 131I administration. The count per minute (CPM) of whole serum (200 μl) was also measured at each time point. Student’s paired t-test and Pearson’s correlation analyses were performed for statistical analysis. Serum Tg levels were significantly concordant between days 2 and 32, irrespective of the serum CPM. Subgroup analysis was performed by classification based on the 131I dose. No difference was noted between the results of the two groups. IRMA using 125I did not show interference from 131I in the serum of patients stimulated by rhTSH.

  20. Improvement of the obtention process of {sup 131} I of ININ through studies of equipment design and process parameters fitting in the simulator; Perfeccionamiento del proceso de obtencion del {sup 131} I del ININ mediante estudios de diseno del equipo y ajustes de parametros del proceso en el simulador

    Energy Technology Data Exchange (ETDEWEB)

    Zepeda M, M C

    2006-07-01

    The main objective of the work was to achieve a high yield of the reaction that happens among the vapors of {sup 131} I and the NaOH to obtain sodium iodide (Na{sup 131} I) in solution optimizing the contact time of the molecules in gaseous state of {sup 131} I with the NaOH molecules through the bubbling velocity of the {sup 131} I in the solution of NaOH 0.1 N, as well as the operation temperature during the distillation process by dry via starting from tellurium dioxide (TeO{sub 2}) with the purpose of that the {sup 131} I that is obtained in the form of Na{sup 131} I solution presents the necessary quality that allows to distribute it in the market. The particular objectives were: a) To improve the distillation equipment used for the obtaining of {sup 131} I starting from irradiated tellurium dioxide redrawing the dilution system with the purpose of recovering the {sup 131} I in a minimum volume of sodium hydroxide (NaOH). b) To achieve a bigger time of contact among the molecules of {sup 131} I in gaseous state with the molecules of NaOH in solution through the bubbling velocity and of the redrawing of the dilution system. c) To implement the production of {sup 131} I by dry distillation via starting from tellurium dioxide, obtaining it with a high radionuclide and radiochemical purity. d) To obtain {sup 131} I with the necessary specifications that it marks the pharmacopoeia and it can be used with medical ends. (Author)

  1. The behavior of {sup 131}I in polymetatelluric acid irradiated in the nuclear reactor

    Energy Technology Data Exchange (ETDEWEB)

    Teofilovski, C [Institute of Nuclear Sciences Boris Kidric, Hot Laboratory Department, Vinca, Beograd (Serbia and Montenegro)

    1966-01-15

    Polymetarelluric acid, whose composition is (H{sub 2}TeO{sub 4}){sub n}, is successfully used at the Institute as a target for obtaining {sup 131}I in the reactor. It is prepared by hearing orthotelluric acid in air at 160 deg C of in a steam of water vapor at 208 deg C. Analysis of the valency states of {sup 131}I in irradiated (H{sub 2}TeO{sub 4}){sub n} prepared in either of the above ways shows a variable ratio of reduced and oxidized forms. A considerable increase of the reduced forms with increasing integral thermal neutron flux during irradiation in the reactor in the given interval has also been observed. In order to explain the above phenomenon (H{sub 2}TeO{sub 4}){sub n} was irradiated in the reactor under different conditions, with measurement of the wall temperature of the quartz ampoules containing the target material. Yields of reduced and oxidized form of {sup 131}I were determined immediately after irradiation and after annealing of the target at temperatures from 60 deg C to 150 deg C. A considerable decrease in the yield of the reduced forms of {sup 131}I on target annealing above 100 deg C was observed (author)

  2. /sup 131/I studies in pulmonary tuberculosis

    Energy Technology Data Exchange (ETDEWEB)

    Yedurappa, K G [K.M. Coll., Hubli (India)

    1975-02-01

    The increased I/sup 131/ uptake in the untreated tuberculous patients is probably due to the complex changes in the entire body metabolic processes as a result of tuberculous infection but not due to thyroid function disorder. Prolonged administration of isoniazid and PAS may depress thyroid hormones production with or without signs of goiter or hypothyroidism when these drugs are commonly used in the treatment of tuberculosis. The blocking effect of INAH and PAS might be in the iodine binding capacity rather than iodide concentrating mechanism.

  3. Pharmacokinetics of gene recombined angiogenesis inhibitor Kringle 5 in vivo using 131I specific markers and SPECT/CT

    Directory of Open Access Journals (Sweden)

    Ge Yan

    2016-10-01

    Full Text Available The previous pharmacokinetic methods can be only limited to drug analysis in vitro, which provide less information on the distribution and metabolismof drugs, and limit the interpretation and assessment of pharmacokinetics, the determination of metabolic principles, and evaluation of treatment effect. The objective of the study was to investigate the pharmacokinetic characteristics of gene recombination angiogenesis inhibitor Kringle 5 in vivo. The SPECT/CT and specific 131I-Kringle 5 marked by Iodogen method were both applied to explore the pharmacokinetic characteristics of 131I-Kringle 5 in vivo, and to investigate the dynamic distributions of 131I-Kringle 5 in target organs. Labeling recombinant angiogenesis inhibitor Kringle 5 using 131I with longer half-life and imaging in vivo using SPECT instead of PET, could overcome the limitations of previous methods. When the doses of 131I-Kringle 5 were 10.0, 7.5 and 5.0 g/kg, respectively, the two-compartment open models can be determined within all the metabolic process in vivo. There were no significant differences in t1/2α, t1/2β, apparent volume of distribution and CL between those three levels. The ratio of AUC(0~∞ among three different groups of 10.0, 7.5 and 5.0 g/kg was 2.56:1.44:1.0, which was close to the ratio (2:1.5:1.0. It could be clear that in the range of 5.0–10.0 g/kg, Kringle 5 was characterized by the first-order pharmacokinetics. Approximately 30 min after 131I-Kringle 5 was injected, 131I-Kringle 5 could be observed to concentrate in the heart, kidneys, liver and other organs by means of planar imaging and tomography. After 1 h of being injected, more radionuclide retained in the bladder, but not in intestinal. It could be concluded that 131I-Kringle 5 is mainly excreted through the kidneys. About 2 h after the injection of 131I-Kringle 5, the radionuclide in the heart, kidneys, liver and other organs was gradually reduced, while more radionuclide was concentrated

  4. Feasibility of a novel positive feedback effect of 131I-promoted Bac-Egr1-hNIS expression in malignant glioma via baculovirus

    International Nuclear Information System (INIS)

    Guo Rui; Tian Lipeng; Han Bing; Xu Haoping; Zhang Miao; Li Biao

    2011-01-01

    Purpose: As intracellular iodine is released rapidly, increased expression of sodium/iodide symporter (NIS) is required for effective radioiodine treatment of tumor. As Egr1 promoter is activated by 131 I and may promote human NIS (hNIS) expression, hNIS also induces 131 I uptake and activates Egr1, so the existence of a positive feedback effect of 131 I-promoted Egr1-hNIS expression is possible. Our purpose was to investigate the possible existence of this positive feedback effect through a series of in vitro pioneer studies. Method: Recombinant baculovirus (Bac-Egr1-hNIS) encoding the hNIS gene under the control of a radiation-inducible Egrl promoter was constructed. To test 131 I-promoted hNIS expression, human malignant glioma U87 cells were transfected with Bac-Egr1-hNIS, stimulated with or without 131 I; the expression of hNIS protein was detected by immunofluorescence and flow cytometry test. In addition, the uptake and efflux of 131 I were determined after the incubation of Bac-Egr1-hNIS-transfected U87 cells with or without 131 I. Results: Immunocytochemical staining and flow cytometry test showed a higher hNIS protein expression in Bac-Egr1-hNIS-transfected U87 cells with 131 I stimulation than in cells without stimulation. Bac-Egr1-hNIS-transfected U87 cells accumulated up to about 4.05 times of 131 I after 131 I stimulation. The amount of 131 I uptake in both groups showed a baculovirus dose-dependent manner. However, rapid efflux of radioactivity was observed in both groups, with 50% lost during the first 2 min after the 131 I-containing medium had been replaced by a nonradioactive medium. Conclusion: Our results indicated that an improved transgene expression of 131 I-stimulated hNIS in U87 cells using a baculovirus vector containing the Egr1 promoter is possible, and the increased expression of hNIS is responsible for a higher 131 I uptake. It might provide a reference for the existence of a positive feedback effect in 131 I-promoted Bac-Egr1-h

  5. Effect of excitation energy and angular momentum on the characteristics of 208Po and 210Po compound nucleus fission fragments

    International Nuclear Information System (INIS)

    Itkis, M.G.; Kalpakchieva, R.; Okolovich, V.N.; Penionzhkevich, Yu.Eh.; Tolstikov, V.N.

    1982-01-01

    To study characteristics of fissioning nucleus fragments, investigated were reactiiiiiiiiiiiiiiiH8Pt+ 12 C → 210 Po in the 12 C ion energy range of 86-110.5 MeV, of 192 Os+ 16 O → 208 Po in 90-131 MeV range, 204 Pb+ 3 He → 207 Po, 206 Pb+ 3 He → 209 Po, 207 Pb+ 3 He → 210 Po with 60 MeV 3 He ion energy. Using a correlation technique for measuring energies of two fragments mass and energy distributions of fission fragments of 208 Po and 210 Po compound nuclei produced in the reactions have been studied. Mass and energy distributions of fragments from fission of 208 Po and 210 Po in the reactions with ions 16 O, 12 C and 3 He were investigated in an ample energy range, using the correlational techniques for measurement of energies of two fragments. An increase in the total kinetic energy with rise of the angular momentum was observed, the fact indicating a weak coupling of one-particle and collective modes of motion in the fissile nucleus resulting in that the rolational energy is transfered mainly to translation energies of the fragments

  6. Testicular impact of the treatment with I-131 in patients with differentiated thyroid carcinoma

    International Nuclear Information System (INIS)

    Chebel, G.; Gutierrez, S.; Fadel, A.; Suarez, S.; Levalle, O.

    2007-01-01

    Young patients carriers differentiated thyroid carcinoma (DTC) are treated with high doses of I-131 for much of his life with very good prognosis and projects with paternity. However, there is scarce information on the effect of radioiodine on the male gonad and their future fertility. This therapy may compromise on a temporary and / or definitively the role of the germinal cells. The testicular irradiation depends on the blood flow, the dose of I-131 administered and of the presence or absence of metastasis pelvic near to the gonads. A single dose of 100 mCi of I-131 throws an absorbed dose at gonadal level of 50-150 cGy. It has been reported that absorbed doses of 50 cGy can produce transitory decrease spermatogenesis and higher doses can also affect the function of the Leydig cells [es

  7. Changes of the serum IL-18 and TRAb in patients with Graves' disease after 131I treatment within one year

    International Nuclear Information System (INIS)

    Li Fangdu; Wei Zhongjia; Xu Ling; Yuan Jimin

    2007-01-01

    To investigate immunological function change in Graves' disease (GD) patients with hypothyroidism within one year after 131 I treatment, and evaluate the relationship between the 131 I treatment and autoimmune thyroid disease. Serum levels of IL-18, TRAb and TPOAb in 41 patients with GD were determined by EIA, IRMA and CLIA, thyroid weight (TDW) were measured by B ultrasonic instrument. The patients were divided into two groups based on whether appear the early hypothyroidism after 131 I treatment during 6-12 months graded as: the hypothyroidism group in 13 and the recovery group in 28; 25 healthy people as control group. Results showed that the serum levels of IL-18 and TRAb in hypothyroidism group and recovery group were significantly increased before 131 I treatment compared with control group (P 3 , FT 4 , sTSH, TDW and 131 I dosage were not significant differences (P>0.05). The serum levels of IL-18 in two groups were decreased (P 131 I treatment (P 3 , FT 4 , TDW(r=0.372 P 131 I therapy and 6/13 after therapy, and in the recovery group were 10/28 before therapy and 12/28 after therapy. These data suggest that radiation has a little influence on GD patients for adjusting immune system during 6-12 months after 131 I treatment. The changes of serum IL-18 and combine with serum TRAb and TPOAb might be valuable implication for assessing the effect and prognosis of 131 I treatment in patients with GD hyperthyroidism. (authors)

  8. Radiation exposure to nuclear medicine technologists from administering I-131 therapy dosages

    International Nuclear Information System (INIS)

    Chaudakshetrin, P.; Pusuwan, P.; Sritongkul, N.; Tuntawiroon, M.

    2007-01-01

    Full text: Therapeutic doses of I-131 for treatment of thyroid cancer are administered orally in liquid or capsule form. During the last few years, a total number of patients loaded in our isolation ward increased from 4 to 10 patients per week. When considering radiation safety precautions for attending technologists, it is preferable to use the dose in capsules. The purpose of this study is to compare radiation exposure to nuclear medicine technologists from administering I-131 therapy dosages in capsules and in liquid form in a closed system. Materials and Methods: Three year radiation exposure to technologists during I-131 administration was analyzed. From January 2004 to June 2005 dose administration was in liquid form (n=263) and from July 2005 to February 2007 in capsules (n=541). Radiation dose assessment was performed with an electronic personal dosimeter (PDM 112). The dose rate in μSv and time spent per patient were recorded. Results: Dose received per patient when I-131 was given in a liquid was 3.50 ± 1.67 μSv and 1.17 ± 0.66 μSv when given in capsules. Compared with the use of a liquid, capsules significantly reduced radiation dose to technologists by 66% (P < 0.001). These doses received depended not only on the administered activity but also on the time, distance and shielding. Time spent per patient, including a brief visit before the time of dosing to explain the procedure and answer questions was reduced slightly from 4.4 ± 2.2 to 3.7 ± 1.8 minutes (P < 0.01). These correspond to a reduction in a yearly dose to 1 technologist by 40%, from 0.63 mSv to 0.38 mSv from dosing to 175 and 325 patients respectively. Conclusions: The measured doses clearly showed that handling of I-131 therapy dosages either in a liquid form or capsules are not the major contributors to the technologist's radiation exposure in routine clinical practice. However, one has to be cautious and follow good work practice to avoid risk of radiation exposure and radioiodine

  9. Study of ablation efficiency of 3600 MBq of I-131 in the treatment of thyroid carcinoma

    International Nuclear Information System (INIS)

    Takavar, A.; Eftekhari, M.; Fard-Esfahani, A.; Beiki, D.

    2005-01-01

    Full text: The basic question of threshold for the ablation of thyroid remnant after surgery remains unanswered. However, radioiodine therapy is still being used as a standard method of treatment. In present investigation treatment responses of 100 patients with thyroid cancer treated with 3600 MBq of 131 I is studied. Response to treatment of 100 patients (33 males and 67 females) was evaluated by serum TSH, Tg levels and areas of thyroid remnant as measured by whole body scan with 131 I performed 6 months after therapy. Treatment response was evident by decreased or lack of 131 I uptake in the thyroid bed and Tg 5 ng/ml. Remnant area was decreased about 74.5% in females and 75.5% in males. No significant difference between sex groups was observed. Because of radiation protection concerns and socioeconomic reasons, lower ablations doses of 131 I ( 1110 MBq) might be as effective, and should be evaluated. (author)

  10. 131I-19-iodocholesterol scintigraphy and suprarenal pathology

    International Nuclear Information System (INIS)

    Leger, F.A.; Baulieu, J.L.; Plouin, P.F.

    The methods used and results obtained by 131 I-19-iodocholesterol scintigraphy (dose 2mCi) are given for 24 patients with various kinds of suprarenal hyperactivity (primary hyperaldosteronism, Cushing's syndrome, malignant adrenocortical tumour, pheochromocytoma). The morphological and quantitative aspects of suprarenal scintigraphy are examined. A technique to determine the iodocholesterol uptake ratio of the two adrenal glands, considered more important than the fixation rate of each is described [fr

  11. The radioprotection problem in 131I-chTNT cancer therapy

    International Nuclear Information System (INIS)

    Chen Yangchun; Cheng Shaoliang; Gu Yucan; Shao Zhenghua; Li Beilei; Shi Hongchen

    2004-01-01

    Aim: Use of a mouse-human chimeric Tumor-Necrosis-Therapy (chTNT) monoclonal antibody has been considered for cancer therapy based on its potential for the radioimmunotherapy of many solid tumors. By estimating the total effective dose equivalent (EDE) to any other individual from exposure to the patient who containing 131 I-chTNT, we tried to determine when the patient could be released. Method: All urine samples were collected over the 168 h period infusion of 131 I-chTNT. The weight and radioactivity of urine collected at each micturition were determined specific activity was calculated, Anterior and posterior whole body imaging was performed at 0.5, 24, 48, 72, 120, 168 h after injection. We followed U.S. Nuclear Regulatory Commission, 1997, Regulatory Guide 8.39 to calculate the EDE to the public, assuming patients being released 7 days after infusion and the exposure time to patients' household members being 0.33 day, and to doctor or nurse being 0.08 or 0.33 day. Result: And as much as (33±9% of the administrated radioactivity was excreted in the urine within 168 h after administration. Its per cent injection dose time curve followed a one-exponential model, and its mean appearance half time value was (3.8±0.4) h. The whole body clearance of 131 I-chTNT also followed a one-exponential model, and its mean disappearance half time value was (4.1±0.4) h. The EDE was (0.18±0.01)μSv/MBq (when exposure time was 0.08 day) or (0.42±0.02)μSv/MBq (when exposure time was 0.33 day) for doctor or nurse, and (0.18±0.02)μSv/MBq for any other individual. When any patient accumulated containing 11100 MBq, the highest dose she or he can infuse, whose household members' EDE may be 2 mSv. And the doctor or nurse who use 131 I-chTNT for cancer therapy (exposure time is 0.08 day) is safety when the accumulated dose under 111000 MBq (3Ci). Conclusion: If we follow this cancer therapy plan, the EDE to the public per year will lower than the national standard. It is safety

  12. Evaluation of irradiation in patient's environment receiving 131I therapy

    International Nuclear Information System (INIS)

    Husar, J.; Fueriova, A.; Borovicova, F.

    1998-01-01

    This article describes measurements made in the bed station of Clinic of Nuclear Medicine in St. Elizabeth Oncological Institute in Bratislava. There are treated thyroid cancer and thyrotoxicosis with the use of 131 I. The aim of the measurements was to determine the possibility of the ambulation treatment of thyrotoxicosis or the possibility of shortening of the patient;s stay in the bed station that the effective dose would not be exceeded suggestions according to the publication of EURATOM. The measurements were made also with thyroid cancer patients but owing to clinical reasons the ambulation treating in this case is not permissible. Therefore this article does not describe the results of these measurements.The effective dose rates were measured in 0.25 m; 0.5 m; 1 m and 2 m distances from the patient's thyroid so the effective dose in the patient's surroundings could be determined. To the present time the results of effective dose rates measurements for 17 patients were evaluated by described way. The age of the patients was from 41 to 82 years, the administered quantity of 131 I was from 259 to 481 MBq, in fractions 37 MBq, 74 MBq, or 111 MBq. The calculated effective half-life of 131 I excretion from the patients body is crucial for the length of patient's necessary staying in the bed station, were from 4.2 days to 8 days. This great extend of values is given by by the different clinical parameters of the treated patients. After the analyse of them can be said that the effective half-life increases, when the patient is elder, has greater mass of thyroid and the accumulation is higher. At the present time authors don't suggest using the ambulation treatment of thyrotoxicosis by 131 I. For discharging the patient from the hospital authors suggest to think criteria according to the model of behaviour D with the effective dose limit 0.5 mSv. For the households with children up to 2 years and/or pregnant women according to the model B with effective dose limit 0

  13. Heterometallic cerium(IV) perrhenate, permanganate, and molybdate complexes supported by the imidodiphosphinate ligand [N(i-Pr2PO)2]-.

    Science.gov (United States)

    Wang, Guo-Cang; Sung, Herman H Y; Dai, Feng-Rong; Chiu, Wai-Hang; Wong, Wai-Yeung; Williams, Ian D; Leung, Wa-Hung

    2013-03-04

    Heterometallic cerium(IV) perrhenate, permanganate, and molybdate complexes containing the imidodiphosphinate ligand [N(i-Pr2PO)2](-) have been synthesized, and their reactivity was investigated. Treatment of Ce[N(i-Pr2PO)2]3Cl (1) with AgMO4 (M = Re, Mn) afforded Ce[N(i-Pr2PO)2]3(ReO4) (2) or Ce2[N(i-Pr2PO)2]6(MnO4)2 (3). In the solid state, 3 is composed of a [Ce2{N(i-Pr2PO)2}6(MnO4)](+) moiety featuring a weak Ce-OMn interaction [Ce-OMn distance = 2.528(8) Å] and a noncoordinating MnO4(-) counteranion. While 3 is stable in the solid state and acetonitrile solution, it decomposes readily in other organic solvents, such as CH2Cl2. 3 can oxidize ethylbenzene to acetophenone at room temperature. Treatment of 1 with AgBF4, followed by reaction with [n-Bu4N]2[MoO4], afforded [Ce{N(i-Pr2PO)2}3]2(μ-MoO4) (4). Reaction of trans-Ce[N(i-Pr2PO)2]2(NO3)2 (5), which was prepared from (NH4)2Ce(NO3)6 and K[N(i-Pr2PO)2], with 2 equiv of [n-Bu4N][Cp*MoO3] yielded trans-Ce[N(i-Pr2PO)2]2(Cp*MoO3)2 (6). 4 can catalyze the oxidation of methyl phenyl sulfide with tert-butyl hydroperoxide with high selectivity. The crystal structures of complexes 3-6 have been determined.

  14. Distribution of 131 I- labeled Bothrops erythromelas venom in mice

    International Nuclear Information System (INIS)

    Vasconcelos, C.M.L.; Valenca, R.C.; Araujo, E.A.; Modesto, J.C.A.; Pontes, M.M.; Guarnieri, M.C.; Brazil, T.K.

    1998-01-01

    Bothrops erythromelas is responsible for many snake bites in northeastern Brazil. In the present study we determined the in vivo distribution of the venom following its subcutaneous injection into mice. B. erythromelas venom and albumin were labeled individually with 131 I by the chloramine T method, and separated in a Sephacryl S-200 column. The efficiency of labeling was 68%.Male Swiss mice (40-45 g), which had been provided with drinking water containing 0.05% KI over a period of 10 days prior to the experiment, were inoculated dorsally (sc) with 0.3 ml (2.35 x 10 5 cpm/mouse) of 131 I-venom (N = 42), 131 -albumin or 131 I (controls, N = 28 each). Thirty minutes and 1,3, 6, 12, 18 and 24 h after inoculation, the animals were perfused with 0.85% Na Cl and skin and various organs were collected in order to determine radioactivity content. There was a high rate of venom absorption int he skin (51%) within the first 30 min compared to albumin (20.1%) and free iodine (8.2%). Up to the third hour after injection there was a tendency for venom and albumin to concentrate in the stomach ( 3 rd h),small intestine (3 rd h) and large intestine (6th h). Both control groups had more radioactivity in the digestive tract, especially in the stomach, but these levels decreased essentially to baseline by 12-18 h postinjection. In the kidneys, the distribution profiles of venom, albumin and iodine were similar. Counts at 30 min postinjection were low in all three groups (1.37, 1.86 and 0.77, respectively), and diminished to essentially 0% by 12-18 h. Albumin tended to concentrate in muscle until the 3 rd h postinjection (1.98%).There was a low binding of labeled venom in the liver (B. erythromelas venom does not specifically target most internal organs. That is, the systemic effects of envenomation ar mainly due to an indirect action. (author)

  15. 131I-SPGP internal dosimetry: animal model and human extrapolation

    International Nuclear Information System (INIS)

    Andrade, Henrique Martins de; Ferreira, Andrea Vidal; Soprani, Juliana; Santos, Raquel Gouvea dos; Figueiredo, Suely Gomes de

    2009-01-01

    Scorpaena plumieri is commonly called moreia-ati or manganga and is the most venomous and one of the most abundant fish species of the Brazilian coast. Soprani 2006, demonstrated that SPGP - an isolated protein from S. plumieri fish- possess high antitumoral activity against malignant tumours and can be a source of template molecules for the development (design) of antitumoral drugs. In the present work, Soprani's 125 ISPGP biokinetic data were treated by MIRD formalism to perform Internal Dosimetry studies. Absorbed doses due to the 131 I-SPGP uptake were determinate in several organs of mice, as well as in the implanted tumor. Doses obtained for animal model were extrapolated to humans assuming a similar ratio for various mouse and human tissues. For the extrapolation, it was used human organ masses from Cristy/Eckerman phantom. Both penetrating and non-penetrating radiation from 131 I were considered. (author)

  16. Thiamazole Pretreatment Lowers the (131)I Activity Needed to Cure Hyperthyroidism in Patients With Nodular Goiter.

    Science.gov (United States)

    Kyrilli, Aglaia; Tang, Bich-Ngoc-Thanh; Huyge, Valérie; Blocklet, Didier; Goldman, Serge; Corvilain, Bernard; Moreno-Reyes, Rodrigo

    2015-06-01

    Relatively low radioiodine uptake (RAIU) represents a common obstacle for radioiodine ((131)I) therapy in patients with multinodular goiter complicated by hyperthyroidism. To evaluate whether thiamazole (MTZ) pretreatment can increase (131)I therapeutic efficacy. Twenty-two patients with multinodular goiter, subclinical hyperthyroidism, and RAIU effective option than LID.

  17. Improvement of the obtention process of 131 I of ININ through studies of equipment design and process parameters fitting in the simulator

    International Nuclear Information System (INIS)

    Zepeda M, M.C.

    2006-01-01

    The main objective of the work was to achieve a high yield of the reaction that happens among the vapors of 131 I and the NaOH to obtain sodium iodide (Na 131 I) in solution optimizing the contact time of the molecules in gaseous state of 131 I with the NaOH molecules through the bubbling velocity of the 131 I in the solution of NaOH 0.1 N, as well as the operation temperature during the distillation process by dry via starting from tellurium dioxide (TeO 2 ) with the purpose of that the 131 I that is obtained in the form of Na 131 I solution presents the necessary quality that allows to distribute it in the market. The particular objectives were: a) To improve the distillation equipment used for the obtaining of 131 I starting from irradiated tellurium dioxide redrawing the dilution system with the purpose of recovering the 131 I in a minimum volume of sodium hydroxide (NaOH). b) To achieve a bigger time of contact among the molecules of 131 I in gaseous state with the molecules of NaOH in solution through the bubbling velocity and of the redrawing of the dilution system. c) To implement the production of 131 I by dry distillation via starting from tellurium dioxide, obtaining it with a high radionuclide and radiochemical purity. d) To obtain 131 I with the necessary specifications that it marks the pharmacopoeia and it can be used with medical ends. (Author)

  18. Conductivity and Structure of Superionic Composite (AgI0.6(NaPO30.4

    Directory of Open Access Journals (Sweden)

    E. Kartini

    2005-01-01

    Full Text Available Superionic conductors are of considerable interest from both application and fundamental points of view. Superionic solid electrolytes can be used for batteries, fuel cells and sensors. We have used melt quenching to make a new superionic composite (AgI0.6(NaPO30.4 which exhibits an ionic conductivity of about 2 x 10-4 S/cm at ambient temperature. The conductivity of crystalline AgI and NaPO3 glass are lower of orders of magnitude. (AgI0.6(NaPO30.4 is a composite material containing both crystalline and glass phases. The paper presents the conductivity as a function of temperature measured by impedance spectroscopy and the crystal structure performed by a high resolution powder diffractometer, VEGA at the Neutron Science Laboratory (KENS, KEK, Japan.

  19. Cu(I) assisted radioiodination of hippuran with no carrier added 131I

    International Nuclear Information System (INIS)

    Al-Kolaly, M.T.; El-Bayoumy, S.; Raieh, M.; El-Mothy, A.

    1993-01-01

    A study on the labeling of hippuran with no-carrier-added 131 I assisted by Cu(I) and excess of ascorbic acids is described. The role of ascorbic acid is to prevent the oxidation of Cu(I) to Cu(II) which activates the hydrolysis of o-iodohippuric acid to o-iodobenzoic acid. The use of Cu(I) allows an almost quantitative (97-99%) labeling yield to be obtained within 10-15 minutes at 100 deg C. The reaction is assumed to take place via the formation of an organocopper complex favoring the exchange reaction between radioiodine and inactive iodine in the hippuran molecule. The activation energy of the reaction was calculated to be E = 12.2 kcal/mol. (author) 21 refs.; 8 figs

  20. Investigation of efficient 131I production from natural uranium at Tehran research reactor

    International Nuclear Information System (INIS)

    Khalafi, H.; Nazari, K.; Ghannadi-Maragheh, M.

    2005-01-01

    Iodine-131, which has a half-life of 8.05 days, is the one of the most widely used radionuclides in medical diagnosis and treats some diseases of thyroid gland. Optimization of 131 I production in Tehran research reactor (TRR) was studied by two different methods. Primarily, standard nuclear codes such as ORIGEN, WIMS and CITATION were applied and then analytical solutions technique was followed. Calculated results and experimental works in the bench scale indicate that, by irradiation of 100 g natural Uranium (UO 2 ) for 100 h at 3.5 x 10 13 (n's/cm 2 s) thermal neutron flux in the TRR, one can produce about 5 Ci of 131 I for medical purposes, on the other hand can produce very useful radionuclides like 99 Mo and 133 Xe in one batch irradiation in the unique production line

  1. Translocation of {sup 3}H-DNA, {sup 131}I-ribonuclease and {sup 3}H-DNA {sup 131}I-ribonuclease complexes in germinated barley grains; Translocation des ADN{sup 3}H, RNase{sup 131}I et complexes ADN{sup 3}H - RNase {sup 131}I dans les orges en germination

    Energy Technology Data Exchange (ETDEWEB)

    Tshitenge, G. [Centre nucléaire TRICO, Kinshasa (Congo, The Democratic Republic of the); Ledoux, L. [Centre d’étude de l' énergie nucléaire Mol (Belgium)

    1970-01-15

    Barley grains, after germinating for 11 hours in the presence of water, were cut into sections at the end opposite the embryo. They were incubated in solutions of {sup 3}H-DNA, {sup 13I}I-ribonuclease, and {sup 3}H-DNA {sup 131}I-ribonuclease complex for three hours. They were then placed in a water-saturated atmosphere for 24 hours. At this stage the different organs of the seedlings were separated and homogenized in a solution containing 0.15M sodium chloride and 0.1 M sodium ethylenediaminetetraacetate at pH 7. By measuring the radioactivity found in the homogenates one can estimate the penetration of the macromolecules under study. The results show that the quantity found varies from one case to the other and depends both on the nature of the macromolecule and of the organ studied. (author) [French] Des orges qui ont germé pendant 11 h en présence d’eau sont sectionnées au bout opposé à l’embryon. Elles sont incubées avec des solutions d’ADN{sup 3}H, de RNase{sup 131}1 et de complexe ADN{sup 3}H - RNase {sup 131}I, pendant 3 h. Elles sont ensuite placées dans une atmosphère saturée d'eau pendant 24 h. A ce moment, les différents organes des plantules sont séparés et homogénéisés en présence d'une solution 0,15M en NaCl et 0,1M en éthylènediamine-tétracétate de Na à pH 7. La mesure de la radioactivité retrouvée dans les homogénats permet d'évaluer la pénétration des macromolécules considérées. Les résultats montrent que la quantité retrouvée varie d'un cas â l'autre et dépend à la fois de la nature de la macromolécule et de l'organe considéré. (author)

  2. The role of mammary gland on 131-I uptake by neonatal of wistar mice

    International Nuclear Information System (INIS)

    Darussalam, M.; Soedjono, I.; Ilyas, R.

    1988-01-01

    The aim of this investigation was to know the role of mammary gland of Wistar mice in transfering Iodine (I) to neonatal that fit in the role of I itself, and the degree of neonate need to I. Twenty four albino Wistar mouse post natal, were divided into 4 groups of six mouse for each, based on the interval observation. Each mice was given per oral 0.25 ml Na131-I with the activity of 300 uCi. The observation were pointed to tissues and organs such as: blood, liver, kidney, digestion cannal, tiroid gland, lymphe, mammary gland and urine; where as for neonatal: blood, kidney, digestion cannal, and the tiroid gland. The resuls show thet the high 131-I repentions were bound on tiroid gland (between 5.72 and 21.76 %) and on mammary gland (batween 9.30 and 21.90 %) of Wistar mice at lactation period in line with the increasing of mammary gland function and increasing the need of iodine for neonatal. In uptake of 131-I the thyroid gland of neonatal seemed superior compared to tissue or other neonatal organs. (author). 5 refs, 2 figs, 4 tabs

  3. Control system of liquid effluents generated in treatment with I-131; Sistema de control de efluentes liquidos generados en el tratamiento con I-131

    Energy Technology Data Exchange (ETDEWEB)

    Garcia M, T.; Ruiz C, M. A.; Angeles C, A.; Ramirez S, R., E-mail: teodoro.garcia@inin.gob.mx [ININ, Carretera Mexico-Toluca s/n, 52750 Ocoyoacac, Estado de Mexico (Mexico)

    2015-09-15

    In recent years, nuclear medicine has developed greatly in our country and around the world. Techniques for both medical diagnosis and therapy have increased the use of radiopharmaceuticals, notably the I-131. In Mexico there are around 150 nuclear medicine establishments authorized by the Comision Nacional de Seguridad Nuclear y Salvaguardias. Most of these establishments do not have an appropriate facility for the treatment of radioactive liquid effluents, to ensure compliance with the concentration limits established in the regulations. The Instituto Nacional de Investigaciones Nucleares (ININ) developed and implemented successfully, a control system of radioactive effluents (named SACEL) from a nuclear medicine facility. This system ensures an effective compliance with regulations and also better management and control of these radioactive effluents. Calculations and design of SACEL were made with respect to I-131, because is one of the most commonly used in radiotherapy and medical diagnostics, besides its half-life is greater in relation to other radionuclides. SACEL is comprised of four storage tanks and decay and a fifth tank for measuring the concentration of I-131 and later discharge to the drain; these tanks are connected to an automated system that controls the effluents passage. The calculation to determine the volume of the tanks was carried out according to the demand that has the hospital, to the maximum activity being poured in effluents and time required to decay. In this paper the design and installation of SACEL system, in addition to functioning as a facility that enables the Hospital meet the required standards is presented. Dose calculations performed with MCNPX and the methodology used in the calibration of the detection system is also presented. (Author)

  4. Comparative study of low dose 131I treatment in patients with Graves' disease

    International Nuclear Information System (INIS)

    Qin Lan; Shan Menglin; Wang Junqi

    2005-01-01

    Objective: To investigate the low dose 131 I therapy for Graves' disease we compared the results of 277 patients in our department with the report of Howarth D et al. Methods: 277 patients were classified as 45 Gy group and 77 Gy group according to the dose level. The results of these two groups were compared separately with results of 60 Gy group and 90 Gy group reported by Howarth D et al. Results: The euthyroidism rate and hypothyroidism rate among these four groups had no significant statistical difference after 6 months of 131 I therapy, but there were high significant statistical difference between our study and Howarth D research about euthyroidism rate and hypothyroidism rate 24 months later. Conclusion: The low dose 131 i management refered by Howarth D et al was an effective method for Graves' disease which could reduce or delay the incidence of hypothyroidism. Our study show that subsection on the foundation of this low dose procedure could further reduce the incidence of hypothyroidism and improve the euthyroidism rate. (authors)

  5. Case of hyperthyroidism complicated with diabetic ketoacidosis following /sup 131/I therapy

    Energy Technology Data Exchange (ETDEWEB)

    Itoh, Mitsuyasu; Funauchi, Masanori; Fukuma, Naobumi; Abe, Yohsuke; Hirooka, Yoshibumi; Nihei, Noriyuki (Hamamatsu Univ. Shizuoka (Japan). School of Medicine)

    1982-10-01

    The coexistence of diabetes mellitus and hyperthyroidism has long been known and, in a few cases, diabetic acidosis complicated with thyroid storm has been reported. We describe a case who developed thyroid storm and diabetic ketoacidosis following /sup 131/I therapy for severe hyperthyroidism. A 50-yr-old man was diagnosed as having hyperthyroidism complicated with diabetes mellitus at the age of 47. After he had been unsuccessfully treated with methimazole and oral hypoglycemic agents, radioactive iodine was administered twice. However, no remarkable effect was observed. After a third treatment with /sup 131/I, the patient showed symptoms like thyroid storm and diabetic ketoacidosis. He was hospitalized on October 3, 1980. Adm of insulin and supportive therapy including correction of dehydration alleviated his symptoms after admission. Administration of methimazole normalized his thyroid function. A 75 g GTT and tolbutamide i.v. test revealed impaired secretion of endogenous insulin. The patient had a high level of serum T/sub 3/ and T/sub 4/ following /sup 131/I therapy, indicating that the released hormone caused a transient condition like thyroid storm, which led to deterioration of glucose metabolism as indicated in high levels of hemoglobin A1c. Diabetic acidosis is the precipitating factor for thyroid storm. Prompt treatment for diabetic ketoacidosis, therefore, might prevent the complications of life-threatening thyroid storm.

  6. A case of hyperthyroidism complicated with diabetic ketoacidosis following 131I therapy

    International Nuclear Information System (INIS)

    Itoh, Mitsuyasu; Funauchi, Masanori; Fukuma, Naobumi; Abe, Yohsuke; Hirooka, Yoshibumi; Nihei, Noriyuki

    1982-01-01

    The coexistence of diabetes mellitus and hyperthyroidism has long been known and, in a few cases, diabetic acidosis complicated with thyroid storm has been reported. We describe a case who developed thyroid storm and diabetic ketoacidosis following 131 I therapy for severe hyperthyroidism. A 50-yr-old man was diagnosed as having hyperthyroidism complicated with diabetes mellitus at the age of 47. After he had been unsuccessfully treated with methimazole and oral hypoglycemic agents, radioactive iodine was administered twice. However, no remarkable effect was observed. After a third treatment with 131 I, the patient showed symptoms like thyroid storm and diabetic ketoacidosis. He was hospitalized on October 3, 1980. Administration of insulin and supportive therapy including correction of dehydration alleviated his symptoms after admission. Administration inistration of methimazole normalized his thyroid function. A 75 g GTT and tolbutamide i.v. test revealed impaired secretion of endogenous insulin. The patient had a high level of serum T 3 and T 4 following 131 I therapy, indicating that the released hormone caused a transient condition like thyroid storm, which led to deterioration of glucose metabolism as indicated in high levels of hemoglobin A1c. Diabetic acidosis is the precipitating factor for thyroid storm. Prompt treatment for diabetic ketoacidosis, therefore, might prevent the complications of life-threatening thyroid storm. (author)

  7. The analogy research study on gamma radiation dose rate of radioisotopes 131Ba and 131I

    International Nuclear Information System (INIS)

    Hu Youhua; Feng Guangwen

    2013-01-01

    Analogy is a inference method ,according some properties of a class of things to inferring the similar things should also have the similar properties. The analogy of same radionuclides is widely used in radioisotope logging environment impact assessment so far. This paper is to provide fFor future providing a theoretical calculation method and analogy method between different radionuclides in radioisotope logging environment impact assessment. In this paper, using the latest decay scheme, through theoretical modeling, the aim is the the establishment of 131 Ba and 131 I radioisotopes gamma radiation dose rate calculation method, and try to carry out analogy research on gamma radiation dose rate of different radioisotopes with the same activity. The results show that the analogy of different radionuclides is feasible, which provides the new method reference for carrying out such radiation environmental impact assessment in future. (authors)

  8. Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of 131I-MIBG

    International Nuclear Information System (INIS)

    Ezziddin, Samer; Sabet, Amir; Ko, Yon-Dschun; Xun, Sunny; Matthies, Alexander; Biersack, Hans-Jürgen

    2012-01-01

    131 I-MIBG therapy for neuroendocrine tumours may be dose limited. The common range of applied cumulative activities is 10-40 GBq. We report the uneventful cumulative administration of 111 GBq (= 3 Ci) 131 I-MIBG in a patient with metastatic paraganglioma. Ten courses of 131 I-MIBG therapy were given within six years, accomplishing symptomatic, hormonal and tumour responses with no serious adverse effects. Chemotherapy with cisplatin/vinblastine/dacarbazine was the final treatment modality with temporary control of disease, but eventually the patient died of progression. The observed cumulative activity of 131 I-MIBG represents the highest value reported to our knowledge, and even though 12.6 GBq of 90 Y-DOTATOC were added intermediately, no associated relevant bone marrow, hepatic or other toxicity were observed. In an individual attempt to palliate metastatic disease high cumulative activity alone should not preclude the patient from repeat treatment

  9. Development of a recovery method of {sup 131}I in the {sup 99}Mo process through the fission of 235{sup U}; Desenvolvimento de metodo de recuperacao de {sup 131}I no processo de producao de 99{sup M}o pela fissao de 2{sup 35}U

    Energy Technology Data Exchange (ETDEWEB)

    Bignardi, Aline Moraes Teixeira

    2013-07-01

    {sup 13}1{sup I} is an iodine radioisotope widely used in nuclear medicine that can be used either for diagnostic or for treatment due to its physical decay by {beta}{sup -} and its high emission of y-rays. It is produced at IPEN using the indirect reaction: {sup 130}Te(n,y){sup 131m}Te {yields} {sup 131}Te {yields} {sup 131}I where TeO{sub 2} targets are irradiated in a Nuclear Reactor. There is also the possibility of producing {sup 131}I by the fission of {sup 235}U, where about 300 different elements are produced together with {sup 131}I. The {sup 131}I produced through this method presents high specific activity and radioactive concentration suitable for the labeling of molecules. The aim of this work was to develop a recovery method of {sup 131}I with the required quality to be used in Nuclear Medicine in the {sup 99}Mo production process through the route of acid dissolution of metallic {sup 235}U targets. {sup 131}I can appear in two phases of the process, both in the gaseous phase produced during the dissolution of metallic U targets and in the dissolution solution. This work studied the recovery of {sup 131}I in these two phases. Several materials were used for the capture and recovery of {sup 131}I at the two phases of the process, the gaseous one and the solution of dissolution of U targets. Columns of alumina with Cu, acid alumina with Cu, Ag microspheres, Cu microspheres, Ag nanospheres, anionic cartridges, Ag cartridges, anion exchange resin and activated charcoal columns were tested. Solutions containing {sup 131}I in 0.1 mol.L{sup -1} NaOH were percolated through the materials and the eluted solutions were analyzed in a dose calibrator. The precipitation of AgI was also studied wth further dissolution of this precipitate with 0.1 mol L{sup -1} NH{sub 4}OH and 5% Na{sub 2}S{sub 2}O{sub 3}. The recovery results varied according to the material, activated charcoal showed recovery yields between 42% and 83% but the recovery yield of the alumina column

  10. The biodistribution and effect on hepatic parenchyma with intraarterial injected I-131 lipiodol into hepatic artery

    International Nuclear Information System (INIS)

    Kim, Dong Ik; Suh, Jung Ho; Yoo, Hyung Sik; Lee, Jong Tae; Kim, Ki Whang; Park, Chan Il; Kim, Byung Ro

    1989-01-01

    Iodized oil has been used as a contrast agent in lymphangiography. One of the commercially available compounds is Lipidol Ultra-fluid(LUF) which contains 38% iodine by weight. Nakakuma et al(1979) reported that LUF was selectively retained in the hypervascular hepatocellular carcinoma when injected directly into the ligated hepatic artery. Since that time, it has been widely utilized in the detection as well as the therapeutic attempts of hepatocellular carcinoma, where it has been mixed with chemotherapeutic agents or labeled with radioactive I-131. Like all significant advances, the mechanism of lipid retention within the hepatocellular carcinoma is not clearly understood, and also there is a lack of information about the biodistribution and kinetics of I-131 Lipiodol. The apparent safety of this technique require confirmation. The present study was aimed to assess the biodistribution and kinetics of intraarterially injected I-131 Lipiodol and the histologic changes in canine livers. It was also to verify the safety of this technique in clinical applications. Radioactive iodized oil was obtained by simple exchange method . 518 ± 19 MBq(14 mCi, about 1 mCi/kg body weight) of I-131 Lipiodol was injected intraarterially in 12 dogs as a experimental group. Serial count rates over the livers under gamma camera were measured, and then it was compared with quantitative analysis of radioactivities distributed in liver, lung, spleen, kidney, thyroid, bile and circulating blood using dose calibrator after sacrifice at various time intervals. Cumulative radiation doses were calculated by Quimby method. The effect of I-131 lipiodol on hepatic function were analysed by serial liver function tests after intrahepatic injection of I-131 Lipiodol and compared with preinjection values. Liver tissue obtained after sacrifice were stained with hematoxylin-eosin, Oil red-O, and also election microscopic examinations were performed. The results were summarized as follows; 1

  11. Production of 131I gelatin capsules

    International Nuclear Information System (INIS)

    Freud, A.; Hirshfeld, N.; Canfi, A.; Melamud, Y.

    1997-01-01

    Radioiodine ( 131 I) hard-gelatin capsules are widely used for the diagnosis and treatment of various thyroid disorders. Until 1980 radioiodine was supplied by us as a liquid dosage. This proved to be a rather inconvenient form since it resulted in inaccurate dosing by the physicians and caused frequent contamination of the patients and the hospital personnel. In an attempt to overcome these problems we have designed and constructed a production facility for capsules in which 1311 is packaged. Because of the extreme precautions necessary in handling radioactive compounds, encapsulation of radioactive materials requires specifically designed production techniques, special instrumentation and unique quality control procedures that are not encountered in the standard capsule production processes in the pharmaceutical industry

  12. Response of monitors of surface contamination to internal exposition control from {sup 131}I in the 'nuclear medicine services'; Respuesta de monitores de contaminacion superficial para el control de la exposicion interna a {sup 131}I en servicios de medicina nuclear

    Energy Technology Data Exchange (ETDEWEB)

    Puerta, Nancy; Rojo, Ana M.; Villella, Adrian; Gossio, Sebastian; Parada, Ines Gomez, E-mail: info@arn.gov.br [Autoridad Regulatoria Nuclear (ARN), Buenos Aires (Argentina); Acosta, Norma; Arenas, German, E-mail: nacosta@fuesmen.edu.ar [Fundacion Escuela de Medina Nuclear (FUESMEN), Mendoza (Argentina)

    2013-11-01

    The IAEA, in its publication RS-G-1.2, proposes individual control of workers occupationally exposed with risk of internal exposure when the potential exposure provided by incorporation leads to a value of annual committed effective dose equal to or greater than 1 mSv. Because the radionuclide {sup 131}I is the most important to control internal exposure in Nuclear Medicine Services, it is evaluated if the surface contamination monitors, commonly used in nuclear medicine centers of Argentina, would implement individual control of internal exposure to {sup 131}I. Selected detectors were calibrated with a dummy neck and thyroid with calibrated sources of {sup 131}I and {sup 133}Ba reference. For each detector is was estimated the detection efficiency for {sup 131}I and its detection limit. Each instrument was evaluated for the lowest effective dose possible to detect compromised by individual routine monitoring with different measurement intervals . We analyzed the response of each team for determining conditions that may be effective for the control of internal exposure of {sup 131}I. Finally , we conclude that the daily individual monitoring surface contamination detectors available in the Nuclear Medicine Services is feasible to implement and ensures detection of significant additions of {sup 131}I.

  13. Relationship between the serum TGA, TMA positiveness and development of hypothyroidism after 131I therapy in patients with Graves' disease

    International Nuclear Information System (INIS)

    Zhao Hui; Xu Xiaohong; Yu Hui

    2007-01-01

    Objective: To study the likelihood of development of hypothyroidism after 131 I therapy in patients with Graves' disease as related to the serum positiveness of TGA and TMA before treatment. Methods: Altogether, 176 patients with Graves' disease were treated with 131 I and followed for 3 years of these patients, serum TGA and TMA were positive in 70 and were negative in 106. Results: In the 70 patients with positive TGA and TMA, development of hypothyroidism after 131 I treatment occurred in 22 subjects three years later (31.4%). However, only 4 of the 106 patients with negative TGA and TMA developed hypothyroidism 3 years after 131 I therapy (3.8%). Difference in the incidence of hypothyroidism was significant (P 131 I be administered to patients with Graves' disease and positive serum TGA, TMA. (authors)

  14. Genetically significant dose and sex ratio of the offsprings of patient treated with 131I for hyperthyroidism

    International Nuclear Information System (INIS)

    Takeshita, Akihisa

    1975-01-01

    The gonadal doses following the 131 I treatment of 6 male and 14 female patients with hyperthyroidism were calculated by the method of MIRD, measuring daily radioactivity in the thyroid gland and circulating blood. The testicular dose was 0.52 +- 0.256 rads and the ovarian dose was 0.632 +- 0.488 rads per mCi. In 1965, the genetically significant dose from 131 I treatment of 925 patients with hyperthyroidism was estimated to be 0.0136 mrads/person/year. The genetically significant dose would amount to 0.0613 mrads/person/year, assuming that the total amount of 131 I supplied for treatment in 1965 was administered to treat the hyperthyroid patients with an age-and sex distribution similar to that of the above mentioned group of patients. Sex ratios of the offspring of male and female patients treated with 131 I from 1953 to 1966 were compared with those of offspring born to male and female patients before the treatment. The proportion of males was higher among the offspring of male patients after 131 I treatment than among the offspring of the controls, but the difference was not statistically significant. The sex ratio of the offspring of female patients was not different from that of controls. The mean age of the parents at the times of their children's birth after 131 I treatment was 2.6 - 6.0 year older in male patients and 2.8 - 2.9 year older in female patients than that of controls. (J.P.N.)

  15. Autoradiographic localization of 131I-labelled thyroxine in the tissues of rat

    International Nuclear Information System (INIS)

    Prakash, P.; Romack, F.E.

    1977-01-01

    An attempt was made to visualize the sites of localization of 131 I-labelled thyroxine in the tissues of the rat by autoradiographic dipping techniques. The maximal uptake of 131 I-thyroxine in rats occured at 12 hours in all the tissues examined. The radioactivity continued to decrease from 12 to 36 hours after the injection. In the liver and kidney, the decline after 12 hours was rather marked. The radioactivity decreased only slightly from 12 to 36 hours in the spleen. After 3 hours of injection, the radioactivity was consistently higher in the thyroid follicular epithelial cells than in the interfollicular connective tissue. A high concentration of radioactivity was found at the periphery of the colloid areas. (author)

  16. Characterization of an in vivo thyroid 131I monitoring system using an imaging plate

    International Nuclear Information System (INIS)

    Hirota, Masahiro; Saze, Takuya; Nishizawa, Kunihide

    2004-01-01

    The effects of neck diameter, thyroid volume, and prethyroid tissue thickness on a count-activity conversion coefficient and the detection limit of a thyroid 131 I monitoring system with an imaging plate (IP) were estimated by using an anthropomorphic thyroid-neck phantom. The conversion coefficient and detection limit of the IP system was approximately constant for normal Japanese adults regardless of their neck diameters, thyroid volumes, and prethyroid tissue thicknesses. The IP system is a new option for thyroid 131 I monitoring

  17. Follow-up studies on children and adolescents with Graves' disease after 131I treatment

    International Nuclear Information System (INIS)

    Chen Danyun; Chen Tanghua

    2006-01-01

    Objective: To observe relative long-term radioactive therapy effects, clinical follow-up after 131 I treatment was conducted in children and adolescent patients with Graves' disease (GD). Methods: In 161 GD patients, aged from 8 to 17 years, m I was given at a dosage of 1.85 to 3.70 MBq per gram of thyroid tissue and a maximum dose ranging from 74 to 1221 MBq per patient. The patients were then followed up for 24 to 104 months [averagely (62±22) months]. Results: After 131 I treatment, ninety-eight (60.87%) patients were found to be euthyroid. Nine (5.59%) patients remained hyperthyroid and another three (1.86%) had recurrence of hyperthyroidism. Thirty-seven (22.98%) patients turned to be hypothyroid. Fourteen patients lost in follow-up. During the follow-up period, no thyroid cancer or genetic abnormalities were ever found in the group of patients, neither in their offsprings. Conclusion: 131 I may well be considered as an effective and safe method for treating children and adolescents with GD. . (authors)

  18. Simultaneous /sup 99m/Tc-p-butyl-IDA and 131I-rose bengal scintigraphy in neonatal jaundice

    International Nuclear Information System (INIS)

    Collier, B.D.; Treves, S.; Davis, M.A.; Heyman, S.; Subramanian, G.; McAfee, J.G.

    1980-01-01

    Eight neonates with jaundice were studied simultaneously with /sup 99m/Tc-p-butyl-IDA and 131 I-rose bengal. Due to physical decay, /sup 99m/Tc-p-butyl-IDA failed to demonstrate delayed excretion through the patent extrahepatic biliary tract in 3 of 5 patients with concomitant hepatitis; 131 I-rose bengal showed small-bowel activity in all 5. Neither agent demonstrated small-bowel activity in 3 neonates with extrahepatic biliary atresia. Based on this clinical trial, 131 I-rose bengal remains the radiopharmaceutical of choice for distinguishing between hepatitis and biliary atresia in these patients

  19. A five-year follow-up of two different 131I treatment methods for Graves' disease and the factors affecting the outcome

    International Nuclear Information System (INIS)

    Yoshimoto, Midori; Iino, Shiro; Yoshimura, Hiroshi; Ishikawa, Naofumi; Momotani, Naoko; Hamada, Noboru; Ito, Kunihiko.

    1994-01-01

    We employed two different methods of 131 I treatment for Graves' disease in 285 patients and compared the results between the two. (We also analyzed the factors affecting the treatment outcome.) A single dose of 131 I adjusted to the patients' thyroid weight was administered to 180 patients in group 1, while a relatively lower dose of 131 I (approximately 30 Gy) was given repeatedly to 105 patients in group 2. A 5-year follow-up showed that in group 1, 34% of the patients were euthyroid, 11% hypothyroid, 11% subclinical hypothyroid and 44% still remained hyperthyroid. In group 2, 43% of the patients were euthyroid, 5% hypothyroid, 35% subclinical hypothyroid and 17% hyperthyroid. The factors affecting the outcome of the treatment in group 1 patients were their thyroid weight, the duration of the disease and TRAb levels. No significant correlation was observed between the efficacy of 131 I treatment and the patients' sex, age, 24 hr 131 I-uptake, effective half life of administered 131 I or titers of antithyorid antibodies. We conclude that the repeated low dose administration of 131 I provides the best outcome in a 5-year follow-up. However, we suggest that an adjusted dose of 131 I in relation to the patients' thyroid weight should be employed to obtain a faster therapeutic response. (author)

  20. The physico-chemical 131I species in the stack exhaust air of a boiling water reactor

    International Nuclear Information System (INIS)

    Deuber, H.

    1982-07-01

    In the stack exhaust air of a German boiling water reactor, the fractions of elemental, particulate and organic 131 I were determined over a period of three years. The average fraction of elemental 131 I, which is decisive for the ingestion dose, was about 20% during the first two years and about 50% during the third year. (orig.) [de

  1. Software for dosimetry hypothyroid patients treated with I131 pick up and using probe gamma camera; Software para la dosimetria de pacientes hipertiroideos tratados con 131I utilizando sonda de captacion y gammacamara

    Energy Technology Data Exchange (ETDEWEB)

    Jimenez Felstrom, D.; Luis simon, J.; Reyes Garcia, R.; Derecho Torres, P.; Herrador Cordoba, M.

    2015-07-01

    In this communication the process recently implemented in our hospital for pre and post treatment of patients treated with I-131 in benign diseases of the thyroid gland internal dosimetry is described. We have developed a proprietary software that facilitates the process of dosimetry. Through scans Planar or pictures Spect be determines the mass of the gland thyroid. In function of the mass, is calculated by Monte Carlo the media power absorbed by disintegration of the I-131 in said gland endocrine. (Author)

  2. Distribution in pregnant mice of radioactivity after injection of 131I, and immunosuppressive effect by the whole body irradiation

    International Nuclear Information System (INIS)

    Sushida, Kiyo; Nakano, Hisao

    1978-01-01

    For the purpose of decreasing resistance to leprous bacilli, 100 μCi of 131 I was injected subcutaneously to 2-3 week pregnant, dd-strain mice. Internal distribution of 131 I was followed up by measuring radioactivity in each organ of parent mice (I-P) and fetal mice (I-F). 300 rad in all of 60 Co was irradiated to 2-3 week pregnant mice (R-P) in two directions from the dorsal side of the abdomen. Immunosuppressive effect of the irradiation was evaluated in the parent mice and their offsprings (R-F) and compared with that in the 131 I-treated mice using a skin graft method. It was shown that 131 I of parent mice stayed in the uterus and was transmitted to their fetus through the placenta, and clarified that 131 I which remained in parent mice was continually supplied to their infant mice through milk still after birth. These findings seem to explaine the result that I-F which had been affected continually by 131 I had higher sensitivity to leprous bacilli than I-P. Immunosuppressive effect on a skin graft disclosed that the chief mechanisms of 131 I are to decrease the function of the reticulo-endothelial system by iodine and to suppress cellular immunity by its radioactivity. The rejecting time for the mouse skin homograft in the untreated mouse was 8.8 days on the average, and the lymph node weight was 33 mg. The order of the duration in the graft survival was R-P>I-F>I-P>R-F> normal mice, while that of lymph node weights was completely inverse. Therefore, the immunosuppressive effect on I-P and I-F mice, when it is compared with normal mice, could be confirmed, and the I-F was said to be favorable further than to I-P when based on this immunity test by transplantation. (Ueda, J.)

  3. Diagnostic evaluation of the adrenal scanning using 131I-adosterol

    International Nuclear Information System (INIS)

    Sugawara, Seiya; Nakamura, Mamoru; Sawai, Yoshikazu; Fukuchi, Soitsu.

    1978-01-01

    We have performed adrenal scanning in the 30 patients with suspected adrenal disorders eight days after the intravenous administration of about 500 μCi of 131 I-adosterol (NCL-6- 131 I), using 5 inch crystal rectilinear scintiscanner. Successful image of the adrenals was obtained in all the patients. In the 30 patients, 27 were proved to have adrenal disorders by surgical and hormonal findings. In 13 patients with primary aldosteronism, the side of adrenal adenoma was diagnosed correctly in all the cases by adrenal scanning. We could detected a small aldosterone-producing adenoma which measured 11 x 8 x 6 mm in size. In two patients with idiopathic hyperaldosteronism, asymmetrical radio-uptake between the two adrenals was seen on the standard scanning, and it was difficult to differentiate between tumor or hyperplasia. Dexamethazone-modified suppression scanning was very effective in lateralizing adenomas in the patients with primary aldosteronism. Two patients with Cushing's syndrome due to adrenal hyperplasia showed prominent and almost equal radioactivity of both the adrenal glands. Adrenal adenomas in 8 patients with Cushing's syndrome were definitely visualized on adrenal scanning, with no uptake in the contralateral sides. In one patient with Cushing's syndrome due to an adrenal carcinoma, adrenal scanning showed significant activity in the area of the carcinoma, and no uptake on the opposite side. In one patient with adrenogenital syndrome due to a virilizing adenoma with focal malignancy, adrenal scanning showed high radioactivity in the region of the tumor, and moderate activity on the opposite side. Also in the case of adrenal carcinoma, we appreciated diagnostic value of the adrenal scanning utilizing 131 I-adosterol. (author)

  4. Diabetes-induced increases in 131I-albumin permeation are unaffected by essential fatty acid depletion

    International Nuclear Information System (INIS)

    Williamson, J.R.; Lefkowith, J.B.; Chang, K.; Tilton, R.G.

    1990-01-01

    The authors assessed effects of essential fatty acid deficiency (EFAD) on regional 131 I-albumin permeation in diabetic and age-matched control rats. Male, Sprague-Dawley rats (50-75 g) were randomized into EFAD diet or normal diet groups. Three months later, diabetes was induced in one half of the rats in each group by injecting i.v. 35-45 mg/kg b.w. streptozotocin. One month later, 131 I-albumin clearance (μ g plasma/g tissue/minute) was assessed as described previously (Circ Res 64;890, 1989). Within controls, EFAD decreased body weight gain 28% but did not affect control values for plasma glucose (118±8 (SD) mg/dl) or glycosylated hemoglobin (1.33±0.22 % of total hemoglobin). In normal diet and EFAD diabetics, plasma glucose (535±64 and 419±161, respectively) and glycosylated hemoglobin (4.38±0.97 and 2.97±1.69) were increased significantly versus controls. Diabetes increased 131 I-albumin clearance in retinal (5.1x controls), choroid (3.4x), anterior uvea (2.7x), aorta (3.5x), and sciatic nerve (2.2x). No differences were evident in tissue 131 I-albumin clearances between both control groups or both diabetic groups. These results suggest that essential fatty acids do not modulate diabetes-induced changes in endothelial cell barrier function

  5. Effect of large doses of 131I-19-iodocholesterol on metapyralone-induced adrenal cortical hyperplasia in dogs

    International Nuclear Information System (INIS)

    Anderson, B.G.; Beierwaltes, W.H.; Nishiyama, R.H.; Ice, R.D.

    1975-01-01

    The potential use of 131 I-19-iodocholesterol to treat ACTH excess Cushing's disease was evaluated in the dog. Three normal female dogs were given LD 50 radiation doses of 131 I-19-iodocholesterol without producing gross or histopathologically demonstrable change of the adrenals at autopsy 3 months later. The adrenal cortices of three dogs were made hyperplastic (to simulate the adrenal cortex in Cushing's disease) with ACTH and three with Metapyralone. In addition these six dogs were given LD 50 doses of 131 I-19-iodocholesterol. Three months after treatment, the adrenal glands of the ACTH-treated dogs were not enlarged, the cortex was thicker than normal, and there were no changes attributable to irradiation. At 3 months, the Metapyralone-treated dogs had enlarged adrenals, widening of the adrenal cortex, and no necrosis or other changes attributable to irradiation. It is concluded that a therapeutic trial of 131 I-19-iodocholesterol in the treatment of Cushing's disease is not indicated. (auth)

  6. Evaluation of absorbed dosis during studies of renal function due AI {sup 123}I / {sup 131}I (Hippuran) and {sup 111} In (DPTA); Evaluacion de la dosis absorbida durante estudios de la funcion renal debido AI I{sup 123} / I{sup 131} (Hippuran) E In{sup 111} (DPTA)

    Energy Technology Data Exchange (ETDEWEB)

    Arteaga, Marcial V.V.; Diestra, Carlos E.C.; Villanueva, Raul A.S.; Alegria, Roberto R.; Salvatierra, Carlos C.; Rosales, Jorge M.; Gonzalez, Denis A.; Cruz, Carlos A.M., E-mail: marvva@hotmail.com [Universidad Nacional de Trujillo (UNT), Trujillo (Peru). Fisica Medica; Rios, Edulfo E.D., E-mail: ediaz@ufrgs.br [Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS (Brazil)

    2014-07-01

    Using the MIRD methodology and Cristy-Eckerman representation for for adult kidneys, it proves that the dosimetric contributions of bodies of the biokinetics of {sup 123} I / {sup 131}I (Hippuran) and {sup 111}In (DTPA) are significant, in the estimated of dose, during studies of renal function. Dosimetric contributions (whole body and urinary bladder, kidney excluding) are given by 11.90% (for {sup 123}I), 4.97% (for {sup 131}I) and 28.32% (for {sup 111} In). In all cases, the dosimetric contributions are mainly due to photons emitted by the entire body.

  7. The change of serum TRAb and its prognosis assess to graves disease with one-off successful 131I therapy

    International Nuclear Information System (INIS)

    Ma Yubo; Liu Ping'an; Gu Aichun; Yan Weili; Yuan Jimin

    2008-01-01

    To investigate dynamic change of serum receptor and antibody of thyrotrophic anti- body (TRAb) and its prognosis value after a one-off successful therapy on Graves disease with 131 I, 257 Graves disease patients were treated with one dose of 131 I therapy. 175 of them with average age of 40 (43 male and 132 female patients) were cured. The 131 I activity given to patients was 207.2±66. 6 MBq. The serum levels of TRAb were determined once every three months before and after 131 I therapy. The results showed that the serum TRAb levels in all patients were positive before 131 I therapy. The serum TRAb levels in 60. 6% of patients were raised once, and then reduced to normal, The serum levels of TRAb in 16.0% of patients were remained high or reduce slowly, and the clinical symptom was improved slowly, but these patients didn't recrudesce. The TRAb levels in 9.7% of patients decreased continually, their prognosis was well. The TRAb levels in 13.7% of patients were raised twice after the therapy, and appear hypothyroidism. The detection of dynamic changes of serum TRAb levels in Graves disease patients may be useful in assessing prognosis after 131 I therapy. (authors)

  8. Equipment and obtention process of 131I by dry distillation starting from TeO2

    International Nuclear Information System (INIS)

    Alanis M, J.

    2000-08-01

    The present invention refers to an equipment and process for the obtaining of 131 I by dry distillation starting from TeO 2 that has three interconnected systems, the manipulation system, the electric system and the distillation system, the combination of these systems, allows to improve the yield and the separation of the 131 I during the distillation process, since inside the electric system it is an oven that has a special design based on a temperature gradient. The more relevant aspects of the equipment its are the design of each one of its components that give as result the effectiveness of the production of 131 I in routinary form (industrial) whose final product can end up reaching a radiochemical purity up to 99% and a radionuclide purity of approximately 100%. The object of this invention is to provide a distillation equipment different to those that at the moment exist, thanks to its novel internal construction whose main characteristics already gather advantages on those existent. The reaction of obtaining of the TeO 2 , the development of the technique and studies of TeO 2 sintering and the irradiation experiments, its contributed to characterize with more precision the 'new process of obtaining of 131 I by dry via starting from the Te' developed in the ININ, and in this way it was achieved a more pure product, more economic, with less risks, from a point of view of Radiological Safety and mainly that it avoids the import to the country and it makes to self-sufficient Mexico in the production of 131 I. (Author)

  9. Efficiency of radioiodine therapy with a fix dose of I-131 in toxic thyroid adenoma

    International Nuclear Information System (INIS)

    Petrovski, Z

    2004-01-01

    Purpose: The aim of this study was to estimate the results obtained using a fix dose of I-131 in the treatment of the solitary toxic thyroid adenoma. Material and Methods: We have performed radioiodine therapy m 64 patients, 49 female (50+ 1 7 yrs) and 15 male (43+-15 yrs) with solitary toxic thyroid adenoma. 45 patients received fix dose I-131 of 850 MBq, while 19 patients were treated with calculated (MBq/gr) dose 555-1100 MBq Previously 39(64%) patients were clinically hyperthyreotic and received thyreostatic meditication which were interruptecf one week before the administration of I-131. Those patients who were euthyreotic, TSH was suppressed(<0.25 MU/m1). 61(95.3%) patients received a single dose, while 3(4, 7%) patients needed two doses. Resulting thyroid matabolism and volume of nodules were evaluated 6-48 months after treatment. Results: From 45 radioiodine treated patients with fix dose 6(9, 8%) became hypothyroidism, 36(85, 3%) euthyroidism and 3(4, 9%) recurrent hyperthyroidism, in comparison with 19 treated patients with calculated I-131 dose: 2(10, 5%) hypothyroidism, 16(84, 3%) euthyroidism and 1(5, 2%) recurrent hyperthyroidism. The size of the nodules became unpalpable m 17(26, 2%), decreased evidently in 33(52, 5%) and remained unchanged in 14(21, 3%) of the treated patients. Conclusion: A fix dose of I-131 is simple, safe and efficient in the treatment of solitary toxic thyroid adenoma. There was not significant different in incidence of late follow-up results of hypothyroidism and recurrent hyperthyroidism between fix dose and calculated MBq/gr dose. (authors)

  10. Early prediction of hypothyroidism following 131I treatment for Graves' disease

    International Nuclear Information System (INIS)

    Wilson, R.; McKillop, J.H.; Jenkins, C.; Thomson, J.A.

    1988-01-01

    The aim of this study was twofold. Firstly to assess the post treatment predictive value of various biochemical and immunological tests for early hypothyroidism after 131 I therapy of Graves' disease, and secondly to determine whether or not pretreatment with Carbimazole protects against post treatment hypothyroidism. The early changes observed in serum T 3 , T 4 , TSH, thyroid microsomal and thyroglobulin antibody levels were found to be of no predictive value. A sharp rise, around 2 months, in TRAb levels following 131 I therapy indicated that hypothyroidism was likely to occur. This rise was thought to reflect a greater degree of thyroid damage. Lower levels of thyroglobulin in patients who had become hypothyroid by 12 months after treatment would support this view. Five weeks Carbimazole pretreatment in this relatively small group of patients did not appear to protect against hypothyroidism. (orig.)

  11. Measurement of inhomogeneous activity distribution in paper chromatography using 131I-labelled rose bengal

    International Nuclear Information System (INIS)

    Strietzel, M.

    1976-01-01

    The inhomogeneous activity distribution of 131 I-labelled rose bengal after paper chromatographic separation has been evaluated. Superposing autoradiograms obtained by different exposure times on the original strip, the fraction boundaries are transferred to the latter and cut out. The cuttings are measured in an automatic sample changer under constant geometrical conditions. The methodical error ranges from 5 to 10 per cent. This method was used to test the stability of 131 I-labelled rose bengal over a period of 4 to 5 half-lives

  12. Radioimmunolocalisation of tumours by external scintigraphy after administration of 131I antibody to carcinoembryonic antigen

    International Nuclear Information System (INIS)

    Searle, F.; Bagshawe, K.D.; Begent, R.H.J.; Jewkes, R.F.; Jones, B.E.; Keep, P.A.; Lewis, J.; Vernon, P.

    1980-01-01

    Investigations of 131 I-labelled antibody to carcinoembryonic antigen (CEA) were performed in nude mice bearing human colonic carcinoma xenografts and in external scintigraphy of patients with various tumours. In mice, the activities of 131 I (antiCEA) and 125 I(normal γ globulin) were measured in the human colon carcinoma xenografts. The results were expressed as a ratio of uptake of specific to non-specific antibody showing that antiCEA was retained in the tumours with a maximum specificity index of 2.2 at 7 days after antibody administration. Palpable carcinomas of the colon were localised by scintiscanning in patients given 131 I-labelled antibody to CEA. However, uptake of antiCEA was also demonstrated in apparently normal colon due to non-specific uptake of antibody and the fact that some CEA is present in normal colon. Thus further development of the technique particularly as regards antibody specificity, is necessary before radioimmunolocalisation could be used as a means of detecting tumours in clinical practice. (UK)

  13. Developing historical food production and consumption data for 131I dose estimates: The Hanford experience

    International Nuclear Information System (INIS)

    Anderson, D.M.; Marsh, T.L.; Deonigi, D.A.

    1996-01-01

    This paper describes the methods used to reconstruct the movement of commercial foods in and through the study area of the Hanford Environmental Dose Reconstruction Project. The most dose-relevant radionuclide released from Hanford separations plants was 131 I via the atmospheric pathway. As a result of atmospheric deposition of 131 I, commercial food supplies may have been contaminated. Because of the half-life of 131 I is relatively short, foods consumed soon after production, such as milk and produce, presented the highest risk. For that reason, this paper deals primarily with the reconstruction of milk and produce production, marketing, and consumption from 1945-1951, the period with the highest known 131 I releases. The reconstructed food production and consumption information was used as input to radiation dose estimates for representative individuals and as default values for real individuals who may not remember where they obtained food or how much they consumed during that period. Specific methods for tracing the movement of commercial milk and produce back from the point of human consumption, through commercial markets, to original production are presented. Results include the characteristics of food consumption exhibited by representative individuals, examples of commercial milk and produce market structures, and a review of commercial milk production and processing practices from 1945-1951

  14. Calibration of CDTN-whole body counter for in vivo measurements of I-131

    International Nuclear Information System (INIS)

    Oliveira, Cassio M.; Silva, Tania V. da; Alonso, Thessa C.; Squair, Peterson L.

    2009-01-01

    Iodine-131 is frequently used in nuclear medicine services for diagnosis and therapy of thyroid diseases. Furthermore, the Nuclear Technology Development Centre (CDTN/CNEN), in Belo Horizonte, uses Iodine-131 for radiobiology and radiopharmacy researches. The increasing use of this radionuclide for medical and research purposes as well as its high volatility creates a demand for feasible methodologies to perform occupational control of internal contamination. Therefore the objective this work is to develop methods of in vivo bioassay for evaluation Iodine-131 incorporation by using NaI(Tl) 6'' x 4'' scintillation detector of the CDTN-Whole Body Counter (WBC). Such detector was calibrated for in vivo measurements with a neck-thyroid phantom, simulating Iodine-131 incorporation. The chosen counting geometry was lying under monitoring bed of CDTNWBC. A methodology for bioassay data interpretation, based on standard ICRP 56 model was established with software AIDE (activity internal dose estimate) version 6.0. It was concluded that in vivo measurements have sufficient sensitivity for the monitoring of Iodine-131 through CDTN-Whole Body Counter. Therefore, the CDTN-Whole Body Counter equipment of Belo Horizonte are ready to attend suspicion intake cases of Iodine- 131 (author)

  15. Calibration of CDTN-whole body counter for in vivo measurements of I-131

    Energy Technology Data Exchange (ETDEWEB)

    Oliveira, Cassio M.; Silva, Tania V. da; Alonso, Thessa C.; Squair, Peterson L. [Centro de Desenvolvimento da Tecnologia Nuclear (CDTN-CNEN/MG), Belo Horizonte, MG (Brazil)], e-mail: cmo@cdtn.br

    2009-07-01

    Iodine-131 is frequently used in nuclear medicine services for diagnosis and therapy of thyroid diseases. Furthermore, the Nuclear Technology Development Centre (CDTN/CNEN), in Belo Horizonte, uses Iodine-131 for radiobiology and radiopharmacy researches. The increasing use of this radionuclide for medical and research purposes as well as its high volatility creates a demand for feasible methodologies to perform occupational control of internal contamination. Therefore the objective this work is to develop methods of in vivo bioassay for evaluation Iodine-131 incorporation by using NaI(Tl) 6'' x 4'' scintillation detector of the CDTN-Whole Body Counter (WBC). Such detector was calibrated for in vivo measurements with a neck-thyroid phantom, simulating Iodine-131 incorporation. The chosen counting geometry was lying under monitoring bed of CDTNWBC. A methodology for bioassay data interpretation, based on standard ICRP 56 model was established with software AIDE (activity internal dose estimate) version 6.0. It was concluded that in vivo measurements have sufficient sensitivity for the monitoring of Iodine-131 through CDTN-Whole Body Counter. Therefore, the CDTN-Whole Body Counter equipment of Belo Horizonte are ready to attend suspicion intake cases of Iodine- 131 (author)

  16. Effects of {sup 40} K on {sup 131} I in vivo monitoring of thyroid; Interferencia do {sup 40} K na monitoracao in vivo de {sup 131} I na tireoide

    Energy Technology Data Exchange (ETDEWEB)

    Venturini, Luzia; Berti, Eduardo A.R.; Campos, Vicente P.; Rodrigues, Leticia L.C. [Instituto de Pesquisas Energeticas e Nucleares (IPEN), Sao Paulo, SP (Brazil)

    1999-11-01

    This paper investigates how the detection limit for {sup 131} I in vivo monitoring is affected by the {sup 40} K body content. Gamma spectral data of 32 non-contaminated subjects were analyzed. The detection limit is determined for each case and the mean value is compared to the detection limit calculated for the shielded room. The detector used was a 3 x 3 NaI(TI) shielded with 3.2 cm lead and 0.7 cm aluminium. The results show that the interference of {sup 40} K is very important in the determination of the activity of {sup 131} I but it can be disregarded, in the occupational routine measurements, if the record level (Bq) is several times greater than the measured activity. (author) 5 refs., 1 tab.; e-mail: lventur at net.ipen.br

  17. Clinical applications of radioiodine 131 (I131) in the thyroid diseases

    International Nuclear Information System (INIS)

    Gonzalez Rivero, Levi; Turcios Trista, Silvia Elena; Velasco Mirabal, Milagros

    2012-01-01

    Radioiodine 131 is a radioactive isotope that is successfully used for the diagnosis and the treatment of benign and malignant thyroid diseases. Its quality of selectively integrating to the thyroid metabolism and emitting a signal allows it to describe the gland functioning through capture studies, and to delimit the morphology and location of the tissues that capture iodine by means of scintigraphy. It is also a simple, safe and cost-effective radiotherapy used as first-line therapeutics in the control of hyperthyroidism. The dose and right time of application should be individualized according to the etiology and the clinic of each patient. Radioiodine 131 offers an efficient alternative to reduce the size of non-toxic goiter in addition to supporting the surgical treatment of the differentiated thyroid carcinoma and destroying with ablative doses the tissular remains and the metastatic lesions that can be detected during the gammagraphic follow-up. Radioiodine 131 depends on the fulfillment of safety regulations against radioactivity

  18. Clinical applications of radioiodine 131 (I131) in the thyroid diseases

    International Nuclear Information System (INIS)

    Gonzalez, Rivero Levi; Turcios Trista, Silvia Elena; Velasco Mirabal, Milagros

    2012-01-01

    Radioiodine 131 is a radioactive isotope that is successfully used for the diagnosis and the treatment of benign and malignant thyroid diseases. Its quality of selectively integrating to the thyroid metabolism and emitting a signal allows it to describe the gland functioning through capture studies, and to delimit the morphology and location of the tissues that capture iodine by means of gammagraphy. It is also a simple, safe and cost-effective radiotherapy used as first-line therapeutics in the control of hyperthyroidism. The dose and right time of application should be individualized according to the etiology and the clinic of each patient. Radioiodine 131 offers an efficient alternative to reduce the size of non-toxic goiter in addition to supporting the surgical treatment of the differentiated thyroid carcinoma and destroying with ablative doses the tissular remains and the metastatic lesions that can be detected during the gammagraphic follow-up. Radioiodine 131 depends on the fulfillment of safety regulations against radioactivity

  19. Advance of study on the influence of different drugs on the efficacy of 131I treatment for Graves' disease

    International Nuclear Information System (INIS)

    Wang Peng; Tan Jian

    2011-01-01

    Graves' disease is the most common cause of hyperthyroidism. 131 I treatment is one main treatment method for Graves' disease, and being used on an increasing scale in China recently. During the peritherapeutic period, however, the application of other drugs may affect the efficacy of 131 I treatment. In this review, the advances of study were summarized on the influence of different drugs on the efficacy of 131 I treatment in recent years. (authors)

  20. Determinants of successful ablation and complete remission after total thyroidectomy and 131I therapy of paediatric differentiated thyroid cancer

    International Nuclear Information System (INIS)

    Verburg, Frederik A.; Maeder, Uwe; Luster, Markus; Haenscheid, Heribert; Reiners, Christoph

    2015-01-01

    In adult differentiated thyroid cancer (DTC) patients, successful ablation and the number of 131 I therapies needed carry a prognostic significance. The goal was to assess the prognosis of DTC in children and adolescents treated in our centre in relation to the number of treatments needed and to establish the determinants of both complete remission (CR) and successful ablation. Seventy-six DTC patients <21 years of age at diagnosis were included. Recurrence and death rates, rates of CR (=negative stimulated thyroglobulin, negative neck ultrasound and negative 131 I whole-body scintigraphy) and successful ablation (=CR after initial 131 I therapy) were studied. No patients died of DTC. Seven patients were treated by surgery alone and did not show signs of recurrence during follow-up. Of the 69 patients also treated with 131 I therapy, 47 patients achieved CR, 25 of whom had successful ablation. In multivariate analysis, female gender and the absence of distant metastases were independent determinants of a higher CR rate. Female gender, lower T stage and higher 131 I activity (successful ablation, median activity 3.1 GBq, unsuccessful ablation 2.6 GBq) were determinants of a higher rate of successful ablation. After 131 I therapy no patient showed recurrence after reaching CR or disease progression if CR was not reached. In our paediatric DTC population prognosis is extremely good with no deaths or recurrences occurring regardless of the number of 131 I therapies needed or whether CR was reached. The determinants of CR and successful ablation can be used to optimize the chance of therapy success. (orig.)

  1. Correlation between micronuclei frequency in peripheral blood lymphocytes and retention of 131-I in thyroid cancer patients

    International Nuclear Information System (INIS)

    Vrndic, O.B.; Milosevic-Djordjevic, O.M.; Mijatovic Teodorovic, L.C.; Zivancevic Simonovic, S.T.; Jeremic, M.Z.; Stosic, I.M.; Grujicic, D.V.

    2013-01-01

    Differentiated thyroid cancers (DTCs) derive from thyroid follicular cells and include papillary and follicular cancers. In patients with DTCs, the initial treatment includes thyroidectomy and radioactive iodine (131-I) therapy. The objective of this study was to examine whether the intensity of DNA damage in peripheral blood lymphocytes (PBLs) of DTC patients depends on the amount of 131-I retained in the selected regions of interest (thyroid and abdominal region) as well as in the whole-body 72 hours after therapy. In addition, the possible influence of other factors that may affect micronuclei (MN) frequency, such as age, gender, smoking habits, and histological type of tumour was analyzed. The study population consisted of 22 DTC patients and 20 healthy donors. Data on the distribution of 131-I were obtained from the whole-body scans. MN frequency and cytokinesis-block proliferation index (CBPI) were measured using cytokinesis-block micronucleus assay. 131-I therapy significantly increased the MN frequency (19.50±6.90 vs. 27.10±19.50 MN) and significantly decreased the CBPI (1.52±0.20 vs. 1.38±0.17) in patients' lymphocytes. There was a clear correlation between the increased MN frequency and 131-I accumulation in the thyroid region in patients without metastases. The MN values did not differ in relation to the factors that could affect MN, such as age, gender, smoking habits, and histological type of tumour. In conclusion, the MN frequency in PBLs of DTC patients without metastases depends on the accumulation of 131-I in the thyroid region and does not depend on the other factors examined. (author)

  2. The influence of I-131 therapy on FDG uptake in differentiated thyroid cancer

    International Nuclear Information System (INIS)

    Hung Guanguei; Lee Kwowhei; Liao Peiyung; Yang Liheng; Yang Kwangtao

    2008-01-01

    18F-fluorodeoxyglucose positron emission tomography (FDG-PET) [or PET/computed tomography (CT)] is more likely to show false-negative results when it is performed shortly after chemotherapy and/or radiotherapy because of ''metabolic stunning''. The present study aimed to evaluate the influence of I-131 therapy on FDG uptake and the detection of recurrence or metastasis of differentiated thyroid cancer (DTC). We retrospectively enrolled 16 consecutive FDG-PET/CT studies which had been performed in patients with DTC with elevated thyroglobulin (TG) but negative I-131 whole-body scan. All studies were performed under L-thyroxine suppression. The patients were divided into groups A and B for PET/CT performed within 4 months of I-131 therapy or no such therapy, respectively. Each lesion identified on PET/CT was characterized using a 5-point scale by visual analysis: 0=definitely benign, 1=probably benign, 2=equivocal, 3=probably